



(51) International Patent Classification:

C07D 471/04 (2006.01) C07D 519/00 (2006.01)

C07D 487/04 (2006.01) A61P 35/00 (2006.01)

C07D 491/048 (2006.01)

(21) International Application Number:

PCT/AU2022/051568

(22) International Filing Date:

22 December 2022 (22.12.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2021904206 22 December 2021 (22.12.2021) AU

(71) Applicant: ANAXIS PHARMA PTY LTD [AU/AU];

Bio21 Institute, 30 Flemington Road, Parkville, Victoria 3052 (AU).

(72) Inventors: BRZOZOWSKI, Martin; c/- Bio21 Insti-

tute, 30 Flemington Road, Parkville, Victoria 3052 (AU).

POITEVIN, Christophe; c/- Bio21 Institute, 30 Fleming-

ton Road, Parkville, Victoria 3052 (AU). GARNIER, Jean-

Marc Daniel; c/- Bio21 Institute, 30 Flemington Road,

Parkville, Victoria 3052 (AU). GARDNER, Christopher;

c/- Bio21 Institute, 30 Flemington Road, Parkville, Victoria

3052 (AU). LESSENE, Guillaume Laurent; c/- Bio21 In-

stitute, 30 Flemington Road, Parkville, Victoria 3052 (AU).

CZABOTAR, Peter Edward; c/- Bio21 Institute, 30 Flem-

ington Road, Parkville, Victoria 3052 (AU). SCHUSTER-

KLEIN, Carole Annie; c/- Bio21 Institute, 30 Flemington

Road, Parkville, Victoria 3052 (AU). DAVIES, Katherine;

c/- Bio21 Institute, 30 Flemington Road, Parkville, Victoria

3052 (AU). COWAN, Angus; c/- Bio21 Institute, 30 Flem-

ington Road, Parkville, Victoria 3052 (AU). KERSTEN,

Wilco; c/- Bio21 Institute, 30 Flemington Road, Parkville,

Victoria 3052 (AU).

(74) Agent: FPA PATENT ATTORNEYS PTY LTD; Lev-

el 19, South Tower, 80 Collins Street, Melbourne, Victoria

3000 (AU).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: ARYLSULPHONAMIDE COMPOUNDS



(57) **Abstract:** This invention relates to compounds of formula (I) and salts, solvates, tautomers, N-oxides, stereoisomers, polymorphs and/or prodrugs thereof. Also disclosed is the use of the compounds of formula (I) to treat necroptosis and/or inhibit MLKL.



Arylsulphonamide compounds

Cross reference

This application claims priority to Australian provisional application no. 2021904206, filed on 22 December 2021, the entire contents of which are incorporated herein by reference.

5 Field

The present disclosure relates to compounds which treat necroptosis and/or inhibit MLKL, and methods for their use.

Background

10 In many diseases, cell death is mediated through apoptotic and/or necrotic pathways. While much is known about the mechanisms of action that control apoptosis, control of necrosis is not as well understood. Understanding the mechanisms in respect of both necrosis and apoptosis in cells is essential to being able to treat conditions, such as neurodegenerative diseases, stroke- coronary heart disease, kidney disease, liver disease, AIDS and the conditions associated with AIDS.

15 Cell death has traditionally been categorized as either apoptotic or necrotic based on morphological characteristics (Wyllie et al., Int. Rev. Cytol. 68: 251 (1980)). These two modes of cell death were also initially thought to occur via regulated (caspase-dependent) and non-regulated processes, respectively. More recent studies, however, demonstrate that the underlying cell death mechanisms resulting in these two phenotypes are much more
20 complicated and under some circumstances interrelated. Furthermore, conditions that lead to necrosis can occur by either regulated caspase-independent or non-regulated processes.

One regulated caspase-independent cell death pathway with morphological features resembling necrosis, called necroptosis, has been described (Degterev *et al.*, *Nat. Chem. Biol.* 1:112, 2005). This cell death modality can be initiated with various stimuli (e.g., TNF-
25 [alpha] and Fas ligand) and in an array of cell types (e.g., monocytes, fibroblasts, lymphocytes, macrophages, epithelial cells and neurons). Necroptosis may represent a significant contributor to and in some cases predominant mode of cellular demise under pathological conditions involving excessive cell stress, rapid energy loss and massive oxidative species generation, where the highly energy-dependent apoptosis process is not
30 operative.

In WO2015/172203, we reported that particular compounds described in US2005/0085637 have been found to be suitable for inhibiting necroptosis. We also discussed particularly suitable compounds for inhibiting necroptosis in WO2016/127213.


5 All publications, patents and patent applications that may be cited herein are hereby incorporated by reference in their entirety.

Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present disclosure as it existed before the priority date of each claim of this application.

Summary

As discussed above, certain compounds described in WO2016/127213, US2005/0085637 and WO2015/172203 have been found to be suitable for inhibiting necroptosis. Surprisingly, the inventors of this invention have now discovered that other types of compounds are also suitable for inhibiting necroptosis. Further, and equally surprising, the compounds described herein target a key effector of the necroptotic pathway, namely mixed lineage kinase domain-like protein (MLKL). In addition, the compounds described herein are potent inhibitors of different MLKL homologues, including human MLKL and murine MLKL. The cross-homologue MLKL potency may provide useful pre-clinical safety and efficacy data.


20 In one aspect, there is provided a compound according to Formula (I)




(I)

wherein

J is selected from the following moieties J1 and J2:



J1



J2

A^1 and A^4 are independently selected from N and C;

A^2 and A^3 are independently selected from N, NR^1 , CH, O and S;

wherein at least one of A^1 , A^2 , A^3 and A^4 is selected from N, NR^1 , O and S;

5 A^5 is CH or N;

A^6 is N or CR^2 ;

R^1 and R^3 are independently selected from H and an optionally substituted C_{1-6} -alkyl;

R^2 is selected from:

- (i) H,
- 10 (ii) optionally substituted C_{1-4} alkylamido,
- (iii) optionally substituted C_{1-4} alkylaryl,
- (iv) optionally substituted C_{2-4} alkynyl,
- (v) optionally substituted aryl,
- (vi) optionally substituted 5- or 6-membered heterocyclyl,
- 15 (vii) cyano;

X is selected from optionally substituted C_{1-6} alkyl, optionally substituted halo C_{1-6} alkyl, optionally substituted C_{2-6} alkynyl, optionally substituted cycloalkyl, optionally substituted halocycloalkyl, optionally substituted aryl, optionally substituted alkylaryl, optionally substituted C_{1-6} alkylcycloalkyl and optionally substituted amino;

20 Y and Z are independently selected from H, R^4 and $-OR^4$;

wherein at least one of Y and Z is H and the remaining one of Y and Z is selected from R^4 and $-OR^4$;

R^4 is selected from optionally substituted C_{1-6} alkyl, optionally substituted aryl, optionally substituted C_{1-6} alkylaryl, optionally substituted heterocyclyl, optionally substituted

C₁₋₆alkylheterocyclyl, optionally substituted cycloalkyl, optionally substituted C₁₋₆alkylC₃₋₁₀cycloalkyl, optionally substituted C₃₋₁₀cycloalkylaryl, optionally substituted C₃₋₁₀cycloalkylheterocyclyl, optionally substituted C₃₋₁₀cycloalkylC₃₋₁₀cycloalkyl, optionally substituted 3-6 membered non-aromatic heterocyclyl-aryl, optionally substituted 3-6 membered non-aromatic heterocyclylC₃₋₁₀cycloalkyl and optionally substituted 3-6 membered non-aromatic heterocyclyl-3-10 membered heterocyclyl; and

R⁵ is selected from H, optionally substituted C₁₋₆alkyl, optionally substituted C₃₋₁₀cycloalkyl and optionally substituted aryl.

In any aspect or embodiment described herein, the compound of the invention may be provided in the form of a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer and/or prodrug thereof.

The inventors have found that compounds of Formula (I) are selective inhibitors of MLKL.

In some embodiments, when Y is -OR⁴, Z is H.

In some embodiments, R² is selected from:

- (i) H,
- (ii) optionally substituted C₁₋₄alkylamido,
- (iii) optionally substituted C₁₋₄alkylaryl,
- (iv) optionally substituted C₂₋₄alkynyl,
- (v) optionally substituted aryl,
- (vi) optionally substituted 5- or 6-membered heterocyclyl.

In some embodiments, the compound of the invention is selected from any of compounds 1-173 described herein.

In some embodiments, the compound of the invention is selected from any of compounds 7, 9, 12, 13, 14, 15, 16, 18, 19, 20 and 72.

In some embodiments, the compound of the invention is selected from any of compounds 1, 7, 9, 12-16, 18-21, 23-32, 35-46, 48, 50-52, 55-62, 72-89, 92-109, 111, 113, 115-117, and 119-123, preferably any of compounds 19, 29-31, 36, 38, 40-41, 75-77, 81, 100-101, 103-104, 109, 120 and 123.

In some embodiments, the compound of the invention is selected from any of compounds 1, 5, 7-9, 11-16, 18-21, 23-32, 35-46, 48, 50-52, 55-62, 66, 69, 70, 72-89, 92-109, 111, 113,

115-117, and 119-123, preferably any of compounds 5, 7-9, 11-13, 15, 18-20, 60, 61, 66, 69, 70 and 72.

In some embodiments, the compound of the invention is selected from any of compounds 3, 11, 13, 19, 29, 30, 46, 79, 80, 81, 97, 98, 99, 103, 104, 109, 113, 116, 120,
5 121 and 122.

In another aspect, there is provided a medicament comprising a compound of the invention.

In another aspect, there is provided a pharmaceutical composition comprising a compound of the invention and a pharmaceutically acceptable excipient.

In another aspect, there is provided a method of treating necroptosis, comprising
10 administering to a subject in need thereof an effective amount of a compound of the invention.

In another aspect, there is provided a method of inhibiting MLKL, comprising contacting a cell with a compound of the invention.

Any embodiment herein shall be taken to apply *mutatis mutandis* to any other embodiment
15 unless specifically stated otherwise.

The present disclosure is not to be limited in scope by the specific embodiments described herein, which are intended for the purpose of exemplification only. Functionally-equivalent products, compositions and methods are clearly within the scope of the invention, as described herein.

20 Throughout this specification, unless specifically stated otherwise or the context requires otherwise, reference to a single step, composition of matter, group of steps or group of compositions of matter shall be taken to encompass one and a plurality (i.e. one or more) of those steps, compositions of matter, groups of steps or group of compositions of matter.

Definitions

25 Unless otherwise herein defined, the following terms will be understood to have the general meanings which follow.

The term "C₁₋₆alkyl" refers to optionally substituted straight chain or branched chain hydrocarbon groups having from 1 to 6 carbon atoms. Examples include methyl (Me), ethyl (Et), propyl (Pr), isopropyl (i-Pr), butyl (Bu), isobutyl (i-Bu), sec-butyl (s-Bu), tert-butyl (t-Bu),
30 pentyl, neopentyl, hexyl and the like. Unless the context requires otherwise, the term

"C₁₋₆alkyl" also encompasses alkyl groups containing one less hydrogen atom such that the group is attached via two positions i.e. divalent. "C₁₋₄alkyl" and "C₁₋₃alkyl" including methyl, ethyl, propyl, isopropyl, n-butyl, iso-butyl, sec-butyl and tert-butyl are preferred with methyl being particularly preferred.

- 5 The term "C₂₋₆alkenyl" refers to optionally substituted straight chain or branched chain hydrocarbon groups having at least one double bond of either *E* or *Z* stereochemistry where applicable and 2 to 6 carbon atoms. Examples include vinyl, 1-propenyl, 1- and 2-butenyl and 2-methyl-2-propenyl. Unless the context requires otherwise, the term "C₂₋₆alkenyl" also encompasses alkenyl groups containing one less hydrogen atom such that the group is
- 10 attached via two positions i.e. divalent. "C₂₋₄alkenyl" and "C₂₋₃alkenyl" including ethenyl, propenyl and butenyl are preferred with ethenyl being particularly preferred.

- The term "C₂₋₆alkynyl" refers to optionally substituted straight chain or branched chain hydrocarbon groups having at least one triple bond and 2 to 6 carbon atoms. Examples include ethynyl, 1-propynyl, 1- and 2-butylnyl, 2-methyl-2-propynyl, 2-pentylnyl, 3-pentylnyl,
- 15 4-pentylnyl, 2-hexynyl, 3-hexynyl, 4-hexynyl and 5-hexynyl and the like. Unless the context indicates otherwise, the term "C₂₋₆alkynyl" also encompasses alkynyl groups containing one less hydrogen atom such that the group is attached via two positions i.e. divalent. C₂₋₄alkynyl or C₂₋₃alkynyl are preferred.

- The term "C₃₋₁₀Cycloalkyl" refers to non-aromatic cyclic groups having from 3 to 10 carbon atoms, including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl and cyclodecyl. It will be understood that cycloalkyl groups may be saturated such as cyclohexyl or unsaturated such as cyclohexenyl. C₃₋₆cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl are preferred. Cycloalkyl groups also include polycyclic carbocycles and include fused, bridged and spirocyclic systems.
- 20

- 25 The terms "hydroxy" and "hydroxyl" refer to the group -OH.

The term "oxo" refers to the group =O.

- The term "C₁₋₆alkoxy" refers to an alkyl group as defined above covalently bound via an O linkage containing 1 to 6 carbon atoms, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy and pentoxy. "C₁₋₄alkoxy" and "C₁₋₃alkoxy" including methoxy, ethoxy, propoxy
- 30 and butoxy are preferred with methoxy being particularly preferred.

The terms “haloC₁₋₆alkyl” and “C₁₋₆alkylhalo” refer to a C₁₋₆alkyl which is substituted with one or more halogens. HaloC₁₋₃alkyl groups are preferred, such as for example, -CH₂CF₃, and -CF₃.

5 The terms “haloC₁₋₆alkoxy” and “C₁₋₆alkoxyhalo” refer to a C₁₋₆alkoxy which is substituted with one or more halogens. C₁₋₃alkoxyhalo groups are preferred, such as for example, -OCF₃.

The term “carboxylate” or “carboxyl” refers to the group -COO- or -COOH.

10 The term “ester” refers to a carboxyl group having the hydrogen replaced with, for example a C₁₋₆alkyl group (“carboxylC₁₋₆alkyl” or “alkylester”), an aryl or aralkyl group (“arylester” or “aralkylester”) and so on. CO₂C₁₋₃alkyl groups are preferred, such as for example, methylester (CO₂Me), ethylester (CO₂Et) and propylester (CO₂Pr) and includes reverse esters thereof (e.g. -OC(O)Me, -OC(O)Et and -OC(O)Pr).

The terms “cyano” and “nitrile” refer to the group -CN.

The term “nitro” refers to the group -NO₂.

15 The term “amino” refers to the group -NH₂.

The term “substituted amino” refers to an amino group having at least one hydrogen replaced with, for example a C₁₋₆alkyl group (“C₁₋₆alkylamino”), an aryl or aralkyl group (“arylamino”, “aralkylamino”) and so on. Substituted amino groups include “monosubstituted amino” (or “secondary amino”) groups, which refer to an amino group having a single
20 hydrogen replaced with, for example a C₁₋₆alkyl group, an aryl or aralkyl group and so on. Preferred secondary amino groups include C₁₋₃alkylamino groups, such as for example, methylamino (NHMe), ethylamino (NHEt) and propylamino (NHPr). Substituted amino groups also include “disubstituted amino” (or “tertiary amino”) groups, which refer to amino groups having both hydrogens replaced with, for example C₁₋₆alkyl groups, which may be the
25 same or different (“dialkylamino”), aryl and alkyl groups (“aryl(alkyl)amino”) and so on. Preferred tertiary amino groups include di(C₁₋₃alkyl)amino groups, such as for example, dimethylamino (NMe₂), diethylamino (NEt₂), dipropylamino (NPr₂) and variations thereof (e.g. N(Me)(Et) and so on).

The term “aldehyde” refers to the group -C(=O)H.

30 The terms “acyl” and “acetyl” refers to the group -C(O)CH₃.

The term “ketone” refers to a carbonyl group which may be represented by -C(O)- .

The term “substituted ketone” refers to a ketone group covalently linked to at least one further group, for example, a C_{1-6} alkyl group (“ C_{1-6} alkylacyl” or “alkylketone” or “ketoalkyl”), an aryl group (“arylketone”), an aralkyl group (“aralkylketone”) and so on. C_{1-3} alkylacyl groups are preferred.

The term “amido” or “amide” refers to the group -C(O)NH_2 .

The term “substituted amido” or “substituted amide” refers to an amido group having a hydrogen replaced with, for example a C_{1-6} alkyl group (“ C_{1-6} alkylamido” or “ C_{1-6} alkylamide”), an aryl (“arylamido”), aralkyl group (“aralkylamido”) and so on. C_{1-3} alkylamide groups are preferred, such as for example, methanamide (-C(O)NHMe), ethanamide (-C(O)NHEt) and propanamide (-C(O)NHPr) and includes reverse amides thereof (e.g. -NHMeC(O)- , -NHEtC(O)- and -NHPrC(O)-).

The term “disubstituted amido” or “disubstituted amide” refers to an amido group having the two hydrogens replaced with, for example a C_{1-6} alkyl group (“ $\text{di(C}_{1-6}\text{alkyl)amido}$ ” or “ $\text{di(C}_{1-6}\text{alkyl)amide}$ ”), an aralkyl and alkyl group (“ $\text{alkyl(aralkyl)amido}$ ”) and so on. $\text{Di(C}_{1-3}\text{alkyl)amide}$ groups are preferred, such as for example, dimethanamide (-C(O)NMe_2), diethanamide (-C(O)NEt_2) and dipropanamide (-C(O)NPr_2) and variations thereof (e.g. -C(O)N(Me)Et and so on) and includes reverse amides thereof.

The term “thiol” refers to the group -SH .

The term “ C_{1-6} alkylthio” refers to a thiol group having the hydrogen replaced with a C_{1-6} alkyl group. C_{1-3} alkylthio groups are preferred, such as for example, thiomethyl, thioethyl and thiopropyl.

The terms “thioxo” refer to the group =S .

The term “sulfinyl” refers to the group -S(=O)H .

The term “substituted sulfinyl” or “sulfoxide” refers to a sulfinyl group having the hydrogen replaced with, for example a C_{1-6} alkyl group (“ C_{1-6} alkylsulfinyl” or “ C_{1-6} alkylsulfoxide”), an aryl (“arylsulfinyl”), an aralkyl (“aralkyl sulfinyl”) and so on. C_{1-3} alkylsulfinyl groups are preferred, such as for example, -SOMethyl , -SOethyl and -SOpropyl .

The term “sulfonyl” refers to the group $\text{-SO}_2\text{H}$.

The term “substituted sulfonyl” refers to a sulfonyl group having the hydrogen replaced with, for example a C₁₋₆alkyl group (“sulfonylC₁₋₆alkyl”), an aryl (“arylsulfonyl”), an aralkyl (“aralkylsulfonyl”) and so on. SulfonylC₁₋₃alkyl groups are preferred, such as for example, -SO₂Me, -SO₂Et and -SO₂Pr.

- 5 The term “sulfonylamido” or “sulfonamide” refers to the group -SO₂NH₂.

The term “substituted sulfonamido” or “substituted sulphonamide” refers to an sulfonylamido group having a hydrogen replaced with, for example a C₁₋₆alkyl group (“sulfonylamidoC₁₋₆alkyl”), an aryl (“arylsulfonamide”), aralkyl (“aralkylsulfonamide”) and so on.

- 10 SulfonylamidoC₁₋₃alkyl groups are preferred, such as for example, -SO₂NHMe, -SO₂NHEt and -SO₂NHPr and includes reverse sulfonamides thereof (e.g. -NHSO₂Me, -NHSO₂Et and -NHSO₂Pr).

- 15 The term “disubstituted sulfonamido” or “disubstituted sulphonamide” refers to an sulfonylamido group having the two hydrogens replaced with, for example a C₁₋₆alkyl group, which may be the same or different (“sulfonylamidodi(C₁₋₆alkyl)”), an aralkyl and alkyl group (“sulfonamido(aralkyl)alkyl”) and so on. Sulfonylamidodi(C₁₋₃alkyl) groups are preferred, such as for example, -SO₂NMe₂, -SO₂NEt₂ and -SO₂NPr₂ and variations thereof (e.g. -SO₂N(Me)Et and so on) and includes reserve sulfonamides thereof (e.g. –N(Me)SO₂Me and so on).

- 20 The term “sulfate” refers to the group OS(O)₂OH and includes groups having the hydrogen replaced with, for example a C₁₋₆alkyl group (“alkylsulfates”), an aryl (“arylsulfate”), an aralkyl (“aralkylsulfate”) and so on. C₁₋₃sulfates are preferred, such as for example, OS(O)₂OMe, OS(O)₂OEt and OS(O)₂OPr.

- 25 The term “sulfonate” refers to the group SO₃H and includes groups having the hydrogen replaced with, for example a C₁₋₆alkyl group (“alkylsulfonate”), an aryl (“arylsulfonate”), an aralkyl (“aralkylsulfonate”) and so on. C₁₋₃sulfonates are preferred, such as for example, SO₃Me, SO₃Et and SO₃Pr.

- 30 The term “aryl” refers to a carbocyclic (non-heterocyclic) aromatic ring or mono-, bi- or tri-cyclic ring system. Poly-cyclic ring systems may be referred to as “aryl” provided at least 1 of the rings within the system is aromatic. The aromatic ring or ring system is generally composed of 6 to 10 carbon atoms. Examples of aryl groups include but are not limited to phenyl, biphenyl, naphthyl and tetrahydronaphthyl. 6-membered aryls such as phenyl are preferred. The term “alkylaryl” refers to C₁₋₆alkylaryl such as benzyl.

The term "alkoxyaryl" refers to C₁₋₆alkyloxyaryl such as benzyloxy.

The term "heterocyclyl" refers to a moiety obtained by removing a hydrogen atom from a ring atom of a heterocyclic compound which moiety has from 3 to 10 ring atoms (unless otherwise specified), of which 1, 2, 3 or 4 are ring heteroatoms each heteroatom being
5 independently selected from O, S and N. Heterocyclyl groups include monocyclic and polycyclic (such as bicyclic) ring systems, such as fused, bridged and spirocyclic systems, provided at least one of the rings of the ring system contains at least one heteroatom.

In this context, the prefixes 3-, 4-, 5-, 6-, 7-, 8-, 9- and 10- membered denote the number of ring atoms, or range of ring atoms, whether carbon atoms or heteroatoms. For example, the
10 term "3-10 membered heterocyclyl", as used herein, pertains to a heterocyclyl group having 3, 4, 5, 6, 7, 8, 9 or 10 ring atoms. Examples of heterocyclyl groups include 5-6-membered monocyclic heterocyclyls and 9-10 membered fused bicyclic heterocyclyls.

Examples of monocyclic heterocyclyl groups include, but are not limited to, those containing one nitrogen atom such as aziridine (3-membered ring), azetidine (4-membered ring),
15 pyrrolidine (tetrahydropyrrole), pyrroline (e.g., 3-pyrroline, 2,5-dihydropyrrole), 2H-pyrrole or 3H-pyrrole (isopyrrole, isoazole) or pyrrolidinone (5-membered rings), piperidine, dihydropyridine, tetrahydropyridine (6-membered rings), and azepine (7-membered ring); those containing two nitrogen atoms such as imidazoline, pyrazolidine (diazolidine),
imidazoline, pyrazoline (dihydropyrazole) (5-membered rings), piperazine (6-membered
20 ring); those containing one oxygen atom such as oxirane (3-membered ring), oxetane (4-membered ring), oxolane (tetrahydrofuran), oxole (dihydrofuran) (5-membered rings), oxane (tetrahydropyran), dihydropyran, pyran (6-membered rings), oxepin (7-membered ring); those containing two oxygen atoms such as dioxolane (5-membered ring), dioxane (6-membered ring), and dioxepane (7-membered ring); those containing three oxygen atoms
25 such as trioxane (6-membered ring); those containing one sulfur atom such as thiirane (3-membered ring), thietane (4-membered ring), thiolane (tetrahydrothiophene) (5-membered ring), thiane (tetrahydrothiopyran) (6-membered ring), thiepane (7-membered ring); those containing one nitrogen and one oxygen atom such as tetrahydrooxazole, dihydrooxazole, tetrahydroisoxazole, dihydroisoxazole (5-membered rings), morpholine, tetrahydrooxazine, dihydrooxazine, oxazine (6-membered rings); those containing one nitrogen and one sulfur
30 atom such as thiazoline, thiazolidine (5-membered rings), thiomorpholine (6-membered ring); those containing two nitrogen and one oxygen atom such as oxadiazine (6-membered ring); those containing one oxygen and one sulfur such as: oxathiole (5-membered ring) and oxathiane (thioxane) (6-membered ring); and those containing one nitrogen, one oxygen and
35 one sulfur atom such as oxathiazine (6-membered ring).

Heterocyclyls encompass aromatic heterocyclyls and non-aromatic heterocyclyls. Such groups may be substituted or unsubstituted.

The term "aromatic heterocyclyl" may be used interchangeably with the term "heteroaromatic" or the term "heteroaryl" or "hetaryl". The heteroatoms in the aromatic heterocyclyl group may be independently selected from N, S and O. The aromatic heterocyclyl groups may comprise 1, 2, 3, 4 or more ring heteroatoms. In the case of fused aromatic heterocyclyl groups, only one of the rings may contain a heteroatom and not all rings must be aromatic.

"Heteroaryl" is used herein to denote a heterocyclic group having aromatic character and embraces aromatic monocyclic ring systems and polycyclic (e.g. bicyclic) ring systems containing one or more aromatic rings. The term aromatic heterocyclyl also encompasses pseudoaromatic heterocyclyls. The term "pseudoaromatic" refers to a ring system which is not strictly aromatic, but which is stabilized by means of delocalization of electrons and behaves in a similar manner to aromatic rings. The term aromatic heterocyclyl therefore covers polycyclic ring systems in which all of the fused rings are aromatic as well as ring systems where one or more rings are non-aromatic, provided that at least one ring is aromatic. In polycyclic systems containing both aromatic and non-aromatic rings fused together, the group may be attached to another moiety by the aromatic ring or by a non-aromatic ring.

Examples of heteroaryl groups are monocyclic and bicyclic groups containing from five to ten ring members. The heteroaryl group can be, for example, a five membered or six membered monocyclic ring or a bicyclic structure formed from fused five and six membered rings or two fused six membered rings or two fused five membered rings. Each ring may contain up to about four heteroatoms typically selected from nitrogen, sulphur and oxygen. The heteroaryl ring will contain up to 4 heteroatoms, more typically up to 3 heteroatoms, more usually up to 2, for example a single heteroatom. In one embodiment, the heteroaryl ring contains at least one ring nitrogen atom. The nitrogen atoms in the heteroaryl rings can be basic, as in the case of an imidazole or pyridine, or essentially non-basic as in the case of an indole or pyrrole nitrogen. In general the number of basic nitrogen atoms present in the heteroaryl group, including any amino group substituents of the ring, will be less than five.

Aromatic heterocyclyl groups may be 5-membered or 6-membered mono-cyclic aromatic ring systems.

Examples of 5-membered monocyclic heteroaryl groups include but are not limited to furanyl, thienyl, pyrrolyl, oxazolyl, oxadiazolyl (including 1,2,3 and 1,2,4 oxadiazolyls and furazanyl i.e. 1,2,5-oxadiazolyl), thiazolyl, isoxazolyl, isothiazolyl, pyrazolyl, imidazolyl, triazolyl (including 1,2,3, 1,2,4 and 1,3,4 triazolyls), oxatriazolyl, tetrazolyl, thiadiazolyl (including 1,2,3 and 1,3,4 thiadiazolyls) and the like.

Examples of 6-membered monocyclic heteroaryl groups include but are not limited to pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, pyranyl, oxazinyl, dioxinyl, thiazinyl, thiadiazinyl and the like. Examples of 6-membered aromatic heterocyclyls containing nitrogen include pyridyl (1 nitrogen), pyrazinyl, pyrimidinyl and pyridazinyl (2 nitrogens).

- 10 Aromatic heterocyclyl groups may also be bicyclic or polycyclic heteroaromatic ring systems such as fused ring systems (including purine, pteridinyl, naphthyridinyl, 1H thieno[2,3-c]pyrazolyl, thieno[2,3-b]furyl and the like) or linked ring systems (such as oligothiophene, polypyrrole and the like). Fused ring systems may also include aromatic 5-membered or 6-membered heterocyclyls fused to carbocyclic aromatic rings such as phenyl, naphthyl, indenyl, azulenyl, fluorenyl, anthracenyl and the like, such as 5-membered aromatic heterocyclyls containing nitrogen fused to phenyl rings, 5-membered aromatic heterocyclyls containing 1 or 2 nitrogens fused to phenyl ring.

- A bicyclic heteroaryl group may be, for example, a group selected from: a) a benzene ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms; b) a pyridine ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms; c) a pyrimidine ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; d) a pyrrole ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms; e) a pyrazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; f) an imidazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; g) an oxazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; h) an isoxazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; i) a thiazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; j) an isothiazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; k) a thiophene ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms; l) a furan ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms; m) a cyclohexyl ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms; and n) a cyclopentyl ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms.

Particular examples of bicyclic heteroaryl groups containing a five membered ring fused to another five membered ring include but are not limited to imidazothiazole (e.g. imidazo[2,1-b]thiazole) and imidazoimidazole (e.g. imidazo[1,2-a]imidazole).

5 Particular examples of bicyclic heteroaryl groups containing a six membered ring fused to a five membered ring include but are not limited to benzofuran, benzothiophene, benzimidazole, benzoxazole, isobenzoxazole, benzisoxazole, benzothiazole, benzisothiazole, isobenzofuran, indole, isoindole, indolizine, indoline, isoindoline, purine (e.g., adenine, guanine), indazole, pyrazolopyrimidine (e.g. pyrazolo[1,5-a]pyrimidine), benzodioxole and pyrazolopyridine (e.g. pyrazolo[1,5-a]pyridine) groups. A further example
10 of a six membered ring fused to a five membered ring is a pyrrolopyridine group such as a pyrrolo[2,3-b]pyridine group.

Particular examples of bicyclic heteroaryl groups containing two fused six membered rings include but are not limited to quinoline, isoquinoline, chroman, thiochroman, chromene, isochromene, isochroman, benzodioxan, quinolizine, benzoxazine, benzodiazine,
15 pyridopyridine, quinoxaline, quinazoline, cinnoline, phthalazine, naphthyridine and pteridine groups.

Examples of heteroaryl groups containing an aromatic ring and a non-aromatic ring include tetrahydronaphthalene, tetrahydroisoquinoline, tetrahydroquinoline, dihydrobenzothiophene, dihydrobenzofuran, 2,3-dihydro- benzo[1,4]dioxine, benzo[1,3]dioxole, 4,5,6,7-
20 tetrahydrobenzofuran, indoline, isoindoline and indane groups.

Examples of aromatic heterocyclyls fused to carbocyclic aromatic rings may therefore include but are not limited to benzothiophenyl, indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzimidazolyl, indazolyl, benzoxazolyl, benzisoxazolyl, isobenzoxazolyl, benzothiazolyl, benzisothiazolyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl,
25 cinnolinyl, benzotriazinyl, phthalazinyl, carbolinyl and the like.

The term "non-aromatic heterocyclyl" encompasses optionally substituted saturated and unsaturated rings which contain at least one heteroatom selected from the group consisting of N, S and O. The ring may contain 1, 2 or 3 heteroatoms. The ring may be a monocyclic ring or part of a polycyclic ring system. Polycyclic ring systems include fused rings and
30 spirocycles. Not every ring in a non-aromatic heterocyclic polycyclic ring system must contain a heteroatom, provided at least one ring contains one or more heteroatoms.

Non-aromatic heterocyclyls may be 3-7 membered mono-cyclic rings.

Examples of 5-membered non-aromatic heterocyclyl rings include 2H-pyrrolyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, pyrrolidinyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, pyrazolinyl, 2-pyrazolinyl, 3-pyrazolinyl, pyrazolidinyl, 2-pyrazolidinyl, 3-pyrazolidinyl, imidazolidinyl, 3-dioxalanyl, thiazolidinyl, isoxazolidinyl, 2-imidazolinyl and the like.

Examples of 6-membered non-aromatic heterocyclyls include piperidinyl, piperidinonyl, pyranlyl, dihydropyranlyl, tetrahydropyranlyl, 2H pyranlyl, 4H pyranlyl, thianlyl, thianlyl oxide, thianlyl dioxide, piperazinyl, dioxanyl, 1,4-dioxinyl, 1,4-dithianyl, 1,3,5-triozalanyl, 1,3,5-trithianyl, 1,4-morpholinyl, thiomorpholinyl, 1,4-oxathianyl, triazinyl, 1,4-thiazinyl and the like.

Examples of 7-membered non-aromatic heterocyclyls include azepanyl, oxepanyl, thiepanyl and the like.

Non-aromatic heterocyclyl rings may also be bicyclic heterocyclyl rings such as linked ring systems (for example uridinyl and the like) or fused ring systems. Fused ring systems include non-aromatic 5-membered, 6-membered or 7-membered heterocyclyls fused to carbocyclic aromatic rings such as phenyl, naphthyl, indenyl, azulenyl, fluorenyl, anthracenyl and the like. Examples of non-aromatic 5-membered, 6-membered or 7-membered heterocyclyls fused to carbocyclic aromatic rings include indolinyl, benzodiazepinyl, benzazepinyl, dihydrobenzofuranyl and the like.

The term "halo" refers to fluoro, chloro, bromo or iodo.

Unless otherwise defined, the term "optionally substituted" or "optional substituent" as used herein refers to a group which may or may not be further substituted with 1, 2, 3, 4 or more groups, preferably 1, 2 or 3, more preferably 1 or 2 groups selected from the group consisting of C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₈cycloalkyl, hydroxyl, oxo, C₁₋₆alkoxy, aryloxy, C₁₋₆alkoxyaryl, halo, C₁₋₆alkylhalo (such as CF₃), C₁₋₆alkoxyhalo (such as OCF₃), carboxyl, esters, cyano, nitro, amino, substituted amino, disubstituted amino, acyl, ketones, substituted ketones, amides, aminoacyl, substituted amides, disubstituted amides, thiol, alkylthio, thioxo, sulfates, sulfonates, sulfinyl, substituted sulfinyl, sulfonyl, substituted sulfonyl, sulfonylamides, substituted sulfonamides, disubstituted sulfonamides, aryl, arC₁₋₆alkyl, heterocyclyl and heteroaryl wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl and heterocyclyl and groups containing them may be further optionally substituted. Optional substituents in the case of heterocycles containing N may also include but are not limited to C₁₋₆alkyl i.e. N-C₁₋₃alkyl, more preferably methyl particularly N-methyl.

For optionally substituted "C₁₋₆alkyl", "C₂₋₆alkenyl" and "C₂₋₆alkynyl", the optional substituent or substituents are preferably selected from halo, aryl, heterocyclyl, C₃₋₈cycloalkyl, C₁₋₆alkoxy, hydroxyl, oxo, aryloxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxyl and carboxyl. Each of these optional substituents may also be optionally substituted with any of the optional substituents referred to above, where nitro, amino, substituted amino, cyano, heterocyclyl (including non-aromatic heterocyclyl and heteroaryl), C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxyl, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, halo, hydroxyl and carboxyl are preferred.

It will be understood that suitable derivatives of aromatic heterocyclyls containing nitrogen include N-oxides thereof.

10 In the case of hybrid naming of substituent radicals describing two moieties that may both form a bond attaching the radical to the rest of the compound, such as alkylamino and alkylaryl, no direction in the order of groups is intended, so the point of attachment may be to any of the moieties included in the hybrid radical. For example, the terms "alkylaryl" and "arylalkyl", are intended to refer to the same group and the point of attachment may be *via* 15 the alkyl or the aryl moiety (or both in the case of diradical species). The direction of attachment of such a hybrid radical may be denoted by inclusion of a bond, for example, "-alkylaryl" or "arylalkyl-" denotes that the point of attachment of the radical to the rest of the compound is *via* the alkyl moiety, and "alkylaryl-" or "-arylalkyl" denotes that the point of attachment is *via* the aryl moiety.

20 It will be appreciated that $\equiv$ denotes a single or a double bond, depending on the required valency. Unless specifically stated otherwise, where all bonds in a ring are denoted by $\equiv$ the ring is intended to be aromatic.

As used herein, except where the context requires otherwise, the term "comprise" and variations of the term, such as "comprising", "comprises" and "comprised", are not intended 25 to exclude further additives, components, integers or steps.

It must be noted that as used herein and in the appended claims, the singular forms "a", "an" and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a salt" may include a plurality of salts and a reference to "at least one heteroatom" may include one or more heteroatoms, and so forth.

30 The term "and/or" can mean "and" or "or".


The term "(s)" following a noun contemplates the singular or plural form, or both.

Various features of the invention are described with reference to a certain value, or range of values. These values are intended to relate to the results of the various appropriate measurement techniques, and therefore should be interpreted as including a margin of error inherent in any particular measurement technique. Some of the values referred to herein are denoted by the term "about" to at least in part account for this variability. The term "about", when used to describe a value, may mean an amount within $\pm 10\%$, $\pm 5\%$, $\pm 1\%$ or $\pm 0.1\%$ of that value.

Further aspects of the present invention and further embodiments of the aspects described in the preceding paragraphs will become apparent from the following description, given by way of example and with reference to the accompanying drawings.

Detailed description of embodiments


The invention provides a compound of Formula (I)




(I)

wherein

J is selected from the following moieties J1 and J2:



J1



J2

A^1 , and A^4 are independently selected from N and C;

A^2 and A^3 are independently selected from N, NR^1 , CH, O and S;

wherein at least one of A¹, A², A³ and A⁴ is selected from N, NR¹, O and S;

A⁵ is CH or N;

A⁶ is N or CR²;

R¹ and R³ are independently selected from H and an optionally substituted C₁₋₆-alkyl;

5 R² is selected from:

- (i) H,
- (ii) optionally substituted C₁₋₄alkylamido,
- (iii) optionally substituted C₁₋₄alkylaryl,
- (iv) optionally substituted C₂₋₄alkynyl,
- 10 (v) optionally substituted aryl,
- (vi) optionally substituted 5- or 6-membered heterocyclyl,
- (vii) cyano;

X is selected from optionally substituted C₁₋₆alkyl, optionally substituted haloC₁₋₆alkyl, optionally substituted C₂₋₆alkynyl, optionally substituted cycloalkyl, optionally substituted
 15 halocycloalkyl, optionally substituted aryl, optionally substituted alkylaryl, optionally substituted C₁₋₆alkylcycloalkyl and optionally substituted amino;

Y and Z are independently selected from H, R⁴ and –OR⁴;

wherein at least one of Y and Z is H and the remaining one of Y and Z is selected from R⁴ and –OR⁴;

20 R⁴ is selected from optionally substituted C₁₋₆alkyl, optionally substituted aryl, optionally substituted C₁₋₆alkylaryl, optionally substituted heterocyclyl, optionally substituted C₁₋₆alkylheterocyclyl, optionally substituted cycloalkyl, optionally substituted C₁₋₆alkylC₃₋₁₀cycloalkyl, optionally substituted C₃₋₁₀cycloalkylaryl, optionally substituted C₃₋₁₀cycloalkylheterocyclyl, optionally substituted C₃₋₁₀cycloalkylC₃₋₁₀cycloalkyl, optionally substituted
 25 substituted 3-6 membered non-aromatic heterocyclyl-aryl, optionally substituted 3-6 membered non-aromatic heterocyclylC₃₋₁₀cycloalkyl and optionally substituted 3-6 membered non-aromatic heterocyclyl-3-10 membered heterocyclyl; and

R⁵ is selected from H, optionally substituted C₁₋₆alkyl, optionally substituted C₃₋₁₀cycloalkyl and optionally substituted aryl.

30 X

In some embodiments, X is selected from C₁₋₆alkyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl, aryl, -(CH₂)_naryl, -(CH₂)_ncycloalkyl, and -N(C₁₋₄alkyl)₂;

wherein

n is 1 or 2, and

- 5 each alkyl and alkynyl is optionally substituted with one or more groups selected from halo, nitrile, -OR⁶, -N(R⁷)R⁸;

R⁶, R⁷ and R⁸ are independently selected from H, C₁₋₆alkyl and haloC₁₋₆alkyl, and

- wherein each aryl and cycloalkyl is optionally substituted with one or more groups that are independently selected from halo, nitrile, C₁₋₄alkyl, C₁₋₄alkoxy, haloC₁₋₄alkyl and haloC₁₋₄alkoxy.

- In some embodiments, X is selected from optionally substituted C₁₋₄alkyl, optionally substituted C₂₋₄alkynyl, optionally substituted C₁₋₄alkylnitrile, optionally substituted haloC₁₋₄alkyl, optionally substituted C₃₋₆cycloalkyl, optionally substituted C₁alkylC₃₋₆cycloalkyl, optionally substituted aryl, optionally substituted haloaryl, optionally substituted C₁alkylaryl, optionally substituted haloC₁alkylaryl, optionally substituted haloC₁alkoxyaryl, optionally substituted benzyl, optionally substituted halobenzyl, optionally substituted C₁alkylbenzyl, optionally substituted C₁alkoxybenzyl and optionally substituted haloC₁alkoxybenzyl.

- In some embodiments, X is selected from an optionally substituted C₁₋₄alkyl, an optionally substituted haloC₁₋₄alkyl and a C₃₋₆cycloalkyl.

In some embodiments, X is selected from an optionally substituted C₁₋₂alkyl, an optionally substituted haloC₁₋₂alkyl and a C₃cycloalkyl.


In some embodiments, X is an optionally substituted haloC₁₋₄alkyl selected from -CHF₂, -CF₃, -CH₂CF₃, -CH₂CHF₂ and -CH₂CH₂CF₃.

- 25 In some embodiments, X is an optionally substituted haloC₁₋₂alkyl.

In some embodiments, X is an optionally substituted amino preferably disubstituted amino, such as -N(C₁₋₄alkyl)₂. In some embodiments, X is -N(CH₃)₂.

In some embodiments, X is selected from any one of the following groups:

methyl, ethyl, isopropyl, *tert*-butyl, $-\text{CHF}_2$, $-\text{CF}_3$, $-\text{CH}_2\text{CF}_3$, $-\text{CH}_2\text{CHF}_2$, $-\text{CH}_2\text{CH}_2\text{CF}_3$, $-\text{CH}_2\text{CH}_2\text{OCH}_3$, $-\text{CH}_2\text{CH}_2\text{NH}_2$, $-\text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_2$, cyclohexyl, cyclopropyl, $-\text{N}(\text{CH}_3)_2$



In some embodiments, X is selected from any one of the following groups: ethyl, difluoromethyl, trifluoroethyl and cyclopropyl.


In some embodiments, X is difluoromethyl.

In some embodiments, X is a group that has a longest linear chain extending from the sulfur atom depicted in formula (I) by not more than 6, 5, 4, 3 or 2 atoms, preferably 3-6 atoms. By “longest linear chain” it is meant the number of atoms from the point of attachment not including any branching or rings. For example, when X is benzyl, the longest linear chain is 6 atoms which includes the methylene carbon atom, four ring atoms and the hydrogen atom attached to the carbon at the 4-position of the benzyl, and when X is $-\text{CH}_2\text{CF}_3$, the longest linear chain is 3. The longest linear chain in each of these exemplary X-substituents is numbered in the partial formulas shown below:



Y and Z


In some embodiments, when Y is $-OR^4$, Z is H. In these embodiments, the compound of formula (I) may be provided as a compound of formula (Ia):



(Ia)

wherein J, A¹, A², A³, A⁴, A⁵, A⁶, n, R¹, R², R³, R⁴, R⁵ and X are as defined for formula (I) or any embodiment thereof.

- 5 In some embodiments, when Z is -OR⁴, Y is H. In these embodiments, the compound of formula (I) may be provided as a compound of formula (Ib):



(Ib)

- 10 wherein J, A¹, A², A³, A⁴, A⁵, A⁶, n, R¹, R², R³, R⁴, R⁵ and X are as defined for formula (I) or any embodiment thereof.

In some embodiments, when Y is -R⁴, Z is H.

In some embodiments, when Z is -R⁴, Y is H.

R⁴

- 15 In some embodiments, R⁴ is selected from C₁₋₆alkyl, aryl, cycloalkyl, heterocyclyl, C₁₋₆alkylcycloalkyl, C₁₋₆alkylaryl and C₁₋₆alkylheterocyclyl,

wherein each alkyl (including when present as an optional substituent) is optionally substituted with one or more groups independently selected from halo, C₁₋₄alkoxy, hydroxy, nitrile, amino, C₁₋₄alkylamino, (C₁₋₄alkyl)₂amino, aryl, cycloalkyl and heterocyclyl;

wherein each aryl (including when present as an optional substituent) is optionally substituted with one or more groups independently selected from halo, hydroxy, nitrile, amino, C₁₋₄alkylamino and (C₁₋₄alkyl)₂amino, C₁₋₄alkyl, C₁₋₄alkoxy, haloC₁₋₄alkyl, haloC₁₋₄alkoxy, aryl, cycloalkyl and heterocyclyl;

- 5 wherein each cycloalkyl (including when present as an optional substituent) is optionally substituted with one or more groups independently selected from halo, hydroxy, nitrile, amino, C₁₋₄alkylamino and (C₁₋₄alkyl)₂amino, C₁₋₄alkyl, C₁₋₄alkoxy, haloC₁₋₄alkyl, haloC₁₋₄alkoxy, aryl, cycloalkyl and heterocyclyl; and

- 10 wherein each heterocyclyl (including when present as an optional substituent) is optionally substituted with one or more groups independently selected from halo, hydroxy, nitrile, amino, C₁₋₄alkylamino and (C₁₋₄alkyl)₂amino, C₁₋₄alkyl, C₁₋₄alkoxy, haloC₁₋₄alkyl, haloC₁₋₄alkoxy, cycloalkyl, heterocyclyl and aryl.

- In some embodiments, R⁴ is selected from C₁₋₆alkyl, aryl, cycloalkyl, heterocyclyl, C₁₋₆alkylcycloalkyl, C₁₋₆alkylaryl, C₁₋₆alkylheterocyclyl, C₃₋₁₀cycloalkylaryl, C₃₋₁₀cycloalkylheterocyclyl, C₃₋₁₀cycloalkylC₃₋₁₀cycloalkyl, 3-6 membered non-aromatic heterocyclyl-aryl, 3-6 membered non-aromatic heterocyclyl-C₃₋₁₀cycloalkyl and 3-6 membered non-aromatic heterocyclyl-3-10 membered heterocyclyl and wherein each cycloalkyl, aryl and heterocyclyl are optionally substituted with one or more groups independently selected from halo, hydroxy, nitrile, amino, C₁₋₄alkylamino and (C₁₋₄alkyl)₂amino, C₁₋₄alkyl, C₁₋₄alkoxy, haloC₁₋₄alkyl and haloC₁₋₄alkoxy.
- 15
20

In some embodiments, R⁴ is selected from C₁₋₆alkyl, aryl, cycloalkyl, heterocyclyl and -(CH₂)_mR⁹,

R⁹ is selected from C₃₋₁₀cycloalkyl, aryl, heterocyclyl, and

m is an integer selected from 1 to 6;

- 25 wherein each cycloalkyl, aryl and heterocyclyl are optionally substituted with one or more groups independently selected from halo, C₁₋₄alkyl, C₁₋₄alkoxy, haloC₁₋₄alkyl and haloC₁₋₄alkoxy.


- In some embodiments, R⁴ is selected from C₁₋₄alkyl, cycloalkyl, haloaryl, -C₁₋₂alkylaryl, -C₁₋₂alkylarylhalo, -C₁₋₂alkylC₃₋₆cycloalkyl, -C₁₋₂alkylheterocyclyl, -C₁₋₂alkylarylC₁alkylhalo, -C₁₋₂alkylarylhaloC₁alkyl, -C₁₋₂alkylaralkylhalo, -C₁₋₂alkylarylhaloalkoxy, cycloalkylaryl, cycloalkylheterocyclyl, cycloalkylcycloalkyl, 3-6 membered non-aromatic heterocyclyl-aryl, 3-
- 30

6 membered non-aromatic heterocyclylcycloalkyl and 3-6 membered non-aromatic heterocyclyl-3-10 membered heterocyclyl

wherein each alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl and alkoxy is optionally substituted with a group selected from halo, hydroxy, nitrile, amino, C₁₋₄alkylamino and (C₁₋₄alkyl)₂amino,

5 C₁₋₄alkyl, C₁₋₄alkoxy, haloC₁₋₄alkyl, haloC₁₋₄alkoxy and acyl.

In some embodiments, R⁴ is an optionally substituted C₁alkylC₆aryl. In some embodiments, the C₁alkyl moiety is substituted. In some embodiments, the aryl moiety is substituted. In some embodiments, the C₁alkylC₆aryl moiety may be represented by the following partial formula:



10

wherein

R^a and R^b are independently selected from H, optionally substituted C₁₋₄alkyl, optionally substituted C₁₋₄alkoxy, optionally substituted C₁₋₄alkylhydroxy, optionally substituted C₁₋₄alkylnitrile, optionally substituted amino, optionally substituted C₁₋₄alkylamino and optionally substituted (C₁₋₄alkyl)₂amino, or

15

R^a and R^b together with the carbon atom to which they are attached form an optionally substituted C₃₋₆cycloalkyl or a 3-6 membered non-aromatic heterocyclyl;

R^c is selected from halo and an optionally substituted C₁₋₄alkyl; and

m is 0, 1 or 2.

20 In some embodiments, R^a and R^b are independently selected from H, optionally substituted C₁₋₄alkyl, optionally substituted C₁₋₄alkoxy, optionally substituted C₁₋₄alkylhydroxy, optionally substituted C₁₋₄alkylnitrile, optionally substituted C₁₋₄alkylamino and optionally substituted (C₁₋₄alkyl)₂amino. When R^a and/or R^b are an optionally substituted C₁₋₄alkylamino, either the C₁₋₄alkyl or amino moiety may be optionally substituted.

25 In some embodiments, R^a and R^b together with the carbon atom to which they are attached form an optionally substituted C₃₋₆cycloalkyl or a 3-6 membered non-aromatic heterocyclyl

selected from an optionally substituted cyclopropyl, an optionally substituted cyclobutyl, an optionally substituted cyclopentyl, an optionally substituted cyclohexyl, an optionally substituted oxetane and an optionally substituted azetidine.

5 In some embodiments, R^a and R^b together with the carbon atom to which they are attached form a 3-6 membered non-aromatic heterocyclyl comprising 1 or 2, preferably 1 heteroatom, preferably selected from O and N.

10 In some embodiments, R^5 is selected from H, C_{1-6} alkyl, C_{3-8} cycloalkyl and aryl. In some embodiments, R^5 is selected from H and optionally substituted C_{1-6} alkyl. In some embodiments, R^5 is selected from H and optionally substituted aryl. In some embodiments, R^5 is selected from H, optionally substituted methyl and optionally substituted phenyl. In some embodiments, R^5 is H.

In some embodiments, m is 0 or 1.

In some embodiments, m is 1 or 2.

15 In some embodiments, at least one R^c is in the para position relative to the benzyl carbon atom.

In some embodiments, R^c is selected from methyl, fluoro and chloro.

In some embodiments, R^a is selected from H and methyl, and R^b is H.

In some embodiments, R^a and R^b together with the carbon atom to which they are attached are cyclopropyl.

20 In some embodiments, R^4 has partial structure (A):



(A)


wherein

25 R^d is selected from H, optionally substituted C_{1-4} alkyl, optionally substituted C_{1-4} alkoxy, optionally substituted C_{1-4} alkoxy C_{1-4} alkyl, optionally substituted C_{1-4} alkylhydroxy, optionally substituted C_{1-4} alkylnitrile, optionally substituted C_{1-4} alkylamino and optionally substituted

(C₁₋₄alkyl)₂amino, optionally substituted cycloalkyl and optionally substituted C₁₋₄alkylcycloalkyl; and

R^e is selected from optionally substituted aryl, optionally substituted C₁₋₅alkylaryl, optionally substituted heterocyclyl, optionally substituted C₁₋₅alkylheterocyclyl, optionally substituted cycloalkyl, and optionally substituted C₁₋₅alkylC₃₋₁₀cycloalkyl.

In these embodiments, the compound of formula (I) may be provided as a compound of formula (IV):



wherein X, R³, R^d, R^e, and J are as defined for any compound herein.

In some embodiments, R^d is methyl.

In some embodiments, R^e is selected from optionally substituted aryl, optionally substituted C₁₋₅alkylaryl, optionally substituted heterocyclyl, optionally substituted C₁₋₄alkylheterocyclyl, optionally substituted cycloalkyl, and optionally substituted C₁₋₄alkylC₃₋₁₀cycloalkyl.

In some embodiments, R^e is selected from optionally substituted aryl, optionally substituted cycloalkyl and optionally substituted heterocyclyl.

In some embodiments, R^e is selected from optionally substituted aryl and optionally substituted heteroaryl.

In some embodiments, R^d is selected from optionally substituted C₁₋₄alkyl, optionally substituted cycloalkyl and optionally substituted C₁₋₄alkylcycloalkyl. In these embodiments, where R^d and R^e are not the same group, the partial structure (A) may contain a chiral centre at the carbon to which R^d and R^e are attached. Therefore, the carbon atom to which R^d and R^e are attached may be enantiomerically enriched. In some embodiments, the carbon atom to which R^d and R^e is attached is enriched as the (S) stereoisomer, for example when R^e has a higher ranking than R^d in the Cahn-Ingold-Prelog rules for stereochemical assignment. In some embodiments, the carbon atom to which R^d and R^e is attached is enriched as the (R)

stereoisomer, for example when R^e has a lower ranking than R^d the Cahn-Ingold-Prelog rules for stereochemical assignment. In some embodiments, R^d is selected from optionally substituted C₁₋₄alkyl, and the carbon atom to which R^d and R^e are attached is enriched in the (S) stereoisomer.


- 5 In some embodiments, partial structure (A) may have the stereochemical configuration shown in by partial structure (A1):



(A1)

- wherein R^e has a higher ranking than R^d in the Cahn-Ingold-Prelog rules for stereochemical assignment. The inventors have surprisingly found that compounds with this configuration at this position possess greater MLKL activity than those with other configuration(s). In some cases, when R^e has a higher ranking than R^d in the Cahn-Ingold-Prelog rules for stereochemical assignment MLKL activity may be greater than 2-fold more active than the other corresponding stereoisomer, and in some embodiments, may be at least about 5-fold or about 10-fold more active than other corresponding stereoisomer(s) for MLKL inhibition.


In some embodiments, the compound is provided as a compound of formula (S):




(S)


- wherein X, J and R³ are as defined for formula (I) and R^e and R^d are as defined for partial formula (A).


In some embodiments, R⁴ is selected from any one of the following groups:






In some embodiments, R^4 is selected from any one of the following groups:







In some embodiments, R^4 is selected from any one of the following groups:



In some embodiments, R^4 is selected from any one of the following groups:



In some embodiments, R^4 is:




R¹ and R³

In some embodiments, R¹ and R³ are H. In some embodiments, R³ is H and R¹ is selected from H, methyl and isopropyl, preferably methyl.

In some embodiments, R¹ is selected from H, methyl and isopropyl. In some embodiments,
5 R¹ is methyl.


J1

In some embodiments, J is J1. In these embodiments, the compound of formula (I) may be provided as a compound of formula (II)




10 wherein X, R², R³, R⁴, A¹, A², A³ and A⁴ are as defined for formula (I) or any embodiment thereof.

In embodiments where J is J1, the compound of formula (I) may also be provided as a compound of formula (IIe)




15 wherein X, R², R³, R⁴, A¹, A², A³ and A⁴ are as defined for formula (I) or any embodiment thereof.


The J1 structure, as shown below (and equivalent structures within other formulas), indicates a conjugated fused aromatic ring system:



For instance, in some embodiments J1 may have the following substitution pattern:



Similarly, in other embodiments J1 may have the following substitution pattern:



5

In compounds wherein J is J1, at least one of A¹, A², A³ and A⁴ is selected from N, NR¹, O and S. In some embodiments, A³ is selected from N, NR¹, O and S.

In some embodiments, A¹ is C or N.

In some embodiments, A¹ is C.

10 In some embodiments, A² is selected from N and CH.

In some embodiments, A⁴ is selected from C and N.

In some embodiments, A¹, A², A³ and A⁴ are selected from the following embodiments:

No.	A ¹	A ²	A ³	A ⁴
1	C	CH	O	C
2	C	N	NMe	C
3	C	CH	N	N
4	C	N	N ⁱ Pr	C
5	C	N	CH	N

6	C	N	S	C
7	C	CH	S	C
8	N	CH	N	C

In some embodiments, any one of embodiment nos. 1-4 are preferred.

In some embodiments, embodiment no. 2 is preferred.

R²

5 In some embodiments, R² is selected from:

- (i) H
- (ii) optionally substituted C₁₋₄alkylamido,
- (iii) optionally substituted C₁₋₄alkylaryl,
- (iv) optionally substituted C₂₋₄alkynyl,
- 10 (v) optionally substituted aryl,
- (vi) optionally substituted 5- or 6-membered heterocyclyl.

In some embodiments, R² is selected from:

- (i) optionally substituted C₁₋₄alkylamido,
- (ii) optionally substituted C₁₋₄alkylaryl,
- 15 (iii) optionally substituted C₂₋₄alkynyl,
- (iv) optionally substituted aryl,
- (v) optionally substituted 5- or 6-membered heterocyclyl.

In some embodiments, R² is optionally substituted with one or more group(s) (preferably 1-3 groups) selected from: halo, an optionally substituted C₁₋₆alkyl, an optionally substituted C₃₋₈cycloalkyl, an optionally substituted C₁₋₆alkyl-N(R¹¹)₂, -N(R¹¹)₂, an optionally substituted (C₁₋₆alkyl)₂amino, an optionally substituted aryl, an optionally substituted heterocyclyl, an optionally substituted haloheterocyclyl, an optionally substituted C₁₋₆alkylheterocyclyl, an optionally substituted haloC₁₋₆alkylheterocyclyl, an optionally substituted C₁₋₄alkoxyheterocyclyl, an optionally substituted acylheterocyclyl, an optionally substituted C₁₋₄alkoxy, an optionally substituted C₁₋₄alkyl-OH, an optionally substituted C₁₋₄alkylhalo, an optionally substituted C₁₋₄alkylheterocyclyl, an optionally substituted C₁₋₄alkylC₃₋₈cycloalkyl, an optionally substituted C₁₋₄alkylaryl, wherein each R¹¹ is independently selected from H, optionally substituted C₁₋₄alkyl and optionally substituted C₁₋₄alkylhalo, or 2 R¹¹ together with the nitrogen atom to which they are attached form a 3-8 membered heterocyclyl.

In some embodiments, R^2 is a 5- or 6-membered heterocyclyl optionally substituted with one or more group(s) selected from: halo, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{3-8} cycloalkyl, an optionally substituted C_{1-6} alkyl- $N(R^{11})_2$, $-N(R^{11})_2$, an optionally substituted $(C_{1-6}alkyl)_2$ amino, an optionally substituted aryl, an optionally substituted heterocyclyl, an optionally substituted haloheterocyclyl, an optionally substituted C_{1-6} alkylheterocyclyl, an optionally substituted halo C_{1-6} alkylheterocyclyl, an optionally substituted C_{1-4} alkoxyheterocyclyl, an optionally substituted acylheterocyclyl, an optionally substituted C_{1-4} alkoxy, an optionally substituted C_{1-4} alkyl-OH, an optionally substituted C_{1-4} alkylhalo, an optionally substituted C_{1-4} alkylheterocyclyl, an optionally substituted C_{1-4} alkyl C_{3-8} cycloalkyl, an optionally substituted C_{1-4} alkylaryl, wherein each R^{11} is independently selected from H, optionally substituted C_{1-4} alkyl and optionally substituted C_{1-4} alkylhalo, or 2 R^{11} together with the nitrogen atom to which they are attached form a 3-8 membered heterocyclyl.

In some embodiments, R^2 is a 5- or 6-membered heterocyclyl optionally substituted with one or more group(s) selected from: halo, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{3-8} cycloalkyl, an optionally substituted aryl, an optionally substituted heterocyclyl, an optionally substituted C_{1-4} alkoxy, an optionally substituted C_{1-4} alkyl-OH, an optionally substituted C_{1-4} alkylhalo, an optionally substituted C_{1-4} alkylheterocyclyl, an optionally substituted C_{1-4} alkyl C_{3-8} cycloalkyl, an optionally substituted C_{1-4} alkylaryl;

In some embodiments, R^2 is H.

In some embodiments, R^2 is cyano.

In some embodiments, R^2 is H or cyano.

In some embodiments, R^2 is optionally substituted C_{1-4} alkylamido or optionally substituted C_{2-4} alkynyl.

In some embodiments, R^2 is selected from optionally substituted C_{1-4} alkylaryl, optionally substituted aryl, and optionally substituted 5- or 6-membered heterocyclyl.

In some embodiments, R^2 is selected from:

- (i) optionally substituted aryl,
- (ii) a 5- or 6-membered heterocyclyl optionally substituted with one or more group(s) selected from: halo, an optionally substituted C_{1-6} alkyl, an optionally substituted C_{3-8} cycloalkyl, an optionally substituted aryl, an optionally substituted heterocyclyl, an optionally substituted C_{1-4} alkoxy, an optionally substituted C_{1-4} alkyl-OH, an optionally

substituted C₁₋₄alkylhalo, an optionally substituted C₁₋₄alkylheterocyclyl, an optionally substituted C₁₋₄alkylC₃₋₈cycloalkyl, an optionally substituted C₁₋₄alkylaryl.

In some embodiments, R² is a 5- or 6-membered heterocyclyl selected from: pyrazolyl, pyridyl, tetrahydropyridyl, isozazolyl, pyrimidinyl, piperidinyl and tetrahydropyranyl,

5 and wherein the 5- or 6-membered heterocyclyl is optionally substituted with one or more group(s) selected from: halo, an optionally substituted C₁₋₆alkyl, an optionally substituted C₃₋₈cycloalkyl, an optionally substituted C₁₋₆alkyl-N(R¹¹)₂, -N(R¹¹)₂, an optionally substituted (C₁₋₆alkyl)₂amino, an optionally substituted aryl, an optionally substituted heterocyclyl, an optionally substituted haloheterocyclyl, an optionally substituted C₁₋₆alkylheterocyclyl, an optionally substituted haloC₁₋₆alkylheterocyclyl, an optionally substituted C₁₋₄alkoxyheterocyclyl, an optionally substituted acylheterocyclyl, an optionally substituted C₁₋₄alkoxy, an optionally substituted C₁₋₄alkyl-OH, an optionally substituted C₁₋₄alkylhalo, an optionally substituted C₁₋₄alkylheterocyclyl, an optionally substituted C₁₋₄alkylC₃₋₈cycloalkyl, an optionally substituted C₁₋₄alkylaryl, wherein each R¹¹ is independently selected from H, optionally substituted C₁₋₄alkyl and optionally substituted C₁₋₄alkylhalo, or 2 R¹¹ together with the nitrogen atom to which they are attached form a 3-8 membered heterocyclyl.

In some embodiments, R² is a 5- or 6-membered heterocyclyl optionally substituted with one or more substituent(s) selected from: halo, optionally substituted C₁₋₆alkyl, optionally substituted C₁₋₆alkylamido, optionally substituted C₃₋₈cycloalkyl, optionally substituted C₁₋₆alkylC₃₋₈cycloalkyl, optionally substituted haloC₁₋₆alkylC₃₋₈cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted C₁₋₆alkylheterocyclyl, optionally substituted C₁₋₆alkoxy, optionally substituted C₁₋₆alkyl-OH and optionally substituted C₁₋₆alkylhalo. In some embodiments, the optionally substituted C₁₋₆alkylamido is provided by -C₁₋₆alkylC(O)NR'R'', wherein R' and R'' are independently selected from H and optionally substituted C₁₋₆alkyl. In some embodiments, any heterocyclyl group of these optional substituents may be a 4-7 membered heterocyclyl (including nonaromatic heterocyclyl and heteroaryl groups).

In some embodiments, R² is a 5- or 6-membered heterocyclyl optionally substituted with one, two or three of any of the optional substituent(s) of R² described herein.

30 In some embodiments, R² is a 5- or 6-membered heterocyclyl optionally substituted with one, two or three groups, preferably one or two groups, selected from: methyl, methoxy, methoxyethyl, trifluoromethyl, difluoromethyl, trifluoroethyl, isopropyl, tert-butyl,

2-hydroxyethyl, dimethylamino, cyclopentyl, oxetanyl, tetrahydrofuranyl, piperidinyl, N-methyl-piperidinyl, tetrahydropyranyl and N-methyl-piperazinyl-2-ethyl.

In some embodiments, R^2 is an optionally substituted 5- or 6-membered heterocyclyl selected from 4-pyridyl, 3-pyridyl, 4-piperidinyl, 1,4-piperazinyl, 4-tetrahydropyranyl, 2*H*,4*H*,5*H*-3-
5 piperidinyl, 3,4-pyrazolyl, 3*H*,5*H*,6*H*-4-tetrahydropyranyl, 2,4-pyrimidinyl and 3,4-isoxazolyl.

In some embodiments, R^2 is an optionally substituted pyrazolyl, preferably a substituted pyrazolyl, more preferably a mono-substituted pyrazolyl. Preferably, the mono-substituted pyrazolyl is substituted at N.

In some embodiments, R^2 is a 5- or 6-membered heterocyclyl optionally substituted with one
10 or more group(s) selected from: optionally substituted C_{1-4} alkylhalo, optionally substituted heterocyclyl, optionally substituted C_{1-6} alkylheterocyclyl and optionally substituted halo C_{1-6} alkylheterocyclyl. In these embodiments, the 5- or 6-membered heterocyclyl is preferably selected from pyrazolyl, pyridyl, tetrahydropyridyl, isoxazolyl, pyrimidinyl, piperidinyl and tetrahydropyranyl, more preferably pyrazolyl, most preferably N-substituted-pyrazolyl.

15 In some embodiments, R^2 is a 5- or 6-membered heterocyclyl optionally substituted with one or more group(s) selected from: optionally substituted C_{1-4} alkylhalo, optionally substituted heterocyclyl, optionally substituted C_{1-6} alkylheterocyclyl and optionally substituted halo C_{1-6} alkylheterocyclyl;

wherein the optionally substituted C_{1-4} alkylhalo, optionally substituted
20 heterocyclyl, optionally substituted C_{1-6} alkylheterocyclyl and optionally substituted halo C_{1-6} alkylheterocyclyl; are optionally substituted with one or more substituent(s) selected from C_{1-4} alkyl and C_{3-4} cycloalkyl. In these embodiments, the 5- or 6-membered heterocyclyl is preferably selected from pyrazolyl, pyridyl, tetrahydropyridyl, isoxazolyl, pyrimidinyl, piperidinyl and tetrahydropyranyl, more preferably pyrazolyl, most preferably N-substituted-pyrazolyl.

25 In some embodiments, R^2 is an optionally substituted 6-membered non-aromatic heterocyclyl.

In some embodiments, R^2 is a 5- or 6-membered heterocyclyl comprising at least 1 nitrogen heteroatom. In some embodiments, R^2 is a 5- or 6-membered heterocyclyl comprising at least 1 oxygen heteroatom. In some embodiments, R^2 is a 5- or 6-membered heterocyclyl comprising at least 1 nitrogen and at least 1 oxygen heteroatom. In some embodiments, R^2
30 is a 5- or 6-membered heterocyclyl comprising 2 nitrogen heteroatoms.

In some embodiments, R^2 is an optionally substituted fused heterocyclyl.

In some embodiments, R² is an optionally substituted 5- or 6-membered heteroaryl.

In some embodiments, R² is an optionally substituted pyridyl.

In some embodiments, R² is an optionally substituted isoxazolyl.

In some embodiments, R² is an optionally substituted morpholinyl.

5 In some embodiments, R² is an optionally substituted pyrimidinyl.

In some embodiments, R² is an optionally substituted pyrrolyl.

In some embodiments, R² is an optionally substituted 1,3-dihydro-2*H*-benzo[*d*]imidazol-2-one, preferably including methyl substitution.

In some embodiments, R² is an optionally substituted 1-methylindolinyl-2-one.


10 In some embodiments, R² is an optionally substituted 1-methyl-1H-indazolyl.


In some embodiments, R² is enriched with one or more of the following minor isotopes: ²H, ³H, ¹³C, ¹⁴C, ¹⁵N and/or ¹⁷O, preferably ²H.


In some embodiments, R² is an optionally substituted C₂₋₄alkynyl. The C₂₋₄alkynyl may optionally be substituted with one or more groups (preferably 1 group) selected from optionally substituted C₃₋₈cycloalkyl, optionally substituted haloC₃₋₈cycloalkyl, optionally substituted (C₁₋₆alkyl)₁₋₃C₃₋₈cycloalkyl, optionally substituted heterocyclyl, optionally substituted halo heterocyclyl, optionally substituted (C₁₋₆alkyl)₁₋₃heterocyclyl and optionally substituted (C₁₋₆alkylhalo)₁₋₃heterocyclyl.

In some embodiments, R² is an optionally substituted C₂₋₄alkynyl. The C₂₋₄alkynyl may optionally be substituted with one or more groups (preferably 1 group) selected from optionally substituted C₃₋₈cycloalkyl, optionally substituted haloC₃₋₈cycloalkyl, optionally substituted (C₁₋₆alkyl)₁₋₃C₃₋₈cycloalkyl, optionally substituted heterocyclyl, optionally substituted halo heterocyclyl and optionally substituted (C₁₋₆alkyl)₁₋₃heterocyclyl.


In some embodiments, R² is selected from: H, cyano, methyl, 3-pyridyl, 4-pyridyl, benzyl,








5 In some embodiments, R^2 is selected from: H, methyl, 3-pyridyl, 4-pyridyl, benzyl,






In some embodiments, R² comprises a basic moiety (such as an optionally substituted amine including an optionally substituted cyclic amine).

In some embodiments, R² comprises a nitrogen-containing heterocyclyl and the nitrogen atom of these cyclic amines may be optionally substituted with a group selected from C₁₋₆alkyl and a substituted ketone (such as acyl).

In some embodiments, R^2 is represented by the following partial formula:



wherein



G is selected from:

- (i) C₁₋₄alkylamido,
- (ii) C₁₋₄alkylaryl,
- 5 (iii) C₂₋₄alkynyl,
- (iv) aryl,
- (v) 5- or 6-membered heterocyclyl

each R¹⁰ is independently selected from: halo, an optionally substituted C₁₋₆alkyl, an optionally substituted C₃₋₈cycloalkyl, an optionally substituted aryl, an optionally substituted heterocyclyl,
 10 an optionally substituted C₁₋₄alkoxy, an optionally substituted C₁₋₄alkyl-OH, an optionally substituted C₁₋₄alkylhalo, an optionally substituted C₁₋₄alkylheterocyclyl, an optionally substituted C₁₋₄alkylC₃₋₈cycloalkyl, an optionally substituted C₁₋₄alkylaryl; and

w is an integer from 0-3.

Accordingly, in some embodiments, the compound is provided as a compound of formula
 15 (IIA) or (IIB):



wherein A¹, A², A³, A⁴, R³, R⁴, R^d, R^e, G, w and R¹⁰ are as defined herein.

In some embodiments, G is a C₂₋₄alkynyl. In some embodiments, G is ethynyl and w is 1.

In some embodiments, G is a 6-membered heterocyclyl. In these embodiments, G may be a 6-membered non-aromatic heterocyclyl or a 6-membered heteroaryl. In these embodiments, each R¹⁰ may be independently selected from halo, an optionally substituted C₁₋₆alkyl, an optionally substituted C₁₋₄alkoxy, an optionally substituted C₁₋₄alkylhalo and an optionally substituted (C₁₋₆alkyl)₂amine. Typically, in these embodiments, w is 1.

In some embodiments, G is a 6-membered non-aromatic heterocyclyl comprising a heteroatom selected from N and O. When the heteroatom is N, R¹⁰ is preferably bonded to an N ring atom.

In some embodiments, G is a 5-membered heterocyclyl. In these embodiments, G may be a 5-membered non-aromatic heterocyclyl or a 5-membered heteroaryl. In some embodiments, the 5-membered heterocyclyl may comprise heteroatom(s) selected from N and O.


In some embodiments, G is a 5- or 6-membered heterocyclyl comprising at least 1 oxygen heteroatom. In some embodiments, G is a 5- or 6-membered heterocyclyl comprising at least 1 nitrogen and at least 1 oxygen heteroatom. In some embodiments, G is a 5- or 6-membered heterocyclyl comprising 2 nitrogen heteroatoms.

In some embodiments, G is an optionally substituted fused heterocyclyl



In some embodiments, G is selected from morpholinyl, pyrimidinyl, pyrrolyl, 1,3-dihydro-2H-benzo[d]imidazol-2-one, 1-methylindolyl-2-one, 1-methyl-1H-indazolyl, pyrazolyl and isoxazolyl.

In some embodiments, G is selected from pyrazolyl and isoxazolyl.

In some embodiments, G is pyrazolyl. In these embodiments, R¹⁰ may be bonded to a nitrogen ring atom. In these embodiments, R² may be represented by the following partial formula:



In these embodiments, the compound may be provided as a compound of formula (IIC) or (IID):



wherein A¹, A², A³, A⁴, R³, R⁴, R^d, R^e and R¹⁰ are as defined herein.

In some embodiments, R¹⁰ is selected from C₁₋₆alkyl, heterocyclyl, C₁₋₆alkyl-OH, C₁₋₆alkyl-NH₂, C₁₋₆alkoxyC₁₋₆alkyl, C₃₋₈cycloalkyl, wherein the heterocyclyl and C₃₋₈cycloalkyl may be further substituted with one or more groups (preferably 1-3 groups, most preferably 1 group) selected from C₁₋₆alkyl, haloC₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkyl-OH, C₁₋₆alkoxyC₁₋₆alkyl, halo, C₁₋₆alkyl-NH₂, C₁₋₆alkylketone (eg acyl) and -NH₂.

In some embodiments, R¹⁰ is heterocyclyl or alkylheterocyclyl optionally substituted with one or more groups (preferably 1-3 groups, most preferably 1 group) selected from C₁₋₆alkyl, haloC₁₋₆alkyl, C₁₋₆alkoxy, C₁₋₆alkyl-OH, C₁₋₆alkoxyC₁₋₆alkyl, halo, C₁₋₆alkyl-NH₂, C₁₋₆alkylketone (eg acyl) and -NH₂.


When R¹⁰ is a group comprising a heterocyclyl moiety, the heterocyclyl may preferably be a 4-8 membered heterocyclyl, preferably comprising one heteroatom selected from N and O, preferably N.

In some embodiments, R¹⁰ is an optionally substituted heterocyclyl selected from an optionally substituted spirocyclic heterocyclyl, optionally substituted fused heterocyclyl or an optionally substituted bridged heterocyclyl. In some embodiments, R¹⁰ is an optionally substituted heterocyclyl selected from an optionally substituted spirocyclic heterocyclyl or an


optionally substituted bridged heterocyclyl. Preferred optional substituents of the spirocyclic, fused and bridged heterocyclyl groups include C₁₋₆alkyl and haloC₁₋₆alkyl.

In some embodiments, R¹⁰ is enriched with one or more of the following minor isotopes: ²H, ³H, ¹³C, ¹⁴C, ¹⁵N and/or ¹⁷O, preferably ²H

- 5 In some embodiments, R¹⁰ is selected from: methyl, difluoromethyl, trifluoromethyl, methoxy, tert-butyl, phenyl, acyl, dimethylamino, tetrahydropyranyl, tetrahydrofuranyl, oxetanyl, hydroxyethyl, methoxyethyl, isopropyl, cyclopentyl, difluorocyclopentyl, piperidiny, N-methylpiperidiny, N-acetylpiperidine, azetidiny,



- 15 In some embodiments, R¹⁰ is selected from: methyl, difluoromethyl, trifluoromethyl, methoxy, tert-butyl, phenyl, acyl, dimethylamino, tetrahydropyranyl, tetrahydrofuranyl, oxetanyl, hydroxyethyl, methoxyethyl, isopropyl, cyclopentyl, difluorocyclopentyl, piperidiny, N-methylpiperidiny, N-acetylpiperidine, azetidiny,





In some embodiments, R¹⁰ is selected from C₃₋₈cycloalkyl, aryl and 4-8 membered heterocyclyl, each of which may be optionally substituted with 1-3 groups selected from C₁₋₄alkyl, C₁₋₄alkyl-OH, C₁₋₄alkyl-NR'R'', wherein R' and R'' are independently selected from H and C₁₋₄alkyl, haloC₁₋₄alkyl, halo, C₁₋₄alkoxy, and C₁₋₄alkoxyC₁₋₄alkyl.

In some embodiments, w is 0 or 1.

In some embodiments, w is selected from 0, 1 and 3.

In these embodiments, the compound may be provided as a compound of formula (IIF) or (IIG):





wherein A¹, A², A³, A⁴, R³, R^d and R^e are as defined herein;

R¹² is one or more groups independently selected from H, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₈cycloalkyl, hydroxyl, oxo, C₁₋₆alkoxy, aryloxy, C₁₋₆alkoxyaryl, halo, C₁₋₆alkylhalo, C₁₋₆alkoxyhalo and amino; and

R¹³ is selected from H, C₁₋₆alkyl and haloC₁₋₆alkyl.


In some embodiments, R¹² is one or more groups independently selected from H, C₁₋₆alkyl and C₃₋₈cycloalkyl. In some embodiments, R¹² is one or more groups independently selected from H, C₁₋₃alkyl and C₃₋₄cycloalkyl; preferably C₁alkyl and C₃cycloalkyl.

10 In some embodiments, R¹² substitutes the carbon alpha to the piperidyl nitrogen.

In some embodiments, R¹³ is selected from H, C₁₋₃alkyl and haloC₁₋₃alkyl; preferably C₁₋₃alkyl; more preferably C₁alkyl.

J2

15 In some embodiments, J is J2. In these embodiments, the compound of formula (I) may be provided as a compound of formula (III)



(III)

wherein X, R³, R⁴, R⁵, A⁵ and A⁶ are as defined for formula (I) and any embodiment thereof described herein.

In some embodiments, A⁵ is CH.

5 In some embodiments, A⁵ is N.

In some embodiments, A⁶ is N.

In some embodiments, A⁶ is CR².

In some embodiments, A⁵ is N and A⁶ is N.

In some embodiments, A⁵ is CH and A⁶ is N.

10 In some embodiments, A⁵ is N and A⁶ is CR².

In some embodiments, at least one of A⁵ and A⁶ is N.

In some embodiments, R⁵ is H.

In some embodiments, the compound is selected from compounds 1-173 described herein.

In some embodiments, the compound is selected from compounds 1-125 described herein.



15 In some embodiments, the compound is selected from compounds 113, 116, 145, 154, 155, 170 and 171 described herein.

Typically, the compounds of the invention may be prepared by techniques known in the art.

In another aspect, there is also provided a process for preparing a compound of formula (I) or a salt, solvate, tautomer, N-oxide, stereoisomer and/or prodrug thereof. In some

20 embodiments, the process comprises any of the following 4 steps:


- reacting a compound of formula (V) with a compound of formula (VI)



wherein X, J and R⁴ are as defined for formula (I) and

LG is a leaving group, such as halo. The leaving group may be any that is capable of activating the sulphonyl moiety of the compound of formula (VI) as an electrophile capable of reacting under appropriate conditions with the free aniline nitrogen of the compound of formula (V).


- reacting a compound of formula (VII) with a compound of formula (VIII)



wherein X, R³, R⁴ and J are as defined for formula (I) or any embodiment thereof;

E¹ and E² are an electrophilic pair suitable to direct a palladium catalysed cross-coupling reaction. In some embodiments, E¹ and E² are selected from halo, a boronic acid, a boronic ester and triflate, or a group capable of conversion to any of these moieties, such as hydroxyl, a mixed anhydride, tetrafluorophenyl ether, etc. In some embodiments, E¹ is halo, and E² is selected from a boronic acid, a boronic ester and triflate. In some embodiments, E² is halo, and E¹ is selected from a boronic acid, a boronic ester and triflate;

- reacting a compound of formula (IX) with a compound of formula (X)



wherein X, R², R³, R⁴, A¹, A², A³ and A⁴ are as defined for formula (I) or any embodiment thereof;

E³ and E⁴ are an electrophilic pair suitable to direct a palladium catalysed cross-coupling reaction. In some embodiments, E³ and E⁴ are selected from halo, a boronic acid, a boronic ester and triflate, or a group capable of conversion to any of these moieties, such as hydroxyl, a mixed anhydride, tetrafluorophenyl ether, etc. In some embodiments, E³ is halo, and E⁴ is selected from a boronic acid, a boronic ester and triflate. In some embodiments, E⁴ is halo, and E³ is selected from a boronic acid, a boronic ester and triflate;

- converting a compound of formula (I) into one of its salts.

In some embodiments of the above process, reactive moieties in the compounds of formulas (V)-(X) are functionalised with an appropriate protecting group.

Embodiments of these steps are shown in the General Schemes below.

The specific reagents and conditions for effecting each of these steps will depend on the specific substituents selected for each reaction partner. The skilled person would readily appreciate how to determine and/or optimise these reagents and conditions. Similarly, where a starting material is not commercially available, the skilled person would be able to design and implement its preparation based on techniques and reactions previously described.

Embodiments of these steps are provided in the Examples with reference to specific compounds described herein.

Methods

In another aspect, there is provided a method for inhibiting necroptosis in a subject in need thereof, the method comprising administering a therapeutically effective amount of a compound according to Formula (I) or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer and/or prodrug thereof.

Without wishing to be bound by theory, it is believed that the compounds of the invention treat necroptosis by binding to the ATP-binding site of the pseudokinase domain of Mixed Lineage Kinase Domain-like (MLKL) protein.

As used herein, the term "effective amount" means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or clinician. Furthermore, the term "therapeutically effective amount" means any amount which, as compared to a

corresponding subject who has not received such amount, results in improved treatment, healing, prevention, or amelioration of a disease, disorder, or side effect, or a decrease in the rate of advancement of a disease or disorder. The term also includes within its scope amounts effective to enhance normal physiological function.

- 5 In one embodiment of the present disclosure, administration of a compound according to Formula (I) inhibits a conformational change of MLKL. In another embodiment, the conformational change of MLKL involves release of the four-helix bundle (4HB) domain of MLKL. In another embodiment, administration of the compound inhibits oligomerisation of MLKL. In yet another embodiment, administration of the compound inhibits translocation of
- 10 MLKL to the cell membrane. In a further embodiment, administration of the compound inhibits a conformational change of MLKL, inhibits oligomerisation of MLKL and inhibits translocation of MLKL to the cell membrane.

It is envisaged that some compounds of the present disclosure can bind to MLKL in various species and inhibit necroptosis.

- 15 As used herein, the term “pseudokinase domain” as understood by a person skilled in the art, means a protein containing a catalytically-inactive or catalytically-defective kinase domain. “Pseudokinase domains” are often referred to as “protein kinase-like domains” as these domains lack conserved residues known to catalyse phosphoryl transfer. It would be understood by a person skilled in the art that although pseudokinase domains are predicted
- 20 to function principally as catalysis independent protein-interaction modules, several pseudokinase domains have been attributed unexpected catalytic functions. Accordingly, in the present disclosure the term “pseudokinase domain” includes “pseudokinase domains” which lack kinase activity and “pseudokinase domains” which possess weak kinase activity.

- As used herein, the term “ATP-binding site” as understood by a person skilled in the art,
- 25 means a specific sequence of protein subunits that promotes the attachment of ATP to a target protein. An ATP binding site is a protein micro-environment where ATP is captured and hydrolyzed to ADP, thereby releasing energy that is utilized by the protein to work by changing the protein shape and/or making the enzyme catalytically active. In pseudokinase domains, the “ATP-binding site” is often referred to as the “pseudoactive site”. The term
- 30 “ATP-binding site” may also be referred to as a “nucleotide-binding site” as binding at this site includes the binding of nucleotides other than ATP. It would be understood by a person skilled in the art that the term “nucleotide” includes any nucleotide. Exemplary nucleotides include, but are not limited to, AMP, ADP, ATP, AMPPNP, GTP, CTP and UTP.

As described herein, inhibition of necroptosis includes both complete and partial inhibition of necroptosis. In one embodiment, inhibition of necroptosis is complete inhibition. In another embodiment, inhibition of necroptosis is partial inhibition.

5 Binding of the compound to the ATP-binding site of the pseudokinase domain of MLKL may inhibit phosphorylation of MLKL by an effector kinase or binding of the compound to the ATP-binding site of the pseudokinase domain of MLKL may not inhibit phosphorylation of MLKL by an effector kinase. The present disclosure demonstrates that compounds that bind to the ATP-binding site of the pseudokinase domain of the MLKL protein, as described
10 herein, can inhibit necroptosis without inhibiting phosphorylation of MLKL by an effector kinase. In one embodiment, binding of the compound to the ATP-binding site of the pseudokinase domain of MLKL does not inhibit phosphorylation of MLKL by an effector kinase. In another embodiment, binding of the compound to the ATP-binding site of the pseudokinase domain of MLKL inhibits phosphorylation of MLKL by an effector kinase.

15 RIP1, RIP3 and MLKL are three proteins implicated in the necroptotic pathway. Upon necroptotic stimulus (e.g. using the combination of TNF, SMAC mimetic and QVD-OPh on suitable cell lines), RIP1 is auto-phosphorylated leading to association with RIP3, which in turn auto-phosphorylates itself. Activated RIP3 phosphorylates MLKL leading to a putative conformational change that triggers its necroptotic activity (Murphy, Immunity, 39, pp 443 – 453, 2013). MLKL acts downstream of RIP1 and RIP3, and is therefore understood to be a
20 key effector of necroptosis. Compounds of this invention may bind to MLKL and block this conformational change or any other key event in its activation.

The compounds of the invention may be selective for MLKL. In some embodiments, the compounds of the invention are selective for MLKL over RIP1. In some embodiments, the compounds of the invention are selective for MLKL over RIP3. In some embodiments, the
25 compounds of the invention are selective for MLKL over RIP1 and RIP3. A selective compound may have 5-fold, 10-fold, 50-fold, 100-fold, 500-fold, 1000-fold or greater selectivity for MLKL compared to RIP1 and/or RIP3. Typically, the relative selectivity may be assessed by comparing K_D values for each respective compound binding to the relevant protein (ie MLKL and either or both of RIP1 and RIP3). Suitable assay conditions are
30 described in the Examples below. Compounds selective for MLKL may avoid undesired side-effects associated with RIP1 and/or RIP3 loss of function.

In another aspect, there is provided use of a compound of Formula (I) a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer and/or prodrug thereof in the preparation of a medicament for the inhibition of necroptosis in a subject.

In another aspect, there is provided use of a composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer and/or prodrug thereof for the inhibition of necroptosis in a subject.

5 In another aspect, there is provided use of a compound of Formula (I) or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer and/or prodrug thereof for inhibiting necroptosis.

In another aspect, there is provided use of a composition comprising a compound of Formula (I) or a salt, solvate, tautomer, N-oxide, stereoisomer and/or prodrug thereof for inhibiting necroptosis.

10 In yet another aspect, there is provided a compound according to Formula (I) or a salt, solvate, tautomer, N-oxide, stereoisomer and/or prodrug thereof for use in inhibiting necroptosis.

In yet another aspect, there is provided a composition comprising a compound according to Formula (I) or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer and/or prodrug thereof for use in inhibiting necroptosis. In some embodiments, the
15 composition is a pharmaceutical composition.

In yet another aspect, there is provided a compound according to Formula (I) or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer and/or prodrug thereof when used for inhibiting necroptosis.

20 In yet another aspect, there is provided a composition comprising a compound according to Formula (I) or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer and/or prodrug thereof when used for inhibiting necroptosis.

In another aspect, there is provided a method of inhibiting MLKL, comprising contacting a cell with an effective amount of a compound of formula (I) or a salt, solvate, tautomer, N-
25 oxide, stereoisomer and/or prodrug thereof.

The salts of the compounds of Formula (I) are preferably pharmaceutically acceptable, but it will be appreciated that non-pharmaceutically acceptable salts also fall within the scope of the present disclosure, for example, as these may be useful as intermediates in the preparation of pharmaceutically acceptable salts or in methods not requiring administration
30 to a subject.

The term "pharmaceutically acceptable" may be used to describe any salt, solvate, tautomer, N-oxide, stereoisomer and/or prodrug thereof, or any other compound which upon administration to a subject, is capable of providing (directly or indirectly) a compound of Formula (I) or an active metabolite or residue thereof and typically that is not deleterious to the subject.

Suitable pharmaceutically acceptable salts include, but are not limited to, salts of pharmaceutically acceptable inorganic acids such as hydrochloric, sulphuric, phosphoric, nitric, carbonic, boric, sulfamic, and hydrobromic acids, or salts of pharmaceutically acceptable organic acids such as acetic, propionic, butyric, tartaric, maleic, hydroxymaleic, fumaric, malic, citric, lactic, mucic, gluconic, benzoic, succinic, oxalic, phenylacetic, methanesulphonic, toluenesulphonic, benzenesulphonic, salicylic, sulphanilic, aspartic, glutamic, edetic, stearic, palmitic, oleic, lauric, pantothenic, tannic, ascorbic and valeric acids.

Base salts include, but are not limited to, those formed with pharmaceutically acceptable cations, such as sodium, potassium, lithium, calcium, magnesium, zinc, ammonium, alkylammonium such as salts formed from triethylamine, alkoxyammonium such as those formed with ethanolamine and salts formed from ethylenediamine, choline or amino acids such as arginine, lysine or histidine. General information on types of pharmaceutically acceptable salts and their formation is known to those skilled in the art and is as described in general texts such as "*Handbook of Pharmaceutical salts*" P.H.Stahl, C.G.Wermuth, 1st edition, 2002, Wiley-VCH.

In the case of compounds that are solids, it will be understood by those skilled in the art that the inventive compounds, agents and salts may exist in different crystalline or polymorphic forms, all of which are intended to be within the scope of the present invention and specified formulae.

The invention includes all crystalline forms of a compound of Formula (I) including anhydrous crystalline forms, hydrates, solvates and mixed solvates. If any of these crystalline forms demonstrates polymorphism, all polymorphs are within the scope of this invention.

Formula (I) is intended to cover, where applicable, solvated as well as unsolvated forms of the compounds. Thus, Formula (I) includes compounds having the indicated structures, including the hydrated or solvated forms, as well as the non-hydrated and non-solvated forms.

The compounds of Formula (I) or salts, tautomers, N-oxides, polymorphs or prodrugs thereof may be provided in the form of solvates. Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent, and may be formed during the process of crystallization with pharmaceutically acceptable solvents such as water, alcohols such as methanol, ethanol or isopropyl alcohol, DMSO, acetonitrile, dimethyl formamide (DMF), acetic acid, and the like with the solvate forming part of the crystal lattice by either non-covalent binding or by occupying a hole in the crystal lattice. Hydrates are formed when the solvent is water, alcoholates are formed when the solvent is alcohol. Solvates of the compounds of the present invention can be conveniently prepared or formed during the processes described herein. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the invention.

Basic nitrogen-containing groups may be quarternised with such agents as C₁₋₆alkyl halide, such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates like dimethyl and diethyl sulfate; and others.

Nitrogen containing groups may also be oxidised to form an N-oxide.

The compound of Formula (I) or salts, tautomers, N-oxides, solvates and/or prodrugs thereof that form crystalline solids may demonstrate polymorphism. All polymorphic forms of the compounds, salts, tautomers, N-oxides, solvates and/or prodrugs are within the scope of the invention.

The compound of Formula (I) may demonstrate tautomerism. Tautomers are two interchangeable forms of a molecule that typically exist within an equilibrium. Any tautomers of the compounds of Formula (I) are to be understood as being within the scope of the invention.

The compound of Formula (I) may contain one or more stereocentres. All stereoisomers of the compounds of formula (I) are within the scope of the invention. Stereoisomers include enantiomers, diastereomers, geometric isomers (*E* and *Z* olefinic forms and *cis* and *trans* substitution patterns) and atropisomers. In some embodiments, the compound is a stereoisomerically enriched form of the compound of formula (I) at any stereocentre. The compound may be enriched in one stereoisomer over another by at least about 60, 70, 80, 90, 95, 98 or 99%.

The compound of Formula (I) or its salts, tautomers, solvates, N-oxides, and/or stereoisomers, may be isotopically enriched with one or more of the isotopes of the atoms present in the compound. For example, the compound may be enriched with one or more of

the following minor isotopes: ^2H , ^3H , ^{13}C , ^{14}C , ^{15}N and/or ^{17}O , preferably ^2H . An isotope may be considered enriched when its abundance is greater than its natural abundance.

A "prodrug" is a compound that may not fully satisfy the structural requirements of the compounds provided herein, but is modified *in vivo*, following administration to a subject or patient, to produce a compound of formula (I) provided herein. For example, a prodrug may be an acylated derivative of a compound as provided herein. Prodrugs include compounds wherein hydroxy, carboxy, amine or sulfhydryl groups are bonded to any group that, when administered to a mammalian subject, cleaves to form a free hydroxy, carboxy, amino, or sulfhydryl group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate, phosphate and benzoate derivatives of alcohol and amine functional groups within the compounds provided herein. Prodrugs of the compounds provided herein may be prepared by modifying functional groups present in the compounds in such a way that the modifications are cleaved *in vivo* to generate the parent compounds.

Prodrugs include compounds wherein an amino acid residue, or a polypeptide chain of two or more (eg, two, three or four) amino acid residues which are covalently joined to free amino, and amido groups of compounds of Formula (I). The amino acid residues include the 20 naturally occurring amino acids commonly designated by three letter symbols and also include, 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvlin, beta-alanine, gamma-aminobutyric acid, citrulline, homocysteine, homoserine, ornithine and methionine sulfone. Prodrugs also include compounds wherein carbonates, carbamates, amides and alkyl esters which are covalently bonded to the above substituents of Formula (I) through the carbonyl carbon prodrug sidechain.

Pharmaceutical compositions may be formulated from compounds according to Formula (I) for any appropriate route of administration including, for example, oral, rectal, nasal, vaginal, topical (including transdermal, buccal, ocular and sublingual), parenteral (including subcutaneous, intraperitoneal, intradermal, intravascular (for example, intravenous), intramuscular, spinal, intracranial, intrathecal, intraocular, periocular, intraorbital, intrasynovial and intraperitoneal injection, intracisternal injection as well as any other similar injection or infusion techniques), inhalation, insufflation, infusion or implantation techniques (e.g., as sterile injectable aqueous or non-aqueous solutions or suspensions).

In certain embodiments, compositions in a form suitable for oral use or parenteral use are preferred. Suitable oral forms include, for example, tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. For intravenous, intramuscular, subcutaneous, or intraperitoneal

administration, one or more compounds may be combined with a sterile aqueous solution which is preferably isotonic with the blood of the recipient. Such formulations may be prepared by dissolving solid active ingredient in water containing physiologically compatible substances such as sodium chloride or glycine, and having a buffered pH compatible with physiological conditions to produce an aqueous solution, and rendering said solution sterile. The formulations may be present in unit or multi-dose containers such as sealed ampoules or vials. Examples of components are described in Martindale – The Extra Pharmacopoeia (Pharmaceutical Press, London 1993), and Remington: *The Science and Practice of Pharmacy*, 21st Ed., 2005, Lippincott Williams & Wilkins. All methods include the step of bringing the active ingredient, for example a compound defined by Formula (I), or a pharmaceutically acceptable salt or prodrug thereof, into association with the carrier which constitutes one or more accessory ingredients. In general, the pharmaceutical compositions are prepared by uniformly and intimately bringing the active ingredient, for example a compound defined by Formula (I), or a pharmaceutically acceptable salt or prodrug thereof, into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation. In the pharmaceutical composition the active object compound is included in an amount sufficient to produce the desired effect. In some embodiments, the method of the invention comprises administering a pharmaceutical comprising a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier, diluent and/or excipient.

In the context of this specification the term “administering” and variations of that term including “administer” and “administration”, includes contacting, applying, delivering or providing a compound or composition of the invention to an organism, or a surface by any appropriate means.

For the inhibition of necroptosis, the dose of the biologically active compound according to the invention may vary within wide limits and may be adjusted to individual requirements. Active compounds according to the present invention are generally administered in a therapeutically effective amount. The daily dose may be administered as a single dose or in a plurality of doses. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the subject treated and the particular mode of administration.

It will be understood, however, that the specific dose level for any particular subject will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex and diet of the subject, time of administration, route of administration, and rate of excretion, drug combination (i.e. other drugs being used

to treat the subject), and the severity of the particular disorder undergoing therapy. Such treatments may be administered as often as necessary and for the period of time judged necessary by the treating physician. A person skilled in the art will appreciate that the dosage regime or therapeutically effective amount of the compound of formula (I) to be administered may need to be optimized for each individual.

It will also be appreciated that different dosages may be required for treating different disorders. An effective amount of an agent is that amount which causes a statistically significant decrease in necroptosis.

For *in vitro* analysis, the necroptosis inhibition may be determined by assays used to measure TSQ-induced necroptosis, as described in the biological tests defined herein.

The terms "treating", "treatment" and "therapy" are used herein to refer to curative therapy, prophylactic therapy and preventative therapy. Thus, in the context of the present disclosure the term "treating" encompasses curing, ameliorating or tempering the severity of necroptosis and/or associated diseases or their symptoms.

"Preventing" or "prevention" means preventing the occurrence of the necroptosis or tempering the severity of the necroptosis if it develops subsequent to the administration of the compounds or pharmaceutical compositions of the present invention.

"Subject" includes any human or non-human animal. Thus, in addition to being useful for human treatment, the compounds of the present invention may also be useful for veterinary treatment of mammals, including companion animals and farm animals, such as, but not limited to dogs, cats, horses, cows, sheep, and pigs.

The term "inhibit" is used to describe any form of inhibition that results in prevention, reduction or otherwise amelioration of necroptosis and/or MLKL function, including complete and partial inhibition.

The compounds of the present invention may be administered along with a pharmaceutical carrier, diluent and/or excipient as described above.

The methods of the present disclosure can be used to prevent or treat the following disease(s), condition(s) and/or disorder(s) in a subject:

- diseases of the bones, joints, connective tissue and of cartilage, such as osteoporosis, osteomyelitis including chronic recurrent multifocal osteomyelitis, arthritises including for example osteoarthritis, rheumatoid arthritis and psoriatic

arthritis, avascular necrosis, progressive fibrodysplasia ossificans, rickets, Cushing's syndrome;

- muscular diseases such as muscular dystrophy, such as for example Duchenne's muscular dystrophy, myotonic dystrophies, myopathies and myasthenias;
- 5 • diseases of the skin, such as dermatitis, eczema, psoriasis, aging or even alterations of scarring;
- cardiovascular diseases such as cardiac and/or vascular ischemia, myocardial infarction, ischemic cardiopathy, chronic or acute congestive heart failure, cardiac dysrhythmia, atrial fibrillation, ventricular fibrillation, paroxysmic tachycardia, congestive
- 10 heart failure, hypertrophic cardiopathy, anoxia, hypoxia, secondary effects due to therapies with anti-cancer agents;
- circulatory diseases such as atherosclerosis, arterial scleroses and peripheral vascular diseases, strokes including cerebrovascular strokes, aneurisms;
- haematological and vascular diseases such as: anemia, aplastic anemia, vascular
- 15 amyloidosis, haemorrhages, drepanocytosis, red cell fragmentation syndrome, neutropenia, leukopenia, medullar aplasia, pancytopenia, thrombocytopenia, haemophilia;
- lung diseases including pneumonia, asthma; obstructive chronic diseases of the lungs such as for example chronic obstructive pulmonary disease (COPD), chronic
- 20 bronchitis and emphysema;
- diseases of the gastro-intestinal tract, such as ulcers; inflammatory bowel diseases (IBD), including Crohn's disease, ulcerative colitis;
- diseases of the liver such as for example hepatitis particularly hepatitis of viral origin or having as causative agent other infectious agents, auto-immune hepatitis,
- 25 fulminating hepatitis, inflammatory hepatitis, certain hereditary metabolic disorders, Wilson's disease, cirrhoses, non-alcoholic fatty liver disease (NAFLD) including non-alcoholic hepatic steatosis and/or non-alcoholic steatohepatitis (NASH), diseases of the liver due to toxins and to drugs such as drug-induced liver injury, ethanol (or alcohol)-induced liver disease;
- 30 • diseases of the pancreas such as for example acute or chronic pancreatitis;

- metabolic diseases such as diabetes, including diabetes mellitus, pre-diabetes and insipid diabetes; thyroiditis;
 - diseases of the kidneys such as acute renal disorders (such as acute kidney injury (AKI), including ischaemic reperfusion injury (IRI)) or glomerulonephritis;
- 5
- viral and bacterial infections such as septicemia;
 - severe intoxications by chemicals, toxins or drugs;
 - degenerative diseases associated with the Acquired Immune Deficiency Syndrome (AIDS);
 - disorders associated with aging such as the syndrome of accelerated aging;
- 10
- inflammatory diseases such as Terminal ileitis including Crohn's disease, rheumatoid polyarthritis, TNF-induced systemic inflammatory syndrome;
 - auto-immune diseases such as erythematous lupus (including systemic lupus erythematosus), cleavage-resistant RIPK1-induced autoinflammatory (CRIA) syndrome;
- 15
- dental disorders such as those resulting in degradation of tissues such as for example periodontitis;
 - ophthalmic diseases or disorders including diabetic retinopathies, glaucoma, macular degenerations, retinal degeneration, retinitis pigmentosa, retinal holes or tears, retinal detachment, retinal ischemia, acute retinopathies associated with trauma,
- 20
- inflammatory degenerations, post-surgical complications, medicinal retinopathies, cataract, cone cell degeneration;
 - disorders of the audition tracts, such as otosclerosis and deafness induced by antibiotics;
 - Ischemic reperfusion injury, including retinal ischaemic reperfusion injury;
- 25
- Neuronal loss, including Alzheimer's disease and neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS; also referred to as motor neuron disease (MND) and Charcot disease);

- 5 diseases associated with mitochondria (mitochondrial pathologies), such as Friedrich's ataxia, congenital muscular dystrophy with structural mitochondrial abnormality, certain myopathies (MELAS syndrome, MERFF syndrome, Pearson's syndrome), MIDD (mitochondrial diabetes and deafness) syndrome, Wolfram's syndrome, dystonia;
- 10 cancer and metastasis including but not limited to cancers of the lung and bronchus, including non-small cell lung cancer (NSCLC), squamous lung cancer, bronchioloalveolar carcinoma (BAC), adenocarcinoma of the lung, and small cell lung cancer (SCLC); prostate cancer, including androgen-dependent and androgen-independent prostate cancer; breast cancer, including metastatic breast cancer; pancreatic cancer; cancers of the colon and rectum; thyroid cancer; cancers of the liver and intrahepatic bile duct; hepatocellular cancer; gastric cancer; endometrial cancer; melanoma; cancers of the kidney, renal pelvis, urinary bladder, uterine corpus and uterine cervix; ovarian cancer, including progressive epithelial or primary

15 peritoneal cancer; multiple myeloma; oesophageal cancer, including squamous cell carcinoma and adenocarcinoma of the oesophagus; acute myelogenous leukemia (AML); chronic myelogenous leukemia (CML), including accelerated CML and CML blast phase (CML-BP); lymphocytic leukemia; myeloid leukemia; acute lymphoblastic leukemia (ALL); chronic lymphocytic leukemia (CLL); Hodgkin's disease (HD); non-Hodgkin's lymphoma (NHL), including follicular lymphoma and mantle cell lymphoma; B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL); T-cell lymphoma; multiple myeloma (MM); amyloidosis; Waldenstrom's macroglobulinemia; myelodysplastic syndromes (MDS), including refractory anemia (RA), refractory anemia with ringed siderblasts (RARS), (refractory anemia with excess blasts (RAEB), and RAEB in transformation (RAEB-T); and myeloproliferative syndromes;

20 cancers of the brain, including glioma/glioblastoma, anaplastic oligodendroglioma, and adult anaplastic astrocytoma; neuroendocrine cancers, including metastatic neuroendocrine tumors; cancers of the head and neck, including , e.g., squamous cell carcinoma of the head and neck, and nasopharyngeal cancer; cancers of the oral cavity, pharynx and small intestine; bone cancer; soft tissue sarcoma; and villous colon adenoma; and

30
- diseases of the central nervous system (CNS), such as multiple sclerosis (MS).

In some embodiments, the methods of the present disclosure may be for treating and/or preventing any one or more of the diseases, conditions and/or disorders disclosed herein. For

35 example, in some embodiments, there is provided a method for treating and/or preventing any

one or more of: retinal ischaemic reperfusion injury, chronic recurrent multifocal osteomyelitis, aplastic anaemia, CRIA, ethanol-induced liver disease, NASH, inflammatory hepatitis, acute kidney injury, IRI, multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, stroke, systemic lupus erythematosus, myocardial infarction, diabetes, Crohn's disease, inflammatory bowel disease and COPD, comprising administering to a subject in need thereof an effective amount of a compound of the invention or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer and/or prodrug thereof.

The methods can also be used for protecting cells, tissues and/or transplanted organs, whether before, during (removal, transport and/or re-implantation) or after transplantation.

- 10 In some embodiments, the compound of the invention may be administered in combination with a further active pharmaceutical ingredient (API). The API may be any that is suitable for treating any of the diseases, conditions and/or disorders associated with necroptosis, such as those described herein. The compound of the invention may be co-formulated with the further API in any of the pharmaceutical compositions described herein, or the compound of the invention may be administered in a concurrent, sequential or separate manner. Concurrent administration includes administering the compound of the invention at the same time as the other API, whether coformulated or in separate dosage forms administered through the same or different route. Sequential administration includes administering, by the same or different route, the compound of the invention and the other API according to a resolved dosage regimen, such as within about 0.5, 1, 2, 3, 4, 5, or 6 hours of the other. When sequentially administered, the compound of the invention may be administered before or after administration of the other API. Separate administration includes administering the compound of the invention and the other API according to regimens that are independent of each other and by any route suitable for either active, which may be the same or different.
- 25 The methods may comprise administering the compound of Formula (I) in any pharmaceutically acceptable form. In some embodiments, the compound of Formula (I) is provided in the form of a pharmaceutically acceptable salt, solvate, N-oxide, polymorph, tautomer or prodrug thereof, or a combination of these forms in any ratio.

- The methods may also comprise administering a pharmaceutical composition comprising the compound of formula (I) or a pharmaceutically acceptable salt, solvate, N-oxide, polymorph, tautomer or prodrug thereof to the subject in need thereof. The pharmaceutical composition may comprise any pharmaceutically acceptable carrier, diluent and/or excipient described herein.

The compounds of Formula (I), or a pharmaceutically acceptable salt or prodrug thereof, as defined herein, may be administered by any suitable means, for example, orally, rectally, nasally, vaginally, topically (including buccal and sub-lingual), parenterally, such as by subcutaneous, intraperitoneal, intravenous, intramuscular, or intracisternal injection, inhalation, insufflation, infusion or implantation techniques (e.g., as sterile injectable aqueous or non-aqueous solutions or suspensions).

The compounds of the invention may be provided as pharmaceutical compositions including those for oral, rectal, nasal, topical (including buccal and sub-lingual), parenteral administration (including intramuscular, intraperitoneal, sub-cutaneous and intravenous), or in a form suitable for administration by inhalation or insufflation. The compounds of Formula (I), or a pharmaceutically acceptable salt or prodrug thereof, together with a conventional adjuvant, carrier or diluent, may thus be placed into the form of pharmaceutical compositions and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids as solutions, suspensions, emulsions, elixirs or capsules filled with the same, all for oral use, or in the form of sterile injectable solutions for parenteral (including subcutaneous) use.

Also provided is a kit of parts, comprising in separate parts:

- a compound of Formula (I) or a pharmaceutically acceptable salt, solvate, N-oxide, polymorph, tautomer or prodrug thereof; and
- instructions for its use in any of the methods of the invention.

Examples

The compounds, compositions, kits and methods described herein are described by the following illustrative and non-limiting examples.

CHEMISTRY

Synthesis

Compounds of the invention, including salts thereof, can be prepared using known organic synthesis techniques and can be synthesized according to any of numerous possible synthetic routes.

The reactions for preparing compounds of the invention can be carried out in suitable solvents, which can be readily selected by one of skill in the art of organic synthesis. Suitable solvents can be substantially nonreactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, e.g., temperatures which

can range from the solvent's freezing temperature to the solvent's boiling temperature. A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected by the skilled artisan.

- 5 Preparation of compounds of the invention can involve the protection and deprotection of various chemical groups. The need for protection and deprotection, and the selection of appropriate protecting groups, can be readily determined by one skilled in the art. The chemistry of protecting groups can be found, for example, in T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 3rd. Ed., Wiley & Sons, Inc., New York (1999), which
10 is incorporated herein by reference in its entirety.

Reactions can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., ^1H or ^{13}C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), or mass spectrometry, or by chromatography such as high-performance liquid
15 chromatography (HPLC) or thin layer chromatography.

The expressions, "ambient temperature," "room temperature," and "RT", as used herein, are understood in the art, and refer generally to a temperature, e.g. a reaction temperature, that is about the temperature of the room in which the reaction is carried out, for example, a temperature from about 20 °C to about 30 °C.

- 20 Compounds of the invention can be prepared according to numerous preparatory routes known in the literature. Example synthetic methods for preparing compounds of the invention are provided in the Schemes below.

General chemistry methods

Definitions:

- | | | |
|----|---------------------------------|--|
| 25 | AcCl | (acetyl chloride); |
| | Ac ₂ O | (acetic anhydride); |
| | AcOH | (acetic acid); |
| | atm | (atmosphere); |
| | B ₂ pin ₂ | (bis(pinacolato)diboron); |
| 30 | BINAP | (2,2'-bis(diphenylphosphino)-1,1'-binaphthyl); |
| | BnBr | (benzyl bromide); |
| | Boc ₂ O | (di- <i>tert</i> -butyl dicarbonate); |
| | c-Hex | (cyclohexane); |
| | CDCl ₃ | (deuterated chloroform); |

	CD ₃ OD	(deuterated methanol);
	CHCl ₃	(chloroform);
	Cs ₂ CO ₃	(cesium carbonate)
	CsF	(cesium fluoride);
5	conc.	(concentrated);
	d	(day);
	DAST	(diethylaminosulphur trifluoride);
	dba	(dibenzylideneacetone);
	DCM	(dichloromethane);
10	DEAD	(diethyl azodicarboxylate);
	DIAD	(diisopropyl azodicarboxylate);
	DIPEA	(<i>N,N</i> -diisopropylethylamine);
	DMAP	(4-dimethylaminopyridine);
	DME	(1,2-dimethoxyethane);
15	DMF	(<i>N,N</i> -dimethylformamide);
	DMSO	(dimethyl sulfoxide);
	DMSO- <i>d</i> ₆	(deuterated dimethyl sulfoxide);
	EDCI	(1-ethyl-3-(3-dimethylaminopropyl)carbodiimide);
	eq	(equivalent);
20	Et ₃ N	(triethylamine);
	Et ₂ O	(diethyl ether);
	EtOAc	(ethyl acetate);
	EtOH	(ethanol);
	EtSO ₂ Cl	(ethanesulfonyl chloride);
25	g	(gram);
	h	(hour);
	H ₂	(hydrogen);
	HATU	(1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate);
30	HCl	(hydrochloric acid/hydrogen chloride);
	HOBt	(hydroxybenzotriazole);
	¹ H NMR	(proton nuclear magnetic resonance);
	Hz	(hertz);
	<i>i</i> -PrOH	(<i>iso</i> -propanol);
35	KF	(potassium fluoride);
	L	(litre);
	LCMS	(liquid chromatography-mass spectrometry);

	LiHMDS	(lithium bis(trimethylsilyl)amide);
	M	(molar);
	MeCN	(acetonitrile);
	Me ₂ NH	(dimethylamine);
5	MeOH	(methanol);
	MeOD- <i>d</i> ₄	(deuterated methanol);
	mg	(milligrams);
	MHz	(megahertz);
	min	(minutes);
10	mL	(millilitres) ;
	mmol	(millimoles);
	MsCl	(methanesulfonyl chloride);
	<i>n</i> -BuLi	(<i>n</i> -butyllithium);
	NaH	(sodium hydride);
15	NaHCO ₃	(sodium bicarbonate);
	NaOEt	(sodium ethoxide);
	NaOH	(sodium hydroxide);
	NaOMe	(sodium methoxide);
	Na ₂ SO ₄	(sodium sulphate);
20	NBS	(<i>N</i> -bromosuccinimide);
	NIS	(<i>N</i> -iodosuccinimide);
	NH ₄ Cl	(ammonium chloride);
	NMP	(<i>N</i> -methyl-2-pyrrolidone);
	Pd/C	(palladium on activated charcoal);
25	Pd ₂ (dba) ₃	(tris(dibenzylideneacetone)dipalladium(0));
	Pd(dppf)Cl ₂	([1,1'-Bis(diphenylphosphino)ferrocene]dichloropalladium(II));
	Pd(dppf)Cl ₂ ·CH ₂ Cl ₂	([1,1'-Bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with DCM);
	Pd(OH) ₂	(palladium(II) hydroxide on carbon - Pearlman's catalyst);
30	PE	(Petroleum Ether)
	prep-HPLC	(preparative high-performance liquid chromatography);
	prep-TLC	(preparative thin layer chromatography);
	ppm	(parts per million);
	psi	(pounds per square inch);
35	<i>p</i> -TSA	(<i>p</i> -toluenesulfonic acid);
	quant.	(quantitative yield)
	RT	(room temperature);

	SEMCI	(2-(trimethylsilyl)ethoxymethyl chloride);
	SPhos	(2-Dicyclohexylphosphino-2',6'-dimethoxybiphenyl);
	TBAF	(tetra- <i>n</i> -butylammonium fluoride);
	<i>t</i> -BuNNH ₂ .HCl	(<i>tert</i> -butylhydrazine hydrochloride);
5	TFA	(trifluoroacetic acid);
	THF	(tetrahydrofuran);
	TLC	(thin layer chromatography);
	v/v	(volume/volume);
	Xantphos	(9,9-Dimethyl-4,5-bis(di- <i>tert</i> -butylphosphino)xanthene);

10

LCMS methodology

Electrospray mass spectroscopy (MS) was carried out using the following method.

Method A (5 minutes): LC model: Method A 1200 (Pump type: Binary Pump, Detector type: DAD) MS model: Method A G6110A Quadrupole. Column: Xbridge-C18, 2.5 µm, 2.1×30 mm. Column temperature: 30 °C. Acquisition of wavelength: 214 nm, 254 nm. Mobile phase: A: 0.07% HCOOH aqueous solution, B: MeOH. Run time: 5 min. MS: Ion source: ES+ (or ES-). MS range: 50~900 m/z. Fragmentor: 60. Drying gas flow: 10 L/min. Nebulizer pressure: 35 psi. Drying gas temperature: 350 °C. Vcap: 3.5 kV.

Method B (3.5 minutes): LC model: Method A 1200 (Pump type: Binary Pump, Detector type: DAD) MS model: Method A G6110A Quadrupole. Column: Xbridge-C18, 2.5 µm, 2.1×30 mm. Column temperature: 30 °C. Acquisition of wavelength: 214 nm, 254 nm. Mobile phase: A: 0.07% HCOOH aqueous solution, B: MeOH. Run time: 5 min. MS: Ion source: ES+ (or ES-). MS range: 50~900 m/z. Fragmentor: 60. Drying gas flow: 10 L/min. Nebulizer pressure: 35 psi. Drying gas temperature: 350 °C. Vcap: 3.5 kV.

Method C: (8 minutes) LC model: Waters 2695 alliance (Pump: Quaternary Pump, Detector: 2996 Photodiode Array Detector) MS model: Micromass ZQ LC: Column: Xbridge-C18, 3.5µm, 2.1×50 mm Column temperature: 20 °C. Acquisition of wavelength: 214 nm, 254 nm Mobile phase: A: 0.05% HCOOH aqueous solution, B: CAN Run time: 8 min MS: Ion source: ES+ (or ES-) MS range: 100~1000 m/z Capillary: 3 kv Cone: 40 V Extractor: 3 V Drying gas flow: 800 L/hr cone: 50 L/hr Desolvation temperature: 500°C Source temperature: 120 °C

Method D: Mass detector: Agilent G6120B MSD Pump: 1260 Infinity G1312B Binary pump Autosampler: 1260 Infinity G1367E HiPALS Detector: 1260 Infinity G4212B DAD Column: Poroshell 120 EC-C18, 2.1 x 30mm 2.7 Micron Column temperature: 30 °C Injection volume: 2 µL Flowrate: 1.0 ml/min Solvent A: Water 0.1% Formic Acid Solvent B: Acetonitrile 0.1%

Formic Acid Gradient: 5-100% B over 3.8 min Acquisition time: 4.1 min Detection: 254 nm and 254 nm Ion source: Single Quadrupole Ion Mode: API-ES Drying gas temperature: 350 °C Capillary voltage (V): 4000 (positive) Capillary voltage (V): 4000 (negative) Scan Range: 100-1000 Step size: 0.1 sec

- 5 **Method E:** Mass detector: Agilent G6120B MSD Pump: 1260 Infinity G1312B Binary pump Autosampler: 1260 Infinity G1367E HiPALS Detector: 1260 Infinity G4212B DAD Column: Atlantis T3, 3uM, 100A, 3.0 x 50mm Column temperature: 30 °C Injection volume: 1 µL Flowrate: 1.0 ml/min Solvent A: Water 0.1% Formic Acid Solvent B: Acetonitrile 0.1% Formic Acid Gradient: 5-50% B over 3.0 min Acquisition time: 4.1 min Detection: 214 and 254nm Ion
- 10 source: Single Quadrupole Ion Mode: API-ES Drying gas temperature: 350 °C Capillary voltage (V): 4000 (positive) Capillary voltage (V): 4000 (negative) Scan Range: 100-1000 Step size: 0.1 sec

Preparative HPLC

- 15 **Method A:** Instrument type: VARIAN 940 LC. Pump type: Binary Pump. Detector type: PDA. LC conditions: Column: Waters SunFire prep C18 OBD, 5 µm, 19×100 mm. Acquisition wavelength: 214 nm, 254 nm. Mobile Phase: A: 0.07% TFA aqueous solution (or 0.1% HCOOH aqueous solution), B: MeOH (or CH₃CN).

- Method B:** Waters ZQ 3100 –Mass Detector, Waters 2545-Pump, Waters SFO System
- 20 Fluidics Organizer, Waters 2996 Diode Array Detector, Waters 2767 Sample Manager. LC conditions: Column: Xbridge TM prep C18 OBD 5µm 19 x 100mm, Solvent A: Water 0.1% Formic Acid, Solvent B: Acetonitrile 0.1% Formic Acid, Gradient: variable, Flow rate: 20 ml/min, Detection: 100-600 nm MS conditions: Ion Source: Single-quadrupole, Ion Mode: ES positive, Source Temp: 150°C, Desolvation Temp: 350 °C, Detection: Ion counting, Capillary
- 25 (KV)-3.00, Cone (V): 30, Extractor (V):3, RF Lens (V): 0.1, Scan Range: 100-1000 Amu, Scan Time: 0.5 sec, Acquisition time: 20min Gas Flow: Desolvation L/hr-650, Cone L/hr-100


- Method C:** Waters ZQ 3100 –Mass Detector, Waters 2545-Pump, Waters SFO System Fluidics Organizer, Waters 2996 Diode Array Detector, Waters 2767 Sample Manager. LC conditions: Column: Xbridge TM prep C18 OBD 5µm 19 x 100mm, Solvent A: Water, Solvent
- 30 B: Acetonitrile, Gradient: variable, Flow rate: 20 ml/min, Detection: 100-600 nm MS conditions: Ion Source: Single-quadrupole, Ion Mode: ES positive, Source Temp: 150°C, Desolvation Temp: 350 °C, Detection: Ion counting, Capillary (KV)-3.00, Cone (V): 30, Extractor (V):3, RF Lens (V): 0.1, Scan Range: 100-1000 Amu, Scan Time: 0.5 sec, Acquisition time: 20min Gas Flow: Desolvation L/hr-650, Cone L/hr-100.

NMR

Nuclear magnetic resonance spectra were recorded on a Bruker 400 MHz or 300 MHz for ^1H nuclei as specified. Samples were recorded in deuterated solvent as specified, and data acquired at 25 °C. Chemical shifts are reported in ppm on the δ scale and referenced to the appropriate solvent peak. In reporting spectral data, the following abbreviations have been used: s, singlet; bs, broad singlet; d, doublet; t, triplet; q, quartet; m, multiplet.

Synthesis of Intermediates A

10 Intermediate A1: 3-iodo-1-methyl-1H-pyrazolo[4,3-c]pyridin-4-amine



Step 1: 4-chloro-3-iodo-1H-pyrazolo[4,3-c]pyridine

To a solution of 4-chloro-1H-pyrazolo[4,3-c]pyridine (25 g, 162 mmol) in DMF (200 mL) was added NIS (43.6 g, 194 mmol) and the mixture was stirred at 85 °C overnight. The mixture was diluted with water (2,500 mL) and the solids were filtered to give the title product (43.0 g, 94%) as a yellow solid. LCMS (Method A): 2.99 min, m/z : 279.9 $[\text{M}+\text{H}]^+$.

Step 2: 4-chloro-3-iodo-1-methyl-1H-pyrazolo[4,3-c]pyridine


To a pre-cooled solution of 4-chloro-3-iodo-1H-pyrazolo[4,3-c]pyridine (43 g, 153 mmol) in DMF (200 mL) at 0 °C was added NaH (60% in oil, 18.4 g, 765 mmol). The mixture was stirred at 0 °C under N_2 for 10 min. Iodomethane (32.5 g, 229 mmol) was then added slowly and the mixture and stirred at rt for 1 h. Water (2,000 mL) was added and the product was extracted with EtOAc (2 x 1000mL). The combined organics were dried over MgSO_4 , concentrated under reduced pressure and the residue was purified by column chromatography (DCM/PE = 4/1, v/v) to give the title product (23.5 g, 52%) as a white solid. LCMS (Method A): 3.42 min, m/z : 293.8 $[\text{M}+\text{H}]^+$.

Step 3: 3-iodo-N-(4-methoxybenzyl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-4-amine

To a solution of 4-chloro-3-iodo-1-methyl-1H-pyrazolo[4,3-c]pyridine (23.5 g, 80.0 mmol) in 1-butanol (200 mL) was added (4-methoxyphenyl)methanamine (44.0 g, 320 mmol) and the mixture was stirred at 110 °C overnight. The mixture was concentrated under reduced pressure before the addition of water (2,000 mL). The precipitate was filtered off to give the title product (33.0 g) as a white solid. LCMS (Method A): 2.58 min, m/z : 395.0 $[\text{M}+\text{H}]^+$.

Step 4: 3-iodo-1-methyl-1H-pyrazolo[4,3-c]pyridin-4-amine

A solution of 3-iodo-N-[(4-methoxyphenyl)methyl]-1-methyl-1H-pyrazolo[4,3-c]pyridin-4-amine (33 g, 83.7 mmol) in TFA (60 mL) was stirred at 70 °C overnight. The mixture was concentrated under reduced pressure and the residue was partitioned between an aqueous solution of Na₂CO₃ (250 mL) and DCM (250 mL). The organics were washed with water, dried over Na₂SO₄ and concentrated under reduced pressure to give the title product (16.4 g, 71% over 2 steps) as a white solid. LCMS (Method A): 0.91 min, m/z: 275.0 [M+H]⁺.

Intermediate A2: 3-iodo-1-isopropyl-1H-pyrazolo[4,3-c]pyridin-4-amine**Step 1: 4-chloro-3-iodo-1-isopropyl-1H-pyrazolo[4,3-c]pyridine**

To a mixture of 4-chloro-3-iodo-1H-pyrazolo[4,3-c]pyridine (6 g, 21.4 mmol) and Cs₂CO₃ (20.8 g, 64.1 mmol) in acetonitrile (200 mL) was added 2-bromopropane (5.26 g, 42.8 mmol) and the reaction mixture was stirred at 70 °C overnight. Water (200 mL) was added, and the product was extracted with EtOAc (2 x 100 mL). The combined organics were dried over Na₂SO₄, concentrated under reduced pressure and the residue was purified by column chromatography (PE/EtOAc = 4/1 to 1/4, v/v) to give the title product (4 g, 58%) as a yellow solid. LCMS (Method A): 2.60 min, m/z: 322.0 [M+H]⁺.

Step 2: 3-iodo-1-isopropyl-N-(4-methoxybenzyl)-1H-pyrazolo[4,3-c]pyridin-4-amine


To a solution of 4-chloro-3-iodo-1-isopropyl-1H-pyrazolo[4,3-c]pyridine (4 g, 12.4 mmol) in 1-butanol (40 mL) was added (4-methoxyphenyl)methanamine (8.50 g, 62.0 mmol) and the mixture was stirred at 110 °C overnight. The reaction mixture was concentrated under reduced pressure and the residue partitioned between water (200 mL) and EtOAc (200 mL). The layers were separated, and the aqueous layer was further extracted with EtOAc (100 mL). The combined organics were washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure to give the crude product (2 g, 38%) as a brown oil. LCMS (Method A): 2.95 min, m/z: 423.1 [M+H]⁺.

Step 3: 3-iodo-1-isopropyl-1H-pyrazolo[4,3-c]pyridin-4-amine

A solution of 3-iodo-1-isopropyl-N-(4-methoxybenzyl)-1H-pyrazolo[4,3-c]pyridin-4-amine (3.7 g, 8.76 mmol) in TFA (20 mL) was stirred at 70 °C overnight. The mixture was concentrated under reduced pressure and the residue was partitioned between an aqueous solution of

Na₂CO₃ (250 mL) and DCM (250 mL). The organics were washed with water, dried over Na₂SO₄ and concentrated under reduced pressure to give the title product (500 mg, 19%) as a yellow solid. LCMS (Method A): 1.83 min, m/z: 303.0 [M+H]⁺.

5 **Intermediate A3: 3-iodopyrazolo[1,5-a]pyrazin-4-amine**



Step 1: N-(2,2-dimethoxyethyl)-1H-pyrazole-5-carboxamide

A mixture of 1H-pyrazole-5-carboxylic acid (10 g, 89.2 mmol) and carbonyldiimidazole (15.9 g, 98.1 mmol) in 1,4-dioxane (100 ml) was stirred at 50 °C under N₂ for 1 hour before the addition of 2,2-dimethoxyethan-1-amine (10.3 g, 98.1 mmol), and the reaction mixture was stirred at 50 °C overnight. The reaction mixture was concentrated under reduced pressure and the residue was poured into water (500 mL). The aqueous solution was adjusted to pH = 5 with 1 M HCl and the organics were extracted with EtOAc (2 x 250 mL). The combined organics were dried over Na₂SO₄ and concentrated under reduced pressure to give the title product (15 g, 84%) as a white solid. LCMS (Method A): 3.32 min; m/z: 222.1 [M+H]⁺.

Step 2: 7-hydroxy-6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one

A solution of N-(2,2-dimethoxyethyl)-1H-pyrazole-5-carboxamide (15 g, 75.2 mmol) in DCM (100 ml) and TFA (100 ml) was stirred at RT overnight. The reaction mixture was concentrated under reduced pressure to give the title product (12 g, 100%) as a brown oil.

20 **Step 3: pyrazolo[1,5-a]pyrazin-4(5H)-one**

A solution of 7-hydroxy-6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one (12 g, 78.3 mmol) in polyphosphoric acid (50 mL) was stirred at 145 °C for 5 hours. The reaction mixture was adjusted to pH = 10 with an aqueous NaOH solution. The mixture was concentrated under reduced pressure and the residue was purified by column chromatography (DCM/MeOH = 20/1, v/v) to give the title product (6.1 g, 58%) as a brown solid. ¹H NMR (400 MHz, DMSO-d₆): δ 11.23 (s, 1H), 7.89 (s, 1H), 7.68 (d, J = 5.8 Hz, 1H), 7.00 (s, 1H), 6.86 (d, J = 11.5 Hz, 1H).

Step 4: 4-chloropyrazolo[1,5-a]pyrazine

A solution of pyrazolo[1,5-a]pyrazin-4(5H)-one (6.1 g, 45.1 mmol) in POCl₃ (50 mL) and DMF (4 drops) was stirred at 130 °C overnight. The reaction mixture was slowly poured into ice water (300 mL), then adjusted to pH = 10 with an aqueous NaOH solution. The organics were extracted with EtOAc (2 x 100 mL) and the combined organics were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography (PE/EtOAc = 10/1, v/v) to give the title product (3.6 g, 85%) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆): δ 8.86 (d, *J* = 5.6 Hz, 1H), 8.26 (s, 1H), 7.75 (d, *J* = 4.7 Hz, 1H), 7.05 (d, *J* = 0.9 Hz, 1H).

Step 5: 4-chloro-3-iodopyrazolo[1,5-a]pyrazine


To a solution of 4-chloropyrazolo[1,5-a]pyrazine (3.6 g, 23.4 mmol) in DMF (100 mL) was added NIS (10.5 g, 46.8 mmol) and the reaction was stirred at 85 °C overnight. The reaction mixture was poured into water (100 mL) and the solids were filtered, washed with water and dried under reduced pressure to give the title product (4.9 g, 75%) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆): δ 8.93 (d, *J* = 4.7 Hz, 1H), 8.37 (s, 1H), 7.75 (d, *J* = 4.7 Hz, 1H).

Step 6: 3-iodopyrazolo[1,5-a]pyrazin-4-amine

To a solution of 4-chloro-3-iodopyrazolo[1,5-a]pyrazine (4.9 g, 17.5 mmol) in MeOH (50 mL) was added a solution of ammonia in MeOH (7M, 100 mL) and the mixture was stirred at 110 °C in a sealed tube overnight. The mixture was concentrated under reduced pressure and the residue was purified by column chromatography (DCM/MeOH = 50/1, v/v) to give the title product (3.00 g, 11.5 mmol) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆): δ 8.08 (d, *J* = 4.7 Hz, 1H), 8.02 (d, *J* = 11.8 Hz, 1H), 7.26 (t, *J* = 4.7 Hz, 1H), 6.68 (d, *J* = 37.2 Hz, 2H).

Synthesis of Intermediates B

Intermediate B1: (S)-1,1-difluoro-N-(2-(1-(4-fluorophenyl)ethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanesulfonamide



Step 1: (S)-4-bromo-2-(1-(4-fluorophenyl)ethoxy)-1-nitrobenzene

To a solution of (1S)-1-(4-fluorophenyl)ethan-1-ol (40 g, 285 mmol) in THF (600 mL) was added NaH (60% in oil, 57.1 g, 1425 mmol) and the mixture was stirred at 0 °C under N₂ for 30 min. 4-Bromo-2-fluoro-1-nitrobenzene (62.6 g, 285 mmol) was then added, and the mixture was stirred at RT overnight. The reaction mixture was diluted with water (500 mL) and extracted with EtOAc (3 x 500 mL). The combined organics were washed with water and brine, dried (Na₂SO₄) and concentrated under reduced pressure to give the crude product (70 g, 72%) as a yellow oil. ¹H NMR (400 MHz, DMSO-*d*₆): δ 7.80 (d, *J* = 8.4 Hz, 1H), 7.54 (d, *J* = 2.0 Hz, 1H), 7.48 (q, *J* = 4.8 Hz, 2H), 7.26 (dd, *J* = 8.8, 2.0 Hz, 1H), 7.20 (t, *J* = 8.8 Hz, 1H), 5.89 (q, *J* = 6.4 Hz, 1H), 1.54 (d, *J* = 6.0 Hz, 3H).

Step 2: 4-bromo-2-[(1S)-1-(4-fluorophenyl)ethoxy]aniline

To a solution of 4-bromo-2-[(1S)-1-(4-fluorophenyl)ethoxy]-1-nitrobenzene (70 g, 205 mmol) in MeOH (500 mL), was added Zn dust (67.0 g, 1025 mmol) followed by sat. aq. NH₄Cl (170 mL). The mixture was stirred at 60 °C for 6 h, then diluted with water (500 mL) and extracted with EtOAc (3 x 500 mL). The combined organics were washed with water and brine, dried (Na₂SO₄) and concentrated under reduced pressure. The residue was purified by column chromatography (PE/EtOAc = 100/1, v/v) to give the title product (40 g, 63%) as a brown oil. LCMS (method A): 4.13 min, *m/z*: 311.0, 312.0 [M+H]⁺.

Step 3: N-{4-bromo-2-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl}-1,1-difluoromethanesulfonamide

To a solution of 4-bromo-2-[(1S)-1-(4-fluorophenyl)ethoxy]aniline (40 g, 128 mmol) in DCM (200 mL) and pyridine (40.5 g, 512 mmol) was added difluoromethanesulfonyl chloride (24.9 g, 166 mmol). After stirring at RT overnight, the residue was diluted with water (500 mL) and extracted with DCM (3 x 500 mL). The combined organics were washed with brine, dried (Na₂SO₄) and concentrated under reduced pressure. The residue was purified by column chromatography (PE/EtOAc = 100/1, v/v) to give the title product (39 g, 72%) as a brown oil. ¹H NMR (400 MHz, DMSO-*d*₆): δ 10.43 (s, 1H), 7.57 (q, *J* = 4.8 Hz, 2H), 7.21-7.15 (m, 3H), 7.07-7.04 (m, 2H), 6.98 (t, *J* = 52.4 Hz, 1H), 5.65 (q, *J* = 6.4 Hz, 1H), 1.54 (d, *J* = 6.0 Hz, 3H).






Step 4: (S)-1,1-difluoro-N-(2-(1-(4-fluorophenyl)ethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanesulfonamide

To a solution of N-{4-bromo-2-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl}-1,1-difluoromethanesulfonamide (39 g, 91.9 mmol) in dioxane (300 mL), was added KOAc (26.9 g, 275 mmol), B₂pin₂ (34.7 g, 137 mmol) and Pd(dppf)Cl₂ (2.01 g, 2.75 mmol). The mixture was stirred at 100 °C under N₂ overnight, then concentrated under reduced pressure. The residue was diluted with water (500 mL) and extracted with EtOAc (3 x 500 mL). The combined organics were washed with water and brine, dried (Na₂SO₄) and concentrated under reduced

pressure. The residue was purified by column chromatography (PE/EtOAc = 50/1, v/v) to give the desired product (41 g, 94%) as a yellow oil.

¹H NMR (400 MHz, DMSO-*d*₆): δ 10.41 (s, 1H), 7.58 (q, *J* = 4.8 Hz, 2H), 7.27 (d, *J* = 7.6 Hz, 1H), 7.20-7.16 (m, 3H), 7.12 (s, 1H), 6.98 (t, *J* = 52.4 Hz, 1H), 5.63 (q, *J* = 6.4 Hz, 1H), 1.54
5 (d, *J* = 6.4 Hz, 3H), 1.25 (d, *J* = 4.8 Hz, 12H).

The following intermediates B were similarly prepared from the appropriate aryl or heteroaryl alcohol (step 1) according to the preparation of (S)-1,1-difluoro-N-(2-(1-(4-fluorophenyl)ethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanesulfonamide (intermediate B1)
10


Compound No	Name	Structure	SM
Intermediate B2	(R)-1,1-difluoro-N-(2-(1-(4-fluorophenyl)ethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanesulfonamide		(1R)-1-(4-fluorophenyl)ethanol-1-ol
Intermediate B3	(S)-N-(2-(1-(3-chlorophenyl)ethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1,1-difluoromethanesulfonamide		(S)-1-(3-chlorophenyl)ethanol-1-ol
Intermediate B4	(S)-1,1-difluoro-N-(2-(1-(2-fluorophenyl)ethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanesulfonamide		(1S)-1-(2-fluorophenyl)ethanol-1-ol
Intermediate B5	1,1-difluoro-N-(2-(1-(4-fluorophenyl)-2-methoxyethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanesulfonamide		1-(4-fluorophenyl)-2-methoxyethanol-1-ol
Intermediate B6	N-(2-((4-chloro-3-fluorobenzyl)oxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1,1-difluoromethanesulfonamide		(4-chloro-3-fluorophenyl)methanol

Intermediate B7	(S)-1,1-difluoro-N-(2-(1-(4-methoxyphenyl)ethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanesulfonamide		(S)-1-(4-methoxyphenyl)ethanol-1-ol
Intermediate B8	N-(2-((3-chlorobenzyl)oxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1,1-difluoromethanesulfonamide		(3-chlorophenyl)methanol
Intermediate B9	N-(2-((6-chloropyridin-3-yl)methoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1,1-difluoromethanesulfonamide		(6-chloropyridin-3-yl)methanol
Intermediate B10	1,1-difluoro-N-(2-(1-(4-fluorophenyl)cyclopropoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanesulfonamide		1-(4-fluorophenyl)cyclopropan-1-ol
Intermediate B11	1,1-difluoro-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(thiazol-2-ylmethoxy)phenyl)methanesulfonamide		thiazol-2-ylmethanol

Intermediate B12	1,1-difluoro-N-(2-isopropoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanesulfonamide		isopropanol
Intermediate B13	N-(2-(cyclohexylmethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1,1-difluoromethanesulfonamide		cyclohexylmethanol
Intermediate B14	1,1-difluoro-N-(2-(oxazol-2-ylmethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanesulfonamide		oxazol-2-ylmethanol
Intermediate B15	(S)-N-(2-(1-(4-chlorophenyl)ethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1,1-difluoromethanesulfonamide		(S)-1-(4-chlorophenyl)ethanol-1-ol
Intermediate B16	N-(2-(benzo[d][1,3]dioxol-5-ylmethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1,1-difluoromethanesulfonamide		benzo[d][1,3]dioxol-5-ylmethanol

Synthesis of Intermediates AB

Intermediate A1B1 : N-(4-{4-amino-7-iodo-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl)-1,1-difluoromethanesulfonamide



Step 1: N-(4-{4-amino-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl)-1,1-difluoromethanesulfonamide (**Compound 17**)


To a solution of 3-iodo-1-methyl-1H-pyrazolo[4,3-c]pyridin-4-amine (8 g, 29.1 mmol) in degassed 1,4-dioxane and H₂O (4/1, 150 mL) was added 1,1-difluoro-N-{2-[(1S)-1-(4-fluorophenyl)ethoxy]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-

yl)phenyl}methanesulfonamide (15.0 g, 32.0 mmol), Na₂CO₃ (6.16 g, 58.2 mmol) and Pd(dppf)Cl₂ (1.18 g, 1.45 mmol) and the mixture was stirred at 100 °C overnight. The mixture was cooled to RT and concentrated under reduced pressure. The residue was purified by column chromatography (DCM/MeOH = 40/1, v/v) to give the title product (12.0 g, 84%) as a yellow solid. LCMS (Method A): 2.92 min, m/z: 492.2 [M+H]⁺.

Step 2: N-(4-{4-amino-7-iodo-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl)-1,1-difluoromethanesulfonamide

To a solution of N-(4-{4-amino-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl)-1,1-difluoromethanesulfonamide (12 g, 24.4 mmol) in DMF (150 mL) was added NIS (6.57 g, 29.2 mmol) and the mixture was stirred at 85 °C overnight. Water (1500 mL) was added and the solids were filtered off, washed with water (200mL), and dried under reduced pressure. The solids were further purified by column chromatography (PE/EA = 1/1, v/v) to give the title product (8.00 g, 53%) as a yellow solid. LCMS (Method A): 3.35 min, m/z: 618.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-*d*₆): δ 8.00 (s, 1H), 7.56 (q, *J* = 4.8 Hz, 2H), 7.40 (dd, *J* = 8.8, 2.0 Hz, 1H), 7.18-7.10 (m, 4H), 7.02 (t, *J* = 52.4 Hz, 1H), 5.85 (s, 2H), 5.64 (q, *J* = 6.4 Hz, 1H), 4.24 (s, 3H), 1.58 (d, *J* = 6.4 Hz, 3H).

Intermediate A2B1: (S)-N-(4-{4-amino-7-iodo-1-isopropyl-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide




Step 1: (S)-N-(4-(4-amino-1-isopropyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide (**Compound 53**)

To a solution of 3-iodo-1-(propan-2-yl)-1H-pyrazolo[4,3-c]pyridin-4-amine (500 mg, 1.65 mmol) in degassed 1,4-dioxane/water (4/1, 20 mL) were added 1,1-difluoro-N-{2- [(1S)-1-(4-fluorophenyl)ethoxy]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl}methanesulfonamide (1.16 g, 1.82 mmol), Na₂CO₃ (98.9 mg, 0.9334 mmol) and Pd(dppf)Cl₂ (38.1 mg, 0.04667 mmol) and the mixture was stirred at 100 °C overnight. The mixture was cooled to RT and concentrated under reduced pressure. The residue was purified by column chromatography (DCM/MeOH = 40/1, v/v) to give the title product (950 mg, >100%) as a yellow solid. LCMS (Method A): 3.17 min, m/z: 520.2 [M+H]⁺. ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.32 (s, 1H), 7.76 (d, *J* = 6.8 Hz, 1H), 7.57 (t, *J* = 8.4 Hz, 2H), 7.40 (d, *J* = 8.0 Hz, 1H), 7.20-7.09 (m, 5H), 7.00 (t, *J* = 52.4 Hz, 1H), 6.55 (s, 2H), 5.64 (q, *J* = 5.6 Hz, 1H), 4.95-4.89 (m, 1H), 1.58 (d, *J* = 6.0 Hz, 3H), 1.45 (q, *J* = 4.8 Hz, 6H).

Step 2: (S)-N-(4-(4-amino-7-iodo-1-isopropyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide

To a solution of N-{4-[4-amino-1-(propan-2-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl}-1,1-difluoromethanesulfonamide (980 mg, 1.88 mmol) in DMF (30 mL) was added NIS (1.05 g, 4.70 mmol) and the mixture was stirred at 85 °C overnight. Water (300 mL) was added and the solids were filtered, washed with water (200mL) and dried under reduced pressure. The solids were further purified by column chromatography (DCM/MeOH = 200/1, v/v) to give the title product (450 mg, 37%) as a brown solid. LCMS (Method A): 3.65 min, m/z: 646.1 [M+H]⁺.

Intermediate A3B1: (S)-N-(4-(4-amino-7-bromopyrazolo[1,5-a]pyrazin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide




Step 1: (S)-N-(4-(4-aminopyrazolo[1,5-a]pyrazin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide (**Compound 22**)

A mixture of 3-iodopyrazolo[1,5-a]pyrazin-4-amine (2.3 g, 8.84 mmol), 1,1-difluoro-N-{2-[(1S)-1-(4-fluorophenyl)ethoxy]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl}methanesulfonamide (4.16 g, 8.84 mmol), Pd(dppf)Cl₂ (1.43 g, 1.76 mmol) and Na₂CO₃ (1.86 g, 17.6 mmol) in degassed 1,4-dioxane/H₂O (4/1, 100 mL) was stirred at 100 °C under N₂ overnight. The mixture was poured into water (100 mL) and extracted with EtOAc (2 x 70 mL). The combined organics were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography (DCM/MeOH = 80/1, v/v) to give the title product (3 g, 71%) as a brown solid. LCMS (Method A): 4.62 min, m/z: 478.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-*d*₆): δ 10.45 (s, 1H), 8.02 (d, *J* = 4.7 Hz, 1H), 7.89 (s, 1H), 7.58 (dd, *J* = 8.7, 5.6 Hz, 2H), 7.34 (d, *J* = 8.0 Hz, 1H), 7.30 (d, *J* = 4.7 Hz, 1H), 7.17 (t, *J* = 8.9 Hz, 2H), 7.05-6.88 (m, 3H), 5.99 (s, 2H), 5.68 (q, *J* = 6.2 Hz, 1H), 1.58 (d, *J* = 6.3 Hz, 3H).



Step 2: (S)-N-(4-(4-amino-7-bromopyrazolo[1,5-a]pyrazin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide


To a solution of (S)-N-(4-(4-aminopyrazolo[1,5-a]pyrazin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide (300 mg, 628 μmol) in DMF (10 mL) was added NBS (122 mg, 690 μmol) and the reaction was stirred at room temperature for 1h. The mixture was poured into water (100 mL) and extracted with EtOAc (4 x 50 mL). The combined organics were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by prep-TLC (DCM/MeOH = 50/1, v/v) to give the title product (100 mg, 28%) as a brown solid.



General Procedure A for the Suzuki reaction between intermediate A1B1 and boronate esters


A mixture of N-(4-{4-amino-7-iodo-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl)-1,1-difluoromethanesulfonamide (1 eq), boronate ester (1.1 eq), Na_2CO_3 (3 eq) and $\text{Pd}(\text{dppf})\text{Cl}_2$ (0.1eq) in degassed 1,4- dioxane/ H_2O (4/1, 0.2 M) was stirred at 80 to 100 °C under N_2 overnight (or at 80 °C for 2h or 4h under MW irradiation). The mixture was diluted with water and extracted with EtOAc (3 x). The combined organics were dried over Na_2SO_4 and concentrated under reduced pressure. The residue was purified by column chromatography (DCM/MeOH) or by prep-TLC (DCM/MeOH) to give the title products.


The following compounds were prepared following the **General procedure A** with intermediate A1B1 and corresponding boronate esters


Compound No	Name	Structure	Yield	LCMS data	¹ H NMR data	Boronate ester
24	(S)-N-(4-(4-amino-1-methyl-7-(2-methylpyridin-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		42%	(Method B): 2.92 min, m/z: 583.2 [M+H] ⁺ .	(400 MHz, DMSO-d ₆): 10.59 (s, 1H), 8.50 (d, J = 5.1 Hz, 1H), 7.63 (s, 1H), 7.60-7.51 (m, 2H), 7.44-7.36 (m, 2H), 7.30 (d, J = 5.1 Hz, 1H), 7.22-6.86 (m, 5H), 5.91 (s, 2H), 5.66 (q, J = 6.5 Hz, 1H), 3.95 (s, 1H), 3.72-3.58 (m, 3H), 2.53 (s, 3H), 1.58 (d, J = 6.3 Hz, 3H).	2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
30	(S)-N-(4-(4-amino-7-(1-cyclopentyl-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		39%	(Method A): 3.14 min, m/z: 626.3 [M+H] ⁺ .	(400 MHz, DMSO-d ₆): 7.97 (s, 1H), 7.63-7.52 (m, 4H), 7.40 (d, J = 8.0 Hz, 1H), 7.15 (dddd, J = 17.7, 9.7, 7.2, 2.1 Hz, 4H), 5.82 (s, 2H), 5.65 (d, J = 6.4 Hz, 1H), 4.75 (p, J = 6.9 Hz, 1H), 3.70 (s, 3H).	1-cyclopentyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole


					3H), 2.10 (dt, $J = 12.3$, 6.2 Hz, 2H), 1.97 (dq, $J = 12.9$, 6.2, 3.2 Hz, 2H), 1.87-1.76 (m, 2H), 1.72-1.62 (m, 2H), 1.58 (d, $J = 6.3$ Hz, 3H).	
Compound 31	(S)-N-(4-(4-amino-7-(1-isopropyl-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		46%	(Method A): 3.22 min, m/z: 600.3 $[M+H]^+$.	(400 MHz, DMSO- d_6): 10.64 (s, 1H), 7.97 (s, 1H), 7.61-7.52 (m, 4H), 7.40 (d, $J = 8.0$ Hz, 1H), 7.20-7.09 (m, 4H), 6.94 (d, $J = 52.6$ Hz, 1H), 5.79 (s, 2H), 5.65 (q, $J = 6.0$ Hz, 1H), 4.55 (p, $J = 6.7$ Hz, 1H), 3.69 (s, 3H), 1.58 (d, $J = 6.2$ Hz, 3H), 1.47 (d, $J = 6.7$ Hz, 6H).	1-(propan-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole


Compound 38	(S)-N-(4-(4-amino-1-methyl-7-(1-(oxetan-3-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		68%	(Method A): 2.94 min, m/z: 614.2 [M+H]⁺.	(400 MHz, DMSO-d₆): 8.12 (s, 1H), 7.77 (s, 1H), 7.56 (t, J = 8.8 Hz, 3H), 7.41 (d, J = 8.0 Hz, 1H), 7.17 (t, J = 8.8 Hz, 3H), 7.12 (d, J = 6.8 Hz, 2H), 7.02 (t, J = 52.4 Hz, 1H), 5.90 (s, 2H), 5.68-5.61 (m, 2H), 4.96 (d, J = 6.8 Hz, 4H), 3.71 (s, 3H), 1.58 (d, J = 6.4 Hz, 3H).	1-(oxetan-3-yl)-4-(4,4,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
Compound 19	(S)-N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		49%	(Method A): 3.08 min, m/z: 642.2 [M+H]⁺.	(400 MHz, DMSO-d₆): 8.01 (s, 1H), 7.61 (s, 1H), 7.58-7.54 (m, 3H), 7.41 (d, J = 8.0 Hz, 1H), 7.18-7.10 (m, 4H), 6.99 (t, J = 52.4 Hz, 1H), 5.74 (s, 2H), 5.65 (q, J = 6.4 Hz, 1H), 4.49-4.24 (m, 1H), 3.99-3.95 (m, 2H),	1-(tetrahydro-2H-pyran-4-yl)-4-(4,4,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole



					3.69 (s, 3H), 3.52-3.45(m, 4H), 2.04-2.00(m, 4H), 1.58 (d, J = 6.4 Hz, 3H)	
Compound 41	N-(4-(4-amino-1-methyl-7-(1-(tetrahydrofuran-3-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		30%	(Method A): 2.97 min, m/z: 628.2 [M+H] ⁺ .	400 MHz, DMSO-d ₆): 10.61 (s, 1H), 8.13 (s, 1H), 7.75 (s, 1H), 7.66-7.54 (m, 5H), 7.44 (d, J = 8.1 Hz, 1H), 7.21-6.90 (m, 6H), 5.11 (ddt, J = 9.2, 6.7, 3.5 Hz, 1H), 4.04-3.92 (m, 3H), 3.85 (td, J = 8.3, 5.3 Hz, 1H), 3.75 (s, 3H), 2.54 (s, 1H), 2.47-2.38 (m, 1H), 2.33 (dddd, J = 13.1, 8.1, 5.3, 3.6 Hz, 1H), 1.59 (d, J = 6.2 Hz, 3H).	1-(oxolan-3-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole



Compound 46	(S)-N-(4-(4-amino-1-methyl-7-(1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		36%	(Method A): 2.53 min, m/z : 655.3 [M+H]⁺.	(400 MHz, DMSO-d₆): 7.98 (s, 1H), 7.63 (s, 1H), 7.58-7.52 (m, 3H), 7.38 (d, J = 8.0 Hz, 1H), 7.15 (t, J = 8.8 Hz, 2H), 7.05 (dd, J = 8.0, 1.6 Hz, 1H), 7.02 (d, J = 2.0 Hz, 1H), 6.77 (t, J = 53.2 Hz, 1H), 5.67 (s, 2H), 5.64 (q, J = 6 Hz, 1H), 4.40-4.32 (m, 1H), 3.68 (s, 3H), 3.23-3.20 (m, 2H), 2.75-2.68 (m, 2H), 2.54 (s, 3H), 2.22-2.17 (m, 4H), 1.56 (d, J = 6.4 Hz, 3H)	1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)piperidine
--------------------	---	---	------------	---	--	---


Compound 21	(S)-N-(4-(4-amino-1-methyl-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		58% (Method A): 2.60 min, m/z: 587.2 [M+H] ⁺ .	(400 MHz, DMSO-d ₆): 7.56-7.51 (m, 2H), 7.45 (s, 1H), 7.37 (d, J = 8.1 Hz, 1H), 7.15 (t, J = 8.9 Hz, 2H), 7.04 (d, J = 9.8 Hz, 1H), 7.00 (s, 1H), 6.77 (t, J = 53.3 Hz, 1H), 5.73 (s, 1H), 5.66 (s, 1H), 5.65-5.61 (m, 1H), 3.94 (s, 3H), 3.47 (s, 2H), 3.05 (s, 2H), 2.62 (s, 3H), 2.52 (d, J = 6.8 Hz, 2H), 1.55 (d, J = 6.3 Hz, 3H).	1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine
------------------------------	--	---	---	---	---



Compound 43	(S)-N-(4-(4-amino-7-(3,6-dihydro-2H-pyran-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		90%	(Method A): 3.14 min, m/z: 574.2 [M+H]⁺.	(400 MHz, DMSO-d₆): 7.57 (dd, J = 8.7, 5.6 Hz, 2H), 7.48 (s, 1H), 7.40 (d, J = 8.0 Hz, 1H), 7.17 (t, J = 8.9 Hz, 2H), 7.14-7.09 (m, 2H), 6.95 (d, J = 52.6 Hz, 1H), 5.87 (s, 1H), 5.84 (s, 1H), 5.65 (q, J = 6.2 Hz, 1H), 4.23 (d, J = 2.5 Hz, 2H), 3.97 (s, 3H), 3.86 (t, J = 5.3 Hz, 2H), 2.34 (s, 2H), 1.57 (d, J = 6.3 Hz, 3H).	2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
--------------------	--	---	------------	--	---	--


Compound 28	(S)-N-(4-(4-amino-7-(6-methoxypyridin-3-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		69%	(Method A): 3.24 min, m/z: 599.2 [M+H] ⁺ .	(400 MHz, DMSO-d ₆): 10.98 (s, 1H), 8.94 (d, J = 2.2 Hz, 1H), 8.80 (dd, J = 4.8, 1.6 Hz, 1H), 8.21-8.14 (m, 2H), 7.69-7.57 (m, 2H), 7.55 (s, 1H), 7.41 (s, 1H), 7.21 (dd, J = 8.3, 1.3 Hz, 1H), 6.17 (s, 2H), 4.08 (d, J = 7.2 Hz, 2H), 3.88 (s, 3H), 3.85-3.79 (m, 2H), 3.23 (td, J = 11.6, 2.1 Hz, 2H), 2.13 (ddp, J = 11.4, 7.9, 3.7 Hz, 1H), 1.46-1.38 (m, 2H), 1.29 (td, J = 12.3, 4.4 Hz, 2H).	2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
------------------------------	--	---	-----	---	--	---



Compound 26	(S)-N-(4-(4-amino-1-methyl-7-(6-methylpyridin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		50%	(Method A): 2.80 min, m/z: 583.2 [M+H]⁺.	(400 MHz, DMSO-d₆): 8.53 (d, J = 2.3 Hz, 1H), 7.80 (dd, J = 7.9, 2.4 Hz, 1H), 7.57 (q, J = 5.6, 5.0 Hz, 3H), 7.42 (d, J = 8.0 Hz, 1H), 7.36 (d, J = 7.9 Hz, 1H), 7.21-7.12 (m, 4H), 5.95 (s, 2H), 5.66 (d, J = 6.3 Hz, 1H), 3.56 (s, 3H), 2.54 (s, 3H), 1.58 (d, J = 6.2 Hz, 3H).	2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
Compound 25	(S)-N-(4-(4-amino-1-methyl-7-(pyridin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		49%	(Method A): 2.94 min, m/z: 569.2 [M+H]⁺.	(400 MHz, DMSO-d₆): 8.68 (d, J = 2.3 Hz, 1H), 8.63 (dd, J = 4.8, 1.7 Hz, 1H), 7.93 (dt, J = 7.8, 2.0 Hz, 1H), 7.61 (s, 1H), 7.59-7.54 (m, 2H), 7.51 (dd, J = 7.8, 4.8 Hz, 1H), 7.42 (d, J = 8.0 Hz, 1H), 7.20-6.89 (m, 5H).	3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine



					5.99 (s, 2H), 5.65 (q, J = 6.2 Hz, 1H), 3.56 (s, 3H), 1.58 (d, J = 6.3 Hz, 3H).	
Compound 32	(S)-N-(4-(4-amino-1-methyl-7-(3-methylpyridin-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		25%	(Method A): 3.04 min, m/z: 583.2 [M+H] ⁺ .	(400 MHz, MeOD- <i>d</i> ₄): 8.54 (s, 1H), 8.48 (d, J = 5.0 Hz, 1H), 7.49 (dd, J = 5.8, 2.3 Hz, 3H), 7.39 (dd, J = 5.1, 2.0 Hz, 1H), 7.17 (d, J = 7.9 Hz, 1H), 7.11-7.03 (m, 3H), 6.64 (s, 1H), 5.57 (d, J = 6.4 Hz, 1H), 3.48 (s, 3H), 2.17 (s, 3H), 1.69 (d, J = 6.4 Hz, 3H).	3-methylpyridin-4-ylboronic acid
Compound 27	(S)-N-(4-(4-amino-7-(2-methoxypyridin-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		63%	(Method A): 3.25 min, m/z: 599.2 [M+H] ⁺ .	(400 MHz, DMSO- <i>d</i> ₆): 8.22 (d, J = 4.4 Hz, 1H), 9.59 (s, 1H), 7.55 (m, 3H), 7.18 (d, J = 7.6 Hz, 1H), 7.17 (d, J = 7.6 Hz, 2H), 7.11 (m, 3H), 6.89 (s, 1H), 6.83 (s, J = 52.3 Hz, 1H), 5.57 (d, J = 6.0 Hz, 1H), 5.49 (s, 1H),	2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine



						3.97 (s, 3H), 3.68 (s, 3H), 1.69 (d, J = 5.6 Hz, 1H)	
Compound 23	(S)-N-(4-(4-amino-1-methyl-7-(2-(trifluoromethyl)pyridin-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		50%	(Method A): 3.26 min, m/z: 637.2 [M+H] ⁺ .		4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)pyridine	





Compound 57	(S)-N-(4-(4-amino-7-(2-(difluoromethyl)pyridin-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide 	34%	(Method A): 3.28 min, m/z: 619.2 [M+H]⁺.	(400 MHz, DMSO-d₆): 8.74 (d, J = 5.2 Hz, 1H), 7.80 (s, 1H), 7.71 (s, 2H), 7.57 (q, J = 4.8 Hz, 2H), 7.42 (d, J = 8.0 Hz, 1H), 7.19-7.12 (m, 4H), 7.01 (t, J = 52.8 Hz, 1H), 5.99 (s, 2H), 5.66 (q, J = 6.0 Hz, 1H), 3.62 (s, 3H), 1.59 (d, J = 6.4 Hz, 3H).	2-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
Compound 48	(S)-N-(4-(4-amino-7-(2-(tert-butyl)pyridin-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide 	22%	(Method A): 3.42 min, m/z: 625.6 [M+H]⁺.	(400 MHz, MeOH-d₄): 8.58 (dd, J = 5.0, 0.8 Hz, 1H), 7.61 (s, 1H), 7.57-7.53 (m, 2H), 7.49 (dd, J = 8.6, 5.4 Hz, 2H), 7.33 (dd, J = 5.1, 1.7 Hz, 1H), 7.19 (dd, J = 8.1, 1.8 Hz, 1H), 7.12 (d, J = 1.8 Hz, 1H), 7.06 (t, J = 8.8 Hz, 2H), 6.70 (s, 1H), 5.57 (q, J = 6.3 Hz, 1H), 3.65	2-(tert-butyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine



			(S)-N-(4-(4-amino-7-(2-(dimethylamino)pyridin-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		57%	(Method A): 2.75 min, m/z: 612.2 [M+H] ⁺ .		(s, 3H), 1.70 (d, J = 6.4 Hz, 3H), 1.42 (s, 9H). (400 MHz, DMSO-d₆): 8.14 (d, J = 4.8 Hz, 1H), 7.64 (s, 1H), 7.57 (t, J = 5.6 Hz, 2H), 7.42 (d, J = 8.0 Hz, 1H), 7.19-7.12 (m, 4H), 7.03 (t, J = 52.4 Hz, 1H), 6.67 (s, 2H), 6.02 (s, 2H), 5.65 (q, J = 6.0 Hz, 1H), 3.66 (s, 3H), 3.07 (s, 6H), 1.59 (d, J = 6.0 Hz, 3H).		N,N-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine
--	--	--	--	---	-----	---	--	---	--	---



Compound 29	(S)-N-(4-(4-amino-7-(1-(2-methoxyethyl)-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide 	60%	(Method A): 2.99 min, m/z: 616.2 [M+H]⁺.	(400 MHz, DMSO-d₆): 7.93 (s, 1H), 7.61 (s, 1H), 7.59-7.55 (m, 3H), 7.41 (d, J = 8.0 Hz, 1H), 7.19-7.12 (m, 4H), 7.02 (t, J = 52.4 Hz, 1H), 5.94 (s, 2H), 5.65 (q, J = 6.0 Hz, 1H), 4.32 (t, J = 5.6 Hz, 2H), 3.73 (t, J = 5.6 Hz, 2H), 3.70 (s, 3H), 1.58 (q, J = 6.0 Hz, 3H).	1-(2-methoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
Compound 33	(S)-N-(4-(4-amino-7-(3,5-dimethylisoxazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide 	21%	(Method A): 3.15 min, m/z: 587.2 [M+H]⁺.	(400 MHz, MeOD-d₄): δ 10.82 (s, 1H), 7.58 (t, J = 8.4 Hz, 2H), 7.55 (s, 1H), 7.40 (d, J = 8.4 Hz, 1H), 7.18 (t, J = 8.8 Hz, 4H), 7.14-6.88 (m, 1H), 6.06 (s, 2H), 5.68 (q, J = 6.0 Hz, 1H), 3.61 (s, 3H), 2.28 (s, 3H), 2.06 (s, 3H).	3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2-oxazole


					3H), 1.57 (d, J = 6.0 Hz, 3H).	
Compound 15	(S)-N-(4-(4-amino-7-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		51%	(Method A): 3.23 min, m/z: 602.2 [M+H] ⁺ .	(400 MHz, DMSO-d ₆): 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]ethan-1-ol (m, 4H), 7.41 (d, J = 8.0 Hz, 1H), 7.19-6.88 (m, 5H), 5.81 (s, 2H), 5.68-5.63 (m, 1H), 4.94 (t, J = 4.4 Hz, 1H), 4.20 (t, J = 5.6 Hz, 2H), 3.80-3.77 (m, 2H), 3.71 (s, 3H), 1.58 (d, J = 6.4 Hz, 3H).	2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]ethan-1-ol
Compound 20	(S)-N-(4-(4-amino-1-methyl-7-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		35%	(Method A): 3.04 min, m/z: 572.2 [M+H] ⁺ .	(400 MHz, DMSO-d ₆): 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (m, 4H), 7.40 (d, J = 8.0 Hz, 1H), 7.20-6.84 (m, 5H), 5.89 (s, 1H), 5.63 (q, J = 6.2 Hz, 1H), 3.90 (s, 3H), 3.71 (s, 3H), 1.57 (d, J = 6.2 Hz, 3H).	1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole


Compound 18	(S)-N-(4-(4-amino-1-methyl-7-(pyridin-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		42%	(Method A): 2.95 min, m/z: 569.2 [M+H]⁺.	(400 MHz, DMSO-d₆): 8.64 (d, J = 6.0 Hz, 2H), 7.64 (s, 1H), 7.56 (dd, J = 8.6, 5.6 Hz, 2H), 7.53-7.50 (m, 2H), 7.41 (d, J = 8.0 Hz, 1H), 7.20-6.86 (m, 5H), 5.94 (s, 2H), 5.65 (q, J = 6.3 Hz, 1H), 3.61 (s, 3H), 1.58 (d, J = 6.3 Hz, 3H).	4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
Compound 34	(S)-N-(4-(4-amino-7-benzyl-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		21%	(Method A): 3.35 min, m/z: 582.2 [M+H]⁺.	(400 MHz, DMSO-d₆): 11.35 (s, 1H), 7.56 (s, 3H), 7.39 (d, J = 8.4 Hz, 1H), 7.33 (d, J = 7.2 Hz, 2H), 7.25-7.10 (m, 8H), 6.98 (t, J = 52.4 Hz, 1H), 6.27 (s, 2H), 5.65 (q, J = 6.0 Hz, 1H), 4.31 (s, 2H), 3.89 (s, 3H), 1.56 (d, J = 6.4 Hz, 3H).	2-benzyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane



Compound 61	(S)-N-(4-(4-amino-1-methyl-7-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide 		51%	(Method A): 2.95 min, m/z: 723.2 [M+H] ⁺ .	(400 MHz, DMSO-d ₆): 10.62 (bs, 1H), 8.00 (s, 1H), 7.60-7.55 (m, 4H), 7.41-7.39 (m, 1H), 7.20-6.86 (m, 5H), 5.73 (bs, 2H), 5.65 (q, J = 12.8, 6.4 Hz, 1H), 4.26-4.19 (m, 1H), 3.30-3.20 (m, 5H), 3.06-3.02 (m, 2H), 2.59-2.52 (m, 2H), 2.05-1.96 (m, 4H), 1.58 (d, J = 6.4 Hz, 3H).	Intermediate E1
Compound 60	(S)-N-(4-(4-amino-1-methyl-7-(1-(2-(4-methylpiperazin-1-yl)ethyl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide 		17%	(Method A): 2.55 min, m/z: 684.1 [M+H] ⁺ .	(400 MHz, DMSO-d ₆): 7.92 (s, 1H), 7.57-7.52 (m, 4H), 7.39 (d, J = 8.0 Hz, 1H), 7.16 (t, J = 8.8 Hz, 2H), 7.07 (dd, J = 8.0, 1.6 Hz, 1H), 7.03 (s, 1H), 6.82 (t, J = 53.2 Hz, 1H), 5.66 - 5.63 (m, 3H), 4.28 (t, J = 6.0 Hz, 2H), 3.70 (s, 3H), 2.79 (t, J = 6.4 Hz, 2H), 2.70 (bs, 4H), 2.55 (bs, 4H), 2.44	Intermediate E2



84	(S)-N-(4-(4-amino-7-(3-chlorophenyl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		26%	(Method A): 2.99 min, m/z: 602.1 [M+H] ⁺ .	(s, 3H), 1.56 (d, J = 6.0 Hz, 3H). (400 MHz, DMSO-d ₆) 10.60 (s, 1H), 7.53 (dt, J = 25.8, 8.3 Hz, 7H), 7.41 (d, J = 7.9 Hz, 1H), 7.21-7.08 (m, 4H), 5.83 (s, 2H), 5.66 (q, J = 6.3 Hz, 1H), 3.55 (s, 3H), 1.58 (d, J = 6.1 Hz, 3H).	2-(3-chlorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
85	(S)-N-(4-(4-amino-7-(2-chlorophenyl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		35%	(Method A): 2.93 min, m/z: 602.1 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 7.63 (dd, J = 6.3, 3.0 Hz, 1H), 7.59 (td, J = 5.7, 2.7 Hz, 2H), 7.55 (s, 1H), 7.50 (qd, J = 6.4, 5.6, 2.1 Hz, 2H), 7.45-7.39 (m, 1H), 7.22-7.17 (m, 3H), 7.16-6.88 (m, 1H), 6.01 (s, 2H), 5.76-5.66 (m, 1H), 3.46 (s, 3H).	2-(2-chlorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane



86	(S)-N-(4-(4-amino-1-methyl-7-phenyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		55%	(Method A): 2.81 min, m/z: 568.2 [M+H] ⁺ .	1.58 (d, J = 6.2 Hz, 3H). (400 MHz, DMSO-d ₆) 10.80 (s, 1H), 7.60-7.56 (m, 3H), 7.58-7.41 (m, 6H), 7.20-7.15 (m, 4H), 7.03 (t, J = 52 Hz, 1H), 6.04 (s, 2H), 5.66 (d, J = 8 Hz, 1H), 3.53 (s, 3H), 1.59 (t, J = 8 Hz, 3H).	phenylboronic acid
87	(S)-N-(4-(4-amino-7-(4-chlorophenyl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		27%	(Method A): 2.99 min, m/z: 602.1 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 10.60 (s, 1H), 7.53 (dt, J = 25.8, 8.3 Hz, 7H), 7.41 (d, J = 7.9 Hz, 1H), 7.21-7.08 (m, 4H), 5.83 (s, 2H), 5.66 (q, J = 6.3 Hz, 1H), 3.55 (s, 3H), 1.58 (d, J = 6.1 Hz, 3H).	2-(4-chlorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane



105	(S)-N-(4-(4-amino-1-methyl-7-(2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		46%	(Method A): 2.65 min, m/z: 669.0 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 8.29 (s, 1H), 8.16 (s, 1H), 7.82 (d, J = 8.3 Hz, 1H), 7.58 (s, 1H), 7.42 (s, 1H), 7.24 (d, J = 8.3 Hz, 1H), 6.19 (s, 2H), 4.08 (d, J = 7.2 Hz, 2H), 3.96 (s, 3H), 3.53 (q, J = 6.8 Hz, 4H), 2.81 (d, J = 11.1 Hz, 2H), 2.19 (s, 3H), 1.95-1.88 (m, 2H), 1.50 (d, J = 12.4 Hz, 2H), 1.33 (d, J = 6.8 Hz, 6H).	2-(4-methylpiperazin-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine
-----	--	---	-----	---	--	--



107	(S)-N-(4-(4-amino-1-methyl-7-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		75%	(Method A): 2.56 min, m/z: 667.2 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 8.19 (s, 1H), 7.68 (d, J = 7.2 Hz, 1H), 7.55 (t, J = 6.4 Hz, 2H), 7.51 (s, 1H), 7.39 (d, J = 8.0 Hz, 1H), 7.16 (t, J = 8.8 Hz, 2H), 7.10-7.05 (m, 2H), 6.98 (d, J = 8.8 Hz, 1H), 6.87 (s, 0.5H), 6.74 (s, 0.2H), 5.77 (s, 2H), 5.65 (q, J = 6.0 Hz, 1H), 3.70 (s, 4H), 3.61 (s, 3H), 2.83 (s, 4H), 1.56 (d, J = 6.0 Hz, 3H), 1.23 (s, 3H).	1-methyl-4-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl]piperazine
-----	--	---	-----	---	--	--



110	(S)-N-(4-(4-amino-1-methyl-7-(2-morpholinopyrimidin-5-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		71%	(Method A): 3.05 min, m/z: 655.0 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 10.77 (s, 1H), 8.50 (s, 2H), 7.58-7.55 (m, 3H), 7.40 (d, J = 8.0 Hz, 1H), 7.19-7.14 (m, 3H), 7.12 (s, 0.5H), 7.09 (s, 1H), 7.01 (s, 0.3H), 6.88 (s, 0.2H), 5.91 (s, 2H), 5.65 (q, J = 5.6 Hz, 1H), 3.75 (d, J = 4.8 Hz, 4H), 3.70 (d, J = 4.4 Hz, 4H), 3.68 (s, 3H), 1.58 (d, J = 6.4 Hz, 3H).	4-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl]morpholine
114	(S)-N-(4-(4-amino-1-methyl-7-(2-(pyrrolidin-1-yl)pyrimidin-5-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		49%	(Method A): 3.31 min, m/z: 639.0 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 8.45, 7.60-7.56 (m), 7.42 (d, J = 8.0 Hz), 7.21-7.11 (m), 6.98 (t, J = 52.6 Hz), 6.14, 5.66 (q, J = 6.1 Hz), 3.69, 3.54 (t, J = 6.5 Hz), 1.99-1.95 (m), 1.59 (d, J = 6.3 Hz).	2-(pyrrolidin-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine


106	(S)-N-(4-(4-amino-7-(2-(dimethylamino)pyrimidin-5-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		47%	(Method A): 3.00 min, m/z: 613.0 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 10.58 (s, 1H), 8.45 (s, 1H), 7.56 (q, J = 4 Hz, 2H), 7.52 (s, 1H), 7.40 (d, J = 8 Hz, 1H), 7.17 (t, J = 10 Hz, 2H), 7.10 (d, J = 8 Hz, 1H), 7.07 (s, 1H), 6.92 (t, J = 8 Hz, 1H), 5.77 (s, 2H), 5.65 (q, J = 20 Hz, 1H), 3.67 (s, 3H), 3.18 (s, 6H), 1.57 (d, J = 8 Hz, 3H)	N,N-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine
138	(S)-N-(4-(4-amino-1-methyl-7-(1-(2-(methylamino)pyrimidin-5-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		41%	(Method A): 2.92 min, m/z: 665.1 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 8.95 (s, 1H), 8.37 (s, 2H), 7.92 (s, 1H), 7.58-7.53 (m, 3H), 7.41 (d, J = 8 Hz, 1H), 7.23 (q, J = 5.2 Hz, 1H), 7.19-7.10 (m, 4H), 6.99 (t, J = 52 Hz, 1H), 6.39 (s, 1H), 5.78 (s, 2H), 5.75 (s, 1H), 5.65 (q, J = 5.2 Hz, 1H), 3.68 (s, 3H), 2.85 (d, J = 4 Hz, 3H), 1.58 (d, J = 8 Hz, 3H).	N-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine



115	(S)-N-(4-(4-amino-1-methyl-7-(6-morpholinopyridin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		38%	(Method A): 3.07 min, m/z: 654.0 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 8.19 (d, J = 1.9 Hz), 7.68 (dd, J = 8.7, 2.1 Hz), 7.60-7.54 (m), 7.41 (d, J = 8.0 Hz), 7.21-7.09 (m), 6.93 (d, J = 8.8 Hz), 5.76, 5.66 (d, J = 6.4 Hz), 3.76-3.70 (m), 3.62, 3.53-3.49 (m), 1.58 (d, J = 6.1 Hz).	4-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl]morpholine
117	(S)-N-(4-(4-amino-1-methyl-7-(6-(trifluoromethyl)pyridin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		25%	(Method A): 3.44 min, m/z: 637.0 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 8.90 (d, J = 2.1 Hz, 1H), 8.22 (dd, J = 8.1, 2.1 Hz, 1H), 7.99 (d, J = 8.1 Hz, 1H), 7.69 (s, 1H), 7.61-7.53 (m, 2H), 7.42 (d, J = 8.0 Hz, 1H), 7.21-7.11 (m, 4H), 6.95 (d, J = 52.6 Hz, 1H), 5.96 (s, 2H), 5.65 (d, J = 6.4 Hz,	5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)pyridine



160	(S)-N-(4-(4-amino-1-methyl-7-(3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		(Method A): 2.62 min, m/z: 638.2 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 1-methyl-6-(4,4,5,5-tetramethyl-1,3,2-oxadiazol-2-yl)-1,3-dioxaborolan-2-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (m, 6H), 7.01 (s, 1H), 6.99 (t, J = 52 Hz, 1H), 5.78 (s, 2H), 5.65 (q, J = 6.8 Hz, 1H), 3.51 (s, 3H), 3.33 (s, 3H), 1.58 (d, J = 8 Hz, 3H).	1H), 3.59 (s, 3H), 1.59 (d, J = 6.2 Hz, 3H).
161	(S)-N-(4-(4-amino-7-(1,3-dimethyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		(Method A): 2.72 min, m/z: 652.2 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 1,3-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-oxadiazol-2-yl)-1,3-dioxaborolan-2-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (m, 7H), 6.99 (t, J = 52 Hz, 1H), 5.79 (s, 2H), 5.65 (q, J = 6.8 Hz, 1H), 3.52 (s, 3H), 3.38 (s, 3H), 3.35 (s, 3H), 1.58 (d, J = 4 Hz, 3H).	1H), 3.59 (s, 3H), 1.59 (d, J = 6.2 Hz, 3H).


165	(S)-N-(4-(4-amino-1-methyl-7-(1-methyl-2-oxoindolin-5-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		(Method A): 2.76 min, m/z: 637.2 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-2-one 10.66 (s, 1H), 7.59 (tetramethyl-1,3,2-dioxaborolan-2-yl)indolin-2-one 7.54 (m, 3H), 7.41 (d, J = 8 Hz, 1H), 7.34 (d, J = 8 Hz, 2H), 7.20-7.13 (m, 4H), 7.07 (d, J = 8 Hz, 1H), 7.01 (t, J = 52 Hz, 1H), 5.79 (s, 2H), 5.66 (q, J = 6.8 Hz, 1H), 3.62 (s, 2H), 3.56 (s, 3H), 3.17 (s, 3H), 1.58 (d, J = 4 Hz, 3H)
166	(S)-N-(4-(4-amino-1-methyl-7-(1-methyl-1H-indazol-5-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		(Method A): 2.74 min, m/z: 622.2 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole 10.66 (s, 1H), 8.10 (s, 1H), 7.80 (s, 1H), 7.73 (dioxaborolan-2-yl)-1H-indazole (d, J = 12 Hz, 1H), 7.59-7.56 (m, 3H), 7.48 (d, J = 8 Hz, 1H), 7.42 (d, J = 8 Hz, 1H), 7.20-7.14 (m, 4H), 7.01 (t, J = 52 Hz, 1H), 5.81 (s, 2H), 5.67 (q, J = 5.2 Hz, 1H), 4.10 (s, 3H)



116	(S)-N-(4-(4-amino-1-methyl-7-(1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		39%	(Method A): 3.17 min, m/z: 640.0 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(2,2,2-trifluoroethyl)-1H-pyrazole 3H), 3.49 (s, 3H), 1.59 (d, J = 4 Hz, 3H) 8.07, 7.77, 7.57, 7.41 (d, J = 8.0 Hz), 7.20-7.10 (m), 6.94 (d, J = 52.6 Hz), 5.78, 5.66 (d, J = 6.3 Hz), 5.21 (q, J = 9.1 Hz), 3.68, 1.58 (d, J = 6.2 Hz).
131	(S)-N-(4-(4-amino-1-methyl-7-(1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide			(Method A): 3.27 min, m/z: 654.1 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(3,3,3-trifluoropropyl)-1H-pyrazole 8.02 (s, 1H), 7.67 (s, 1H), 7.59 (dd, J = 8.2, 1H), 7.55 (s, 1H), 7.43 (d, J = 8.0 Hz, 1H), 7.18 (dd, J = 19.6, 10.6 Hz, 4H), 6.95 (d, J = 52.7 Hz, 1H), 5.76 (s, 2H), 5.68 (q, J = 6.2 Hz, 1H), 4.48 (t, J = 6.7 Hz, 2H), 3.71 (s, 3H), 3.02-


134	(S)-N-(4-(4-amino-1-methyl-7-(1-(trifluoromethyl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide				(Method A): 3.37 min, m/z: 626.0 [M+H] ⁺ .	2.89 (m, 2H), 1.61 (d, J = 6.2 Hz, 3H).	4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
-----	---	---	--	--	---	---	---



123	(S)-N-(4-(4-amino-7-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		30%	(Method A): 3.39 min, m/z: 608.0 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 1-(Difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 8.46 (s, 1H), 8.01 (s, 1H), 7.79 (d, J = 59.1 Hz, 1H), 7.60 (s, 3H), 7.41 (d, J = 8.0 Hz, 1H), 7.20-7.09 (m, 4H), 6.94 (d, J = 52.7 Hz, 1H), 5.81 (s, 2H), 5.65 (q, J = 6.2 Hz, 1H), 3.70 (s, 3H), 1.58 (d, J = 6.2 Hz, 3H).
142	N-(4-(4-amino-1-methyl-7-(1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide			(Method A): 3.31 min, m/z: 654.1 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole 8.16 (s, 1H), 7.76 (s, 2H), 7.59-7.55 (m, 3H), 7.41 (d, J = 8 Hz, 1H), 7.19-7.11 (m, 4H), 7.10 (t, J = 32 Hz, 1H), 5.86 (s, 2H), 5.66 (q, J = 6.8 Hz, 1H), 5.49-5.41 (m, 1H), 3.68 (s, 3H), 1.74 (d, J = 8 Hz, 3H), 1.58 (d, J = 4 Hz, 3H).



97	(S)-N-(4-(4-amino-7-(1-(1-hydroxy-2-methylpropan-2-yl)-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		53%	(Method A): 3.07 min, m/z: 630.3 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 2-methyl-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]propan-1-ol
75	(S)-N-(4-(4-amino-7-(1-(2-(3,3-dimethylazetidin-1-yl)ethyl)-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		52%	(Method A): 2.58 min, m/z: 669.2 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) Intermediate E3



82	(S)-N-(4-(4-amino-1-methyl-7-(1-(2-(methylamino)ethyl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		19%	(Method A): 2.01 min, m/z: 615.3 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 7.95 (s, 1H), 7.68 (s, 1H), 7.57-7.49 (m, 3H), 7.37- 7.35 (m, 1H), 7.16-7.11 (m, 2H), 6.96-6.93 (m, 1H), 6.88-6.87 (m, 1H), 6.57-6.30 (m, 1H), 5.68-5.64 (m, 3H), 4.40-4.37 (m, 2H), 3.70 (s, 3H), 3.29-3.26 (m, 2H), 2.52 (s, 3 H), 1.53-1.51 (d, J = 6.4 Hz, 2H).	Intermediate E4
----	--	---	-----	---	---	-----------------



100	(S)-N-(4-(4-amino-7-(1-(2-(dimethylamino)ethyl)-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		33%	(Method A): 1.99 min, m/z: 629.2 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 7.93 (s, 1H), 7.59 (s, 1H), 7.57-7.52 (m, 3H), 7.42-7.38 (m, 1H), 7.19-7.14 (m, 2H), 7.13-7.04 (m, 2H), 6.96-6.69 (m, 1H), 5.75-5.63 (m, 3H), 4.31-4.28 (m, 2H), 3.70 (s, 3H), 2.85-2.82 (m, 2H), 2.29 (s, 6H), 1.57-1.56 (d, J = 6.4 Hz, 3H).	Intermediate E5
73	N-(4-(4-amino-1-methyl-7-(1-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		24%	(Method A): 2.80 min, m/z: 681.5 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 10.96 (s, 1H), 8.29 (s, 1H), 8.00 (d, J = 47.3 Hz, 1H), 7.80 (s, 1H), 7.70 (s, 2H), 7.60-7.53 (m, 3H), 7.40 (d, J = 8.1 Hz, 1H), 7.13 (dt, J = 27.3, 9.1 Hz, 4H), 5.65 (q, J = 6.2 Hz, 1H), 3.72 (s, 3H), 3.06-2.93 (m, 2H), 2.82 (d, J = 20.6 Hz, 3H), 2.71-2.56 (m, 4H), 2.09-2.00 (m, 2H), 1.73 (t, J	Intermediate E6



126	(S)-N-(4-(4-amino-1-methyl-7-(1-methyl-1H-pyrrol-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		3%	(Method A): 3.21 min, m/z: 571.1 [M+H] ⁺ .	= 7.1 Hz, 2H), 1.57 (d, J = 6.2 Hz, 3H).	1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrole
-----	---	---	----	---	--	---


83	(S)-N-(4-(4-amino-7-(5-cyano-1-methyl-1H-pyrrol-3-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		3%	(Method C): 4.08 min, m/z: 596.0 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 7.63-7.49 (m, 3H), 7.44-7.33 (m, 2H), 7.15 (td, J = 15.5, 13.5, 6.9 Hz, 5H), 6.95 (d, J = 52.6 Hz, 1H), 5.77 (s, 2H), 5.66 (d, J = 6.4 Hz, 1H), 3.83 (s, 3H), 3.72 (s, 3H), 1.58 (d, J = 6.2 Hz, 3H).	Intermediate E7
98	(S)-N-(4-(4-amino-7-(1-(3-(cyanomethyl)oxetan-3-yl)-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		9%	(Method A): 3.04 min, m/z: 653.0 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 8.31 (s, 1H), 7.82 (s, 1H), 7.60 (s, 1H), 7.57 (dd, J = 8.6, 5.7 Hz, 2H), 7.41 (d, J = 8.0 Hz, 1H), 7.19-7.11 (m, 4H), 7.01 (t, J = 52 Hz, 1H), 5.78 (s, 2H), 5.66 (q, J = 6.3 Hz, 1H), 5.08 (d, J = 7.2 Hz, 2H), 4.82 (d, J = 7.2 Hz, 2H), 3.71 (s, 3H), 3.66 (s, 2H), 1.59 (d, J = 6.2 Hz, 3H).	Intermediate E8

101	N-(4-(4-amino-7-(1-(1-(isopropyl(methyl)amino)propan-2-yl)-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		46%	(Method C): 2.16 min, m/z: 671.3 [M+H] ⁺ .	(400MHz, DMSO-d ₆) 7.93 (s, 1H), 7.61-7.53 (m, 4H), 7.40-7.38 (m, 1H), 7.18-7.06 (m, 3H), 7.02-6.56 (m, 1H), 5.67-5.63 (m, 3H), 4.54-4.49 (m, 1H), 3.70 (s, 3H), 2.83-2.67 (m, 3H), 2.20 (s, 3H), 1.58-1.56 (d, J = 6.4 Hz, 3H), 1.46-1.44 (d, J = 6.8 Hz, 3H), 0.95-0.84 (m, 6H).	Intermediate E9
96	(S)-N-(4-(4-amino-7-(1-(1-cyanocyclopropyl)-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		43%	(Method C): 2.94 min, m/z: 623.3 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 10.59 (brs, 1H), 8.23 (s, 1H), 7.79 (s, 1H), 7.59-7.55 (m, 3H), 7.41 (d, J = 7.6 Hz, 1H), 7.19-6.88 (m, 5H), 5.77 (brs, 2H), 5.66 (q, J = 12.8, 6.4 Hz, 1H), 3.70 (s, 3H), 1.96-1.93 (m, 2H), 1.90-1.86 (m, 2H), 1.58 (d, J = 6.0 Hz, 3H).	Intermediate E10


103	(S)-N-(4-(4-amino-1-methyl-7-(1-(1-(methyl-d3)piperidin-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		19%	(Method A): 2.54 min, m/z: 658.1 [M+H] ⁺ .	(400MHz, DMSO-d ₆) 7.97 (s, 1H), 7.61 (s, 1H), 7.55-7.52 (m, 3H), 7.37 (d, J = 8 Hz, 1H), 7.15 (t, J = 8.8 Hz, 2H), 7.02 (dd, J = 1.2, 8.4 Hz, 2H), 7.98 (s, 1H), 6.70 (t, J = 53.6 Hz, 1H), 5.67-5.62 (m, 3H), 4.33-4.26 (m, 1H), 3.67 (s, 3 H), 3.13-3.10 (m, 3H), 2.11-2.00 (m, 5H), 1.54 (d, J = 5.6 Hz, 3H).	Intermediate E11
93	N-(4-(4-amino-1-methyl-7-(1-(1-methylpyrrolidin-3-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		25%	(Method A): 2.79 min, m/z: 641.3 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 8.03 (s, 1H), 7.66 (s, 1H), 7.57-7.52 (m, 3H), 7.39 (d, J = 8.1 Hz, 1H), 7.16 (t, J = 8.9 Hz, 2H), 7.07 (dd, J = 8.1, 1.7 Hz, 1H), 7.03 (d, J = 1.5 Hz, 1H), 6.84 (t, J = 53.2 Hz, 1H), 5.71 (s, 2H), 5.65 (q, J = 6.2 Hz, 1H), 5.10 (tt, J = 8.8, 4.6 Hz, 1H), 3.69 (s, 4H), 3.33-3.27 (m, 3H), 3.20 (d, J = 4.2 Hz, 1H), 3.14 (d, J =	Intermediate E16

76	(S)-N-(4-(4-amino-7-(1-(1-isopropylazetidin-3-yl)-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		21%	(Method A): 3.10 min, m/z: 655.1 [M+H] ⁺ .	16.4 Hz, 3H), 2.98-2.88 (m, 2H), 2.58 (s, 3H), 1.56 (d, J = 6.3 Hz, 3H).	Intermediate E17
92	(S)-N-(4-(4-amino-1-methyl-7-(1-(1-methylazetidin-3-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		18%	(Method A): 3.05 min, m/z: 627.0 [M+H] ⁺ .	(400 MHz, MeOD-d ₄) 7.94 (s, 1H), 7.69 (s, 1H), 7.54-7.45 (m, 3H), 7.36 (d, J = 8.0 Hz, 1H), 7.08-6.99 (m, 3H), 6.90 (d, J = 1.8 Hz, 1H), 6.36 (t, J = 54.8 Hz, 1H), 5.51 (q, J = 6.3 Hz, 1H), 5.09 (p, J = 7.2 Hz, 1H), 3.90 (td, J = 7.3, 1.8 Hz, 2H), 3.72 (s, 3H), 3.67 (dd,	Intermediate E18

					$J = 8.9, 7.0 \text{ Hz, 2H), 2.49 (s, 3H), 1.65 (d, } J = 6.4 \text{ Hz, 3H).}$	
77	(S)-N-(4-(4-amino-1-methyl-7-(1-(1-(2,2,2-trifluoroethyl)azetidin-3-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		33%	(Method C): 3.00 min, m/z: 695.1 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 10.62 (s, 1H), 8.11 (s, 1H), 7.7 (s, 1H), 7.59-7.55 (m, 3H), 7.40 (d, J = 8.0 Hz, 1H), 7.19-7.11 (m, 4 H), 7.00-6.87 (m, 1H), 5.75 (s, 2H), 5.67-5.63 (m, 1H), 5.17-5.09 (m, 1H), 3.92 (t, J = 7.6 Hz, 2H), 3.74-3.71 (m, 5H), 3.40-3.35 (m, 2H), 1.58 (d, J = 6.4 Hz, 3H).	Intermediate E19
81	2-(4-(4-amino-3-(4-((difluoromethyl)sulfonamido)-3-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-7-yl)-1H-pyrazol-1-yl)-N-isopropyl-N-methylpropanamide		36%	(Method A): 2.66 min, m/z: 685.3 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 10.61 (s, 1H), 8.00-7.94 (m, 1H), 7.59-7.53 (m, 4H), 7.42-7.40 (m, 1H), 7.19-6.86 (m, 5H), 5.75-5.74 (m, 2H), 5.70-5.63 (m, 1.5H), 5.58-5.53 (m, 0.5H), 4.67-4.60	Intermediate E20

168	N-(4-(4-amino-7-(1-(3-(dimethylamino)cyclopentyl)-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		11%	(Method A): 2.34 min, m/z: 669.2 [M+H] ⁺	(400 MHz, DMSO-d ₆) Intermediate E22 8.25 (s, 1H), 7.97 (s, 1H), 7.62 (s, 1H), 7.56-7.51 (m, 3H), 7.36 (d, J = 8 Hz, 1H), 7.14 (t, J = 8.4 Hz, 2H), 7.01 (dd, J = 2, 8 Hz, 1H), 6.96 (d, J = 2 Hz, 1H), 6.62 (t, J = 5.4 Hz, 1H), 5.75-5.62 (m, 3H), 4.88 (s, 1H), 3.67 (s, 3H), 3.57-3.49 (m, 1H), 2.58 (s, 6H), 2.32-1.74 (m, 7H), 1.54 (d, J = 6 Hz, 3H)
-----	--	---	-----	---	--


General procedure B for the Suzuki reaction followed by acidic deprotection between intermediate A1B1 and Boc protected boronate esters






A mixture of N-(4-{4-amino-7-iodo-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl)-1,1-difluoromethanesulfonamide (1 eq), Boc protected boronate ester (1.1 eq), Na₂CO₃ (3 eq) and Pd(dppf)Cl₂ (0.1eq) in degassed 1,4- dioxane/H₂O (4/1, 0.2 M) was stirred at 100 °C under N₂ overnight (or at 80 °C for 2h under MW irradiation). The mixture was diluted with water and extracted with EtOAc (3 x). The combined organics were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography (DCM/MeOH) to give the Boc protected products.



The solids were dissolved in HCOOH neat (2M) and the reaction mixture was stirred at RT for 30 min or until completion. The reaction mixture was concentrated under reduced pressure and the residue was adjusted to pH=8 with a saturated aqueous Na₂CO₃ solution. The residue was further diluted with water and the organics were extracted with EtOAc (3 times). The combined organics were washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by prep-TLC (DCM/MeOH) followed by preparative HPLC (neutral condition method C) if needed to give the desired products


The following compounds were prepared following the **General procedure B**

Compound No	Name	Structure	Yield (over 2 steps)	LCMS data	¹ H NMR data	Boronate ester
Compound 59	(S)-N-(4-(4-amino-1-methyl-7-(1-(piperidin-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		17%	LCMS (Method A): 2.72 min, m/z: 641.2 [M+H] ⁺ .	(400 MHz, DMSO-d ₆): 7.89 (s, 1H), 7.63 (s, 1H), 7.51 - 7.48 (m, 3H), 7.12 (t, J = 8.4 Hz, 1H), 6.91 (dd, J = 8.0, 0.8 Hz, 1, 3, 2-1H), 6.84 (s, 1H), 6.32 (t, J = 54.8 Hz, 1H), 5.64 - 5.62 (m, 3H), 4.49 - 4.44 (m, 1H), 3.65 (s, 3H), 3.34-3.32 (m, 2H), 2.96 (m, 2H), 2.20 (m, 4H), 1.51 (d, J = 6.4 Hz, 3H).	4-[4-tert-butyl (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]piperidine-1-carboxylate


95	N-(4-(4-amino-1-methyl-7-(1-(5-methylpiperidin-3-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		26%	(Method A): 2.67 min, m/z: 655.2 [M+H] ⁺ .	(400 MHz, DMSO-d ₆): 9.26 (s, 1H), 8.15 (s, 1H), 7.74 (s, 1H), 7.56-7.53 (m, 3H), 7.39 (d, J = 8.0 Hz, 1H), 7.16 (t, J = 8.8 Hz, 2H), 7.07 (d, J = 8.0 Hz, 1H), 7.02 (s, 1H), 6.96 (s, 0.3H), 6.83 (s, 0.4H), 6.70 (s, 0.3H), 5.74 (s, 1H), 5.64 (q, J = 6.0 Hz, 1H), 4.78 (s, 1H), 3.77 (s, 2H), 3.72 (s, 3H), 3.17 (d, J = 12.0 Hz, 2H), 2.73 (t, J = 10.8 Hz, 1H), 2.24 (d, J = 14.0 Hz, 1H), 2.02-1.97 (m, 1H), 1.84-1.78 (m, 1H), 1.56 (d, J = 6.0 Hz, 3H), 0.97 (d, J = 6.8 Hz, 3H).	Intermediate E12
----	--	---	-----	---	--	------------------



88	N-(4-(4-amino-1-methyl-7-(1-(pyrrolidin-2-ylmethyl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		17%	(Method A): 2.06 min, m/z: 641.2 [M+H] ⁺ .	(400 MHz, DMSO-d ₆): 7.96 (s, 1H), 7.71 (s, 1H), 7.50 (d, J = 8.0 Hz, 3H), 7.36-7.34 (m, 1H), 7.12 (d, J = 12.0 Hz, 2H), 6.94-6.92 (m, 1H), 6.87-6.86 (brs, 1H), 5.65-5.64 (m, 3H), 4.46-4.33 (m, 2 H), 3.88-3.84 (m, 1H), 3.88 (s, 3H), 3.31-3.09 (m, 2H), 2.04-1.86 (m, 1H), 1.84-1.81 (m, 2H), 1.67-1.50 (m, 4 H).	Intermediate E13
94	(S)-N-(4-(4-amino-7-(1-(azetidin-3-yl)-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		13%	(Method A): 2.94 min, m/z: 613.0 [M+H] ⁺ .	(400 MHz, DMSO-d ₆): 9.23 (s, 1H), 8.12 (s, 1H), 7.88 (s, 1H), 7.61-7.54 (m, 3H), 7.42 (d, J = 8.0 Hz, 1H), 7.22-6.89 (m, 5H), 6.36 (s, 1H), 5.64 (q, J = 6.2 Hz, 1H), 5.49 (p, J = 7.6 Hz, 1H), 4.48-4.37 (m, 4H), 3.73 (s, 3H), 1.58 (d, J = 6.3 Hz, 3H).	tert-butyl 3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)azetidine-1-carboxylate



90	(S)-N-(4-(4-amino-1-methyl-7-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		14%	(Method A): 2.74 min, m/z: 613.2 [M+H] ⁺ .	(400 MHz, MeOD-d ₄): 8.29 (s, 1H), 7.66 (s, 1H), 7.55 (d, J = 8.1 Hz, 1H), 7.51-7.46 (m, 3H), 7.18 (d, J = 8.1 Hz, 1H), 7.11-7.04 (m, 3H), 5.57 (q, J = 6.4 Hz, 1H), 4.31 (t, J = 5.7 Hz, 2H), 4.06 (s, 2H), 3.74 (s, 3H), 3.47 (t, J = 5.7 Hz, 2H), 1.70 (d, J = 6.3 Hz, 3H).	tert-butyl bromo-6,7-dihydropyrazolo[1,5-a]pyrazine-5(4H)-carboxylate
78	(S)-N-(4-(7-(1-(2-azaspiro[3.3]heptan-6-yl)-1H-pyrazol-4-yl)-4-amino-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		26%	(Method A): 2.75 min, m/z: 653.2 [M+H] ⁺ .	(400 MHz, DMSO-d ₆): 8.00 (d, J = 2.4 Hz, 1H), 7.64 (d, J = 1.8 Hz, 1H), 7.58-7.52 (m, 3H), 7.40 (d, J = 8.0 Hz, 1H), 7.20-7.06 (m, 5H), 5.68 (d, J = 9.5 Hz, 2H), 5.65 (d, J = 6.3 Hz, 1H), 4.83 (p, J = 8.0 Hz, 1H), 4.23 (s, 1H), 4.14 (s, 1H), 3.95 (s, 1H), 3.86 (s, 1H), 3.70 (s, 3H), 2.74-2.65 (m, 4H), 1.74 (d, J = 5.2 Hz, 3H).	Intermediate E14



74	N-(4-(4-amino-7-(1-(azepan-4-yl)-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonyl amide		14%	(Method C): 3.15 min, m/z: 655.2 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 8.52 (s, 1H), 7.94-7.88 (m, 1H), 7.53-7.48 (m, 4H), 7.34-7.29 (m, 1H), 7.11 (t, J = 8.0 Hz, 2H), 6.89-6.81 (m, 2H), 6.38-6.10 (m, 1H), 5.67-5.60 (m, 3H), 4.48-4.42 (m, 1H), 3.65 (s, 3H), 2.91-2.70 (m, 3H), 2.11-1.97 (m, 6H), 1.76-1.72 (m, 1H), 1.63-1.57 (m, 1H), 1.49 (d, J = 6.4 Hz, 3H).	Intermediate E15
----	---	---	-----	---	--	------------------



The following compounds were prepared following the **General procedure A** with 1-(tetrahydro-2H-pyran-4-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole and intermediate B2-B16



Compound No	Name	Structure	LCMS data	¹ H NMR data	Intermediate B
121	(R)-N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		(Method C): 3.10 min, m/z: 642.0 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 10.64 (s, 1H), 8.02 (s, 1H), 7.61 (s, 1H), 7.58-7.53 (m, 3H), 7.40 (d, J = 8.0 Hz, 1H), 7.20-7.09 (m, 4H), 6.93 (d, J = 52.7 Hz, 1H), 5.74 (s, 2H), 5.65 (q, J = 6.2 Hz, 1H), 4.45 (tt, J = 10.3, 5.3 Hz, 1H), 4.00-3.93 (m, 2H), 3.69 (s, 3H), 3.48 (td, J = 11.4, 3.5 Hz, 2H), 2.00 (td, J = 11.2, 10.3, 4.5 Hz, 4H), 1.57 (d, J = 6.3 Hz, 3H).	B2

122	(S)-N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(3-chlorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		(Method A): 3.07 min, m/z: 658.0 [M+H] ⁺ . (400 MHz, DMSO-d ₆) 8.03 (s, 1H), 7.67 (s, 1H), 7.62 (s, 1H), 7.55 (s, 1H), 7.48 (d, J = 8.0 Hz, 1H), 7.43-7.31 (m, 3H), 7.15-7.09 (m, 2H), 7.00 (t, J = 52 Hz, 1H), 5.71-5.66 (m, 2H), 4.47-4.44 (m, 1H), 4.04-3.96 (m, 2H), 3.70 (s, 3H), 3.50-3.38 (m, 2H), 2.03-1.99 (m, 4H), 1.58 (d, J = 6.4 Hz, 3H).	B3
118	(S)-N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(2-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		(Method A): 2.98 min, m/z: 642.0 [M+H] ⁺ . (400 MHz, DMSO-d ₆) 8.06 (s, 1H), 7.67 (d, J = 8.0 Hz, 1H), 7.63 (s, 1H), 7.57 (s, 1H), 7.42 (d, J = 8.0 Hz, 1H), 7.35-7.30 (m, 1H), 7.22-7.14 (m, 3H), 7.02 (s, 1H), 6.88 (s, 0.2H), 6.23 (s, 1.5H), 5.81 (q, J = 6.0 Hz, 1H), 4.50-4.42 (m, 1H), 3.97 (d, J = 11.2 Hz, 2H), 3.69 (s, 3H), 3.50 (d, J = 11.2 Hz, 2H), 2.02-1.99 (m, 4H), 1.63 (d, J = 6.4 Hz, 3H).	B4



102	N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(4-fluorophenyl)-2-methoxyethoxy)phenyl difluoromethanesulfonamide		(Method A): 3.11 min, m/z: 672.1 [M+H] ⁺ .	(400 MHz, CDCl ₃) 7.75 (d, J = 8.4 Hz, 1H), 7.61 (s, 1H), 7.55 (s, 1H), 7.50 (s, 1H), 7.44-7.37 (m, 2H), 7.33 (dd, J = 8.4, 1.9 Hz, 1H), 7.08 (t, J = 8.6 Hz, 2H), 6.97 (d, J = 1.9 Hz, 1H), 6.38 (t, J = 53.6 Hz, 1H), 5.00 (dd, J = 9.4, 2.7 Hz, 1H), 4.42 (tt, J = 10.7, 4.8 Hz, 1H), 4.19-4.09 (m, 2H), 3.81 (t, J = 9.9 Hz, 1H), 3.73 (s, 3H), 3.65 (t, J = 6.6 Hz, 1H), 3.61-3.55 (m, 2H), 3.54 (s, 3H), 2.15 (qd, J = 12.6, 11.8, 4.3 Hz, 4H).	B5
132	N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(4-chloro-3-fluorobenzyl)oxy)phenyl difluoromethanesulfonamide		(Method A): 3.08 min, m/z: 662.0 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 8.04 (s, 1H), 7.73-7.66 (m, 1H), 7.64 (d, J = 7.7 Hz, 2H), 7.60 (d, J = 12.1 Hz, 1H), 7.43 (dd, J = 14.4, 8.3 Hz, 2H), 7.34 (d, J = 1.8 Hz, 1H), 7.23 (dd, J = 8.0, 1.8 Hz, 1H), 7.08-6.76 (m, 1H), 5.89 (s, 2H), 5.26 (s, 2H), 4.47 (tt, J = 10.3, 5.5 Hz, 1H), 4.04-3.94 (m, 2H), 3.74 (s, 3H), 3.50 (dt, J = 10.8, 5.4 Hz, 3H), 2.03 (q, J = 4.4 Hz, 3H).	B6

129	(S)-N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-methoxyphenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		(Method A): 1.70 min, m/z: 652.2 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 8.04 (d, J = 8.1 Hz, 1H), 7.64 (d, J = 6.9 Hz, 1H), 7.57 (s, 1H), 7.47-7.23 (m, 3H), 7.15-7.07 (m, 2H), 6.99 (d, J = 6.8 Hz, 1H), 6.93-6.86 (m, 2H), 6.08-5.51 (m, 3H), 4.49 (s, 1H), 4.00 (d, J = 10.9 Hz, 3H), 3.74 (s, 3H), 3.71 (s, 3H), 2.03 (d, J = 18.1 Hz, 5H), 1.60 (d, J = 6.2 Hz, 1H), 1.38-1.17 (m, 3H).	B7
130	N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((3-chlorobenzyl)oxy)phenyl)-1,1-difluoromethanesulfonamide		(Method A): 3.17 min, m/z: 644.1 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 8.03 (s, 1H), 7.68 (s, 1H), 7.63 (s, 1H), 7.58 (s, 1H), 7.50 (d, J = 7.2 Hz, 1H), 7.46-7.32 (m, 4H), 7.23 (dd, J = 8.1, 1.8 Hz, 1H), 6.93 (t, J = 52.8 Hz, 1H), 5.86 (s, 2H), 5.25 (s, 2H), 4.47 (tt, J = 10.5, 5.5 Hz, 1H), 3.98 (dt, J = 12.2, 3.0 Hz, 2H), 3.74 (s, 3H), 3.51 (dd, J = 11.2, 3.3 Hz, 2H), 2.03 (q, J = 4.4 Hz, 4H).	B8

136	N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((5-chloropyridin-2-yl)methoxy)phenyl)-1,1-difluoromethanesulfonamide		(Method A): 2.90 min, m/z: 645.1 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 8.64 (d, J = 2.4 Hz, 1H), 8.05 (s, 2H), 7.80 (d, J = 8.4 Hz, 1H), 7.62 (d, J = 22.2 Hz, 2H), 7.45 (d, J = 8.0 Hz, 1H), 7.33 (d, J = 8.7 Hz, 1H), 7.22 (d, J = 7.8 Hz, 1H), 6.89 (t, J = 53.1 Hz, 1H), 5.88 (s, 2H), 5.32 (s, 2H), 4.55-4.44 (m, 1H), 3.99 (d, J = 5.7 Hz, 2H), 3.75 (s, 3H), 3.54 (d, J = 3.4 Hz, 2H), 2.05 (d, J = 5.1 Hz, 4H).	B9
140	N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)cyclopropoxy)phenyl)-1,1-difluoromethanesulfonamide		(Method A): 3.10 min, m/z: 654.1 [M+H] ⁺ .	(400 MHz, CDCl ₃) 7.65 (d, J = 8.2 Hz, 1H), 7.60 (s, 1H), 7.54 (s, 1H), 7.46 (s, 1H), 7.24 (d, J = 1.9 Hz, 1H), 7.18 (d, J = 1.8 Hz, 1H), 7.12 (dd, J = 8.7, 5.1 Hz, 2H), 6.98 (t, J = 8.6 Hz, 2H), 6.35 (t, J = 53.8 Hz, 1H), 4.95 (s, 2H), 4.40 (ddd, J = 15.8, 10.7, 4.5 Hz, 1H), 4.18-4.09 (m, 2H), 3.73 (s, 3H), 3.57 (td, J = 11.6, 2.8 Hz, 2H), 2.20-2.02 (m, 5H), 1.43 (d, J = 5.4 Hz, 2H), 1.34 (d, J = 6.1 Hz, 3H).	B10


143	N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(thiazol-2-yl)methoxyphenyl)-1,1-difluoromethanesulfonamide		(Method A): 2.77 min, m/z: 617.1 [M+H] ⁺ .	(400 MHz, CDCl ₃) 7.83 (d, J = 3.2 Hz, 1H), 7.72 (d, J = 8.2 Hz, 1H), 7.62 (s, 1H), 7.59 (s, 1H), 7.55 (s, 1H), 7.43 (d, J = 3.2 Hz, 1H), 7.39 (d, J = 1.8 Hz, 1H), 7.32 (d, J = 8.2 Hz, 1H), 6.33 (t, J = 53.6 Hz, 1H), 5.80 (s, 1H), 5.53 (s, 2H), 4.44 (dt, J = 11.0, 5.8 Hz, 1H), 4.15 (d, J = 11.9 Hz, 2H), 3.79 (s, 3H), 3.65-3.53 (m, 2H), 2.22-2.10 (m, 4H)	B11
144	N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-isopropoxyphenyl)-1,1-difluoromethanesulfonamide		(Method A): 4.25 min, m/z: 562.2 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 8.03 (s, 1H), 7.62 (s, 1H), 7.58 (s, 1H), 7.39 (dd, J = 8.1, 3.0 Hz, 1H), 7.26-7.22 (m, 1H), 7.15 (dd, J = 8.0, 1.8 Hz, 1H), 5.96 (s, 2H), 4.73 (p, J = 6.0 Hz, 1H), 4.47 (td, J = 10.2, 5.0 Hz, 1H), 4.01-3.96 (m, 2H), 3.74 (s, 3H), 3.49 (d, J = 3.2 Hz, 2H), 3.17 (s, 1H), 2.02 (td, J = 10.8, 10.0, 4.0 Hz, 4H), 1.33 (d, J = 5.9 Hz, 6H).	B12

150	N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(cyclohexylmethoxy)phenyl)-1,1-difluoromethanesulfonamide		(Method A): 2.40 min, m/z: 616.1 [M+H] ⁺ .	(400 MHz, MeOD-d ₄) 7.91 (d, J = 3.7 Hz, 1H), 7.64 (s, 1H), 7.61-7.45 (m, 4H), 7.28 (d, J = 1.8 Hz, 1H), 7.20 (dd, J = 8.1, 1.8 Hz, 1H), 6.62 (t, J = 53.3 Hz, 1H), 4.50 (dd, J = 10.4, 5.0 Hz, 1H), 4.09 (dt, J = 11.5, 3.3 Hz, 2H), 3.92 (d, J = 6.2 Hz, 2H), 3.77 (s, 3H), 3.60 (td, J = 11.3, 3.8 Hz, 2H), 3.35 (s, 1H), 2.12 (q, J = 4.0 Hz, 3H), 1.95 (d, J = 12.8 Hz, 2H), 1.78 (d, J = 14.9 Hz, 2H), 1.42-1.22 (m, 6H), 1.12 (td, J = 12.1, 11.5, 4.4 Hz, 3H).	B13
151	N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(oxazol-2-ylmethoxy)phenyl)-1,1-difluoromethanesulfonamide		(Method A): 2.34 min, m/z: 601.2 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 10.98 (s, 1H), 8.21 (s, 1H), 8.06 (s, 1H), 7.65 (s, 1H), 7.60 (s, 1H), 7.48 (s, 1H), 7.42 (d, J = 12 Hz, 1H), 7.30 (s, 1H), 7.25 (d, J = 8 Hz, 1H), 6.96 (t, J = 52 Hz, 1H), 6.20 (s, 2H), 5.37 (s, 2H), 4.51-5.43 (m, 1H), 4.00-3.97 (m, 2H), 3.75 (s, 3H), 3.53-3.46 (m, 2H), 2.05-1.99 (m, 4H).	B14

137	(S)-N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-chlorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		(Method A): 3.08 min, m/z: 658.1 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 10.66 (s, 1H), 8.02 (s, 1H), 7.61 (s, 1H), 7.55 (d, J = 7.4 Hz, 3H), 7.41 (d, J = 7.9 Hz, 3H), 7.14 (d, J = 7.5 Hz, 1H), 7.09 (s, 1H), 7.00 (s, 1H), 5.66 (d, J = 6.6 Hz, 1H), 4.46 (dt, J = 10.2, 5.6 Hz, 1H), 3.98 (d, J = 11.8 Hz, 2H), 3.69 (s, 3H), 3.49 (ddd, J = 14.0, 10.8, 3.3 Hz, 2H), 2.06-1.97 (m, 4H), 1.58 (d, J = 6.2 Hz, 3H).	B15
169	N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(benzo[d][1,3]dioxol-5-ylmethoxy)phenyl)-1,1-difluoromethanesulfonamide		(Method A): 2.91 min, m/z: 654.1 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 8.04 (s, 1H), 7.63 (s, 1H), 7.58 (s, 1H), 7.41 (d, J = 8 Hz, 1H), 7.34 (s, 1H), 7.21 (d, J = 8 Hz, 1H), 7.17 (s, 1H), 7.01-6.90 (m, 2H), 6.77 (t, J = 52 Hz, 1H), 6.02 (s, 2H), 5.87 (s, 1H), 5.13 (s, 2H), 3.98 (d, J = 12 Hz, 2H), 3.67 (s, 3H), 3.46-3.42 (m, 2H), 2.05-1.99 (m, 4H).	B16

Synthesis of boronate ester intermediates E

Intermediate E1: 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)-1-(2,2,2-trifluoroethyl)piperidine



5 Step 1: tert-butyl 4-(benzyloxy)piperidine-1-carboxylate

To a solution of tert-butyl 4-hydroxypiperidine-1-carboxylate (1 g, 4.96 mmol) in dry DMF (10 mL) at 0 °C was added NaH (60% in oil, 238 mg, 9.92 mmol). The mixture was stirred at 0 °C for 30 mins, then (chloromethyl)benzene (755 mg, 5.95 mmol) was added and the mixture was stirred at RT overnight. The reaction mixture was partitioned between water (10 mL) and EtOAc (10 mL). The aqueous layer was extracted with EtOAc (3 x 30 mL) and the combined organics were washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography (PE/EtOAc = 10/1, v/v) to give the title product (1.30 g, 92%) as a colourless oil. ¹HNMR (400 MHz, CD₃OD): 7.27-7.18 (m, 5H), 4.48 (s, 2H), 3.73-3.67 (m, 2H), 3.51-3.46 (m, 1H), 3.06-3.00 (m, 2H), 1.80-1.75 (m, 2H), 1.55-1.48 (m, 2H), 1.38 (s, 9H).

Step 2: 4-(benzyloxy)piperidine hydrochloride

To a solution of tert-butyl 4-(benzyloxy)piperidine-1-carboxylate (1.3 g, 4.46 mmol) in dioxane (5 mL) was added HCl in dioxane (4M, 10 mL) and the reaction mixture was stirred at RT overnight. The solution was concentrated under reduced pressure to give the title product (2.10 g, 100%) as a white solid. ¹HNMR (400 MHz, MeOD-*d*₄): 7.38-7.26 (m, 5H), 4.58 (s, 2H), 3.81-3.76 (m, 1H), 3.37-3.31 (m, 2H), 3.16-3.10 (m, 2H), 2.08-2.01 (m, 2H), 1.97-1.91 (m, 2H).

Step 3: 4-(benzyloxy)-1-(2,2,2-trifluoroethyl)piperidine

To a solution of 4-(benzyloxy)piperidine hydrochloride (2.1 g, 9.22 mmol) in DMF (15 mL) was added 1,1,1-trifluoro-2-iodoethane (5.79 g, 27.6 mmol) and K₂CO₃ (3.81 g, 27.6 mmol). The reaction mixture was stirred at 130 °C for 1.5 h under microwave irradiation. The reaction mixture was partitioned between water (10 mL) and EtOAc (10 mL), and the aqueous layer was extracted with EtOAc (2 x 20 mL). The combined organics were washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography (PE/EtOAc = 10/1, v/v) to give the title product (896 mg, 36%) as a yellow oil.

¹HNMR (400 MHz, MeOD-*d*₄): 7.36-7.24 (m, 5H), 4.54 (s, 2H), 3.50-3.43 (m, 1H), 3.07-2.99 (m, 2H), 2.92-2.87 (m, 2H), 2.51-2.45 (m, 2H), 1.95-1.89 (m, 2H), 1.70-1.61 (m, 2H).

Step 4: 1-(2,2,2-trifluoroethyl)piperidin-4-ol


To a solution of 4-(benzyloxy)-1-(2,2,2-trifluoroethyl)piperidine (890 mg, 3.25 mmol) in MeOH (10 mL) was added Pd(OH)₂ (91.2 mg). The mixture was stirred at 55 °C under H₂ overnight. The reaction mixture was filtered, and the organics were concentrated under reduced pressure to give the title product (590 mg, 98%) as colorless oil. ¹HNMR (400 MHz, CDCl₃): 3.72-3.67 (m, 1H), 3.00-2.91 (m, 2H), 2.90-2.85 (m, 2H), 2.51-2.44 (m, 2H), 1.91-1.84 (m, 2H), 1.64-1.55 (m, 2H).

Step 5: 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)-1-(2,2,2-trifluoroethyl)piperidine

To a solution of 1-(2,2,2-trifluoroethyl)piperidin-4-ol (590 mg, 3.22 mmol) in DCM (10 mL) was added Et₃N (1.45 g, 14.4 mmol), followed by MsCl (1.10 g, 9.66 mmol), and the mixture was stirred at RT overnight. The mixture was partitioned between water (10 mL) and DCM (10 mL) and the organic layer was washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure to give the crude mesylate (880 mg, 100%) as a yellow oil. ¹HNMR (400 MHz, CDCl₃): 4.78-4.73 (m, 1H), 3.13 (s, 1H), 3.01-2.94 (m, 7H), 2.90-2.85 (m, 2H), 2.64-2.60 (m, 2H), 2.05-1.99 (m, 2H), 1.94-1.88 (m, 2H).

The crude mesylate was dissolved in DMF (10 mL), and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (465 mg, 2.40 mmol), Cs₂CO₃ (1.30 g, 4.00 mmol) and KI (44.3 mg, 267 μmol) were added. The reaction mixture was stirred at 100 °C in a sealed tube overnight. Water (10 mL) was added, and the mixture was extracted with EtOAc (2 x 40 mL). The combined organics were washed with water and brine, dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by prep-TLC (PE/EtOAc = 70/30, v/v) to give the title product (70.0 mg, 7%) as a colourless oil. LCMS (method A): 1.36 min, m/z: 360.2 [M+H]⁺.

Intermediate E2: 1-methyl-4-(2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)ethyl)piperazine




Step 1: 1-(2-bromoethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole

To a solution of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (500 mg, 2.57 mmol) in DMSO (5 mL) was added KOH (1.43 g, 25.6 mmol). After stirring at RT for 1 h, 1,2-dibromoethane (9.63 g, 51.3 mmol) was added. The mixture was stirred at RT overnight, then
5 diluted with water (10 mL) and extracted with EtOAc (3 x 15 mL). The combined organics were washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography (PE/EtOAc = 5/1, v/v) to give the title product (320 mg, 41%) as a colourless oil. LCMS (Method A): 2.03 min, m/z 301.1/303.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-*d*₆): 7.99 (s, 1H), 7.62 (s, 1H), 4.52 (d, *J* = 6.4 Hz, 2H), 3.85 (d, *J* = 6.0 Hz,
10 2H), 1.26 (s, 12H).

Step 2: 1-methyl-4-(2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)ethyl)piperazine

To a solution of 1-(2-bromoethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (100 mg, 332 μmol) in MeCN (3 mL) were added 1-methylpiperazine (49.8 mg, 498 μmol) and
15 Cs₂CO₃ (216 mg, 664 μmol). The mixture was stirred at 90 °C for 6h. Water (10 mL) was added, and the organics were extracted with EtOAc (3 x 15mL). The combined organics were washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure to give the title product (60.0 mg, 56%) as a light-yellow oil, which was used directly without further purification. LCMS (Method B): 1.43 min, m/z: 321.3 [M+H]⁺.


20

Intermediate E3: 1-(2-(3,3-dimethylazetidin-1-yl)ethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole**Step 1:** 1-(2-(3,3-dimethylazetidin-1-yl)ethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
25

To a solution of 1-(2-bromoethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (100 mg, 332 μmol) in MeCN (3 mL) was added cesium carbonate (540 mg, 1.66 mmol) and 3,3-dimethylazetidine hydrochloride (60.5 mg, 498 μmol). The reaction mixture was refluxed for 4 h. The mixture was cooled to RT, filtered, and the residue was washed with MeCN (2 x

3mL). The combined filtrates were concentrated under reduced pressure to give the title product (105 mg, >100%) as a light-yellow solid. Used directly in the next step without further purification. LCMS (Method A): 0.32 min; m/z : 307.1 $[M+H]^+$. ^1H NMR (400 MHz, DMSO- d_6): 7.88 (s, 1H), 7.54 (s, 1H), 4.04-4.01 (m, 2H), 2.81-2.80 (m, 4H), 2.72 (t, J = 6.4 Hz, 2H), 1.26-1.24 (m, 12H), 1.12 (s, 6H).


Intermediate E4: N-methyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)ethan-1-amine



Step 1: N-methyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)ethan-1-amine

To a solution of 1-(2-bromoethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (100 mg, 332 μ mol) in MeCN (3 mL) were added methylamine hydrochloride (44.1 mg, 664 μ mol), CS_2CO_3 (540 mg, 1.66 mmol) and KI (5.51 mg, 33.2 μ mol) at RT. The reaction mixture was refluxed for 4 h under N_2 atmosphere. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to give the title product (118 mg, >100%) as a yellow oil. Used as crude in the next step. LCMS (Method A): 0.30 min; m/z 169.9 $[M+H]^+$.


Intermediate E5: N,N-dimethyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)ethan-1-amine



Step 1: N,N-dimethyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)ethan-1-amine

To a solution of 1-(2-bromoethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (100 mg, 0.332 mmol) in MeCN (3 mL) were added dimethylamine (22.4 mg, 0.498 mmol), Cs₂CO₃ (540 mg, 1.66 mmol) and KI (5.51 mg, 0.033 mmol) at RT. The reaction mixture was stirred at 90 °C for 4 h under N₂. The solids were removed by filtration, washed with EtOAc (5 mL) and the combined organics were concentrated under reduced pressure to afford the title product (120 mg, >100%) as a black oil. Used directly as crude in the next step. LCMS (Method A): 0.45 min, m/z 266.1 [M+H]⁺.

Intermediate E6: 8-methyl-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]-8-azabicyclo[3.2.1]octane



Step 1: 8-methyl-8-azabicyclo[3.2.1]octan-3-yl methanesulfonate


A mixture of 8-methyl-8-azabicyclo[3.2.1]octan-3-ol (3 g, 21.2 mmol) and Et₃N (5.57 g, 55.1 mmol) in DCM (30 mL) was stirred at 0 °C. MsCl (3.14 g, 27.5 mmol) was added at 0 °C and the reaction mixture was stirred at RT for 2 h. The mixture was poured into water (40 mL) and extracted with EtOAc (40 mL x 2). The combined organics were dried over Na₂SO₄ and concentrated under reduced pressure to give the crude title product (2.00 g, 9.11 mmol) as an orange solid. Used as crude in the next step. LCMS (Method A): 0.72 min, m/z 219.9 [M+H]⁺.

Step 2: 8-methyl-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]-8-azabicyclo[3.2.1]octane

A mixture of 8-methyl-8-azabicyclo[3.2.1]octan-3-yl methanesulfonate (500 mg, 2.27 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (440 mg, 2.27 mmol) and K₂CO₃ (941 mg, 6.81 mmol) in MeCN (10 mL) was stirred at 80 °C for 12 h. The reaction mixture was concentrated under reduced pressure and the residue was poured into water (40 mL) and extracted with EtOAc (40 mL x 2). The combined organic phases were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by silica gel column

chromatography (PE:EtOAc; 4/1 to 1/4) to give the title product (200 mg, 28%) as a brown solid. LCMS (Method B): 2.58 min, m/z 318.2 $[M+H]^+$

Intermediate E7: 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrole-2-carbonitrile




Step 1: 4-bromo-1-methyl-1H-pyrrole-2-carbonitrile

To a solution of 1-methyl-1H-pyrrole-2-carbonitrile (500 mg, 4.71 mmol) in DMF (5 mL) was added NBS (838 mg, 4.71 mmol). The reaction mixture was stirred at RT overnight. The mixture was poured into water (20 mL) and extracted with EtOAc (50 mL x 2). The combined organic phases were dried over Na_2SO_4 and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (PE:EtOAc; 4:1) to give the title product (700 mg, 80%) as a white solid. ^1H NMR (400 MHz, $CDCl_3$): 6.81 (s, 1H), 6.76 (s, 1H), 3.77 (s, 3H).

Step 2: 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrole-2-carbonitrile

To a solution of 4-bromo-1-methyl-1H-pyrrole-2-carbonitrile (300 mg, 1.62 mmol), B_2pin_2 (431 mg, 1.70 mmol) and AcOK (476 mg, 4.86 mmol) in degassed 1,4-dioxane (10 mL) was added $Pd(dppf)Cl_2$ (74.1 mg, 81.0 μ mol). The mixture was stirred at 100 °C under N_2 overnight. The mixture was concentrated under reduced pressure and the residue was purified by silica gel column chromatography (PE:EtOAc; 2:1) to give the title product (200 mg, 53%) as a white solid. No mass ion

Intermediate E8: 2-{3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]oxetan-3-yl}acetonitrile




Step 1: 2-{3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]oxetan-3-yl}acetonitrile

To a mixture of 2-(oxetan-3-ylidene)acetonitrile (200 mg, 2.10 mmol) and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (520 mg, 2.68 mmol) in MeCN (15 mL) was added DBU (639 mg, 4.20 mmol) and the reaction mixture was stirred at 60 °C for 18 h. The mixture was concentrated under reduced pressure and the residue was diluted with water (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organics were washed with brine (50 mL), dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by Prep-TLC (PE:EtOAc; 4:1) to give the title product (250 mg, 41%) as a yellow oil.

¹H NMR (400 MHz, DMSO-*d*₆): 8.30 (s, 1H), 7.76 (s, 1H), 5.01 (d, *J* = 7.2 Hz, 2H), 4.74 (d, *J* = 7.2 Hz, 2H), 3.61 (s, 2H), 1.27 (s, 12H).

Intermediate E9: N-isopropyl-N-methyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propan-1-amine



Step 1: 2-chloro-N-isopropyl-N-methylpropanamide

To a solution of methyl(propan-2-yl)amine (1 g, 13.6 mmol) in DCM (14 mL) was added Et₃N (2.28 g, 22.6 mmol) followed by 2-chloropropanoyl chloride (1.43 g, 11.3 mmol) at 0 °C. The solution was stirred at 0 °C for 1 h under N₂. The solution was diluted with EtOAc (50 mL), washed with water (10 mL) and brine (3 mL), dried over Na₂SO₄ and concentrated under reduced pressure to give the title product (1.70 g, 76%) as a white oil. LCMS (Method C): 0.74 min; *m/z*: 163.9 [M+H]⁺

Step 2: 2-(4-bromo-1H-pyrazol-1-yl)-N-isopropyl-N-methylpropanamide

To a solution of 2-chloro-N-methyl-N-(propan-2-yl)propanamide (1.56 g, 9.53 mmol) in DMF (25 mL) were added 4-bromo-1H-pyrazole (1.16 g, 7.94 mmol) and K₂CO₃ (3.28 g, 23.8 mmol) at RT. The solution was stirred at 130 °C overnight under N₂. The solution was diluted with

water (25 mL) and the organics were extracted with EtOAc (2 x 10 mL). The combined organics were washed with water (10 mL) and brine (10 mL), dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE:EtOAc; 5:1) to give the title product (2.00 g, 76%) as a colourless oil.

5 LCMS (Method C): 1.20 min; m/z: 275.9 [M+H]⁺


Step 3: 2-(4-bromo-1H-pyrazol-1-yl)-N-isopropyl-N-methylpropan-1-amine

To a solution of 2-(4-bromo-1H-pyrazol-1-yl)-N-methyl-N-(propan-2-yl)propanamide (500 mg, 1.82 mmol) in THF (8 mL) was added LiAlH₄ (138 mg, 3.64 mmol) at RT. The solution was stirred at RT for 1 h under N₂. The solution was diluted with water (25 mL) and the organics were extracted with EtOAc (2 x 10 mL). The combined organics were washed with water (10 mL) and brine (10 mL), dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (DCM:MeOH; 100/1) to give the title product (205 mg, 43%) as a white solid. LCMS (Method C): 0.29 min; m/z 259.9 [M+H]⁺

Step 4: methyl(propan-2-yl){2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]propyl}amine

To a solution of 2-(4-bromo-1H-pyrazol-1-yl)-N-isopropyl-N-methylpropan-1-amine (100 mg, 384 μmol) in 1,4-dioxane (4 mL) were added B₂pin₂ (146 mg, 576 μmol), Pd(dppf)Cl₂ (28.0 mg, 38.4 μmol) and AcOK (94.2 mg, 960 μmol). The solution was stirred at 100 °C for 8 h under N₂. The solution was concentrated and the crude was purified by silica gel column chromatography (PE/EtOAc = 1/1) to give the title compound (18.0 mg, 15%) as a white oil. LCMS (method C): 0.36 min; m/z: 307.9 [M+H]⁺

Intermediate E10: 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)cyclopropane-1-carbonitrile



Step 1: 2-(4-iodo-1H-pyrazol-1-yl)acetonitrile

To a solution of 4-iodo-1H-pyrazole (1 g, 5.15 mmol) in DMF (10 mL) were added K₂CO₃ (1.42 g, 10.3 mmol) and 2-bromoacetonitrile (678 mg, 5.66 mmol) at RT. The reaction mixture was stirred at 50 °C overnight. The reaction mixture was extracted with EtOAc (2 x 30mL) and the combined organics were washed with water and brine, dried over Na₂SO₄ and concentrated

under reduced pressure. The crude product was purified by silica gel column chromatography (PE:EtOAc; 5:1) to give title product (1.10 g, 92%) as a white solid. ¹HNMR (400 MHz, DMSO-*d*₆): 8.02 (s, 1H), 7.68 (s, 1H), 5.49 (s, 2H).


Step 2: 1-(4-iodo-1H-pyrazol-1-yl)cyclopropane-1-carbonitrile

- 5 To a solution of 2-(4-iodo-1H-pyrazol-1-yl)acetonitrile (1.1 g, 4.72 mmol) in DMSO (8 mL) was added NaH (60% in oil, 451 mg, 18.8 mmol) at 0°C and the mixture was stirred at 0°C for 30 mins. 1,2-dibromoethane (2.64 g, 14.1 mmol) in DMSO (2 mL) was added dropwise and the reaction was stirred at RT for 8 h. The reaction was quenched with water (10 mL) and the organics were extracted with EtOAc (30 mL x 2). The combined organics were washed with
- 10 brine, dried over Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (PE: EtOAc; 10/1) to give title product (274 mg, 22%) as yellow oil. LCMS (method E): 0.95 min; *m/z*: 259.9 [M+H]⁺

Step 3: 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)cyclopropane-1-carbonitrile

- 15 To a solution of 1-(4-iodo-1H-pyrazol-1-yl)cyclopropane-1-carbonitrile (255 mg, 984 μmol) in degassed DMSO (10 mL) were added B₂(pin)₂ (373 mg, 1.47 mmol), Pd(dppf)Cl₂ (71.9 mg, 98.3 μmol) and AcOK (289 mg, 2.95 mmol) at RT and the reaction mixture was stirred at 80 °C for 3 h. The mixture was partitioned between H₂O (10mL) and EtOAc (10 mL), and the layers were separated. The aqueous fraction was extracted with EtOAc (30 mL x 2). The
- 20 combined organics were washed with water and brine, dried over Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (PE: EtOAc; 20/1 to 5/1) to give title product (150 mg, 59%) as a white solid. LCMS (Method E): 1.03 min; *m/z*: 259.9 [M+H]⁺

- 25 **Intermediate E11:** 1-(methyl-*d*₃)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)piperidine




Step 1: 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)piperidine

A solution of tert-butyl 4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]piperidine-1-carboxylate (377 mg, 999 μ mol) in HCOOH (2 mL) was stirred at RT for 1 h. The mixture was concentrated under reduced pressure to give the title compound as a formate salt (270 mg, 97%) as a colorless oil. LCMS (Method A): 2.17 min, m/z 278.1 [M+H]⁺

5 Step 2: 1-(methyl-d3)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)piperidine

To a solution of 4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]piperidine (270 mg, 974 μ mol) in MeCN (5 mL) was added K₂CO₃ (134 mg, 974 μ mol) and CD₃I (141 mg, 974 μ mol). The reaction mixture was stirred at 80 °C for 2 h. The mixture was poured into
 10 water (5 mL) and extracted with EtOAc (3 x 5 mL). The combined organics were washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure to give the title product (290 mg, >100%) as a white solid. Used as crude in the next step. LCMS (Method A): 2.09 min, m/z 295.1 [M+H]⁺

15 Intermediate E12: tert-butyl 3-methyl-5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate



Step 1: tert-butyl 3-methyl-5-(tosyloxy)piperidine-1-carboxylate

To a solution of tert-butyl 3-hydroxy-5-methylpiperidine-1-carboxylate (575 mg, 2.67 mmol) in
 20 DCM (10 mL) and pyridine (10 mL) was added TsCl (610 mg, 3.20 mmol). After stirring at RT overnight, the reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE:EtOAc; 25/1) to give the title product (800 mg, 81%) as a white solid. LCMS (Method A): 4.28 min; 392.2 [M+Na]⁺

Step 2: tert-butyl 3-(4-bromo-1H-pyrazol-1-yl)-5-methylpiperidine-1-carboxylate


25 To a solution of tert-butyl 3-methyl-5-(tosyloxy)piperidine-1-carboxylate (500 mg, 1.35 mmol) in DMF (10 mL) were added 4-bromo-1H-pyrazole (257 mg, 1.75 mmol) and Cs₂CO₃ (1.31 g, 4.05 mmol). After stirring at 100 °C overnight under N₂, the reaction mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography

(PE:EtOAc; 5/1) to give the title product (230 mg, 50%) as a colorless oil. LCMS (Method A): 4.19 min; m/z: 288.0, 290.0 [M+H]⁺

Step 3: tert-butyl 3-methyl-5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate

- 5 To a solution of tert-butyl 3-(4-bromo-1H-pyrazol-1-yl)-5-methylpiperidine-1-carboxylate (200 mg, 0.581 mmol) in DME (10 mL) were added AcOK (113 mg, 1.16 mmol), B₂pin₂ (221 mg, 871 μmol) and Pd(dppf)Cl₂ (42.4 mg, 58.0 μmol). After stirring at 100 °C overnight under N₂, the mixture was concentrated under reduced pressure. The residue was diluted with water (100 mL) and extracted with EtOAc (100 mL x 3). The combined organic phases were washed
- 10 with water and brine, dried over Na₂SO₄ and concentrated under reduced pressure to give the title product (400 mg, >100%) as a black oil. Used as crude in the next step. LCMS (Method A): 3.50 min; m/z: 392.3 [M+H]⁺

- Intermediate E13:** tert-butyl 2-((4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)methyl)pyrrolidine-1-carboxylate
- 15



Step 1: tert-butyl 2-(hydroxymethyl)pyrrolidine-1-carboxylate

- To a solution of (pyrrolidin-2-yl)methanol (500 mg, 4.94 mmol) in DCM (5 mL) was added Et₃N (2.49 g, 24.7 mmol) followed by Boc₂O (1.29 g, 5.92 mmol). The reaction mixture was stirred
- 20 at RT for 16 h. The solvents were removed under reduced pressure and the residue was purified by silica gel column chromatography (PE:EA, 1:1) to give the title product (850 mg, 85%) as a yellow oil.

Step 2: tert-butyl 2-((4-methylbenzenesulfonyl)oxy)methylpyrrolidine-1-carboxylate

- To a solution of tert-butyl 2-(hydroxymethyl)pyrrolidine-1-carboxylate (850 mg, 4.22 mmol) in
- 25 DCM (5 mL) were added TsCl (2.40 g, 12.6 mmol) and Et₃N (2.56 g, 25.3 mmol). The mixture was stirred at RT overnight. Water (10 mL) was added and the organics were extracted with DCM (2 x 10mL). The combined organics were dried over Na₂SO₄ and concentrated under

reduced pressure. The residue was purified by silica gel column chromatography (PE:EA, 4:1) to give the title product (1.40 g, 93%) as a yellow oil.


Step 3: tert-butyl 2-[(4-bromo-1H-pyrazol-1-yl)methyl]pyrrolidine-1-carboxylate

To a solution of tert-butyl 2-[(4-methylbenzenesulfonyl)oxy]methyl]pyrrolidine-1-carboxylate (1.4 g, 3.93 mmol) in DMF (10 mL) were added Cs₂CO₃ (3.80 g, 11.7 mmol) and 4-bromo-1H-pyrazole (692 mg, 4.71 mmol). The reaction mixture was stirred at 100 °C for 16 h. Water (10 mL) was added and the organics were extracted with EtOAc (2 x 20 mL). The combined organics were washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE:EA, 2:1) to give the title product (1.30 g, 100%) as a colorless oil.

Step 4: tert-butyl 2-[(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)methyl]pyrrolidine-1-carboxylate

To a solution of tert-butyl 2-[(4-bromo-1H-pyrazol-1-yl)methyl]pyrrolidine-1-carboxylate (1.3 g, 3.93 mmol) in DME (10 mL) were added AcOK (1.14 g, 11.7 mmol), B₂(pin)₂ (1.19 g, 4.71 mmol) and Pd(dppf)Cl₂ (287 mg, 393 μmol). The reaction mixture was stirred at 100 °C for 16 h under N₂. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel column chromatography (PE:EtOAc, 3:1) to give the title compound (1.0 g, 67%) as a colorless oil. ¹H NMR (400 MHz, DMSO-*d*₆): 7.82 (s, 1H), 7.58 (s, 1H), 4.22-4.13 (m, 3H), 3.20-3.10 (m, 2H), 1.75-1.69 (m, 4H), 1.41-1.37 (m, 9H), 1.24 (s, 12 H)

Intermediate E14: 6-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptane-2-carboxylate




Step 1: tert-butyl 6-[(4-methylbenzenesulfonyl)oxy]-2-azaspiro[3.3]heptane-2-carboxylate

To a solution of tert-butyl 6-hydroxy-2-azaspiro [3.3]heptane-2-carboxylate (3.0 g, 14.0 mmol) in DCM/pyridine (4/1, 100 mL) was added Ts Cl (2.93 g, 15.4 mmol). The mixture was stirred at RT for 12 h. Water (50 mL) was added and the organics were extracted with EtOAc (3 x 50 mL). The combined organics were washed with brine (50 mL), dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (PE:EA; 5:1) to give the title product (3.00 g, 58%) as a white solid.

Step 2: tert-butyl 6-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptane-2-carboxylate

To a solution of tert-butyl 6-[(4-methylbenzenesulfonyl)oxy]-2-azaspiro[3.3]heptane-2-carboxylate (1.2 g, 3.26 mmol) in DMF (40 mL) were added Cs₂CO₃ (2.12 g, 6.52 mmol) and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (632 mg, 3.26 mmol), and the mixture was stirred at 100 °C overnight. The solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography (PE:EA; 3:1) to give the title product (800 mg, 63%) as a yellow solid.

Intermediate E15: tert-butyl 4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]azepane-1-carboxylate



Step 1: tert-butyl 4-((methanesulfonyl)oxy)azepane-1-carboxylate

To a 0 °C solution of tert-butyl 4-hydroxyazepane-1-carboxylate (860 mg, 3.99 mmol) in DCM (10 mL) were added Et₃N (808 mg, 7.98 mmol) and MsCl (684 mg, 5.98 mol). The reaction was stirred at room temperature for 1 h under N₂. Water (10 mL) was added and the organics were extracted with DCM (3 x 15 mL). The combined organics were washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure to give the title compound (1.1 g, 94%) as a yellow oil. ¹HNMR: (400 MHz, DMSO-*d*₆): 3.36-3.32(m, 3H), 3.22 (brs, 2H), 3.16 (s, 3H), 2.00-1.95 (m, 1H), 1.84-1.77 (m, 4H), 1.64-1.61(m, 1H), 1.40 (s, 9H).


Step 2: tert-butyl 4-(4-bromo-1H-pyrazol-1-yl)azepane-1-carboxylate

To a solution of tert-butyl 4-(methanesulfonyloxy)azepane-1-carboxylate (1.1 g, 3.74 mmol) in DMF (15 mL) were added Cs₂CO₃ (3.64 g, 11.2 mmol) and 4-bromo-1H-pyrazole (549 mg, 3.74 mmol) at RT. The reaction mixture was refluxed for 4 h. The solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography (PE:EtOAc; 5:1) to give the title product (1.0 g, 77%) as a yellow oil. LCMS (method A): 1.20 min; *m/z* 287.7, 289.7 [M+H-*t*Bu]⁺. ¹HNMR: (400 MHz, DMSO-*d*₆): 8.03 (s, 1H), 7.51 (s, 1H), 4.32-4.26 (m, 1H), 3.60-3.52 (m, 1H), 3.38-3.36 (m, 2H), 3.23-3.17 (m, 1H), 2.03-1.81 (m, 5H), 1.61-1.62 (m, 1H), 1.41 (s, 9H).

Step 3: tert-butyl 4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]azepane-1-carboxylate

A mixture of tert-butyl 4-(4-bromo-1H-pyrazol-1-yl)azepane-1-carboxylate (700 mg, 2.03 mmol), AcOK (595 mg, 6.08 mmol), B₂(pin)₂ (771 mg, 3.04 mmol) and Pd(dppf)Cl₂ (147 mg, 202 μmol) in degassed 1,4-dioxane (15 mL) was stirred at 80 °C for 8 h under N₂. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE:EtOAc; 5:1) to give the title compound (700 mg, 1.78 mmol) as a yellow oil. LCMS (method A): 1.80 min; m/z 391.9 [M+H]⁺


Intermediate E16: 1-(1-methylpyrrolidin-3-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole



Step 1: 1-(1-methylpyrrolidin-3-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole

A mixture of 1-(pyrrolidin-3-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (200 mg, 760 μmol), formaldehyde (184 mg, 2.28 mmol) and NaBH(OAc)₃ (1.28 g, 6.07 mmol) in DCM (10 mL) was stirred at RT overnight. The mixture was poured into water and extracted with EtOAc (50 mL x 3). The combined organics were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (PE/EA: 95/5) to give the title product (140 mg, 67%) as a yellow oil. LCMS (Method A): 3.04 min; m/z 278.2 [M+H]⁺

Intermediate E17: 1-(1-isopropylazetidin-3-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole



Step 1: tert-butyl 3-((methylsulfonyl)oxy)azetidine-1-carboxylate

To a mixture of tert-butyl 3-hydroxyazetidine-1-carboxylate (5.0 g, 28.9 mmol) and Et₃N (8.75 g, 86.60 mmol) in DCM (50 mL) at 0 °C was added MsCl (4.94 g, 43.30mmol) and the reaction was stirred at 0 °C for 3 h. Water (20 mL) was added and the organics were extracted with DCM (2 x 20mL). The combined organics were washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure to give the title compound (7.2 g, >100%) as a white solid. LCMS (Method C): 1.07 min; m/z 195.8 [M+H-*t*bu]⁺

Step 2: tert-butyl 3-(4-bromo-1H-pyrazol-1-yl)azetidine-1-carboxylate

To a solution of tert-butyl 3-((methylsulfonyl)oxy)azetidine-1-carboxylate (7.2 g, 28.65 mmol) in DMF (200 ml) were added Cs₂CO₃ (27.9 g, 85.95 mmol) and 4-bromo-1H-pyrazole (4.63 g, 31.51 mmol) and the reaction mixture was stirred at 80 °C for 3 h. Water (200 mL) was added and the organics were extracted with EtOAc (2 x 100mL). The combined organics were washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE:EtOAc; 5/1) to give the title compound (7.7 g). LCMS (Method C): 0.79 min; m/z 245.0 [M+H-*t*bu]⁺

Step 3: tert-butyl 3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)azetidine-1-carboxylate

To a mixture of tert-butyl 3-(4-bromo-1H-pyrazol-1-yl)azetidine-1-carboxylate (7.7 g, 25.48 mmol), Pd(dppf)Cl₂ (1.86 g, 2.55 mmol) and AcOK (7.49 g, 76.44 mmol) in degassed 1,4-dioxane (500 mL) was added B₂(pin)₂ (9.71 g, 38.22 mmol) and the reaction was stirred at 100 °C for 6 h under N₂. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel column chromatography (PE:EtOAc; 3:1) to give the title compound (8.2 g) as a colorless oil. LCMS (Method C): 1.04 min; m/z 293.5 [M+H-*t*bu]⁺


Step 4: 1-(azetidin-3-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole hydrochloride

To a solution of tert-butyl 3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)azetidine-1-carboxylate (8.2 g, 23.47 mmol) in 1,4-dioxane (10 mL) was added HCl (4M in 1,4-dioxane; 20mL) and the reaction mixture was stirred at RT for 4 h. The reaction mixture was concentrated under reduced pressure to afford the title product (6.7 g) as a yellow oil. LCMS (Method C): 0.76 min; m/z 250.2 [M+H]⁺

Step 5: 1-(1-isopropylazetidin-3-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole

To a solution of 1-(azetidin-3-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (500 mg, 2.00 mmol) in MeCN (10 mL) were added 2-iodopropane (1.01 g, 6.00 mmol) and K_2CO_3 (276 mg, 2.00 mmol) and the reaction was stirred at 45 °C overnight. Water (10 mL) was added and the organics were extracted with EtOAc (2 x 40 mL). The combined organics were washed with water and brine, dried over Na_2SO_4 and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (DCM:MeOH; 50/1) to give the title product (70 mg) as a colorless oil. LCMS (Method C): 0.44 min; m/z 292.1 $[M+H]^+$

Intermediate E18: 1-(1-methylazetidin-3-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole



Step 1: tert-butyl 3-oxoazetidine-1-carboxylate

A mixture of azetidin-3-one hydrochloride (1 g, 9.29 mmol), Boc_2O (3.03 g, 13.9 mmol) and Et_3N (2.81 g, 27.8 mmol) in DCM (40 mL) was stirred at RT overnight. The mixture was washed with brine (2 x 20 mL) and concentrated under reduced pressure to give the title product (1.17 g, 73.5%) as a yellow oil. ^1H NMR (400 MHz, $DMSO-d_6$): 4.67 (s, 4H), 1.42 (s, 9H).

Step 2: tert-butyl 3-hydroxyazetidine-1-carboxylate

A mixture of tert-butyl 3-oxoazetidine-1-carboxylate (6.77 g, 39.5 mmol) and $NaBH_4$ (2.98 g, 79.0 mmol) in MeOH (80 mL) was stirred at RT for 30 min. The mixture was concentrated under reduced pressure to give the title product (4.30 g, 63%) as a yellowish oil. ^1H NMR (400 MHz, $DMSO-d_6$): 5.62 (d, $J = 6.5$ Hz, 1H), 4.36 (qt, $J = 6.7, 4.5$ Hz, 1H), 4.03-3.92 (m, 2H), 3.57 (dd, $J = 9.2, 4.5$ Hz, 2H), 1.36 (s, 9H).

Step 3: tert-butyl 3-[(4-methylbenzenesulfonyl)oxy]azetidine-1-carboxylate

A mixture of tert-butyl 3-hydroxyazetidine-1-carboxylate (2 g, 11.5 mmol), TsCl (2.28 g, 12.0 mmol) and Et₃N (2.32 g, 23.0 mmol) in DCM (5 mL) was stirred at RT overnight. The reaction mixture was washed with brine (50 mL x 2), dried over Na₂SO₄ and concentrated under reduced pressure to give the title product (1.25 g, 33%) as a colorless oil. ¹H NMR (400 MHz, DMSO-*d*₆): 7.81 (d, *J* = 8.4 Hz, 2H), 7.50 (d, *J* = 8.2 Hz, 2H), 5.08 (tt, *J* = 6.6, 3.9 Hz, 1H), 4.13-4.00 (m, 2H), 3.81-3.67 (m, 2H), 2.43 (s, 3H), 1.34 (s, 9H).

Step 4: tert-butyl 3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]azetidine-1-carboxylate

A mixture of tert-butyl 3-[(4-methylbenzenesulfonyl)oxy]azetidine-1-carboxylate (1.45 g, 4.42 mmol), Cs₂CO₃ (2.88 g, 8.84 mmol) and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1.28 g, 6.63 mmol) in DMF (40 mL) was stirred at 110 °C overnight. The mixture was poured into water (150 mL) and extracted with EtOAc (2 x 100 mL). The combined organics were washed with brine (2 x 100 mL), dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE:EtOAc; 10:1) to give the title product (750 mg, 49%) as a yellow oil. ¹H NMR (400 MHz, DMSO-*d*₆): 8.07 (s, 1H), 7.70 (s, 1H), 5.22 (ddd, *J* = 13.2, 8.0, 5.3 Hz, 1H), 4.26 (t, *J* = 8.3 Hz, 2H), 4.11 (s, 2H), 1.40 (s, 9H), 1.25 (s, 12H).


Step 5: 1-(azetidin-3-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole

A mixture of tert-butyl 3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]azetidine-1-carboxylate (500 mg, 1.43 mmol) in aqueous HCl (1M, 2 mL) was stirred at RT for 1 h. The reaction mixture was concentrated under reduced pressure to give the title product (350 mg, 1.40 mmol, 98.3%) as a yellow oil. LCMS (Method A): 1.03 min, *m/z* 250.0 [M+H]⁺.

Step 6: 1-(1-methylazetidin-3-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole

A mixture of 1-(azetidin-3-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (500 mg, 1.40 mmol), paraformaldehyde (337 mg, 4.19 mmol) and NaBH(OAc)₃ (2.37 g, 11.2 mmol) in DCM (30 mL) was stirred at RT for 45 min. The solution was diluted with DCM (30 mL) before the addition of sat. aq. NaHCO₃ (30 mL). The aqueous layer was extracted with a DCM/MeOH mixture (9:1; 3 x 10 mL). The combined organic layers were concentrated under reduced pressure to give the title product (70 mg, 19%) as a yellow solid. LCMS (Method A): 1.39 min, *m/z* 264.1 [M+H]⁺.

Intermediate E19: 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(1-(2,2,2-trifluoroethyl)azetidin-3-yl)-1H-pyrazole



Step 1: tert-butyl 3-(benzyloxy)azetidine-1-carboxylate

- 5 To a 0 °C solution of tert-butyl 3-hydroxyazetidine-1-carboxylate (5 g, 28.9 mmol) in DMF (50 mL) was added NaH (60% in oil, 2.3 g, 57.8 mmol). The solution was stirred at 0 °C for 1 h. benzyl chloride (4.4 g, 34.7 mmol) was added to the solution at 0 °C and the reaction mixture was stirred at RT for 2 h. Water (250 mL) was added and the organics were extracted with EtOAc (2 x 300 mL). The combined organic layers were washed with brine (500 mL), dried
- 10 over Na₂SO₄ and concentrated under reduced pressure to afford the title product (7.1 g, 93%) as a white solid. LCMS (Method C): 1.53 min; m/z 208 [M+H-*t*Bu]⁺

Step 2: 3-(benzyloxy)azetidine

- To a solution of tert-butyl 3-(benzyloxy)azetidine-1-carboxylate (4.8 g, 18.2 mmol) in DCM (30 mL) was added TFA (10 mL) and the solution was stirred at RT for 2 h. The solution was
- 15 concentrated under reduced pressure and the residue was dissolved in MeOH (3 mL). The pH was adjust to pH = 8 with the addition of sat. aq. NaHCO₃. The organics were extracted with DCM (2 x 50 mL), and the combined organics were washed with brine (100 mL), dried over Na₂SO₄ and concentrated under reduced pressure to give the title product (4.10 g, >100%) as a colorless oil. Used as crude in the next step. ¹H NMR (400 MHz, DMSO-*d*₆):
- 20 7.36-7.35 (m, 5H), 4.46 (s, 2H), 4.43-4.38 (m, 1H), 4.03-3.98 (m, 2H), 3.77-3.74 (m, 2H).

Step 3: 3-(benzyloxy)-1-(2,2,2-trifluoroethyl)azetidine

- To a solution of 3-(benzyloxy)azetidine (200 mg, 1.22 mmol) and 1,1,1-trifluoro-2-iodoethane (768 mg, 3.66 mmol) in DMF (3 mL) was added K₂CO₃ (337 mg, 2.44 mmol) and the reaction was stirred at 130 °C for 90 min. Water (20 mL) was added, and the organics were extracted
- 25 with EtOAc (3 x 20 mL). The combined organics were washed with water (50 mL) and brine (50 mL), dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE:EtOAc; 10:1) to give the title compound (80mg, 27%) as a light yellow oil. LCMS (Method A): 1.82 min; m/z: 246.0 [M+H]⁺. ¹H NMR

(400 MHz, DMSO- d_6): 7.37-7.29 (m, 5H), 4.39 (s, 2H), 4.19-4.15 (m, 1H), 3.60-3.57 (m, 2H), 3.22-3.08 (m, 4H).

Step 4: 1-(2,2,2-trifluoroethyl)azetidin-3-ol

To a solution of 3-(benzyloxy)-1-(2,2,2-trifluoroethyl)azetidine (130 mg, 530 μ mol) in MeOH (10 mL) was added Pd(OH)₂ (37.2 mg, 265 μ mol) and the reaction mixture was stirred under H₂ overnight. The mixture was filtered over Celite, and the filtrate was concentrated under reduced pressure to afford the title product (80.0 mg, 97%) as a colorless oil. ¹H NMR (400 MHz, DMSO- d_6): 5.37 (s, 1H), 4.23-4.19 (m, 1H), 3.61-3.58 (m, 2H), 3.17-3.09 (m, 2H), 3.00-2.96 (m, 2H).


Step 5: 1-(2,2,2-trifluoroethyl)azetidin-3-yl methanesulfonate

To a 0 °C solution of 1-(2,2,2-trifluoroethyl)azetidin-3-ol (80 mg, 515 μ mol) in DCM (5 mL) were added Et₃N (103 mg, 1.02 mmol) and MsCl (70.7 mg, 618 μ mol). The solution was stirred at RT for 1 h, then poured into water (10 mL) and extracted with DCM (2 x 20mL). The combined organic phases were dried over Na₂SO₄ and concentrated under reduced pressure to give the title product (100 mg, 83%) as a light yellow oil. LCMS (Method C): 0.72 min; m/z: 233.8 [M+H]⁺

Step 6: 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-[1-(2,2,2-trifluoroethyl)azetidin-3-yl]-1H-pyrazole

To a solution of 1-(2,2,2-trifluoroethyl)azetidin-3-yl methanesulfonate (500 mg, 2.14 mmol) in DMF (2 mL) were added Cs₂CO₃ (1.04g, 3.21 mmol), KI (935 mg, 0.21 mmol) and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (372 mg, 1.92 mmol), and the reaction was stirred at 80 °C for 2 h. Water (10 mL) was added and the organics were extracted with EtOAc (2 x 10 mL). The combined organics were washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE:EA; 5:1 to 1:1) to give the title product (130 mg, 20%) as a colourless oil. LCMS (Method C): 1.25 min; m/z: 331.9 [M+H]⁺

Intermediate E20: N-methyl-N-(propan-2-yl)-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1Hpyrazol-1-yl]propenamide




Step 1: give 2-chloro-N-methyl-N-(propan-2-yl)propanamide

To a solution of methyl(propan-2-yl)amine (1 g, 13.6 mmol) in DCM (14 mL) were added Et₃N (2.28 g, 22.6 mmol) and 2-chloropropanoyl chloride (1.43 g, 11.3 mmol) at 0 °C. The solution was stirred at 0 °C for 1h under N₂. The solution was partitioned between water (20 mL) and DCM (20mL), then the organics were collected, wash with brine (10 mL), dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE/EtOAc; 5/1) to give the title product (1.46 g, 66%) as a white oil.

Step 2: N-methyl-N-(propan-2-yl)-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]propanamide

To a solution of 2-chloro-N-methyl-N-(propan-2-yl)propanamide (1.45 g, 8.86 mmol) in DMF (25 mL) were added K₂CO₃ (3.05 g, 22.1 mmol) and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1Hpyrazole (1.43 g, 7.38 mmol). The solution was stirred at 130 °C overnight under N₂. Water (20 mL) was added and the organics were extracted with EtOAc (2 x 10 mL). The combined organics were washed with brine (10 mL), dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE/EtOAc, 5/1) to give the title product (1.46 g, 51%) as a white solid.

Intermediate E21: tert-butyl 2,2-dimethyl-5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate



Step 1: tert-butyl 2,2-dimethyl-5-((methylsulfonyl)oxy)piperidine-1-carboxylate


To a mixture of tert-butyl 5-hydroxy-2,2-dimethylpiperidine-1-carboxylate (50 mg, 218 μmol) in DCM (5 mL) were added Et₃N (51.7 mg, 654 μmol) and MsCl (29.8 mg, 261 μmol), and the mixture was stirred at RT overnight. The mixture was poured into water (10 mL) and the

organics were extracted with EtOAc (3 x 10 mL). The combined organics were washed with brine (10 mL) and concentrated under reduced pressure to give the title compound (60.0 mg, 89%) as a colorless oil.

Step 2: tert-butyl 2,2-dimethyl-5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate

A mixture of tert-butyl 2,2-dimethyl-5-((methylsulfonyl)oxy)piperidine-1-carboxylate (370 mg, 1.20 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (242 mg, 1.25 mmol) and Cs₂CO₃ (779 mg, 2.40 mmol) in DMF (15 mL) was stirred at 90 °C overnight. The mixture was poured into water (20 mL) and extracted with EtOAc (10 mL x 2). The combined organic phases were dried over Na₂SO₄ and concentrated. The residue was purified by prep-TLC (DCM/MeOH = 99/1) to give the title product as a yellow solid.

Intermediate E22: N,N-dimethyl-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]cyclopentan-1-amine



Step 1: 3-hydroxycyclopentyl 4-methylbenzene-1-sulfonate

A mixture of cyclopentane-1,3-diol (1g, 9.79 mmol), Et₃N (3.95 g, 39.1 mmol) and TsCl (1.94 g, 10.2 mmol) in DCM (5 mL) was stirred at 0 °C for 2 h. The mixture was diluted with H₂O (100 mL) and extracted with EtOAc (3 x 200 mL). The combined organic layers were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE:EtOAc= 2:1) to afford the title product (1.20 g, 48%) as a yellow oil. LCMS (Method A): 2.93 min, m/z 279.0 [M+Na]⁺

Step 2: 3-(4-bromo-1H-pyrazol-1-yl)cyclopentan-1-ol

A mixture of 3-hydroxycyclopentyl 4-methylbenzene-1-sulfonate (1.2g, 4.68 mmol), Cs₂CO₃ (2.77 g, 4.68 mmol) and 4-bromo-1H-pyrazole (687 mg, 4.68 mmol) in DMF (30 mL) was stirred at 50 °C overnight. The reaction mixture was concentrated under reduced pressure, and the residue was diluted with water (30 mL) and extracted with EtOAc (3 x 30mL). The combined organic phases were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by Prep-TLC (DCM/MeOH = 20/1) to give the title product (750 mg, 69%) as a yellow solid. LCMS (Method A): 4.25 min; m/z 231.0 [M+H]⁺

Step 3: 3-(4-bromo-1H-pyrazol-1-yl)cyclopentyl 4- methylbenzene-1-sulfonate

A mixture of 3-(4-bromo-1H-pyrazol-1-yl)cyclopentan-1-ol (750 mg, 3.24 mmol), Et₃N (1.30 g, 12.9 mmol) and TsCl (739 mg, 3.88 mmol) in DCM (5 mL) was stirred at 0 °C for 2 h. The mixture was diluted with H₂O (100 mL) and extracted with EtOAc (3 x 200 mL). The combined organic layers were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE:EtOAc = 2:1) to afford the title product (100 mg, 8%) as a yellow oil. LCMS (Method A): 2.93 min, m/z 386.0 [M+H]⁺.

Step 4: 3-(4-bromo-1H-pyrazol-1-yl)-N,N-dimethylcyclopentan-1-amine


To a mixture of 3-(4-bromo-1H-pyrazol-1-yl)cyclopentyl 4-methylbenzene-1-sulfonate (100 mg, 259 μmol) and K₂CO₃ (253 mg, 777 μmol) in DMF (3 mL) was added dimethylamine (1.2 eq) and the mixture was stirred at 80 °C overnight. The reaction mixture was concentrated under reduced pressure, and the residue was diluted with water (30 mL) and extracted with EtOAc (3 x 30mL). The combined organic phases were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by Prep-TLC (DCM/MeOH = 20/1) to give the title product (110mg, >100%) as a yellow solid. LCMS (Method B): 1.00 min; m/z 258.0 [M+H]⁺.

Step 5: N,N-dimethyl-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]cyclopentan-1-amine

A mixture of 3-(4-bromo-1H-pyrazol-1-yl)-N,N-dimethylcyclopentan-1-amine (110 mg, 426 μmol), B₂(pin)₂ (129 mg, 511 μmol), Pd(dppf)Cl₂ (31.1 mg, 42.6 μmol) and AcOK (83.6 mg, 852 μmol) in degassed 1,4-dioxane (2 mL) was stirred at 100 °C under N₂ overnight. The mixture was concentrated under reduced pressure and the residue was purified by Prep-TLC (DCM/MeOH = 20/1) to give the title product (60mg, 46%) as a yellow solid. LCMS (Method B): 3.5 min; m/z 306.0 [M+H]⁺

Synthesis of halogenopyrazole intermediates F

Intermediate F1: tert-butyl (3aR,6aS)-5-(4-bromo-1H-pyrazol-1-yl)-octahydrocyclopenta[c]pyrrole-2-carboxylate



5 Step 1: tert-butyl (3aR,6aS)-5-hydroxy-octahydrocyclopenta[c]pyrrole-2-carboxylate

To a solution of tert-butyl (3aR,6aS)-5-oxo-octahydrocyclopenta[c]pyrrole-2-carboxylate (2.3 g, 10.2 mmol) in MeOH (50 mL) was added NaBH₄ (1.92 g, 50.9 mmol) and the mixture was stirred at 60 °C overnight. The mixture was concentrated under reduced pressure and the residue was partitioned between DCM (10 mL) and H₂O (10 mL). The organic phase was removed and the aqueous was extracted with DCM (2 x 25 mL). The combined organics were dried over Na₂SO₄ and concentrated under reduced pressure to give the title product (2.20 g, 95%) as a yellow oil. LCMS: (Method A): 2.70 min; m/z: 228.1 [M+H]⁺

Step 2: tert-butyl (3aR,6aS)-5-(methanesulfonyloxy)-octahydrocyclopenta[c]pyrrole-2-carboxylate


To a solution of tert-butyl (3aR,6aS)-5-hydroxy-octahydrocyclopenta[c]pyrrole-2-carboxylate (2.2 g, 9.67 mmol) and Et₃N (2.93 g, 29.0 mmol) in DCM (50 mL) was added MsCl (1.65 g, 14.5 mmol). The mixture was stirred at RT for 1 h. The organics were extracted with DCM (2 x 100 mL), and the combined organics were dried over Na₂SO₄ and concentrated under reduced pressure to give the title product (3.00 g, >100%) as a yellow oil. LCMS: (Method A), 3.22 min; m/z: 306.1 [M+H]⁺.

Step 3: tert-butyl (3aR,6aS)-5-(4-bromo-1H-pyrazol-1-yl)-octahydrocyclopenta[c]pyrrole-2-carboxylate


To a mixture of tert-butyl (3aR,6aS)-5-(methanesulfonyloxy)-octahydrocyclopenta[c]pyrrole-2-carboxylate (3 g, 9.82 mmol) and Cs₂CO₃ (6.38 g, 19.6 mmol) in MeCN (60 mL) was added 4-bromo-1H-pyrazole (2.16 g, 14.7 mmol) and the mixture was stirred at 80 °C overnight. The mixture was concentrated under reduced pressure and the residue was partitioned in DCM

(10 mL) and H₂O (10 mL). The organic phase was collected and the aqueous was extracted with DCM (2 x 25ml). The combined organics were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (PE/EtOAc = 1/1) to give the title product (2.17g, 62%) as a yellow solid. LCMS: (Method A),
 5 2,19 min; m/z: 378.1, 380.1 [M+Na]⁺

The following intermediate **F13** were prepared according to the synthesis of intermediate F1 with 4-iodo-1H-pyrazole and tert-butyl 4-oxo-2-(trifluoromethyl)piperidine-1-carboxylate

Halogenopyrazole	LCMS	Intermediate F
	(Method A): 4.13 min, m/z: 446.1 [M+H] ⁺	Intermediate F13

Intermediate F2: 7-(4-bromo-1H-pyrazol-1-yl)-4-methyl-4-azaspiro[2.5]octane



Step 1: of tert-butyl 7-hydroxy-4-azaspiro[2.5]octane-4-carboxylate

To a solution of tert-butyl 7-oxo-4-azaspiro[2.5]octane-4-carboxylate (25 g, 110 mmol) in MeOH (400 mL) was added NaBH₄ (12.4 g, 330 mmol) and the mixture was stirred at RT overnight. The mixture was concentrated under reduced pressure and the residue was diluted with EtOAc (200 mL). The organics were washed with water (3 x 200 mL), dried over Na₂SO₄ and concentrated under reduced pressure to give the title product (26.0 g, >100%) as a colourless oil. Used as crude in the next step. LCMS: (Method A): 1.29 min, m/z 250.2 [M+Na]⁺

Step 2: tert-butyl 7-(methanesulfonyloxy)-4-azaspiro[2.5]octane-4-carboxylate

To a solution of tert-butyl 7-hydroxy-4-azaspiro[2.5]octane-4-carboxylate (26 g, 114 mmol) and Et₃N (34.5 g, 342 mmol) in DCM (300 mL) was added MsCl (15.5 g, 136 mmol) and the mixture was stirred at RT for 1 h. The mixture was washed with water (3 x 200 mL), then the organics were dried over Na₂SO₄ and concentrated under reduced pressure to give the title product (34.0 g, 97%) as a yellow oil. LCMS: (Method A): 2.04 min, m/z 328.2 [M+Na]⁺

Step 3: tert-butyl 7-(4-bromo-1H-pyrazol-1-yl)-4-azaspiro[2.5]octane-4-carboxylate

A mixture of tert-butyl 7-(methanesulfonyloxy)-4-azaspiro[2.5]octane-4-carboxylate (34 g, 111 mmol), 4-bromo-1H-pyrazole (19.5 g, 133 mmol) and Cs₂CO₃ (72.3 g, 222 mmol) in MeCN (350 mL) was stirred at 80 °C overnight. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel column chromatography (PE/EA = 20/1 to 1/1) to give the title product (28.0 g, 71%) as a colourless oil. LCMS: (Method A): 1.90 min, m/z 378.2, 380.2 [M+Na]⁺







Step 4: 7-(4-bromo-1H-pyrazol-1-yl)-4-azaspiro[2.5]octane




A solution of tert-butyl 7-(4-bromo-1H-pyrazol-1-yl)-4-azaspiro[2.5]octane-4-carboxylate (28 g, 78.5 mmol) in HCl in dioxane (4M, 60 mL) was stirred at RT for 1 h. The reaction mixture was concentrated under reduced pressure to give the title product as a HCl salt (26.0 g) as a white solid. LCMS: (Method A) 0.93 min, m/z 256.1, 258.1 [M+H]⁺

Step 5: 7-(4-bromo-1H-pyrazol-1-yl)-4-methyl-4-azaspiro[2.5]octane


To a solution of 7-(4-bromo-1H-pyrazol-1-yl)-4-azaspiro[2.5]octane (26 g, 101 mmol) and (CH₂O)_n (15.2 g, 505 mmol) in DCM (300 mL) was added NaBH(OAc)₃ (31.9 g, 151 mmol) and the mixture was stirred at RT for 1 h. H₂O (100mL) was added and the organics were separated. The organic layer was washed with water (2 x 100 mL), dried over Na₂SO₄ and concentrated under reduced pressure to give the title product (20.0 g, 73%) as a colorless oil. LCMS: (Method A) 0.64 min, m/z 270.2, 272.2 [M+H]⁺

The following intermediates **F3-F10** were prepared according to the synthesis of intermediate F2

Halogenopyrazole	LCMS	Intermediate F
	(Method A): 1.37 min, m/z: 270.1, 272.1 [M+H] ⁺	Intermediate F3
	(Method A): 4.09 min, m/z: 275.1, 277.1 [M+H] ⁺	Intermediate F4
	(Method A): 3.65 min, m/z: 338.1, 340.1 [M+H] ⁺	Intermediate F5
	(Method A): 1.88 min, m/z: 286.1, 288.1 [M+H] ⁺	Intermediate F6
	(Method A): 1.82 min, m/z: 286.1, 288.1 [M+H] ⁺	Intermediate F7
	(Method A): 1.26 min, m/z: 294.0, 296.0 [M+H] ⁺	Intermediate F8

	(Method A): 1.97 min, m/z: 300.1, 302.1 [M+H] ⁺	Intermediate F9
	(Method A): 3.86 min, m/z: 340.1, 342.1 [M+H] ⁺	Intermediate F10
	(Method B): 1.49 min, m/z: 272.1, 274.1 [M+H] ⁺	Intermediate F15


Intermediate F11 and F12: (R)-4-(4-bromo-1H-pyrazol-1-yl)-1,2,2-trimethylpiperidine and (S)-4-(4-bromo-1H-pyrazol-1-yl)-1,2,2-trimethylpiperidine



- 5 (R)-4-(4-bromo-1H-pyrazol-1-yl)-1,2,2-trimethylpiperidine and (S)-4-(4-bromo-1H-pyrazol-1-yl)-1,2,2-trimethylpiperidine were obtained by chiral SFC purification of the racemic mixture (4-(4-bromo-1H-pyrazol-1-yl)-2,2-dimethylpiperidine-1-carboxylate (obtained from tert-butyl 4-(4-(4-amino-3-(4-((difluoromethyl)sulfonamido)-3-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-7-yl)-1H-pyrazol-1-yl)-2,2-dimethylpiperidine-1-carboxylate
- 10 step 4 compound 13, following the synthesis of intermediate F2 step 4 and 5). Instrument SFC-150mgm, column: YMC Cellulose-SC (20*250 mm, 5 um), temperature: 30 °C, Mobile phase: CO₂/IPA[0.5%NH₃(7M in MeOH)]=95/5, Flow rate: 40 ml/min, Back pressure: 100 bar. Peak 1 = 0.89 min, Peak 2 = 1.09 min

The enantiomeric excess was calculated on UPCC (Waters), Column: YMC Cellulose-SC (4.6*100mm 3um), Temperature: 40 °C, Mobile phase: CO₂/IPA [1.0% NH₃ (7M in MeOH)] = 90/10, Flow rate: 3 mL/min. Both enantiomers have an enantiomeric excess >98% ee.

Intermediate F13 and F14: (R)-7-(4-bromo-1H-pyrazol-1-yl)-4-methyl-4-azaspiro[2.5]octane and (S)-7-(4-bromo-1H-pyrazol-1-yl)-4-methyl-4-azaspiro[2.5]octane




(R)-7-(4-bromo-1H-pyrazol-1-yl)-4-methyl-4-azaspiro[2.5]octane and (S)-7-(4-bromo-1H-pyrazol-1-yl)-4-methyl-4-azaspiro[2.5]octane were obtained by chiral HPLC purification of the racemic 7-(4-bromo-1H-pyrazol-1-yl)-4-methyl-4-azaspiro[2.5]octane (intermediate F2).

10 Column: CHIRALCEL® AD-H; Column size: 21.2 ×250 mm, 5 µm; mobile phase : n-Hexane/Ethanol/Diethylamine= 70/30/0.1 (v/v/v); flow rate: 20 mL/min; temperature: 35 °C.

The enantiomeric excess was calculated :CHIRALCEL®AD-H, column size: 0.46 cm I.D. ×25 cm L ×5 µm, injection : 5µL, mobile phase : n-Hexane/Ethanol/Diethylamine = 70/30/0.1 (v/v/v), flow rate : 1.0 mL/min, sample solution:1.1 mg/mL in MeOH/EtOH = 1/1 (v/v). Peak 1 = 4.72 min, Peak 2 = 9.64 min. Both enantiomers have an enantiomeric excess >99% ee.

15


General procedure A2 for the Sonogashira reaction between intermediate A1B1 and alkynes




To a solution of N-(4-{4-amino-7-iodo-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl)-1,1-difluoromethanesulfonamide (1 eq.), CuI (1 eq.), Et₃N (3 eq) and the alkyne (2 eq) in degassed DMF (0.2 M) was added Pd(dppf)Cl₂ (0.1 eq) and the mixture was stirred at 130 °C under MW for 1h, or until reaction completion as checked by TLC. The mixture was concentrated under reduced pressure and the residue was purified by column chromatography (DCM/MeOH) or prep-TLC to give the title compound as a yellow solid.

The following compounds were prepared following the **General procedure A2**

Compound No	Name	Structure	Yield	LC/MS data	¹ H NMR data	Alkyne SM
56	(S)-N-(4-(4-amino-1-methyl-7-(prop-1-yn-1-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		35%	(Method A): 3.37 min, m/z: 530.2 [M+H] ⁺ .	(400 MHz, DMSO- <i>d</i> ₆): 7.85 (s, 1H), 7.64-7.55 (m, 1H), 7.40 (d, <i>J</i> = 8.8 Hz, 1H), 7.18-7.12 (m, 4H), 7.01 (t, <i>J</i> = 52.8 Hz, 1H), 5.99 (s, 2H), 5.66 (q, <i>J</i> = 6.4 Hz, 1H), 4.22 (s, 3H), 2.12 (s, 3H), 1.58 (d, <i>J</i> = 6.4 Hz, 3H)	Propyne (1M in DMF)
58	(S)-N-(4-(4-amino-1-methyl-7-((tetrahydro-2H-pyran-4-yl)ethynyl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		62%	(Method A): 3.29 min, m/z: 600.2 [M+H] ⁺ .	(400 MHz, DMSO- <i>d</i> ₆): 7.66-7.16 (m, 8H), 6.09-5.74 (m, 3H), 4.23 (s, 3H), 3.84-3.80 (m, 2H), 3.48-3.42 (m, 3H), 3.32-2.96 (m, 1H), 1.89-1.85 (m, 3H)	4-ethynyltetrahydro-2H-pyran

128	(S)-N-(4-(4-amino-1-methyl-7-((1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethynyl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		11%	(Method A): 3.54 min, m/z: 681.1 [M+H] ⁺ .	(400 MHz, DMSO-d ₆) 10.56 (s, 1H), 7.82 (s, 1H), 8.06 (s, 1H), 7.56 (q, J = 5.2 Hz, 2H), 7.40 (d, J = 8 Hz, 1H), 7.18-7.11 (m, 4H), 7.01 (t, J = 52 Hz, 1H), 6.02 (s, 2H), 5.65 (q, J = 6.8 Hz, 1H), 4.23 (s, 3H), 3.17 (q, J = 10.7 Hz, 2H), 2.89-2.84 (m, 2H), 2.75-2.71 (m, 1H), 2.53 (s, 2H), 1.92-1.88 (m, 2H), 1.71-1.62 (m, 2H), 1.59 (d, J = 4 Hz, 3H).	4-ethynyl-1-(2,2,2-trifluoroethyl)piperidine
-----	---	---	-----	---	---	--


General procedure A3 for the Suzuki reaction between intermediate A2B1 and boronate esters





5 A mixture of (S)-N-(4-(4-amino-7-iodo-1-isopropyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide (1 eq), boronate ester (1.1 eq), Na_2CO_3 (3 eq) and $\text{Pd}(\text{dppf})\text{Cl}_2$ (0.1 eq) in degassed 1,4-dioxane/ H_2O (4/1, 0.2 M) was stirred at 100 °C overnight under N_2 . The mixture was diluted with water and the organics were extracted with EtOAc (3 x). The combined organics were dried over Na_2SO_4 and concentrated under reduced pressure. The residue was purified by column chromatography (DCM/MeOH)

10 to give the title product as a yellow solid.


The following compounds were prepared following the **General procedure A3**

Compound No	Name	Structure	Yield	LC/MS data	¹ H NMR data	Boronate ester
50	(S)-N-(4-(4-amino-1-isopropyl-7-(pyridin-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		55%	(Method A): 3.07 min, m/z: 597.2 [M+H] ⁺ .	(400 MHz, DMSO-d ₆): 8.68 (d, J = 5.6 Hz, 2H), 7.59-7.56 (m, 3H), 7.53 (d, J = 5.6 Hz, 2H), 7.42 (d, J = 8.0 Hz, 1H), 7.18 (t, J = 8.8 Hz, 3H), 7.14 (t, J = 52.4 Hz, 1H), 6.14 (s, 2H), 5.64 (q, J = 6.0 Hz, 1H), 4.27-4.20 (m, 1H), 1.60 (d, J = 6.4 Hz, 3H), 1.24 (dd, J = 2.4, 2.0 Hz, 6H).	4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

Compound	(S)-N-(4-(4-amino-1-isopropyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		19%	(Method A): 3.28 min, m/z: 670.2 [M+H] ⁺ .	(400 MHz, DMSO-d ₆): 1-(tetrahydro-2H-pyran-4-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
----------	---	---	-----	---	---



Compound 52	(S)-N-(4-(4-amino-1-isopropyl-7-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		16%	LCMS (Method A): 3.19 min, m/z: 600.2 [M+H] ⁺ .	(400 MHz, DMSO-d ₆): 7.92 (s, 1H), 7.64-7.56 (m, 4, 4, 5, 5-A), 7.50 (s, 1H), 7.41 (d, tetramethyl-1,3,2-amin, J = 8.0 Hz, 1H), 7.19-7.14 (dioxaborolan-2-(m, 4H), 7.12 (s, 1H), 7.03 (yl)-1H-pyrazole (s, 0.4H), 6.90 (s, 0.2H), 6.33 (s, 2H), 5.62 (q, J = 6.0 Hz, 1H), 4.59-4.53 (m, 1H), 3.92 (s, 3H), 1.59 (d, J = 5.6 Hz, 3H), 1.28 (t, J = 5.6 Hz, 6H).
--------------------	---	---	-----	---	--


General procedure A4 for the Suzuki reaction between intermediate A3B1 and boronate esters




A mixture of (S)-N-(4-(4-amino-7-bromopyrazolo[1,5-a]pyrazin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide (1 eq), boronate ester (1.1 eq), Na_2CO_3 (3 eq) and $\text{Pd}(\text{dppf})\text{Cl}_2$ (0.1 eq) in degassed 1,4-dioxane/ H_2O (4/1, 0.2 M) was stirred at 100 °C overnight under N_2 . The mixture was diluted with water and the organics were extracted with EtOAc (3 x). The combined organics were dried over Na_2SO_4 and concentrated under reduced pressure. The residue was purified by column chromatography (DCM/MeOH or PE/EtOAc) to give the title product as a yellow solid.


The following compounds were prepared following the **General procedure A4**

Compound No	Name	Structure	Yield	LCMS data	¹ H NMR data	Boronate ester
Compound 35	(S)-N-(4-(4-amino-7-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		31%	(Method A): 3.36 min, m/z: 558.2 [M+H] ⁺ .	(400 MHz, CDCl ₃): 8.40 (s, 1H), 8.01 (s, 1H), 7.79 (s, 1H), 7.65-7.60 (m, 2H), 7.31 (dd, J = 8.6, 5.2 Hz, 2H), 7.10-7.03 (m, 3H), 6.86 (s, 1H), 6.37 (t, J = 53.5 Hz, 1H), 5.45-5.39 (m, 1H), 4.78 (s, 2H), 4.00 (s, 3H), 1.70 (d, J = 6.4 Hz, 3H).	1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
Compound 36	(S)-N-(4-(4-amino-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		52%	(Method A): 3.41 min, m/z: 628.2 [M+H] ⁺ .	(400 MHz, DMSO-d ₆): 10.47 (s, 1H), 8.64 (s, 1H), 8.24 (s, 1H), 8.01 (s, 1H), 7.82 (s, 1H), 7.64-7.54 (m, 2H), 7.36 (d, J = 7.9 Hz, 1H), 7.18 (t, J = 8.5 Hz, 2H), 7.11-6.64 (m, 3H), 5.91 (s, 2H), 5.68 (d, J = 6.2 Hz, 1H), 4.51 (td, J = 10.9, 6.0 Hz, 1H), 3.98 (d,	1-(tetrahydro-2H-pyran-4-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole

					$J = 10.6 \text{ Hz, 2H, 3.50 (dd, } J = 11.2, 3.2 \text{ Hz, 2H), 2.10-1.92 (m, 5H), 1.59 (d, } J = 6.1 \text{ Hz, 3H).$	
Compound 37	(S)-N-(4-(4-amino-7-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		32%	(Method A): 3.10 min, m/z : 588.2 $[M+H]^+$.	(400 MHz, DMSO- d_6): 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]ethanol	

Compound 39	(S)-N-(4-(4-amino-7-(pyridin-4-yl)pyrazolo[1,5-a]pyrazin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		33%	(Method A): 3.15 min, m/z: 555.2 [M+H]⁺.	(400 MHz, DMSO-d₆): 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine 10.50 (s, 1H), 8.71 (d, J = 8.0 Hz, 1H), 7.99 (d, J = 8.0 Hz, 1H), 7.77 (s, 1H), 7.58 (dd, J = 8.5, 5.6 Hz, 2H), 7.37 (d, J = 8.0 Hz, 1H), 7.23-7.14 (m, 2H), 7.10-6.86 (m, 3H), 6.42-6.22 (m, 2H), 5.68 (q, J = 6.1 Hz, 1H), 1.59 (d, J = 6.2 Hz, 3H).
--------------------	--	---	------------	--	--

Compounds 79 and 80



Step 1: tert-butyl 4-(2-{4-amino-3-[4-(difluoromethanesulfonamido)-3-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl]-1-methyl-1H-pyrazolo[4,3-c]pyridin-7-yl}ethynyl)piperidine-1-carboxylate

Following general procedure A2 with tert-butyl 4-ethynylpiperidine-1-carboxylate, the title compound (88%) was obtained as a yellow solid.

Step 2: (S)-N-(4-(4-amino-1-methyl-7-(piperidin-4-ylethynyl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide (**Compound 79**)


To a solution of tert-butyl 4-(2-{4-amino-3-[4-(difluoromethanesulfonamido)-3-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl]-1-methyl-1H-pyrazolo[4,3-c]pyridin-7-yl}ethynyl)piperidine-1-carboxylate (300 mg, 429 μ mol) in HCO_2H (2 mL) was stirred at RT for 1 h. The reaction mixture was concentrated under reduced pressure and the residue was adjusted to pH=8 with sat. aq. Na_2CO_3 . The residue was diluted with water (5 mL) and the organics were extracted with EtOAc (3 x 5 mL). The combined organics were washed with brine, dried over Na_2SO_4 and concentrated under reduced pressure. The residue was purified by prep-TLC (DCM/MeOH: 95/5) to give the title product (140 mg, 54%) as a white solid. LCMS (Method A): 2.83 min, m/z 599.1 $[\text{MH}]^+$. ^1H NMR (400 MHz, $\text{DMSO}-d_6$): 7.80 (s, 1H), 7.64-7.53 (m, 1H), 7.50 (q, J = 4 Hz, 2H), 7.34 (d, J = 8 Hz, 1H), 7.12 (t, J = 8 Hz, 1H), 6.90 (d, J = 8 Hz, 1H), 7.18-7.10 (m, 1H), 6.84 (s, 1H), 6.33 (t, J = 52 Hz, 1H), 6.00 (s, 2H), 5.63 (q, J = 8 Hz, 1H), 4.15 (s, 3H), 3.23 (s, 2H), 3.00 (s, 3H), 2.04 (s, 2H), 1.76 (s, 2H), 1.50 (d, J = 6.2 Hz, 3H)

Step 3: (S)-N-(4-(4-amino-1-methyl-7-((1-methylpiperidin-4-yl)ethynyl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide (**Compound 80**)

To a solution of N-(4-{4-amino-1-methyl-7-[2-(piperidin-4-yl)ethynyl]-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl)-1,1-difluoromethanesulfonamide (120 mg, 0.2 mmol) in DCM (10 mL) were added paraformaldehyde (11.9 mg, 0.4 mmol) and

NaBH(OAc)₃ (127 mg, 0.6 mmol), and the reaction mixture was stirred at RT overnight. The mixture was concentrated under reduced pressure and the residue was purified by prep-TLC (MeOH/DCM: 1/20) to give the title compound (40 mg, 32%) as a yellow solid. LCMS (Method A): 2.80 min, m/z 613.3 [M+H]⁺. ¹H NMR (400 MHz, DMSO-*d*₆): 10.96 (s, 1H), 7.88 (s, 1H), 7.57 (q, *J* = 4 Hz, 2H), 7.40 (d, *J* = 8 Hz, 1H), 7.18-7.10 (m, 4H), 7.13 (t, *J* = 52 Hz, 1H), 6.11 (s, 2H), 5.65 (q, *J* = 4 Hz, 1H), 4.22 (s, 3H), 3.16 (s, 2H), 2.89 (s, 1H), 2.70 (s, 3H), 2.18-1.98 (m, 4H), 1.57 (d, *J* = 6.2 Hz, 3H), 1.23 (s, 2H).

Compound 91: (S)-N-(4-(4-amino-1-methyl-7-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide






Step 1: (S)-N-(4-(4-amino-1-methyl-7-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide

To a solution of (S)-N-(4-(4-amino-1-methyl-7-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide (**Compound 90**, 34 mg, 55.4 μmol) in DCM (5 mL) were added paraformaldehyde (5.37 mg, 66.4 μmol) and NaBH(OAc)₃ (58.7 mg, 277 μmol). The reaction mixture was stirred at RT for 45 min before sat. aq. NaHCO₃ (10 mL) was added, and the aqueous layer was extracted with EtOAc (3 x 10 mL). The combined organics were concentrated under reduced pressure and the residue was purified by silica gel column chromatography (DCM:MeOH; 10:1) to give the title compound (10 mg, 29%) as a yellow solid. LCMS (Method B): 2.85 min; m/z: 627.2 [M+H]⁺. ¹H NMR (400 MHz, DMSO-*d*₆): 7.60 (s, 1H), 7.53 (d, *J* = 8.1 Hz, 1H), 7.48 (dd, *J* = 8.4, 5.4 Hz, 3H), 7.16 (d, *J* = 8.1 Hz, 1H), 7.10-7.02 (m, 3H), 5.56 (q, *J* = 6.2 Hz, 1H), 4.29 (t, *J* = 5.5 Hz, 2H), 3.70 (s, 3H), 3.57 (s, 2H), 3.04 (t, *J* = 5.4 Hz, 2H), 2.48 (s, 3H), 1.69 (d, *J* = 6.3 Hz, 3H).

The following compounds were prepared similarly to compound 91

Compound No	Name	Structure	Yield	LCMS data	¹ H NMR data	Starting material
99	(S)-N-(4-(4-amino-1-methyl-7-(1-(2-methyl-2-azaspiro[3.3]heptan-6-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		19%	(Method A): 2.78 min, m/z: 667.2 [M+H] ⁺ .	(400 MHz, MeOD-d ₄): 7.83 (t, 1H), 7.66 (s, 1H), 7.49 (t, 1H), 7.14 (dd, J = 4.5 Hz, 4H), 7.08 (dd, J = 8.2, 1.8 Hz, 1H), 7.08–7.02 (m, 3H), 5.55 (q, J = 6.3 Hz, 1H), 4.20 (s, 2H), 4.14 (s, 2H), 3.72 (s, 3H), 2.95–2.85 (m, 4H), 2.84 (s, 4H), 1.69 (d, J = 6.4 Hz, 3H).	

143	N-(4-(4-amino-1-methyl-7-(1-(1-methyl-2-(trifluoromethyl)piperidin-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		23%	(Method A): 2.92 min, m/z: 723.2 [M+H] ⁺	(400 MHz, MeOD-d ₄): 7.83 (s, 1H), 7.54 (s, 1H), 7.42 (t, J = 4.1 Hz, 2H), 7.41-7.35 (m, 2H), 7.06 (dd, J = 8.0, 1.8 Hz, 1H), 7.02-6.92 (m, 3H), 6.58 (t, J = 53.3 Hz, 1H), 5.46 (q, J = 6.4 Hz, 1H), 4.55-4.44 (m, 1H), 3.63 (s, 3H), 3.55-3.46 (m, 1H), 2.96 (d, J = 11.7 Hz, 1H), 2.76 (d, J = 12.8 Hz, 1H), 2.54 (d, J = 2.2 Hz, 3H), 2.38-2.29 (m, 1H), 2.22 (d, J = 14.1 Hz, 1H), 2.12 (td, J = 13.8, 12.8, 5.0 Hz, 1H), 2.00 (dd, J = 12.7, 4.0 Hz, 1H), 1.59 (d, J = 6.4 Hz, 3H).	149
164	N-(4-(4-amino-1-methyl-7-(1-(1-methyl-2-(trifluoromethyl)piperidin-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		31%	(Method A): 2.29 min, m/z: 681.2 [M+H] ⁺	(400 MHz, DMSO-d ₆): 10.69 (s, 1H), 7.96 (s, 1H), 7.60 (s, 1H), 7.56-7.53 (m, 3H), 7.38 (d, J = 8 Hz, 1H), 7.17-7.01 (m, 4H), 6.78 (t, J = 52 Hz, 1H), 5.68 (s, 2H), 5.65 (q, J = 6.8 Hz, 1H), 5.05-4.98 (m, 1H), 3.68 (s, 3H), 3.24 (s, 2H), 2.96 (s, 4H), 2.66 (s, 3H), 2.28-2.08 (m, 4H), 1.55 (d, J = 4 Hz, 3H).	163

Compound 54 and Compound 55

Step 1: (S)-N-(4-(4-amino-1-methyl-7-(1,2,5,6-tetrahydropyridin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide

5 (Compound 54)


To a solution of tert-butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (1 g, 3.23 mmol) in 1,4-dioxane (15 mL) was added a 2M HCl in dioxane (10 mL) and the mixture was stirred at RT for 10 min. The solution was concentrated under reduced pressure to give a white solid. The solids were dissolved in degassed 1,4-dioxane/H₂O (4/1, 10 mL) and (S)-N-(4-(4-amino-7-iodo-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide (700 mg, 1.13 mmol), Na₂CO₃ (358 mg, 3.38 mmol) and Pd(dppf)Cl₂ (92.2 mg, 113 μmol) were added. The solution was then stirred at 100 °C for 12 h. The reaction mixture was concentrated under reduced pressure, and the residue was poured into water (20 mL) and extracted with EtOAc (2 x 20 mL). The combined organics were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by prep-TLC (DCM/MeOH = 10/1) to give the title product (300 mg, 46%) as a brown solid. LCMS (Method A): 2.63 min, m/z: 573.2 [M+H]⁺. ¹H NMR (400 MHz, DMSO-*d*₆): 10.85 (s, 1H), 7.54 (dd, *J* = 8.7, 5.6 Hz, 2H), 7.48 (s, 1H), 7.37 (d, *J* = 8.1 Hz, 1H), 7.15 (t, *J* = 8.9 Hz, 2H), 7.06-6.98 (m, 2H), 5.87 (s, 1H), 5.64 (q, *J* = 6.3 Hz, 1H), 3.97 (s, 3H), 3.52 (s, 2H), 2.99 (s, 2H), 2.61 (s, 3H), 2.47 (s, 2H), 1.55 (d, *J* = 6.3 Hz, 3H).

Step 2: (S)-N-(4-(4-amino-1-methyl-7-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide (**Compound 55**)

A mixture of (S)-N-(4-(4-amino-1-methyl-7-(1,2,5,6-tetrahydropyridin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide (20 mg, 34.9 μmol) and paraformaldehyde (20.8 mg, 348 μmol) in MeOH (3 mL) was stirred at RT for 12 h. NaBH₃CN (8.73 mg, 139 μmol) was added and the mixture was stirred at RT for 20 min. The reaction mixture was poured into water (40 mL) and the organics were extracted with EtOAc (2 x 40 mL). The combined organics were dried over Na₂SO₄ and concentrated under

reduced pressure. The residue was purified by column chromatography (DCM/MeOH = 15/1) to give the title product (10.0 mg, 49%) as a brown solid. LCMS (Method A): 3.73 min, m/z: 611.2 [M+Na]⁺. ¹H NMR (400 MHz, DMSO-*d*₆): 10.85 (s, 1H), 7.54 (dd, *J* = 8.7, 5.6 Hz, 2H), 7.48 (s, 1H), 7.37 (d, *J* = 8.1 Hz, 1H), 7.15 (t, *J* = 8.9 Hz, 2H), 7.06-6.98 (m, 2H), 5.87 (s, 1H), 5.64 (q, *J* = 6.3 Hz, 1H), 3.97 (s, 3H), 3.52 (s, 2H), 2.99 (s, 2H), 2.61 (s, 3H), 2.47 (s, 2H), 1.55 (d, *J* = 6.3 Hz, 3H).

Compound 42: (S)-N-(4-(4-amino-1-methyl-7-(1-methylpiperidin-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide




Step 1: (S)-N-(4-(4-amino-1-methyl-7-(1-methylpiperidin-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide

A mixture of (S)-N-(4-(4-amino-1-methyl-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-

difluoromethanesulfonamide (90 mg, 153 μmol), NaBH₄ (11.5 mg, 306 μmol) and AcOH (27.5 mg, 459 μmol) in THF (10 mL) was stirred at 45 °C overnight. HCl (1 M, 5 mL) was added, and the reaction mixture was stirred for 5 min. The reaction mixture was adjusted to pH = 8 with sat. aq. Na₂CO₃ and the organics were extracted with EtOAc (2 x 30 mL). The combined organic phases were dried over Na₂SO₄ and concentrated. The residue was purified by prep-TLC (DCM/MeOH = 15/1) to give the title product (7 mg, 7%) as a white solid. LCMS (Method A): 3.30 min, m/z 589.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃): 7.86 (s, 1H), 7.69 (d, *J* = 8.2 Hz, 1H), 7.34-7.29 (m, 2H), 7.15 (d, *J* = 8.2 Hz, 1H), 7.08 (t, *J* = 8.6 Hz, 2H), 6.92 (s, 1H), 6.35 (t, *J* = 53.6 Hz, 1H), 5.72 (s, 2H), 5.43 (q, *J* = 6.1 Hz, 1H), 4.21 (s, 3H), 3.26 (d, *J* = 8.1 Hz, 2H), 2.99 (s, 2H), 2.74 (s, 3H), 2.22 (d, *J* = 15.3 Hz, 1H), 2.00 (s, 2H), 1.82 (s, 2H), 1.70 (d, *J* = 6.4 Hz, 3H).


Compound 40: (S)-N-(4-(4-amino-1-methyl-7-(pyrimidin-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide



Step 1: (S)-N-(4-(4-amino-1-methyl-7-(pyrimidin-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide

To a solution of (S)-N-(4-(4-amino-7-iodo-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide (70 mg, 113 μ mol) in degassed MePh (2 mL) were added Pd(PPh₃)₄ (13.0 mg, 11.3 μ mol), KF (32.8 mg, 565 μ mol) and 4-(tributylstannyl)pyrimidine (41.7 mg, 113 μ mol), and the mixture was stirred at 130 °C with μ W irradiation for 2 h. The mixture was concentrated under reduced pressure and the residue was purified by Prep TLC (DCM/MeOH = 40/1) to give the title product (7.0 mg, 11%) as a yellow solid. LCMS (method C): 3.30 min, m/z 570.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃): 9.30 (s, 1H), 8.81 (d, *J* = 5.2Hz, 1H), 7.92 (s, 1H), 7.68 (d, *J* = 8.4Hz, 1H), 7.59 (d, *J* = 4.4 Hz, 1H), 7.32 (q, *J* = 4.4 Hz, 2H), 7.21 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.07-7.02 (m, 3H), 6.35 (t, *J* = 53.6 Hz, 1H), 5.47 (q, *J* = 6.4 Hz, 1H), 5.13 (s, 2H), 3.95 (s, 3H), 1.69 (d, *J* = 6.4Hz, 3H).


Compound 109: (S)-N-(4-(7-(1-(1-acetylpiperidin-4-yl)-1H-pyrazol-4-yl)-4-amino-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide



Step 1: (S)-N-(4-(7-(1-(1-acetylpiperidin-4-yl)-1H-pyrazol-4-yl)-4-amino-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide

To a solution of **compound 59** (150 mg, 234 μ mol) and Et₃N (70.9 mg, 702 μ mol) in DCM (10 mL) was added AcCl (18.3 mg, 234 μ mol). The reaction mixture was stirred at RT for 10 min. The mixture was concentrated under reduced pressure and the residue was purified by prep-TLC (DCM:MeOH; 20:1) to give the title product (80.0 mg, 50%) as a yellow solid. LCMS (Method A) 2.88 min; m/z 683.2 [M+H]⁺. ¹H NMR (400MHz, DMSO-d₆): 7.99 (s, 1H), 7.61 (s, 1H), 7.59-7.55 (m, 3H), 7.43-7.41 (d, J = 8 Hz, 1H), 7.18-7.14 (m, 4H), 6.99 (t, J = 52 Hz, 1H), 5.82 (s, 2H), 5.66 (q, J = 4 Hz, 1H), 4.55-4.44 (m, 2H), 3.70 (s, 3H), 2.80-2.74 (m, 1H), 2.15-2.11 (m, 2H), 2.05 (s, 3H), 1.99-1.80 (m, 2H), 1.60 (d, J = 8 Hz, 3H).


Compound 89: (S)-N-(4-(4-amino-7-(1-(1-(aminomethyl)cyclopropyl)-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide



Step 1: (S)-N-(4-(4-amino-7-(1-(1-(aminomethyl)cyclopropyl)-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide

To a 0 °C solution of N-(4-{4-amino-7-[1-(1-(cyanocyclopropyl)-1H-pyrazol-4-yl]-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl)-1,1-difluoromethanesulfonamide **96** (30 mg, 48.1 μ mol) in dry THF (2 mL) was added LiAlH₄ (3.65 mg, 96.2 μ mol). The reaction mixture was stirred at RT for 1 h under N₂, then concentrated under reduced pressure. The residue was purified by prep-TLC (DCM:MeOH; 98:2) to give the title product (15.0 mg, 50%) as yellow solid. LCMS (Method E): 0.34 min, m/z: 627.3 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆): 7.99 (s, 1H), 7.71 (s, 1H), 7.53-7.49 (m, 3H), 7.36-7.34 (m, 1H), 7.13 (t, J = 8.4 Hz, 2H), 6.95-6.87 (m, 2H), 6.40 (t, J = 14.4 Hz, 1H), 5.65 (brs, 3H), 3.72 (s, 3H), 3.27 (s, 2H), 1.52-1.23 (m, 7H).


Compound 141: N-{4-[4-amino-1-methyl-7-(morpholin-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl}-1,1-difluoromethanesulfonamide



Step 1: N-{4-[4-amino-1-methyl-7-(morpholin-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl}-1,1-difluoromethanesulfonamide

A mixture of N-(4-[4-amino-7-iodo-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl)-1,1-difluoromethanesulfonamide (300 mg, 485 μ mol), morpholine (422 mg, 4.85 mmol) and K_2CO_3 (200 mg, 1.45 mmol) in ethylene glycol (3 mL) was stirred at 130 $^{\circ}C$ overnight. The reaction mixture was concentrated under reduced pressure and the crude mixture was purified by Prep-TLC (DCM/MeOH: 99/1) to give the title compound (8 mg, 3%) as a yellow solid. LCMS (Method A): 3.04 min, m/z : 577.1 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$): 7.67 (d, J = 8.2 Hz, 1H), 7.50 (s, 1H), 7.35-7.29 (m, 2H), 7.16 (dd, J = 8.2, 1.8 Hz, 1H), 7.07-6.99 (m, 3H), 6.35 (t, J = 53.6 Hz, 1H), 5.83 (s, 2H), 5.46 (q, J = 6.3 Hz, 1H), 4.35 (s, 3H), 3.97 (d, J = 9.4 Hz, 2H), 3.82-3.67 (m, 2H), 3.00 (d, J = 16.7 Hz, 4H), 1.68 (d, J = 6.4 Hz, 3H).


Compound 133: N-(4-[4-amino-7-cyano-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl]-2-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl)-1,1-difluoromethanesulfonamide



Step 1: N-(4-{4-amino-7-cyano-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl)-1,1-difluoromethanesulfonamide

A mixture of N-(4-{4-amino-7-iodo-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl)-1,1-difluoromethanesulfonamide (50 mg, 80.9 μ mol), CuI (15.4 mg, 80.9 μ mol) and Zn(CN)₂ (9.49 mg, 80.9 μ mol) in NMP (4 mL) was stirred at 130 °C under N₂ overnight. The reaction was poured into EtOAc (20 mL), then the organics were washed with water (20 mL x 3) and brine (10 mL), dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by Prep-TLC (DCM/MeOH = 15/1) to give the title product (7 mg, 17%) as a brown solid. LCMS (Method A): 3.69 min, m/z 517.0 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃): 8.21 (s, 1H), 7.70 (d, J = 8.5 Hz, 1H), 7.32 (t, J = 6.9 Hz, 2H), 7.18 (d, J = 8.5 Hz, 1H), 7.06 (t, J = 8.4 Hz, 2H), 7.01 (s, 1H), 6.35 (t, J = 52 Hz, 1H), 5.47 (q, J = 6.6 Hz, 1H), 5.30 (s, 2H), 4.27 (s, 3H), 1.71 (d, J = 6.4 Hz, 3H).

Compound 44: (S)-N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-2,2,2-trifluoroethane-1-sulfonamide



Step 1: (S)-3-(3-(1-(4-fluorophenyl)ethoxy)-4-nitrophenyl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-4-amine

A mixture of 3-iodo-1-methyl-1H-pyrazolo[4,3-c]pyridin-4-amine (4 g, 14.5 mmol), (S)-2-(3-(1-(4-fluorophenyl)ethoxy)-4-nitrophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (5.61 g, 14.5 mmol), K₂CO₃ (6.01 g, 43.5 mmol) and Pd(dppf)Cl₂ (1.18 g, 1.45 mmol) in degassed 1,4-dioxane/H₂O (4/1, 125 mL) was stirred at 100 °C for 10 h under N₂. The mixture was

concentrated under reduced pressure and the residue was purified by column chromatography (PE/EtOAc = 4:1 to 1:4) to give the title product (5.2 g, 88%) as a yellow solid. LCMS (Method A): 3.31 min, m/z: 408.4 [M+H]⁺.

Step 2: (S)-3-(3-(1-(4-fluorophenyl)ethoxy)-4-nitrophenyl)-7-iodo-1-methyl-1H-pyrazolo[4,3-c]pyridin-4-amine

A mixture of (S)-3-(3-(1-(4-fluorophenyl)ethoxy)-4-nitrophenyl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-4-amine (2.5 g, 6.13 mmol) and NIS (2.74 g, 12.2 mmol) in DMF (50 mL) was stirred at 85 °C for 6 h under N₂. The mixture was concentrated under reduced pressure and the residue was purified by column chromatography (PE/EtOAc = 4:1 to 1:4) to give the title product (1.1 g, 33%) as a yellow solid. LCMS (Method A): 3.51 min, m/z: 534.3 [M+H]⁺.

Step 3: (S)-3-(3-(1-(4-fluorophenyl)ethoxy)-4-nitrophenyl)-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-4-amine

A mixture of (S)-3-(3-(1-(4-fluorophenyl)ethoxy)-4-nitrophenyl)-7-iodo-1-methyl-1H-pyrazolo[4,3-c]pyridin-4-amine (1.1 g, 2.06 mmol), 1-(tetrahydro-2H-pyran-4-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (573 mg, 2.06 mmol), K₂CO₃ (854 mg, 6.18 mmol) and Pd(dppf)Cl₂ (168 mg, 206 μmol) in 1,4-dioxane/H₂O (4/1, 25 mL) was stirred at 100 °C for 10 h under N₂. The mixture was concentrated under reduced pressure and the residue was purified by column chromatography (PE/EtOAc = 4:1 to 1:4) to give the title product (0.9 g, 76%) as a yellow solid. LCMS (Method A): 3.10 min, m/z: 558.6 [M+H]⁺.

Step 4: (S)-3-(4-amino-3-(1-(4-fluorophenyl)ethoxy)phenyl)-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-4-amine


A mixture of (S)-3-(3-(1-(4-fluorophenyl)ethoxy)-4-nitrophenyl)-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-4-amine (0.9 g, 1.61 mmol) and Zn dust (525 mg, 8.04 mmol) in MeOH (18 mL) and sat. aq. NH₄Cl (6 mL) was stirred at 60 °C for 8 h. The mixture was poured into water (20 mL) and the organics were extracted with DCM (2 x 10 mL). The combined organic phases were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography (PE/EtOAc = 1:4 to 1:10) to give the title product (330 mg 39%) as a white solid. LCMS (Method A): 2.85 min, m/z: 528.6 [M+H]⁺.


Step 5: (S)-N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-2,2,2-trifluoroethane-1-sulfonamide

A solution of (S)-3-(4-amino-3-(1-(4-fluorophenyl)ethoxy)phenyl)-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-4-amine (100 mg, 189 μmol) and


- 2,2,2-trifluoroethanesulfonyl chloride (51.6 mg, 283 μ mol) in DCM (2.5 mL) and pyridine (0.5 mL) was stirred at 35 °C for 10 h. The mixture was concentrated under reduced pressure and the residue was purified by column chromatography (DCM/MeOH = 20/1) to give the title product (7 mg, 6%) as a white solid. LCMS (Method A): 3.17 min, m/z : 674.7 $[M+H]^+$. ^1H NMR (400 MHz, $CDCl_3$): 7.71 (d, J = 8.2 Hz, 1H), 7.62 (s, 1H), 7.58 (s, 1H), 7.54 (s, 1H), 7.36-7.28 (m, 2H), 7.25-7.20 (m, 1H), 7.11-7.00 (m, 3H), 5.47 (q, J = 6.4 Hz, 1H), 4.43 (tt, J = 10.4, 4.8 Hz, 1H), 4.15 (dt, J = 11.8, 3.1 Hz, 2H), 3.92 (q, J = 8.7 Hz, 2H), 3.77 (s, 3H), 3.59 (td, J = 11.6, 2.8 Hz, 2H), 2.26-2.09 (m, 4H), 1.69 (d, J = 6.4 Hz, 3H).
- 10 The following compounds were prepared similarly to the synthesis of (S)-N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-2,2,2-trifluoroethane-1-sulfonamide (compound 44) with the indicated sulfonyl chloride in step 5.

Compound No	Compound Name	Structure	Yield	LCMS data	¹ H NMR data	Sulfonyl chloride
45	(S)-N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)ethanesulfonamide		26%	LCMS (Method A): (s, 1H), 8.04 (s, 1H), 7.64-2.97 min, 7.55 (m, 4H), 7.45 (d, J = 2.97 Hz, 2H), 7.17 (t, J = 8.9 Hz, 2H), 7.12 (s, 2H), 5.89 (s, 2H), 5.66 (d, J = 6.3 Hz, 1H), 4.47 (tt, J = 10.4, 5.3 Hz, 1H), 4.03-3.94 (m, 2H), 3.70 (s, 3H), 3.51 (dd, J = 11.2, 3.2 Hz, 2H), 3.16-3.10 (m, 2H), 2.02 (q, J = 4.3 Hz, 4H), 1.60 (d, J = 6.2 Hz, 3H), 1.34-1.28 (m, 3H).	(400 MHz, DMSO-d ₆): 9.24 (s, 1H), 8.04 (s, 1H), 7.64-2.97 min, 7.55 (m, 4H), 7.45 (d, J = 2.97 Hz, 2H), 7.17 (t, J = 8.9 Hz, 2H), 7.12 (s, 2H), 5.89 (s, 2H), 5.66 (d, J = 6.3 Hz, 1H), 4.47 (tt, J = 10.4, 5.3 Hz, 1H), 4.03-3.94 (m, 2H), 3.70 (s, 3H), 3.51 (dd, J = 11.2, 3.2 Hz, 2H), 3.16-3.10 (m, 2H), 2.02 (q, J = 4.3 Hz, 4H), 1.60 (d, J = 6.2 Hz, 3H), 1.34-1.28 (m, 3H).	ethanesulfonyl chloride

124	3-{4- [(dimethylsulfamoyl)amino]- 3-[(1S)-1-(4- fluorophenyl)ethoxy]phenyl]- 1-methyl-7-[1-9oxan-4-yl)- 1H-pyrazol-4-yl]-1H- pyrazolo[4,3-c]pyridin-4- amine		78%	LCMS (Method A): 3.03 min, m/z: 635.1 [M+H] ⁺ .	(400 MHz, DMSO-d ₆): 9.16 (s, 1H), 8.00 (s, 1H), 7.61 (d, J = 6.3 Hz, 3H), 7.54 (s, 1H), 7.49 (d, J = 8.0 Hz, 1H), 7.16 (t, J = 8.9 Hz, 2H), 7.09 (d, J = 10.3 Hz, 2H), 5.67 (q, J = 6.2 Hz, 1H), 5.60 (s, 2H), 4.46 (tt, J = 9.8, 4.7 Hz, 1H), 4.01-3.92 (m, 2H), 3.69 (s, 3H), 3.49 (td, J = 11.0, 3.3 Hz, 2H), 2.73 (s, 6H), 2.09-1.98 (m, 4H), 1.62 (d, J = 6.2 Hz, 3H).	N,N-dimethylsulfamoyl chloride
-----	---	---	-----	--	--	--------------------------------


125	(S)-N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1-phenylmethanesulfonamide 		LCMS (Method A): 9.18 min, 7.61-7.55 (s, 1H), 7.55 (s, 1H), 7.37-7.34 (m, 6H), 7.17 (t, J = 8.8 Hz, 2H), 7.11 (s, 1H), 7.04 (d, J = 8 Hz, 1H), 5.67 (q, J = 6.4 Hz, 3H), 4.54 (s, 2H), 4.50-4.43 (m, 1H), 3.99-3.93 (m, 2H), 3.69 (s, 3H), 3.52-3.46 (m, 2H), 2.04-1.98 (m, 4H), 1.62 (d, J = 6 Hz, 3H).	phenylmethanesulfonamide
-----	---	--	---	--------------------------



General procedure FA for the cross coupling reaction between intermediate A1B1 and halogenopyrazoles F





A mixture of N-(4-((4-amino-7-iodo-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-[(1S)-1-(4-
 5 fluorophenyl)ethoxy]phenyl)-1,1-difluoromethanesulfonamide (1 eq), halogenopyrazole (1.0
 eq), $B_2(\text{pin})_2$ (2 eq), $\text{Pd}(\text{OAc})_2$ (0.2 eq) bis(adamantan-1-yl)(butyl)phosphane (0.4 eq) and
 K_2CO_3 (2 eq) were dissolved in degassed 1,4-dioxane/ H_2O (4/1, 0.2 M) and the solution was
 stirred at 100 °C under N_2 overnight (or at 80 °C for 2 h under μW irradiation). The mixture
 was diluted with water and extracted with EtOAc (3 x). The combined organics were dried over
 10 Na_2SO_4 and concentrated under reduced pressure. The residue was purified by column
 chromatography (DCM/MeOH or EtOAc/PE) or prep TLC (DCM/MeOH)


The following compounds were prepared following the **General procedure FA**



Compound No	Name	Structure	LCMS data	¹ H NMR data	Intermediate
145	N-(4-(4-amino-1-methyl-7-(1-(4-methyl-4-azaspiro[2.5]octan-7-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		(Method A): 2.31 min, m/z: 681.1 [M+H] ⁺	(400 MHz, CDCl ₃): 8.09 (s, 1H), 7.59-7.53 (m, 3H), 7.39 (d, J = 8 Hz, 1H), 7.18-7.02 (m, 4H), 6.89 (t, J = 52 Hz, 1H), 5.67-5.63 (m, 3H), 4.45-4.37 (m, 1H), 3.69 (s, 3H), 2.97-2.89 (m, 2H), 2.39 (s, 3H), 2.23-2.15 (m, 1H), 2.02 (s, 1H), 1.82-1.74 (m, 2H), 1.57 (d, J = 8 Hz, 3H), 1.25-1.23 (m, 1H), 0.66-0.40 (m, 4H).	F F2


146	(S)-N-(4-(4-amino-7-(1-(4,4-difluorocyclohexyl)-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		(Method A): 3.00 min, m/z: 676.2 [M+H] ⁺	(400 MHz, DMSO-d ₆): 8.02 (s, 1H), 7.62-7.55 (m, 4H), 7.40 (d, J = 8 Hz, 1H), 7.19-7.11 (m, 4H), 7.00 (d, J = 52 Hz, 1H), 5.76 (s, 2H), 5.65 (q, J = 8 Hz, 1H), 4.46 (s, 1H), 3.69 (s, 3H), 2.17-1.99 (m, 8H), 1.58 (d, J = 8 Hz, 3H).	F3
152	N-(4-(4-amino-7-(1-(2,2-dimethyl-1-(methyl-d3)piperidin-4-yl)-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		(Method A): 2.29 min, m/z: 686.2 [M+H] ⁺	(400 MHz, DMSO-d ₆): 7.95 (s, 1H), 7.62 (s, 1H), 7.55-7.51 (m, 3H), 7.37 (d, J = 8 Hz, 1H), 7.15 (t, J = 8 Hz, 1H), 7.04-6.96 (m, 2H), 6.69 (t, J = 52 Hz, 1H), 5.67-5.64 (m, 3H), 4.59 (s, 1H), 3.67 (s, 3H), 3.09-3.01 (m, 2H), 2.17-2.06 (m, 4H), 1.55 (d, J = 4 Hz, 3H), 1.27 (d, J = 20 Hz, 6H)	F4



153	N-(4-(4-amino-1-methyl-7-(1-(8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octan-3-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		(Method A): 2.99 min, m/z: 749.2 [M+H] ⁺	(400 MHz, DMSO-d ₆): 8.17 (s, 1H), 7.64-7.51 (m, 4H), 7.41 (d, J = 8.0 Hz, 1H), 7.22-7.07 (m, 5H), 6.93 (d, J = 52.6 Hz, 1H), 5.65 (d, J = 6.3 Hz, 1H), 4.39 (t, J = 3.2 Hz, 1H), 3.70 (d, J = 11.1 Hz, 3H), 3.08 (d, J = 10.1 Hz, 2H), 2.61-2.52 (m, 2H), 2.32 (dt, J = 14.2, 4.1 Hz, 2H), 2.19-2.07 (m, 1H), 2.04-1.86 (m, 2H), 1.81-1.69 (m, 2H), 1.58 (d, J = 6.2 Hz, 3H), 1.47 (d, J = 7.7 Hz, 2H), 0.91-0.75 (m, 1H)
-----	--	---	---	--



156	N-(4-(4-amino-1-methyl-7-(3-methyl-1-(1,2,2-trimethylpiperidin-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		(Method A): 2.35 min, m/z: 697.3 [M+H]⁺	(400 MHz, DMSO-d₆): F6 10.81 (s, 1H), 7.60-7.56 (m, 3H), 7.50 (s, 1H), 7.41 (d, J = 4 Hz, 1H), 7.20-7.14 (m, 4H), 7.02 (t, J = 52 Hz, 1H), 6.34 (s, 2H), 5.66 (q, J = 5.2 Hz, 1H), 4.70-4.63 (m, 1H), 3.58 (s, 3H), 3.38-3.35 (m, 2H), 2.67 (s, 3H), 2.21 (s, 3H), 2.08-2.05 (m, 2H), 1.58 (d, J = 4 Hz, 3H), 1.44 (d, J = 16 Hz, 6H), 1.30-1.21 (m, 2H)
-----	---	---	---	---


157	N-(4-(4-amino-1-methyl-7-(5-methyl-1-(1,2,2-trimethylpiperidin-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		(Method A): 2.29 min, m/z: 697.3 [M+H] ⁺	(400 MHz, DMSO-d ₆): 7.81 (s, 1H), 7.59-7.55 (m, 2H), 7.49 (s, 1H), 7.40 (d, J = 8 Hz, 1H), 7.19-7.11 (m, 4H), 6.95 (t, J = 52 Hz, 1H), 5.77 (s, 2H), 5.66 (q, J = 6.8 Hz, 1H), 4.64-4.57 (m, 1H), 3.58 (s, 3H), 3.38-3.35 (m, 2H), 2.65 (s, 3H), 2.31-2.16 (m, 4H), 2.05 (s, 3H), 1.58 (d, J = 4 Hz, 3H), 1.39 (d, J = 16 Hz, 6H)	F7
-----	--	---	--	--	----

158	N-(4-(4-amino-7-(1-(2-(difluoromethyl)-1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		(Method A): 2.36 min, m/z: 706.2 [M+H] ⁺	(400 MHz, DMSO-d ₆): 8.01 (s, 1H), 7.62 (s, 1H), 7.58-7.55 (m, 3H), 7.40 (d, J = 8 Hz, 1H), 7.19-7.10 (m, 4H), 6.98 (t, J = 52 Hz, 1H), 6.25 (m, 1H), 5.73 (s, 2H), 5.65 (q, J = 6.8 Hz, 1H), 4.37-4.28 (m, 1H), 3.69 (s, 3H), 2.95 (d, J = 12 Hz, 1H), 2.58-2.53 (m, 1H), 2.37-2.33 (m, 1H), 2.32 (s, 3H), 2.22-1.82 (m, 5H), 1.58 (d, J = 4 Hz, 3H)	F8
162	(S)-N-(4-(4-amino-1-methyl-7-(1-(1,2,2,6,6-pentamethylpiperidin-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		(Method A): 2.30 min, m/z: 711.3 [M+H] ⁺	(400 MHz, DMSO-d ₆): 7.98 (s, 1H), 7.62 (s, 1H), 7.55-7.51 (m, 3H), 7.37 (d, J = 8 Hz, 1H), 7.17-7.12 (m, 2H), 7.04-6.98 (m, 2H), 6.68 (t, J = 52 Hz, 1H), 5.67-5.63 (m, 3H), 4.74 (s, 1H), 3.68 (s, 3H), 2.45 (s, 3H), 2.09-2.02 (m, 4H), 1.54 (d, J = 4 Hz, 3H), 1.26 (d, J = 12 Hz, 12H)	F9


167	N-(4-(4-amino-7-(1-(2,2-dimethyl-1-(2,2,2-trifluoroethyl)piperidin-4-yl)-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide 	(Method A): 3.12 min, m/z: 751.3 [M+H]⁺	(400 MHz, DMSO-d₆): F10 10.68 (s, 1H), 8.01 (s, 1H), 7.59-7.54 (m, 4H), 7.40 (d, J = 8 Hz, 1H), 7.18-7.09 (m, 4H), 6.96 (t, J = 52 Hz, 1H), 5.87 (s, 2H), 5.65 (q, J = 6.4 Hz, 1H), 4.49-4.43 (m, 1H), 3.68 (s, 3H), 3.56-3.52 (m, 1H), 2.88-2.73 (m, 3H), 2.02-1.86 (m, 4H), 1.57 (d, J = 6 Hz, 3H), 1.15 (s, 3H), 1.06 (s, 3H)
-----	--	---	---

154	N-(4-(4-amino-1-methyl-7-(1-((R*)-1,2,2-trimethylpiperidin-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		(Method A): 2.36 min, m/z: 683.3 [M+H] ⁺	(400 MHz, DMSO-d ₆): 7.98 (s, 1H), 7.66 (s, 1H), 7.58-7.54 (m, 3H), 7.40 (d, J = 8 Hz, 1H), 7.19-7.08 (m, 4H), 6.97 (t, J = 52 Hz, 1H), 5.77 (s, 2H), 5.65 (q, J = 5.2 Hz, 1H), 4.73-4.67 (m, 1H), 3.69 (s, 3H), 3.39-3.35 (m, 2H), 2.66 (s, 3H), 2.35-2.20 (m, 4H), 1.58 (d, J = 8 Hz, 3H), 1.40 (d, J = 16 Hz, 6H)	F11
155	N-(4-(4-amino-1-methyl-7-(1-((S*)-1,2,2-trimethylpiperidin-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		(Method A): 2.34 min, m/z: 683.1 [M+H] ⁺	(400 MHz, DMSO-d ₆): 7.99 (s, 1H), 7.66 (s, 1H), 7.58-7.55 (m, 3H), 7.41 (d, J = 8 Hz, 1H), 7.19-7.09 (m, 4H), 6.99 (t, J = 52 Hz, 1H), 5.83 (s, 2H), 5.65 (q, J = 5.2 Hz, 1H), 4.75-4.67 (m, 1H), 3.69 (s, 3H), 3.38-3.35 (m, 2H), 2.67 (s, 3H), 2.35-2.21 (m, 4H), 1.58 (d, J = 8 Hz, 3H), 1.42 (d, J = 16 Hz, 6H)	F12

170	N-(4-(4-amino-1-methyl-7-(1-((S*)-4-methyl-4-azaspiro[2.5]octan-7-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		(Method B): 1.45 min, m/z: 341.2 [M+2H] ²⁺	(400 MHz, DMSO-d ₆): 8.03 (s, 1H), 7.59 (s, 1H), 7.60-7.55 (m, 3H), 7.39 (d, J = 8 Hz, 1H), 7.16 (m, 2H), 7.09 (m, 2H), 6.93 (t, J = 52 Hz, 1H), 5.70-5.63 (m, 3H), 4.47-4.41 (m, 1H), 3.69 (s, 3H), 3.06-2.98 (m, 2H), 2.56 (m, 1H), 2.45 (s, 3H), 2.24 (m, 1H), 1.88-1.85 (m, 2H), 1.57 (d, J = 8 Hz, 3H), 1.30 (m, 1H), 0.70 (m, 2H), 0.54-0.45 (m, 2H)	F13
171	N-(4-(4-amino-1-methyl-7-(1-((R*)-4-methyl-4-azaspiro[2.5]octan-7-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		(Method B): 1.42 min, m/z: 341.2 [M+2H] ²⁺	(400 MHz, DMSO-d ₆): 8.03 (s, 1H), 7.59 (s, 1H), 7.57-7.53 (m, 3H), 7.39 (d, J = 8 Hz, 1H), 7.15 (m, 2H), 7.07 (m, 2H), 6.87 (t, J = 52 Hz, 1H), 5.67-5.63 (m, 3H), 4.45-4.37 (m, 1H), 3.69 (s, 3H), 3.02-2.89 (m, 2H), 2.60 (m, 1H), 2.45 (s, 3H), 2.22 (m, 1H), 1.85-1.82 (m, 2H), 1.56 (d, J = 8 Hz, 3H), 1.31 (m, 1H), 0.70 (m, 2H), 0.55-0.46 (m, 2H)	F14

172	N-(4-{4-amino-1-methyl-7-[1-(1,3,5-trimethylpiperidin-4-yl)-1H-pyrazol-4-yl]-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl)-1,1-difluoromethanesulfonamide		(Method B): 1.76 min, m/z: 683.3 [M+H] ⁺	(400 MHz, DMSO) δ 10.94 (s, 1H), 8.02 (s, 1H), 7.75 (s, 1H), 7.58-7.54 (m, 3H), 7.40 (d, J = 8 Hz, 1H), 7.18-7.09 (m, 5H), 6.99 (t, J = 52.8 Hz, 1H), 5.88 (s, 2H), 5.65 (q, J = 6.4 Hz, 1H), 4.48 (t, J = 4 Hz, 1H), 3.69 (s, 3H), 2.82 (s, 3H), 2.64-2.60 (m, 2H), 2.48 (s, 1H), 2.15 (s, 2H), 1.58 (d, J = 6 Hz, 3H), 0.67 (d, J = 6.8 Hz, 6H).	F15
-----	--	---	--	---	-----

General procedure FB for the Cross coupling reaction followed by acidic deprotection between intermediate A1B1 and Boc protected halogenopyrazoles F




A mixture of N-(4-((4-amino-7-iodo-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((1S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide (1 eq), halogenopyrazole (1.0 eq), $B_2(\text{pin})_2$ (2 eq), $\text{Pd}(\text{OAc})_2$ (0.2 eq) bis(adamantan-1-yl)(butyl)phosphane (0.4 eq) and K_2CO_3 (2 eq) were dissolved in degassed 1,4-dioxane/ H_2O (4/1, 0.2 M) and the solution was stirred at 100 °C under N_2 overnight (or at 80 °C for 2 h under μW irradiation). The mixture was diluted with water and extracted with EtOAc (3 x). The combined organics were dried over Na_2SO_4 and concentrated under reduced pressure. The residue was purified by column chromatography (DCM/MeOH or EtOAc/PE) or prep-TLC (DCM/MeOH)


The solids were dissolved in HCOOH neat (2 M) and the reaction mixture was stirred at RT for 30 min or until completion. The reaction mixture was concentrated under reduced pressure and the residue was adjusted to pH=8 with sat. aq. Na_2CO_3 . The residue was further diluted with water and the organics were extracted with EtOAc (3 times). The combined organics were washed with brine, dried over Na_2SO_4 and concentrated under reduced pressure. The residue was purified by prep-TLC (DCM/MeOH) followed by preparative HPLC (neutral condition method C) if needed to give the desired products

The following compounds were prepared following the **General procedure FB**

Compound No	Name	Structure	LCMS data	¹ H NMR data	Intermediate
149	N-(4-(4-amino-1-methyl-7-(1-(2-(trifluoromethyl)piperidin-4-yl)-1H-pyrazol-4-yl)-2-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		(Method A): 2.61 min, 709.2 m/z: [M+H] ⁺	(400 MHz, MeOD-d ₄): 7.92 (s, 1H), 7.66 (s, 1H), 7.57-7.46 (m, 4H), 7.18 (dd, J = 8.1, 1.8 Hz, 1H), 7.13-7.02 (m, 3H), 6.69 (t, J = 53.3 Hz, 1H), 5.58 (q, J = 6.3 Hz, 1H), 4.48 (ddd, J = 12.0, 7.9, 4.1 Hz, 1H), 3.75 (s, 3H), 3.49 (ddd, J = 11.9, 7.0, 2.6 Hz, 1H), 3.28 (s, 1H), 2.86 (td, J = 12.8, 2.8 Hz, 1H), 2.41-2.34 (m, 1H), 2.19-2.14 (m, 1H), 2.02 (d, J = 8.1 Hz, 1H), 1.70 (d, J = 6.4 Hz, 3H)	F13

163	N-(4-(4-amino-1-methyl-7-(1-((3aR,6aS)-octahydrocyclopenta[c]pyrrol-5-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide 	(Method A): (400 MHz, DMSO-<i>d</i>₆): 9.29 (F1, 2.27 min, (s, 1H), 7.96 (s, 1H), 7.61 m/z: 667.2 [M+H]⁺ 7.39 (d, <i>J</i> = 8 Hz, 1H), 7.18-7.04 (m, 4H), 6.86 (t, <i>J</i> = 5.2 Hz, 1H), 5.71 (s, 2H), 5.65 (q, <i>J</i> = 6.8 Hz, 1H), 5.00-4.97 (m, 1H), 3.69 (s, 3H), 3.00 (d, <i>J</i> = 8 Hz, 4H), 2.34-2.27 (m, 2H), 2.13-2.07 (m, 2H), 1.56 (d, <i>J</i> = 4 Hz, 3H)
-----	--	---

Compound 120: N-(4-{4-amino-7-[1-(3,3-difluorocyclopentyl)-1H-pyrazol-4-yl]-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl)-1,1-difluoromethanesulfonamide



5 Step 1: 3-(4-iodo-1H-pyrazol-1-yl)cyclopentan-1-one

To a mixture of 4-iodo-1H-pyrazole (500 mg, 2.57 mmol) and cyclopent-2-en-1-one (316 mg, 3.85 mmol) in DCM (10 mL) was added ScCl_3 (77.7 mg, 514 μmol). The reaction mixture was stirred at RT for 4 h. The mixture was concentrated under reduced pressure and the residue was purified by silica gel column chromatography (PE/EtOAc 95/5 to 20/80) to give the title product (657 mg, 93%) as a clear oil. LCMS (Method A): 3.21 min, m/z 277.0 $[\text{M}+\text{H}]^+$

Step 2: 1-(3,3-difluorocyclopentyl)-4-iodo-1H-pyrazole


To a 0 °C solution of 3-(4-iodo-1H-pyrazol-1-yl)cyclopentan-1-one (1.43 g, 5.17 mmol) in anhydrous DCM (10 mL) was added DAST (2.49 g, 15.5 mmol) in a dropwise manner, and the reaction mixture was allowed to warm to RT and stirred overnight under N_2 . The reaction mixture was quenched with 1.5 M KH_2PO_4 (10 mL) and the organics were extracted 3 times with EtOAc. The combined organics were washed with brine, dried over Na_2SO_4 and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE/EtOAc 95/5 to 20/80) to give the title product (978 mg, 63%) as a clear oil.

20 Step 3: N-(4-{4-amino-7-[1-(3,3-difluorocyclopentyl)-1H-pyrazol-4-yl]-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl)-1,1-difluoromethanesulfonamide

A mixture of 1-(3,3-difluorocyclopentyl)-4-iodo-1H-pyrazole (47.9 mg, 161 μmol), N-(4-{4-amino-7-iodo-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl)-1,1-difluoromethanesulfonamide (1 eq), $\text{Pd}(\text{OAc})_2$ (3.61 mg, 16.1 μmol), K_2CO_3 (22.2

mg, 161 μmol), Butyldi-1-adamantylphosphine (11.5 mg, 32.3 μmol) and B_2Pin_2 (40.8 mg, 161 μmol) in degassed 1,4-dioxane (4 mL) and H_2O (1 mL) was heated at 100 $^\circ\text{C}$ for 12 h under N_2 . The solvents were evaporated, and the residue was purified by silica gel column chromatography (PE/EtOAc 80/20 to 20/80) to give the title product (5.00 mg, 9%) as a yellow solid. LCMS (Method A): 3.86 min, m/z 662.0 $[\text{M}+\text{H}]^+$. ^1H NMR (400 MHz, $\text{DMSO}-d_6$): 8.03 (s, 1H), 7.66 (s, 1H), 7.60-7.55 (m, 2H), 7.54 (d, $J = 1.7$ Hz, 1H), 7.40 (d, $J = 8.0$ Hz, 1H), 7.20-7.10 (m, 4H), 7.10-6.85 (m, 1H), 5.75 (s, 2H), 5.65 (q, $J = 6.3$ Hz, 1H), 5.00 (p, $J = 7.4$ Hz, 1H), 2.80-2.70 (m, 1H), 2.64 (dd, $J = 15.7, 7.5$ Hz, 1H), 2.37 (dddd, $J = 19.1, 9.7, 6.0, 4.0$ Hz, 2H), 2.28-2.16 (m, 2H), 1.58 (d, $J = 6.3$ Hz, 3H).

- 10 **Compound 113:** N-(4-(4-amino-1-methyl-7-(1-(1,2,2-trimethylpiperidin-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide



Step 1: tert-butyl 4-hydroxy-2,2-dimethylpiperidine-1-carboxylate

- 15 To a solution of tert-butyl 2,2-dimethyl-4-oxopiperidine-1-carboxylate (1 g, 4.39 mmol) in MeOH (20 mL) was added NaBH_4 (495 mg, 13.1 mmol). The reaction mixture was stirred at RT overnight. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel column chromatography (PE/EtOAc: 90/10 to 10/90) to give the title product (740 mg) as yellow oil.

Step 2: tert-butyl 4-(methanesulfonyloxy)-2,2-dimethylpiperidine-1-carboxylate

To a solution of tert-butyl 4-hydroxy-2,2-dimethylpiperidine-1-carboxylate (740 mg, 3.22mmol) in DCM (5 mL) were added Et₃N (764 mg, 9.66 mmol) and MsCl (553 mg, 4.83mmol). The mixture was stirred at RT for 16 h. The mixture was poured into water (20 mL) and the organics were extracted with EtOAc (3 x 50 mL). The combined organics were washed with brine (50 mL), dried over Na₂SO₄ and concentrated under reduced pressure to give the title product (900 mg, 2.92 mmol) as a colourless oil. Used as crude in the next step. LCMS (Method A): 3.96 min, m/z 674.4 [M+H]⁺

Step 3: tert-butyl 4-(4-bromo-1H-pyrazol-1-yl)-2,2-dimethylpiperidine-1-carboxylate

A mixture of tert-butyl 4-(methanesulfonyloxy)-2,2-dimethylpiperidine-1-carboxylate (900 mg, 2.92 mmol), 4-bromo-1H-pyrazole (557 mg, 3.79 mmol) and Cs₂CO₃ (2.84 g, 8.76 mmol) in DMF (20 mL) was stirred at 100 °C overnight. The mixture was poured into water (50 mL) and the organics were extracted with EtOAc (50 mL x 2). The combined organics were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by prep-TLC (PE/EtOAc; 10/1) to give the title product (420 mg, 40 %) as a white solid.

Step 4: tert-butyl 4-(4-(4-amino-3-(4-((difluoromethyl)sulfonamido)-3-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-7-yl)-1H-pyrazol-1-yl)-2,2-dimethylpiperidine-1-carboxylate

To a mixture of N-(4-(4-amino-7-iodo-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl)-1,1-difluoromethanesulfonamide (344 mg, 558 μmol) and tert-butyl 4-(4-bromo-1H-pyrazol-1-yl)-2,2-dimethylpiperidine-1-carboxylate (200 mg, 558 μmol) in degassed 1,4-dioxane (8 mL) and H₂O (2 mL) were added Pd(OAc)₂ (24.9 mg, 111 μmol), K₂CO₃ (153 mg, 1.11 mmol), butyl-di-1-adamantylphosphine (79.9 mg, 223 μmol) and B₂pin₂ (281 mg, 1.11 mmol). The mixture was stirred at 100 °C for 12 h under N₂. The mixture was poured into water (50 mL) and the organics were extracted with EtOAc (50 mL x 2). The combined organics were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (DCM/MeOH = 95/5) to give the title product (170 mg, 39%) as a yellow solid. LCMS (Method A): 3.57 min, m/z 769.1 [M+H]⁺


Step 5: N-(4-(4-amino-7-(1-(2,2-dimethylpiperidin-4-yl)-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide

A solution of tert-butyl 4-(4-{4-amino-3-[4-(difluoromethanesulfonamido)-3-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl]-1-methyl-1H-pyrazolo[4,3-c]pyridin-7-yl]-1H-pyrazol-1-yl)-2,2-dimethylpiperidine-1-carboxylate (150 mg, 195 μ mol) in HCOOH (3 mL) was stirred at RT for 4 h under N₂. The mixture was adjusted to pH=8 with the addition of sat. aq. Na₂CO₃ and concentrated under reduced pressure. The solids were washed with EtOAc (2 x 5 mL) and dried under reduced pressure to give the title product (120 mg, 92%) as a white solid. LCMS (Method A): 2.73 min, m/z 670.1 [M+H]⁺


Step 6: N-(4-(4-amino-1-methyl-7-(1-(1,2,2-trimethylpiperidin-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide

A mixture of N-(4-{4-amino-7-[1-(2,2-dimethylpiperidin-4-yl)-1H-pyrazol-4-yl]-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl)-1,1-difluoromethanesulfonamide (120 mg, 179.4 μ mol), paraformaldehyde (72.7 mg, 897 μ mol) and NaBH(OAc)₃ (190 mg, 897 μ mol) in MeOH (5 mL) was stirred at RT for 45 min. The mixture was concentrated under reduced pressure and the residue was purified by silica gel column chromatography (DCM/MeOH; 95/5) to give the title product (30 mg, 25%) as a yellow solid. LCMS (Method A): 2.88 min, m/z 683.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆): 7.93 (s, 1H), 7.62 (s, 1H), 7.56-7.50 (m, 2H), 7.50 (d, J = 1.5 Hz, 1H), 7.36 (d, J = 8.1 Hz, 1H), 7.18-7.12 (m, 2H), 7.01 (dd, J = 8.1, 1.9 Hz, 1H), 6.96 (d, J = 1.9 Hz, 1H), 6.65 (s, 1H), 5.66 (s, 2H), 5.64 (d, J = 6.3 Hz, 1H), 4.58 (dd, J = 10.9, 5.4 Hz, 1H), 3.67 (s, 3H), 3.13-3.02 (m, 3H), 2.19-2.11 (m, 2H), 2.10-2.07 (m, 1H), 2.04-1.92 (m, 1H), 1.54 (d, J = 6.3 Hz, 3H), 1.29 (s, 3H), 1.24 (s, 3H).

The following compound was prepared similarly to compound 113

Compound No	Name	Structure	LCMS data	¹ H NMR data
147	N-(4-(4-amino-7-(1-(1,2-dimethylazetidin-3-yl)-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		(Method A): 2.19 min, m/z: 641.2 [M+H] ⁺ .	(400 MHz, DMSO-d ₆): 8.21 (s, 1H), 7.81 (s, 1H), 7.58-7.55 (m, 3H), 7.40 (d, J = 8 Hz, 1H), 7.19-7.08 (m, 4H), 6.98 (d, J = 52.6 Hz, 1H), 5.96 (s, 1H), 5.65 (q, J = 5.2 Hz, 1H), 4.35 (s, 1H), 3.72 (s, 3H), 2.81 (s, 3H), 1.78-1.65 (m, 4H), 1.57 (d, J = 8 Hz, 3H), 1.54 (d, J = 8 Hz, 3H)

Compound 104: N-(4-{4-amino-1-methyl-7-[1-(1,6,6-trimethylpiperidin-3-yl)-1H-pyrazol-4-yl]-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl)-1,1-difluoromethanesulfonamide



5

Step 1: N-(4-{4-amino-7-[1-(6,6-dimethylpiperidin-3-yl)-1H-pyrazol-4-yl]-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl)-1,1-difluoromethanesulfonamide


Following **General procedure B** for the Suzuki reaction followed by acidic deprotection
 10 between **intermediate A1B1** and tert-butyl 2,2-dimethyl-4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]piperidine-1-carboxylate (**Intermediate E21**, 100 mg, 246

μmol), the title compound (20 mg, 19%) was obtained as a colorless oil. LCMS (Method A): 2.71 min, m/z 335.2 [M+2H]²⁺

Step 2: N-(4-{4-amino-1-methyl-7-[1-(1,6,6-trimethylpiperidin-3-yl)-1H-pyrazol-4-yl]-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl)-1,1-difluoromethanesulfonamide

A mixture of N-(4-{4-amino-7-[1-(6,6-dimethylpiperidin-3-yl)-1H-pyrazol-4-yl]-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl)-1,1-difluoromethanesulfonamide (30 mg, 44.8 μmol), paraformaldehyde (5.43 mg, 67.2 μmol) and NaBH(OAc)₃ (47.4 mg, 224 μmol) in MeOH (5 mL) was stirred at RT for 45 min. The mixture was diluted with sat. aq. NaHCO₃ (30 mL) and DCM (30 mL). The aqueous layer was extracted with a DCM/MeOH mixture (9/1; 3 x 10 mL). The combined organic layers were concentrated under reduced pressure and the residue was purified by silica gel column chromatography (DCM/MeOH 97/3) to give the title product (10.0 mg, 19%) as a yellow solid. LCMS (Method A): 2.64 min; m/z 683.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d₆): 7.65 (d, J = 3.6 Hz, 2H), 7.56 (m, 2H), 7.34-7.26 (m, 2H), 7.20 (dd, J = 2.0, 8.0 Hz, 1H), 7.06-7.01 (m, 3H), 6.35 (t, J = 53.6 Hz, 1H), 5.47 (q, J = 2.4 Hz, 1H), 3.75 (s, 3H), 3.30-3.22 (m, 2H), 2.56 (s, 3H), 2.30-2.12 (m, 4H), 1.80-1.76 (m, 1H), 1.69 (d, J = 6.4 Hz, 3H), 1.29 (s, 6H).

Compound 111: (R)-N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)-2-methoxyethoxy)phenyl)-1,1-difluoromethanesulfonamide



(R)-N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)-2-methoxyethoxy)phenyl)-1,1-difluoromethanesulfonamide was obtained by chiral HPLC purification of the racemic mixture (compound 102). The separation was performed on a UniChiral CND-5H (column size 21.2


mm I.D. × 250 mm L) using n-Hexane/Ethanol/TFA = 50/50/0.1 as the mobile phase and flow rate 25 mL/min at 25 °C. Product retention time = 5.38 min.

The residue was adjusted to pH=8 with sat. aq. Na₂CO₃ solution. The residue was further diluted with water and the organics were extracted with EtOAc (3 times). The combined organics were washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure.

The enantiomeric excess was calculated on UniChiral CND-5H, 4.6*250 mm (50% n-hexane/50% Ethanol/0.1% TFA, flow rate 1 mL/min, injection 10 µL, temperature 30 °C, retention time 5.38 min) ee>98%

LCMS (Method A): 3.10 min, m/z 672.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃): 7.80 (d, *J* = 8.3 Hz, 1H), 7.58 (s, 1H), 7.56 (s, 1H), 7.41 (dd, *J* = 8.5, 5.2 Hz, 2H), 7.28-7.27 (m, 1H), 7.12 (t, *J* = 8.6 Hz, 2H), 6.86 (d, *J* = 1.5 Hz, 1H), 6.40 (t, *J* = 53.5 Hz, 1H), 4.96 (dd, *J* = 9.6, 2.7 Hz, 1H), 4.43 (tt, *J* = 10.2, 4.8 Hz, 1H), 4.19-4.11 (m, 2H), 3.76 (s, 3H), 3.58 (t, *J* = 2.8 Hz, 4H), 3.55 (s, 3H), 2.17-2.09 (m, 4H).

Compound 112: (S)-N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)-2-methoxyethoxy)phenyl)-1,1-difluoromethanesulfonamide



(S)-N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)-2-methoxyethoxy)phenyl)-1,1-difluoromethanesulfonamide was obtained by chiral HPLC purification of the racemic mixture (compound 102). The separation was performed on a UniChiral CND-5H (column size 21.2 mm I.D. × 250 mm L) using n-Hexane/Ethanol/TFA = 50/50/0.1 as the mobile phase and flow rate 25 mL/min at 25 °C. Product retention time = 7.14 min.

The residue was adjusted to pH=8 with sat. aq. Na₂CO₃ solution. The residue was further diluted with water and the organics were extracted with EtOAc (3 times). The combined organics were washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure.



- 5 The enantiomeric excess was calculated on UniChiral CND-5H,4.6*250 mm (50%n-hexane/50%Ethanol/0.1%TFA, flow rate 1 mL/min, injection 10 µL, temperature 30 °C, retention time 5.38 min) ee>98%



LCMS (Method A): 3.12 min, m/z 672.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃): 7.80 (d, *J* = 8.3 Hz, 1H), 7.68 (s, 1H), 7.60 (s, 1H), 7.41 (dd, *J* = 8.5, 5.2 Hz, 2H), 7.28-7.27 (m, 1H), 7.10 (t, *J* = 8.6 Hz, 2H), 6.86 (d, *J* = 1.5 Hz, 1H), 6.37 (t, *J* = 53.5 Hz, 1H), 4.99 (dd, *J* = 9.6, 2.7 Hz, 1H), 4.43 (tt, *J* = 10.2, 4.8 Hz, 1H), 4.19-4.11 (m, 2H), 3.76 (s, 3H), 3.58 (t, *J* = 2.8 Hz, 4H), 3.55 (s, 3H), 2.17-2.09 (m, 4H).

10


Further exemplary compounds prepared by the method similar to those described herein are detailed in Table below

15

Compound No	Name	Structure	LCMS data	¹ H NMR data
139	N-(4-(4-amino-1-methyl-7-(1-(1-methylpiperidin-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)-2-methoxyethoxy)phenyl)-1,1-difluoromethanesulfonamide		LCMS: (Method A), 2.57 min, m/z: 685.1 [M+H] ⁺	(400 MHz, DMSO-d ₆): 7.97 (s, 1H), 7.61 (s, 2H), 7.57-7.52 (m, 3H), 7.37 (d, J = 8 Hz, 1H), 7.18-7.13 (m, 2H), 7.06-7.01 (m, 2H), 6.77 (t, J = 52 Hz, 1H), 5.69 (t, J = 8 Hz, 1H), 5.62 (s, 2H), 4.29 (s, 1H), 3.81-3.77 (m, 1H), 3.67 (s, 3H), 3.62-3.58 (m, 2H), 3.17 (s, 1H), 3.13-3.10 (m, 2H), 2.45 (s, 3H), 2.12-2.07 (m, 3H).
159	N-(4-(4-amino-1-methyl-7-(1-(1,2,2-trimethylpiperidin-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-chlorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		LCMS: (Method A), 3.03 min, m/z 699.2 [M+H] ⁺	(400 MHz, DMSO-d ₆): 7.96 (s, 1H), 7.61 (s, 1H), 7.52-7.50 (m, 3H), 7.39-7.36 (m, 3H), 7.01-6.94 (m, 2H), 6.59 (t, J = 52 Hz, 1H), 5.66-5.64 (m, 2H), 4.55 (s, 1H), 3.67 (s, 3H), 2.44 (s, 3H), 2.12-2.01 (m, 6H), 1.74-1.66 (m, 3H), 1.53 (d, J = 4 Hz, 3H), 1.25 (d, J = 12 Hz, 6H).

135	N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-3-((3-fluorobenzyl)oxy)phenyl)-1,1-difluoromethanesulfonamide		LCMS: (Method A), 2.95 min, m/z 628.1 [M+H] ⁺	(400 MHz, DMSO-d ₆): 8.05 (s, 1H), 7.64 (s, 1H), 7.53 (s, 1H), 7.32 (q, J = 7.4, 6.9 Hz, 1H), 7.26 (d, J = 8.1 Hz, 1H), 7.14 (d, J = 7.8 Hz, 1H), 7.09 (d, J = 9.7 Hz, 2H), 7.01 (s, 1H), 6.95 (s, 1H), 5.92 (s, 2H), 5.11 (s, 2H), 4.46 (dt, J = 10.5, 5.0 Hz, 1H), 3.98 (d, J = 11.0 Hz, 2H), 3.73 (s, 3H), 3.50 (d, J = 12.1 Hz, 2H), 3.46 (s, 1H), 2.02 (dt, J = 12.0, 5.5 Hz, 4H).
127	(S)-N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1-phenylmethanesulfonamide		LCMS: (Method A), 3.16 min, m/z 682.1 [M+H] ⁺	(400 MHz, DMSO-d ₆): 9.18 (s, 1H), 8.02 (s, 1H), 7.61-7.58 (m, 3H), 7.55 (s, 1H), 7.37-7.44 (m, 6H), 7.17 (t, J = 8.4 Hz, 2H), 7.11 (s, 1H), 7.04 (d, J = 8 Hz, 2H), 5.68-5.66 (m, 3H), 4.54 (s, 2H), 4.50-4.43 (m, 1H), 3.99-3.94 (m, 2H), 3.69 (s, 3H), 3.49 (td, J = 10.8, 2.8 Hz, 2H), 2.04-1.98 (m, 4H), 1.62 (d, J = 6 Hz, 3H)

Intermediate C: ,1-difluoro-N-{2-[(4-fluorophenyl)methoxy]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl}methanesulfonamide



Step 1: 4-bromo-2-((4-fluorobenzyl)oxy)-1-nitrobenzene

- 5 A mixture of 5-bromo-2-nitrophenol (10 g, 45.8 mmol), K_2CO_3 (12.6 g, 91.6 mmol), and 1-(bromomethyl)-4-fluorobenzene (8.65 g, 45.8 mmol) in MeCN (100 mL) was stirred at 70 °C under N_2 for 16 h. The mixture was diluted with H_2O (100 mL) and extracted with EtOAc (3 x 200 mL). The combined organic layers were dried (Na_2SO_4) and then concentrated under reduced pressure to give the title product (15.0 g, 100%) as a white solid.

10 **Step 2:** 4-bromo-2-((4-fluorobenzyl)oxy)aniline

- To a solution of 4-bromo-2-((4-fluorobenzyl)oxy)-1-nitrobenzene (15 g, 45.9 mmol) in MeOH (300 mL) and sat. aq. NH_4Cl (100 mL), was added Zn dust (14.9 g, 229 mmol) and the reaction mixture was stirred at 60 °C for 4 h. The mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was partitioned between H_2O (250 mL) and EtOAc (300 mL) and the organic layer was separated, dried (Na_2SO_4) and then concentrated under reduced pressure to give the title product (13.0 g, 96%) as a black oil. LCMS (method A): 4.24 min, m/z: 296.0 $[M+H]^+$.
- 15


Step 3: N-[4-bromo-2-[(4-fluorophenyl)methoxy]phenyl]-1,1-difluoromethanesulfonamide

- To a solution of 4-bromo-2-[(4-fluorophenyl)methoxy]aniline (8.2 g, 27.6 mmol) in DCM (10 mL) were added pyridine (6.54 g, 82.8 mmol) and difluoromethanesulfonyl chloride (4.98 g, 33.1 mmol), and the resulting mixture was stirred at RT overnight. The reaction mixture was concentrated under reduced pressure and the residue was purified by column chromatography (PE/EtOAc = 30/1) to give the title product (7.77 g, 69%) as a white solid.
- 20

Step 4: 1,1-difluoro-N-{2-[(4-fluorophenyl)methoxy]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl}methanesulfonamide

A mixture of N-{4-bromo-2-[(4-fluorophenyl)methoxy]phenyl}-1,1-difluoromethanesulfonamide (7.77 g, 18.9 mmol), B₂(pin)₂ (5.25 g, 20.7 mmol), AcOK (3.70 g, 37.8 mmol) and Pd(dppf)Cl₂ (1.38 g, 1.89 mmol) in degassed 1,4-dioxane (100 mL) was stirred at 100 °C overnight under N₂. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel column chromatography (PE/EtOAc = 10/1) to give the title product (7.14 g, 82%) as a white solid.

Intermediate AC: N-(4-(4-amino-7-iodo-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((4-fluorobenzyl)oxy)phenyl)-1,1-difluoromethanesulfonamide



Step 1: N-(4-{4-amino-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-[(4-fluorophenyl)methoxy]phenyl)-1,1-difluoromethanesulfonamide (**Compound 10**)


A mixture of methyl 3-iodo-1-methyl-1H-pyrazolo[4,3-c]pyridin-4-amine (100 mg, 0.365 mmol), 1,1-difluoro-N-{2-[(4-fluorophenyl)methoxy]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl}methanesulfonamide (166 mg, 0.365 mmol), Na₂CO₃ (77.3 mg, 0.7296 mmol) and Pd(dppf)Cl₂ (29.7 mg, 0.03648 mmol) in 1,4-dioxane/H₂O (4/1, 7.5 mL) was stirred at 100 °C for 16 h under N₂. The mixture was poured into water (100 mL) and extracted with EtOAc (2 x 50 mL). The combined organic phases were dried over Na₂SO₄ and concentrated. The residue was purified by column chromatography (DCM/MeOH = 20/1) to give the title product (130 mg, 75%) as a grey solid. LCMS (Method A): 3.04 min, m/z: 478.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-*d*₆): 7.81 (d, *J* = 8.0 Hz, 1H), 7.64-7.60 (m, 2H), 7.45-7.40 (m, 2H), 7.28-7.24 (m, 3H), 7.03-6.76 (m, 2H), 6.33 (s, 2H), 5.23 (s, 2H), 4.03 (s, 3H).

Step 2: N-(4-(4-amino-7-iodo-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((4-fluorobenzyl)oxy)phenyl)-1,1-difluoromethanesulfonamide

A mixture of N-(4-{4-amino-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-[(4-fluorophenyl)methoxy]phenyl)-1,1-difluoromethanesulfonamide (1.28 g, 2.68 mmol), NIS (661 mg, 2.94 mmol) in DMF (15 mL) was stirred at 85 °C for 16 h under N₂. The mixture was poured into water (100 mL) and extracted with EtOAc (2 x 50 mL). The combined organic phases were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by


column chromatography (DCM/MeOH = 20/1) to give the title product (550 mg, 34%) as a yellow solid. LCMS (Method A): 3.60 min, m/z: 604.2 [M+H]⁺.



General procedure C for the Suzuki reaction between intermediate AC and boronate esters




A mixture of N-(4-(4-amino-7-iodo-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((4-fluorobenzyl)oxy)phenyl)-1,1-difluoromethanesulfonamide (1 eq), boronate ester (1.1 eq), Na₂CO₃ (3 eq) and Pd(dppf)Cl₂ (0.1 eq) in degassed 1,4-dioxane/H₂O (4/1, 0.2 M) was stirred at 100 °C overnight under N₂. The mixture was diluted with water and the organics were extracted with EtOAc (3 x). The combined organics were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography (DCM/MeOH) to give the title product as a yellow solid.


The following compounds were prepared following the **General procedure C**

Compound No	Name	Structure	Yield	LCMS data	¹ H NMR data	Boronate ester
13	N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((4-fluorobenzyl)oxy)phenyl)-1,1-difluoromethanesulfonamide		48%	(Method A): 3.14 min, m/z: 628.2 [M+H] ⁺ .	(400 MHz, DMSO-d ₆): 8.04 (s, 1H), 7.63-7.57 (3, 3, 4, 4- min, m, 4H), 7.42 (d, J = 8 Hz, 1H), 7.36 (d, J = 1.6 Hz, 1H), 7.26-7.21 (m, 3H), 6.89 (t, J = 52.8 Hz, 1H), 5.93 (s, 2H), 5.21 (s, 2H), 4.50-4.43 (m, 1H), 3.99-3.96 (m, 3H), 3.74 (s, 3H), 2.04-1.95 (m, 4H).	1-(oxan-4-yl)-4-

Compound 12	N-(4-(4-amino-7-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((4-fluorobenzyl)oxy)phenyl)-1,1-difluoromethanesulfonamide		51%	(Method A): 3.07 min, m/z: 588.1 [M+H] ⁺ .	(400 MHz, DMSO-d ₆): 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]ethan-1-ol 7.93 (s, 1H), 7.62-7.57 (m, 4H), 7.43 (d, J = 8.0 Hz, 1H), 7.38 (d, J = 1.2 Hz, 1H), 7.27-7.22 (m, 3H), 6.92 (t, J = 52 Hz, 1H), 5.99 (s, 1H), 5.22 (s, 2H), 4.96-4.93 (m, 3H), 4.23-4.20 (m, 2H), 3.81-3.77 (m, 2H), 3.76 (s, 2H).	
Compound 16	N-(4-(4-amino-1-methyl-7-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((4-fluorobenzyl)oxy)phenyl)-1,1-difluoromethanesulfonamide		38%	(Method A): 3.12 min, m/z: 558.2 [M+H] ⁺ .	(400 MHz, DMSO-d ₆): 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 7.93 (s, 1H), 7.87 (s, 1H), 7.59-7.52 (m, 3H), 7.49 (s, 1H), 7.35 (d, J = 8.1 Hz, 1H), 7.19 (t, J = 8.9 Hz, 2H), 7.11 (d, J = 2.0 Hz, 1H), 7.03 (dd, J = 8.1, 1.9 Hz, 1H), 6.44 (t, J = 54.1 Hz, 1H), 5.75 (s, 2H), 5.11 (s, 2H), 3.89 (s, 3H), 3.71 (s, 3H).	

Compound 14	N-(4-(4-amino-1-methyl-7-(pyridin-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((4-fluorobenzyl)oxy)phenyl)-1,1-difluoromethanesulfonamide		38%	(Method A): 2.93 min, m/z: 554.1 [M+H] ⁺ .	(400 MHz, DMSO-d ₆): 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine 8.66 (d, J = 6.0 Hz, 2H), 7.68 (s, 1H), 7.63 - 7.59 (m, 2H), 7.55-7.53 (m, 2H), 7.44 (d, J = 8.0 Hz, 1H), 7.39 (d, J = 1.6 Hz, 1H), 7.27-7.23 (m, 3H), 6.93 (t, J = 52.8 Hz, 1H), 6.10 (s, 2H), 5.23 (s, 2H), 3.66 (s, 3H).
--------------------	--	---	-----	---	---

Intermediate D: N-(2-((4-fluorobenzyl)oxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethanesulfonamide



Step 1: N-(4-bromo-2-((4-fluorobenzyl)oxy)phenyl)ethanesulfonamide


- 5 A mixture of 4-bromo-2-((4-fluorobenzyl)oxy)aniline (13 g, 43.8 mmol), EtSO₂Cl (8.43 g, 65.6 mmol), pyridine (50 mL) and CHCl₃ (50 mL) was stirred at RT for 3 h. The mixture was concentrated under reduced pressure and the crude residue was purified by column chromatography (PE/EtOAc = 1/1) to give the title product (12.5 g, 73%) as a yellow solid. LCMS (method A): 4.24 min, m/z: 410.0 [M+H]⁺.

- 10 **Step 2:** N-(2-((4-fluorobenzyl)oxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethanesulfonamide

- A mixture of N-(4-bromo-2-((4-fluorobenzyl)oxy)phenyl)ethanesulfonamide (12.5 g, 32.1 mmol) Pd(dppf)Cl₂ (1.46 g, 1.60 mmol), AcOK (6.29 g, 64.2 mmol) and B₂pin₂ (8.96 g, 35.2 mmol) in degassed 1,4-dioxane (200 mL) was stirred at 100 °C for 16 h under N₂. The mixture was concentrated under reduced pressure and the crude residue was purified by column chromatography (PE/EtOAc = 2/1) to give the title product (14.8 g, >100%) as a brown solid. LCMS (method A): 4.51 min, m/z: 453.2 [M+H]⁺. ¹H NMR (400 MHz, DMSO-*d*₆): 8.99 (s, 1H), 7.63-7.60 (m, 2H), 7.38-7.32 (m, 2H), 7.28-7.21 (m, 3H), 5.15 (s, 2H), 3.03 (q, *J* = 7.2 Hz, 2H), 1.29 (s, 12H), 1.11 (t, *J* = 7.2 Hz, 3H).

20

Intermediate AD: N-(4-(4-amino-7-iodo-1-methyl-1H-pyrazolo[4,3-*c*]pyridin-3-yl)-2-((4-fluorobenzyl)oxy)phenyl)ethanesulfonamide




Step 1: N-(4-{4-amino-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-[(4-fluorophenyl)methoxy]phenyl)ethane-1-sulfonamide

A mixture of 3-iodo-1-methyl-1H-pyrazolo[4,3-c]pyridin-4-amine (50 mg, 182 μ mol), N-{2-[(4-fluorophenyl)methoxy]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl}ethane-1-sulfonamide (94.8 mg, 218 μ mol), Pd(dppf)Cl₂ (14.8 mg, 18.2 μ mol) and Na₂CO₃ (57.8 mg, 546 μ mol) in degassed 1,4-dioxane/H₂O (4/1, 10 mL) was stirred at 100 °C for 1 h under μ W. The mixture was poured into water (10 mL) and extracted with EtOAc (2 x 10 mL). The combined organics were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by Prep-TLC (DCM/MeOH = 20/1) to give the title product (20 mg, 24%) as a brown solid.

Step 2 : N-(4-(4-amino-7-iodo-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((4-fluorobenzyl)oxy)phenyl)ethanesulfonamide

A mixture of N-(4-{4-amino-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-[(4-fluorophenyl)methoxy]phenyl)ethane-1-sulfonamide (3.5 g, 7.68 mmol) and NIS (3.44 g, 15.3 mmol) in DMF (100 mL) was stirred at 85 °C overnight. The mixture was poured into water (100 mL) and the organics were extracted with EtOAc (2 x 50 mL). The combined organics were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography (PE/EtOAc = 4/1 to 1/4, v/v) to give the title product (1.5 g, 47%) as a yellow solid.


General procedure D for the Suzuki reaction between intermediate AD and boronate esters/boronic acids




A mixture of N-(4-(4-amino-7-iodo-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((4-fluorobenzyl)oxy)phenyl)ethanesulfonamide (1 eq), boronate ester/boronic acid (1.1 eq), Na₂CO₃ (3 eq) and Pd(dppf)Cl₂ (0.1eq) in degassed 1,4-dioxane/H₂O (4/1, 0.2 M) was stirred at 100 °C overnight under N₂. The mixture was diluted with water and the organics were extracted with EtOAc (3 x). The combined organics were dried over Na₂SO₄ and concentrated

under reduced pressure. The residue was purified by column chromatography (DCM/MeOH) to give the desired product as a yellow solid.

The following compounds were prepared following the **General procedure D**

Compound No	Name	Structure	Yield	LCMS data	¹ H NMR data	SM
1	N-(4-(4-amino-1-methyl-7-(pyridin-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((4-fluorobenzyl)oxy)phenyl)ethanesulfonamide		39%	(Method A): 2.95 min, m/z: 533.2 [M+H] ⁺ .	(400 MHz, 4-(4,4,5,5-tetramethyl-1H), 8.65 (d, J = 1, 3, 2-6.0 Hz, 1H), 7.67 (dioxaborolan-(s, 1H), 7.62 (q, 3-y)pyridine J = 14.4 Hz, 2H), 7.52 (m, 2H), 7.47 (d, 8 Hz, 1H), 7.37 (d, J = 1.6Hz, 1H), 7.23 (m, 3H), 6.04 (s, 2H), 5.21 (s, 2H), 3.66 (s, 3H), 3.06 (q, J = 7.4 Hz), 1.16 (t, J = 7.4 Hz).	


Compound 64: N-(4-(4-Aminopyrazolo[1,5-a]pyrazin-3-yl)-2-((4-fluorophenyl)methoxy)phenyl)ethane-1-sulfonamide



Step 1: N-(4-(4-Aminopyrazolo[1,5-a]pyrazin-3-yl)-2-((4-fluorophenyl)methoxy)phenyl)ethane-1-sulfonamide

To a mixture of 3-iodopyrazolo[1,5-a]pyrazin-4-amine (20 mg, 0.08 mmol), N-(2-((4-fluorophenyl)methoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethane-1-sulfonamide (36.8 mg, 0.08 mmol) and Na₂CO₃ (16.3 mg, 0.15 mmol) in 1,4-dioxane/water (4/1, 2 mL) was added Pd(dppf)Cl₂ (5.62 mg, 8 μmol), and the reaction was heated at 120 °C with μW irradiation for 1 h. The mixture was filtered over Celite, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (0-100% EtOAc:c-Hex) to give the title product (5.6 mg, 17%) as a brown solid. LCMS (Method D): 1.45 min, m/z 442.2 [M+H]⁺. ¹H NMR (300 MHz, CDCl₃): 7.88 (d, J = 5.0 Hz, 1H), 7.84 (s, 1H), 7.66 (d, J = 8.2 Hz, 1H), 7.37 (dd, J = 8.7, 5.3 Hz, 2H), 7.31 (d, J = 5.0 Hz, 1H), 7.13-7.07 (m, 4H), 5.12 (s, 2H), 3.15 (q, J = 7.4 Hz, 2H), 1.36 (t, J = 7.4 Hz, 3H).

Compound 63: N-(4-(8-Aminoimidazo[1,5-a]pyrazin-1-yl)-2-((4-fluorophenyl)methoxy)phenyl)ethane-1-sulfonamide



Step 1: N-((3-Chloropyrazin-2-yl)methyl)formamide

A solution of 1-(3-chloropyrazin-2-yl)methanamine hydrochloride (1.0 g, 5.55 mmol) in HC(OMe)₃ (6.06 mL, 55.5 mmol) was heated at 110 °C under an atmosphere of N₂ overnight. The mixture was concentrated *in vacuo* and the residue was taken up in DCM. The organic

phase was washed with water and brine, dried over MgSO_4 and concentrated *in vacuo* to give the title product (772 mg, 81%) as a yellow solid. LCMS (Method E): 0.33 min, m/z 172.0 $[\text{M}+\text{H}]^+$. ^1H NMR (300 MHz, CDCl_3): 8.46 (d, $J = 2.6$ Hz, 1 H), 8.38 (d, $J = 1.0$ Hz, 1 H), 8.35-8.33 (m, 1 H), 6.94 (bs, 1 H), 4.76-4.74 (m, 2 H).

5 **Step 2: 8-Chloroimidazo[1,5-a]pyrazine**

A solution of *N*-((3-chloropyrazin-2-yl)methyl)formamide (0.83 g, 4.83 mmol) in MeCN (20 mL) was cooled to 0 °C before POCl_3 (1.34 mL, 14.4 mmol) was added dropwise. The reaction was stirred at 0 °C for 5 min before DMF (2 drops) was added. The reaction was warmed to RT and stirred overnight. The mixture was concentrated *in vacuo* and the residue
10 was diluted with water. The pH was adjusted to ~8 with sat. aq. NaHCO_3 and the aqueous mixture was extracted with DCM. The combined organics were dried over MgSO_4 and concentrated *in vacuo* to give the title product (631 mg, 85%) as a pink solid. LCMS (Method D): 0.62 min, m/z 154.2 $[\text{M}+\text{H}]^+$. ^1H NMR (300 MHz, $\text{DMSO}-d_6$): 8.70 (d, $J = 0.6$ Hz, 1 H), 8.39 (dd, $J = 4.9, 1.0$ Hz, 1 H), 7.88 (d, $J = 1.0$ Hz, 1 H), 7.41 (d, $J = 4.9$ Hz, 1 H).

15 **Step 3: 8-Chloro-1-iodoimidazo[1,5-a]pyrazine**

To a solution of 8-chloroimidazo[1,5-a]pyrazine (150 mg, 0.98 mmol) in DMF (20 mL) was added NIS (240 mg, 1.07 mmol) and the reaction was stirred at RT overnight. The mixture was diluted with water (40 mL) and extracted with EtOAc (2 x 50 mL). The combined organics were dried over MgSO_4 and concentrated *in vacuo*. The residue was purified by column
20 chromatography (0-5% MeOH:DCM) to give the title product (51.9 mg, 19%) as a pale-yellow solid. LCMS (Method D): 1.15 min, m/z 280.0 $[\text{M}+\text{H}]^+$. ^1H NMR (300 MHz, $\text{DMSO}-d_6$): 8.68 (s, 1 H), 8.43 (d, $J = 4.9$ Hz, 1 H), 7.40 (d, $J = 4.9$ Hz, 1 H).

Step 4: 1-Iodoimidazo[1,5-a]pyrazin-8-amine


To a solution of 8-chloro-1-iodoimidazo[1,5-a]pyrazine (50 mg, 0.18 mmol) in MeOH (1 mL)
25 was added 7M NH_3 in MeOH (3 mL) and the reaction was heated at 100 °C in a sealed tube overnight. Once cooled, the mixture was concentrated *in vacuo* and the residue was purified by column chromatography (0-10% MeOH:DCM) to give the title product (24.9 mg, 54%) as a yellow solid. LCMS (Method D): 0.21 min, m/z 261.0 $[\text{M}+\text{H}]^+$. ^1H NMR (300 MHz, $\text{DMSO}-d_6$): 8.35 (s, 1 H), 7.23 (d, $J = 4.9$ Hz, 1 H), 6.98 (d, $J = 4.9$ Hz, 1 H), 6.58 (bs, 2 H).

30 **Step 5: *N*-(4-(8-Aminoimidazo[1,5-a]pyrazin-1-yl)-2-((4-fluorophenyl)methoxy)phenyl)ethane-1-sulfonamide**

To a mixture of 1-iodoimidazo[1,5-a]pyrazin-8-amine (50 mg, 0.19 mmol), *N*-(2-((4-fluorophenyl)methoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethane-1-sulfonamide (92.0 mg, 0.21 mmol) and Na_2CO_3 (40.7 mg, 0.38 mmol) in degassed 1,4-

dioxane/water (4/1, 3 mL) was added Pd(dppf)Cl₂ (14.0 mg, 19.2 μmol), and the reaction was heated at 120 °C with μW irradiation for 1 h. The mixture was filtered over Celite, and the filtrate was concentrated *in vacuo*. The residue was purified by column chromatography (0-5% MeOH:DCM), followed by prep-HPLC (method B, gradient 30-60% MeCN) to give the title product (12.1 mg, 14%) as an orange solid (formate salt). LCMS (Method D): 1.26 min, m/z 442.2 [M+H]⁺. ¹H NMR (300 MHz, DMSO-*d*₆): 9.06 (s, 1 H), 8.43 (s, 1 H), 8.14 (s, 1 H), 7.70 (d, *J* = 4.8 Hz, 1 H), 7.64-7.59 (m, 2 H), 7.40 (d, *J* = 8.1 Hz, 1 H), 7.36 (s, 1 H), 7.27-7.16 (m, 3 H), 7.04 (d, *J* = 4.8 Hz, 1 H), 6.13 (s, 2 H), 5.19 (s, 2 H), 3.04 (q, *J* = 7.3 Hz, 2 H), 1.15 (t, *J* = 7.3 Hz, 3 H).

Compound 2: N-(4-amino-3-(4-(ethylsulfonamido)-3-((4-fluorobenzyl)oxy)phenyl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-7-yl)acetamide



Step 1: 3-iodo-7-nitro-1H-pyrazolo[4,3-c]pyridin-4-amine

To a solution of 3-iodo-1H-pyrazolo[4,3-c]pyridin-4-amine (500 mg, 1.92 mmol) in H₂SO₄ (50 mL) was added HNO₃ (238 μL, 5.76 mmol) and the solution was stirred at 25 °C overnight. The reaction mixture was poured into water (150 mL) and adjusted to pH = 8 with an aq. NaOH solution. The mixture was extracted with EtOAc (250 mL x 3) and the combined organics were washed with water and brine, dried over Na₂SO₄ and concentrated under reduced pressure to give the title product (270 mg, 46%) as a yellow solid. LCMS (method A): 2.34 min, m/z: 305.9 [M+H]⁺.

Step 2: 3-iodo-1-methyl-7-nitro-1H-pyrazolo[4,3-c]pyridin-4-amine

A mixture of 3-iodo-7-nitro-1H-pyrazolo[4,3-c]pyridin-4-amine (160 mg, 0.52 mmol), K₂CO₃ (72.3 mg, 0.52 mmol) and iodomethane (74.4 mg, 0.52 mmol) in DMF (4 mL) was stirred at

RT overnight. Water (20 mL) was added and the solids were filtered. The filter cake was washed with water (5 mL) and dried under reduced pressure to give the title product (160 mg 96%). LCMS (method A): 3.14 min, m/z: 319.9 [M+H]⁺.

Step 3: N-(4-{4-amino-1-methyl-7-nitro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-[(4-fluorophenyl)methoxy]phenyl)ethane-1-sulfonamide

A mixture of 3-iodo-1-methyl-7-nitro-1H-pyrazolo[4,3-c]pyridin-4-amine (190 mg, 0.59 mmol), N-{2-[(4-fluorophenyl)methoxy]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl}ethane-1-sulfonamide (259 mg, 0.60 mmol), Pd(dppf)Cl₂ (24.3 mg, 0.03 mmol) and K₂CO₃ (245 mg, 1.78 mmol) in degassed 1,4-dioxane/H₂O (4/1, 2.5 mL) was stirred at 100 °C overnight. The mixture was poured into water (20 mL) and extracted with EtOAc (2 x 50 mL). The combined organics were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography (PE/EA = 1/1) to give the title product (200 mg 67%) as a yellow solid. LCMS (method A): 3.78 min, m/z: 501.1 [M+H]⁺.


Step 4: N-(4-{4,7-diamino-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-[(4-fluorophenyl)methoxy]phenyl)ethane-1-sulfonamide

A mixture of N-(4-{4-amino-1-methyl-7-nitro-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-[(4-fluorophenyl)methoxy]phenyl)ethane-1-sulfonamide (125 mg, 0.25 mmol) and Zn dust (81.0 mg, 1.24 mmol) in MeOH (5 mL) and aqueous NH₄Cl (5 mL) was stirred at 60 °C for 2 h. The reaction mixture was poured into water (50 mL) and the organics were extracted with EtOAc (2 x 50 mL). The combined organics were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by prep-TLC (DCM/MeOH = 10/1) to give the title product (27 mg, 23%) as a brown solid. LCMS (Method A): 2.97 min, m/z: 471.1 [M+H]⁺.


Step 5: N-(4-amino-3-(4-(ethylsulfonamido)-3-((4-fluorobenzyl)oxy)phenyl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-7-yl)acetamide

To a solution of N-(4-{4,7-diamino-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-[(4-fluorophenyl)methoxy]phenyl)ethane-1-sulfonamide (27 mg, 0.057 mmol), AcOH (3.44 mg, 57 μmol) and DIEA (22.2 mg, 0.17 mmol) in DMF (1 mL) was added HATU (30.5 mg, 0.12 mmol), and the reaction was stirred at RT for 6 h. The mixture was poured into water (10 mL) and extracted with EtOAc (3 x 50 mL). The combined organics were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by prep-TLC (DCM/MeOH = 20/1) to give the title product (8 mg, 27%) as a brown solid. LCMS (Method B): 2.80 min, m/z: 513.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-*d*₆): 9.60 (s, 1H), 9.08 (bs, 1H), 7.64 - 7.60 (m, 2H), 7.46-7.44 (m, 2H), 7.35 (d, *J* = 1.6 Hz, 1H), 7.26-7.19 (m, 3H), 5.78 (s, 2H), 5.20 (s, 2H), 3.99 (s, 3H), 3.05 (q, *J* = 7.6 Hz, 2H), 2.09 (s, 3H), 1.15 (t, *J* = 7.2 Hz, 3H).

Similarly, the compound below was prepared using **intermediate B1** (S)-1,1-difluoro-N-(2-(1-(4-fluorophenyl)ethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methane sulfonamide in step 3 of Compound 2 synthesis.

Compound No	name	Structure	Yield	LCMS data	¹ H NMR data
Compound 47	(S)-N-(4-amino-3-(4-((difluoromethyl)sulfonamido)-3-(1-(4-fluorophenyl)ethoxy)phenyl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-7-yl)acetamide			(Method A): 2.92 min, m/z: 549.2 [M+H] ⁺ .	(400 MHz, DMSO-d ₆): 9.61 (s, 1H), 7.59-7.54 (m, 2H), 7.44 (s, 1H), 7.39 (d, J = 8.5 Hz, 1H), 7.23-7.08 (m, 5H), 6.92 (t, J = 52.7 Hz, 1H), 5.72-5.62 (m, 3H), 3.95 (s, 3H), 2.08 (s, 3H), 1.57 (d, J = 6.3 Hz, 3H).

Intermediate BB: N-(4-{4-amino-7-iodofuro[3,2-c]pyridin-3-yl}-2-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl)-1,1-difluoromethanesulfonamide



Step 1: 3-bromofuro[3,2-c]pyridin-4-amine


5 A solution of 3-bromo-4-chlorofuro[3,2-c]pyridine (1 g, 4.30 mmol) in aq. NH_3 (200 mL) and 1,4-dioxane (20 mL) was stirred at 150 °C for 36 h in a sealed tube. The mixture was concentrated under reduced pressure and the residue was purified by column chromatography (PE/EA = 5/1) to give the title product (400 mg, 44%) as a white solid. LCMS (Method A): 0.89 min, m/z: 212.9, 214.9 $[\text{M}+\text{H}]^+$.

10 **Step 2:** N-(4-{4-aminofuro[3,2-c]pyridin-3-yl}-2-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl)-1,1-difluoromethanesulfonamide

To a solution of 3-bromofuro[3,2-c]pyridin-4-amine (350 mg, 1.64 mmol) in degassed 1,4-dioxane/ H_2O (4/1, 20 mL) were added 1,1-difluoro-N-[2-[(1S)-1-(4-fluorophenyl)ethoxy]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methanesulfonamide (772 mg, 0.542 mmol), Na_2CO_3 (396 mg, 3.74 mmol) and $\text{Pd}(\text{dppf})\text{Cl}_2$ (152 mg, 0.187 mmol). The reaction was stirred at 100 °C under N_2 overnight. The mixture was concentrated under reduced pressure and the residue was diluted with water (50 mL). The organics were extracted with EtOAc (2 x 50 mL), dried over Na_2SO_4 and concentrated under reduced pressure. The residue was purified by column chromatography (DCM/MeOH = 50/1) to give the title product (400 mg, 51%) as a black solid. LCMS (Method A): 3.02 min, m/z: 478.1 $[\text{M}+\text{H}]^+$.


Step 3: N-(4-{4-amino-7-iodofuro[3,2-c]pyridin-3-yl}-2-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl)-1,1-difluoromethanesulfonamide



To a solution of N-(4-{4-aminofuro[3,2-c]pyridin-3-yl}-2-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl)-1,1-difluoromethanesulfonamide (400 mg, 0.838 mmol) in DMF (5 mL) was added NIS (375 mg, 1.67 mmol). After stirring at 85 °C for 4 h under N_2 , the mixture was concentrated *in vacuo*. The residue was diluted with water (50 mL) and the organics were extracted with EtOAc (3 x 50 mL). The combined organics were washed with water and brine, dried over Na_2SO_4 and concentrated *in vacuo*. The residue was purified by prep-TLC (DCM/MeOH = 25/1) to give the title product (90 mg, 18%) as a black solid. LCMS (Method A): 3.82 min, m/z: 604.0 $[\text{M}+\text{H}]^+$.

General procedure B1 for the Suzuki reaction between intermediate BB and boronate esters


5 A mixture of N-(4-{4-amino-7-iodofuro[3,2-c]pyridin-3-yl}-2-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl)-1,1-difluoromethanesulfonamide (1 eq), boronate ester (1.1 eq), Na₂CO₃ (3 eq) and Pd(dppf)Cl₂ (0.1 eq) in degassed 1,4-dioxane/H₂O (4/1, 0.2 M) was stirred at 100 °C overnight under N₂. The mixture was diluted with water and the organics were extracted with EtOAc (3 x). The combined organics were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography (DCM/MeOH) to give the title product as
10 a yellow solid.

The following compounds were prepared following the **General procedure B1**

Compound No	Compound Name	Structure	Yield	LC-MS data	¹ H NMR data	SM
7	(S)-N-(4-(4-amino-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)furo[3,2-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		48%	(Method A): 3.28 min, m/z: 628.2 [M+H] ⁺ .	(400 MHz, DMSO-d ₆): 10.56 (s, 1H), 8.28 (s, 1H), 8.21 (s, 1H), 7.99 (d, J = 4.0 Hz, 2H), 7.59 (t, J = 4.0 Hz, 2H), 7.37 (t, J = 8.0 Hz, 1H), 7.17 (t, J = 8.0 Hz, 2H), 7.01 (t, J = 54.8 Hz, 1H), 5.67 (t, J = 8.0 Hz, 1H), 5.45 (s, 2H), 4.51-4.44 (m, 1H), 3.98 (d, J = 8.0 Hz, 2H), 3.48 (t, J = 8.0 Hz, 2H), 2.01 (s, 4H), 1.58 (d, J = 4.0 Hz, 3H).	1-(oxan-4-yl)-4-(4,4,5,5-tetramethyl-3,2-dioxaborolan-2-yl)-1H-pyrazole

Compound 9	(S)-N-(4-(4-amino-7-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)furo[3,2-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		34%	(Method A): 3.07 (s, 2H), 7.96 (d, J = 8.0 Hz, tetramethyl- min, m/z: 2H), 7.57 (t, J = 4.0 Hz, 2H), 1.3, 2- 588.2 [M+H]⁺.	(400 MHz, DMSO-d₆): 8.192-[4-(4,4,5,5- min, m/z: 2H), 7.57 (t, J = 4.0 Hz, 2H), 1.3, 2- 588.2 [M+H]⁺.	(400 MHz, DMSO-d₆): 8.192-[4-(4,4,5,5- min, m/z: 2H), 7.57 (t, J = 4.0 Hz, 2H), 1.3, 2- 588.2 [M+H]⁺.
Compound 8	(S)-N-(4-(4-amino-7-(1-methyl-1H-pyrazol-4-yl)furo[3,2-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide		45%	(Method A): 3.22 (s, 1H), 8.18 (s, 2H), 7.96 (d, J = 8.0 Hz, tetramethyl- min, m/z: 2H), 7.57 (t, J = 4.0 Hz, 2H), 1.3, 2- 558.1 [M+H]⁺.	(400 MHz, DMSO-d₆): 10.481-methyl-4- min, m/z: 2H), 7.57 (t, J = 4.0 Hz, 2H), 1.3, 2- 558.1 [M+H]⁺.	(400 MHz, DMSO-d₆): 10.481-methyl-4- min, m/z: 2H), 7.57 (t, J = 4.0 Hz, 2H), 1.3, 2- 558.1 [M+H]⁺.

Intermediate BC: N-(4-{4-amino-7-iodofuro[3,2-c]pyridin-3-yl}-2-[(4-fluorophenyl)methoxy]phenyl)-1,1-difluoromethanesulfonamide



Step 1: 3-{4-amino-3-[(4-fluorophenyl)methoxy]phenyl}furo[3,2-c]pyridin-4-amine

- 5 To a solution of 3-bromofuro[3,2-c]pyridin-4-amine (400 mg, 1.87 mmol) in degassed 1,4-dioxane/H₂O (4/1, 20 mL) were added 2-[(4-fluorophenyl)methoxy]-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (641 mg, 0.5418 mmol), Na₂CO₃ (396 mg, 3.74 mmol) and Pd(dppf)Cl₂ (152 mg, 0.187 mmol). After stirring at 100 °C overnight under N₂, the mixture was concentrated under reduced pressure. The residue was diluted with water (50 mL) and
- 10 extracted with EtOAc (3 x 50 mL). The combined organics were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography (DCM/MeOH = 50/1) to give the title product (460 mg, 70%) as a brown oil. LCMS (Method A): 2.89 min, m/z: 350.1 [M+H]⁺.


Step 2: N-(4-{4-aminofuro[3,2-c]pyridin-3-yl}-2-[(4-fluorophenyl)methoxy]phenyl)-1,1-difluoromethanesulfonamide

15

- To a solution of 3-{4-amino-3-[(4-fluorophenyl)methoxy]phenyl}furo[3,2-c]pyridin-4-amine (480 mg, 1.37 mmol) in DCM (10 mL) and pyridine (541 mg, 6.85 mmol) was added difluoromethanesulfonyl chloride (550 µL, 2.05 mmol). After stirring at RT overnight, the mixture was concentrated under reduced pressure. The residue was purified by column
- 20 chromatography (DCM/MeOH = 50/1) to give the title product (240 mg, 38%) as a yellow solid. LCMS (Method A): 3.22 min, m/z: 464.1 [M+H]⁺.

Step 3: N-(4-{4-amino-7-iodofuro[3,2-c]pyridin-3-yl}-2-[(4-fluorophenyl)methoxy]phenyl)-1,1-difluoromethanesulfonamide


- To a solution of N-(4-{4-aminofuro[3,2-c]pyridin-3-yl}-2-[(4-fluorophenyl)methoxy]phenyl)-1,1-difluoromethanesulfonamide (120 mg, 0.259 mmol) in DMF (3 mL) was added NIS (116 mg, 0.518 mmol). After stirring at 85 °C for 6 h under N₂, the mixture was diluted with water (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organics were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column
- 25 chromatography (DCM/MeOH = 25/1) to give the title product (20 mg, 13%) as a yellow solid.
- 30 LCMS (Method A): 3.78 min, m/z: 590.0 [M+H]⁺.


General procedure B2 for the Suzuki reaction between intermediate BC and boronate esters

5 A mixture of N-(4-{4-amino-7-iodofuro[3,2-c]pyridin-3-yl}-2-[(4-fluorophenyl)methoxy]phenyl)-1,1-difluoromethanesulfonamide (1 eq), boronate ester (1.1 eq), Na₂CO₃ (3 eq) and Pd(dppf)Cl₂·CH₂Cl₂ (0.1 eq) in degassed 1,4-dioxane/H₂O (4/1, 0.2 M) was stirred at 100 °C overnight under N₂. The mixture was diluted with water and the organics were extracted with EtOAc (3 x). The combined organics were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography (DCM/MeOH) to give the title product as a yellow solid.


10

The following compounds were prepared following the **General procedure B2**

Compound No	Name	Structure	Yield	LCMS data	¹ H NMR data	Boronic ester
5	N-(4-(4-amino-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)furo[3,2-c]pyridin-3-yl)-2-((4-fluorobenzyl)oxy)phenyl)-1,1-difluoromethanesulfonamide		48%	(Method A): 3.28 min, m/z: 614.2 [M+H] ⁺ .	(400 MHz, DMSO-d ₆): 10.53 (s, 1H), 8.30 (s, 1H), 8.23 (s, 1H), 8.10 (s, 1H), 8.01 (s, 1H), 7.60 (s, 2H), 7.40 (d, J = 8.0 Hz, 1H), 7.34 (s, 2H), 7.25 (t, J = 7.2 Hz, 3H), 7.14 (d, J = 8.0 Hz, 1H), 6.90 (t, J = 52.8 Hz, 1H), 5.56 (s, 2H), 5.23 (s, 2H), 4.49 (s, 1H), 3.98 (d, J = 10.0 Hz, 2H), 2.02 (s, 4H).	1-(tetrahydro-2H-pyran-4-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole

Compound 6	N-(4-(4-amino-7-(1-(2-(hydroxyethyl)-1H-pyrazol-4-yl)furo[3,2-c]pyridin-3-yl)-2-((4-fluorobenzyl)oxy)phenyl)-1,1-difluoromethanesulfonamide		51%	(Method A): 3.04 min, m/z: 574.1 [M+H] ⁺ .	(400 MHz, DMSO-d ₆): 10.55 (s, 1H), 8.23 (d, J = 2.0 Hz, 2H), 8.12 (s, 1H), 7.63-7.59 (m, y)-1H-pyrazol-1-2H), 7.40 (d, J = 8.0 Hz, y]ethan-1-ol 1H), 7.35 (s, 1H), 7.25 (t, J = 8.8 Hz, 2H), 7.17-7.14 (m, 1H), 6.92 (t, J = 52.8 Hz, 1H), 5.57 (s, 2H), 5.23 (s, 2H), 4.94 (t, J = 5.2 Hz, 1H), 4.21 (t, J = 5.6 Hz, 2H), 3.81-3.77 (m, 2H).	12-[4-(4,4,5,5-
-----------------------------	---	---	-----	---	--	-----------------

Compound 3: N-(4-(4-amino-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)furo[3,2-c]pyridin-3-yl)-2-((4-fluorobenzyl)oxy)phenyl)ethanesulfonamide



Step 1: N-(4-{4-amino-3-[(4-fluorophenyl)methoxy]phenyl}furo[3,2-c]pyridin-3-yl)-2-[(4-fluorophenyl)methoxy]phenyl) ethane-1-sulfonamide

To a solution of 3-{4-amino-3-[(4-fluorophenyl)methoxy]phenyl}furo[3,2-c]pyridin-4-amine (420 mg, 1.20 mmol) in DCM (20 mL) and pyridine (510 μ L, 5.99 mmol) was added EtSO₂Cl (230 mg, 1.79 mmol). The solution was stirred at RT overnight before being diluted with water (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organics were washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography (DCM/MeOH = 50/1) to give the title product (400 mg, 76%) as a yellow solid. LCMS (Method A): 3.04 min, m/z: 442.1 [M+H]⁺.

Step 2: N-(4-{4-amino-7-iodofuro[3,2-c]pyridin-3-yl}-2-[(4-fluorophenyl)methoxy]phenyl) ethane-1-sulfonamide


To a solution of N-(4-{4-amino-3-[(4-fluorophenyl)methoxy]phenyl}furo[3,2-c]pyridin-3-yl)-2-[(4-fluorophenyl)methoxy]phenyl)ethane-1-sulfonamide (200 mg, 0.45 mmol) in DMF (5 mL) was added NIS (203 mg, 0.91 mmol). After stirring at 85 °C for 6 h under N₂, the mixture was concentrated under reduced pressure. The residue was diluted with water (50 mL) and the organics were extracted with EtOAc (3 x 50 mL). The combined organics were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by prep-TLC (DCM/MeOH = 25/1) to give the title product (80 mg, 31%) as a yellow solid. LCMS (Method A): 3.63 min, m/z: 568.0 [M+H]⁺.

Step 3: N-(4-(4-amino-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)furo[3,2-c]pyridin-3-yl)-2-((4-fluorobenzyl)oxy)phenyl)ethanesulfonamide


To a solution of N-(4-{4-amino-7-iodofuro[3,2-c]pyridin-3-yl}-2-[(4-fluorophenyl)methoxy]phenyl)ethane-1-sulfonamide (50 mg, 88 μ mol) in degassed 1,4-dioxane/H₂O (4/1, 1.25 mL) were added 1-(tetrahydro-2H-pyran-4-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (24.0 mg, 88 μ mol), Pd(dppf)₂Cl₂ (7.19 mg, 8.8 μ mol) and Na₂CO₃ (18.6 mg, 0.1762 mmol). After stirring at 100 °C for 1 h with μ W irradiation, the mixture was concentrated under reduced pressure. The residue was diluted with water (5

mL) and the organics were extracted with EtOAc (2 x 5mL). The combined organic phases were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (DCM/MeOH = 20/1) to give the title product (30 mg, 58%) as a brown solid. LCMS (Method A): 3.13 min, m/z: 592.2 [M+H]⁺. ¹H NMR (400 5 MHz, DMSO-*d*₆): 9.10 (s, 1H), 8.30 (s, 1H), 8.23 (s, 1H), 8.07 (s, 1H), 8.01 (s, 1H), 7.63 (t, *J* = 5.6 Hz, 2H), 7.43 (d, *J* = 8.0 Hz, 1H), 7.33 (s, 1H), 7.24 (t, *J* = 9.2 Hz, 2H), 7.12 (d, *J* = 8.0 Hz, 1H), 5.58 (s, 2H), 5.21 (s, 2H), 4.51-4.46 (m, 1H), 3.99 (d, *J* = 8.8 Hz, 2H), 3.52-3.46 (m, 2H), 3.02 (q, *J* = 7.6 Hz, 2H), 2.04-1.98 (m, 4H), 1.15 (t, *J* = 7.2 Hz, 3H).

10 The following compound was similarly prepared following step 3 of **Compound 3**

Compound No	Name	Structure	Yield	LCMS data	¹ H NMR data	Boronic ester
4	N-(4-(4-amino-7-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)furo[3,2-c]pyridin-3-yl)-2-(4-fluorobenzyl)oxy)phenyl)ethanesulfonamide		69%	(Method A): 2.93 min, m/z: 552.2 [M+H] ⁺ .	(400 MHz, DMSO- _d ₆): 9.10 (s, 1H), 8.23 (s, 1H), 8.09 (s, 1H), 8.00 (s, 1H), 7.63 (t, J = 5.6 Hz, 1H), 7.43 (d, J = 8.0 Hz, 1H), 7.33 (s, 1H), 7.24 (t, J = 8.8 Hz, 2H), 7.13 (d, J = 8.0 Hz, 1H), 5.62 (s, 2H), 5.21 (s, 2H), 4.95 (t, J = 5.2 Hz, 1H), 4.22 (t, J = 5.6 Hz, 2H), 3.78 (q, J = 5.6 Hz, 2H), 3.04 (q, J = 7.2 Hz, 2H), 1.15 (t, J = 7.2 Hz, 3H).	2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)ethan-1-ol

Compound 11: N-(4-(4-amino-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)furo[3,2-c]pyridin-3-yl)-2-((4-fluorobenzyl)oxy)phenyl)-2,2,2-trifluoroethane-1-sulfonamide



Step 1: 3-{3-[(4-fluorophenyl)methoxy]-4-nitrophenyl}furo[3,2-c]pyridin-4-amine

- 5 To a solution of 3-bromofuro[3,2-c]pyridin-4-amine (570 mg, 2.67 mmol) in degassed 1,4-dioxane/H₂O (4/1, 30 mL) were added 2-{3-[(4-fluorophenyl)methoxy]-4-nitrophenyl}-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (996 mg, 2.67 mmol), Na₂CO₃ (396 mg, 3.74 mmol) and Pd(dppf)Cl₂ (152 mg, 0.19 mmol). After stirring at 100 °C overnight under N₂, the mixture was concentrated under reduced pressure and the residue was purified by column chromatography (DCM/MeOH = 100/1) to give the title product (610 mg, 60%) as a yellow solid. LCMS (Method A): 3.13 min, m/z: 380.1 [M+H]⁺.
- 10

Step 2: 3-{3-[(4-fluorophenyl)methoxy]-4-nitrophenyl}-7-iodofuro[3,2-c]pyridin-4-amine

- To a solution of 3-{3-[(4-fluorophenyl)methoxy]-4-nitrophenyl}furo[3,2-c]pyridin-4-amine (550 mg, 1.44 mmol) in DMF (11 mL) was added NIS (647 mg, 2.88 mmol). After stirring at 85 °C for 4 h under N₂, the reaction mixture was concentrated under reduced pressure. The residue was diluted with water (50 mL) and the organics were extracted with EtOAc (3 x 50 mL). The combined organic phases were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography (PE/EA = 1/1) to give the title product (530 mg, 73%) as a brown solid. LCMS (Method A): 4.01 min, m/z: 506.0 [M+H]⁺.
- 15

- 20 **Step 3:** 3-{3-[(4-fluorophenyl)methoxy]-4-nitrophenyl}-7-[1-(oxan-4-yl)-1H-pyrazol-4-yl]furo[3,2-c]pyridin-4-amine

- To a solution of 3-{3-[(4-fluorophenyl)methoxy]-4-nitrophenyl}-7-iodofuro[3,2-c]pyridin-4-amine (200 mg, 396 μmol) in degassed 1,4-dioxane/H₂O (4/1, 5 mL) were added 1-(oxan-4-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (110 mg, 396 μmol), Pd(dppf)Cl₂ (32.3 mg, 39.6 μmol) and Na₂CO₃ (83.9 mg, 0.79 mmol). After stirring at 100 °C for 2 h with μW
- 25

irradiation, the mixture was concentrated under reduced pressure. The residue was diluted with water (5 mL) and the organics were extracted with EtOAc (3 x 5 mL). The combined organic phases were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography (DCM/MeOH = 20/1) to give the title product (45 mg, 22%) as a yellow solid. LCMS (Method A): 3.40 min, m/z: 530.2 [M+H]⁺.


Step 4: 3-{4-amino-3-[(4-fluorophenyl)methoxy]phenyl}-7-[1-(oxan-4-yl)-1H-pyrazol-4-yl]furo[3,2-c]pyridin-4-amine

To a solution of 3-{3-[(4-fluorophenyl)methoxy]-4-nitrophenyl}-7-[1-(oxan-4-yl)-1H-pyrazol-4-yl]furo[3,2-c]pyridin-4-amine (45 mg, 0.085 mmol) in MeOH (6 mL) was added sat. aq. NH₄Cl (2 mL) followed by Zn dust (27.7 mg, 0.425 mmol). After stirring at 60 °C overnight, the reaction mixture was concentrated under reduced pressure. The residue was diluted with water (5 mL) and extracted with EtOAc (3 x 5 mL). The combined organic phases were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography (DCM/MeOH = 20/1) to give the title product (40 mg, 94%) as a yellow solid. LCMS (Method A): 3.16 min, m/z: 500.2 [M+H]⁺.

Step 5: N-(4-(4-amino-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)furo[3,2-c]pyridin-3-yl)-2-((4-fluorobenzyl)oxy)phenyl)-2,2,2-trifluoroethane-1-sulfonamide

To a solution of 3-{4-amino-3-[(4-fluorophenyl)methoxy]phenyl}-7-[1-(oxan-4-yl)-1H-pyrazol-4-yl]furo[3,2-c]pyridin-4-amine (50 mg, 0.1 mmol) in DCM (5 mL) and pyridine (40.2 μL, 0.5 mmol) was added 2,2,2-trifluoroethane-1-sulfonyl chloride (18.2 mg, 0.1 mmol). After stirring at RT overnight, the mixture was concentrated under reduced pressure and the residue was purified by column chromatography (DCM/MeOH = 20/1) to give the title product (30 mg, 47%) as a yellow solid. LCMS (Method A): 3.32 min, m/z: 646.2 [M+H]⁺. ¹H NMR (400 MHz, DMSO-*d*₆): 9.92 (s, 1H), 8.29 (s, 1H), 8.22 (s, 1H), 8.09 (s, 1H), 8.01 (s, 1H), 7.60 (t, *J* = 8.0 Hz, 2H), 7.40 (d, *J* = 1.0 Hz, 1H), 7.34 (s, 1H), 7.23 (t, *J* = 8.0 Hz, 2H), 7.15 (d, *J* = 8.0 Hz, 1H), 5.59 (s, 2H), 5.21 (s, 2H), 4.51 - 4.44 (m, 1H), 4.29 (q, *J* = 9.6 Hz, 2H), 3.98 (d, *J* = 11.2 Hz, 4H), 2.01 (s, 4H).

Compound 62: N-(4-(3-Amino-1H-indazol-4-yl)-2-((4-fluorophenyl)methoxy)phenyl)ethane-1-sulfonamide




Step 1: 4-Bromo-1H-indazol-3-amine

To a solution of 2-bromo-6-fluorobenzonitrile (200 mg, 1.00 mmol) in EtOH (2 mL) was added $\text{NH}_2\text{NH}_2 \cdot \text{H}_2\text{O}$ (241 μL , 4.99 mmol) and the reaction was heated at reflux for 12 h. Water was added, and the mixture was chilled on ice. The precipitate was collected *via* filtration and air-dried to give the title product (195 mg, 92%) as a white solid. LCMS (Method D): 1.07 min, m/z 214.0 $[\text{M}+\text{H}]^+$. ^1H NMR (300 MHz, $\text{DMSO}-d_6$): 7.26 (dd, $J = 7.5, 1.6$ Hz, 1H), 7.13-7.05 (m, 2H), 5.13 (s, 2H).

Step 2: *N*-(4-(3-Amino-1*H*-indazol-4-yl)-2-((4-fluorophenyl)methoxy)phenyl)ethane-1-sulfonamide

To a mixture of 4-bromo-1*H*-indazol-3-amine (50 mg, 0.24 mmol), *N*-(2-((4-fluorophenyl)methoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethane-1-sulfonamide (112 mg, 0.26 mmol) and Na_2CO_3 (49.9 mg, 0.47 mmol) in 1,4-dioxane/ H_2O (4/1, 5 mL) was added $\text{Pd}(\text{dppf})\text{Cl}_2$ (17.2 mg, 0.02 mmol), and the reaction was heated at 100 $^\circ\text{C}$ with μW irradiation for 30 min. The mixture was filtered over Celite, and the filtrate was concentrated *in vacuo*. The residue was purified by column chromatography (0-5% MeOH:DCM) to give the title compound (89.9 mg, 87%) as a brown solid. LCMS (Method D): 1.88 min, m/z 441.2 $[\text{M}+\text{H}]^+$. ^1H NMR (300 MHz, $\text{DMSO}-d_6$): 9.06 (s, 1H), 7.61 (dd, $J = 8.8, 5.6$ Hz, 2H), 7.40 (d, $J = 8.1$ Hz, 1H), 7.21-7.29 (m, 5H), 7.04 (dd, $J = 8.1, 1.8$ Hz, 1H), 6.82 (dd, $J = 3.8, 3.8$ Hz, 1H), 5.21 (s, 2H), 4.34 (s, 2H), 3.04 (q, $J = 7.3$ Hz, 2H), 1.16 (t, $J = 7.3$ Hz, 3H).

Compound 67: *N*-(4-(3-Amino-1*H*-pyrazolo[3,4-*b*]pyridin-4-yl)-2-((4-fluorophenyl)methoxy)phenyl)-2,2,2-trifluoroethane-1-sulfonamide



Step 1: 2-Chloro-4-iodopyridine-3-carbonitrile

To a solution of 2-chloro-4-iodopyridine-3-carbaldehyde (1.0 g, 3.73 mmol) in THF (11 mL) were added 25% NH_4OH (11 mL, 69.9 mmol) and I_2 (1.04 g, 4.10 mmol), and the reaction was stirred at RT for 18 h. The reaction was quenched by the addition of sat. NaHSO_3 and extracted with

EtOAc. The organic phase was washed with brine, dried over MgSO_4 and concentrated *in vacuo* to give the title compound (970 mg, 98%) as a yellow solid. LCMS (Method D): 1.54 min, m/z 264.8 $[\text{M}+\text{H}]^+$. ^1H NMR (300 MHz, CDCl_3): 8.18 (d, $J = 5.3$ Hz, 1H), 7.83 (d, $J = 5.3$ Hz, 1H).

Step 2: 2-Chloro-4-(3-((4-fluorophenyl)methoxy)-4-nitrophenyl)pyridine-3-carbonitrile

- 5 To a mixture of 2-chloro-4-iodopyridine-3-carbonitrile (970 mg, 3.66 mmol), 2-(3-((4-fluorophenyl)methoxy)-4-nitrophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.50 g, 4.02 mmol) and Na_2CO_3 (775 mg, 7.32 mmol) in 1,4-dioxane/water (9/1, 37 mL) was added $\text{Pd}(\text{dppf})\text{Cl}_2 \cdot \text{CH}_2\text{Cl}_2$ (298 mg, 0.37 mmol), and the reaction was heated at 100 °C under N_2 for 20 h. Once cooled, the mixture was concentrated *in vacuo* and the residue was partitioned between
- 10 EtOAc (50 mL) and water (50 mL). The phases were separated, and the aqueous phase was extracted with EtOAc (3 x 50 mL). The combined organics were washed with brine, dried over MgSO_4 and concentrated *in vacuo*. The residue was purified by column chromatography (0-50% EtOAc: n-Hep) to give the title compound (1.08 g, 77%) as a yellow solid. LCMS (Method D): 2.52 min, molecular ion not observed. ^1H NMR (300 MHz, $\text{DMSO}-d_6$): 8.82 (d, $J = 5.2$ Hz, 1H), 8.12 (d, $J = 8.3$ Hz, 1H), 7.83 (d, $J = 1.6$ Hz, 1H), 7.80 (d, $J = 5.2$ Hz, 1H), 7.54 - 7.48 (m, 2H), 7.46 (d, $J = 1.6$ Hz, 1H), 7.26 (dd, $J = 8.9$ Hz, 2H), 5.34 (s, 2H).
- 15

Step 3: 4-(3-((4-Fluorophenyl)methoxy)-4-nitrophenyl)-1H-pyrazolo[3,4-b]pyridin-3-amine

- To a solution of 2-chloro-4-(3-((4-fluorophenyl)methoxy)-4-nitrophenyl)pyridine-3-carbonitrile (1.05 g, 2.73 mmol) in *i*-PrOH (27 mL) was added $\text{NH}_2\text{NH}_2 \cdot \text{H}_2\text{O}$ (264 μL , 5.46 mmol) and the
- 20 reaction was heated at 80 °C with μW irradiation for 1 h. Once cooled, the precipitate was collected *via* filtration to give the title product (878 mg, 85%) as an orange solid. LCMS (Method D): 1.97 min, m/z 380.0 $[\text{M}+\text{H}]^+$. ^1H NMR (300 MHz, $\text{DMSO}-d_6$): 12.45 (bs, 1H), 8.46 (d, $J = 4.7$ Hz, 1H), 8.06 (d, $J = 8.3$ Hz, 1H), 7.67 (d, $J = 1.6$ Hz, 1H), 7.52 (dd, $J = 8.8, 5.5$ Hz, 2H), 7.35 (dd, $J = 8.3, 1.6$ Hz, 1H), 7.26 (dd, $J = 8.8$ Hz, 2H), 7.03 (d, $J = 4.7$ Hz, 1H), 5.39 (s, 2H), 4.76 (s, 2H).


25 **Step 4: 4-(4-Amino-3-((4-fluorophenyl)methoxy)phenyl)-1H-pyrazolo[3,4-b]pyridin-3-amine**

- To a solution of 4-(3-((4-fluorophenyl)methoxy)-4-nitrophenyl)-1H-pyrazolo[3,4-b]pyridin-3-amine (878 mg, 2.31 mmol) in EtOH:THF: H_2O (4:4:1, 36 mL) were added Fe (642 mg, 11.5 mmol) and NH_4Cl (123 mg, 2.31 mmol), and the reaction was heated at reflux overnight. Whilst hot, the mixture was filtered over Celite and the pad was rinsed with EtOH. The combined filtrates were
- 30 concentrated *in vacuo* and the residue was purified by column chromatography (0-20% MeOH:DCM) to give the title product (445 mg, 55%) as a yellow glass. LCMS (Method D): 1.50 min, m/z 350.2 $[\text{M}+\text{H}]^+$. ^1H NMR (300 MHz, $\text{DMSO}-d_6$): 12.16 (s, 1H), 8.29 (d, $J = 4.8$ Hz, 1H), 7.57 (dd, $J = 8.8, 5.6$ Hz, 2H), 7.72 (dd, $J = 8.8$ Hz, 2H), 7.16 (d, $J = 1.8$ Hz, 1H), 6.99 (dd, $J = 8.0, 1.8$ Hz, 1H), 6.84 (d, $J = 4.8$ Hz, 1H), 6.81 (d, $J = 8.0$ Hz, 1H), 5.17 (s, 2H), 4.61 (s, 2H).

Step 5: *N*-(4-(3-Amino-1*H*-pyrazolo[3,4-*b*]pyridin-4-yl)-2-((4-fluorophenyl)methoxy) phenyl)-2,2,2-trifluoroethane-1-sulfonamide

To a solution of 4-(4-amino-3-((4-fluorophenyl)methoxy)phenyl)-1*H*-pyrazolo[3,4-*b*]pyridin-3-amine (103.5 mg, 0.29 mmol) in CHCl₃ (3 mL) were added pyridine (71.1 μL, 0.88 mmol) and 2,2,2-trifluoroethanesulfonyl chloride (80.7 mg, 0.44 mmol), and the reaction was stirred under N₂ overnight. The mixture was concentrated *in vacuo* and the residue was purified by column chromatography (0-10% MeOH:DCM) followed by prep-HPLC purification (method B, gradient 30-60% MeCN) to give the title compound (13.3 mg, 9%) as a yellow solid. LCMS (Method D): 1.93 min, *m/z* 496.0 [M+H]⁺. ¹H NMR (300 MHz, DMSO-*d*₆): 12.33 (s, 1H), 9.94 (s, 1H), 8.40 (d, *J* = 4.7 Hz, 1H), 7.65-7.55 (m, 2H), 7.44 (d, *J* = 8.1 Hz, 1H), 7.40 (d, *J* = 1.8 Hz, 1H), 7.29-7.15 (m, 3H), 6.95 (d, *J* = 4.7 Hz, 1H), 5.24 (s, 2H), 4.67 (s, 2H), 4.33 (q, *J* = 9.8 Hz, 2H).


Compound 66: *N*-(4-(3-Amino-1*H*-pyrazolo[3,4-*b*]pyridin-4-yl)-2-((4-fluorophenyl)methoxy) phenyl)-1,1-difluoromethanesulfonamide



Step 1: *N*-(4-(3-Amino-1*H*-pyrazolo[3,4-*b*]pyridin-4-yl)-2-((4-fluorophenyl)methoxy) phenyl)-1,1-difluoromethanesulfonamide

To a solution of 4-(4-amino-3-((4-fluorophenyl)methoxy)phenyl)-1*H*-pyrazolo[3,4-*b*]pyridin-3-amine (90 mg, 0.26 mmol) in pyridine (2.5 mL) was added difluoromethanesulfonyl chloride (45.6 μL, 0.52 mmol), and the reaction was stirred at RT under N₂ overnight. The mixture was concentrated *in vacuo* and the residue was azeotropically distilled with MePh. The residue was purified by column chromatography (0-20% MeOH:DCM) followed by prep-HPLC purification (Method B, gradient 30-60% MeCN) to give the title product (3.50 mg, 3%) as a yellow solid. LCMS (Method D): 1.78 min, *m/z* 464.0 [M+H]⁺. ¹H NMR (300 MHz, DMSO-*d*₆): 10.54 (s, 1H), 8.38 (d, *J* = 4.8 Hz, 1H), 7.59 (dd, *J* = 8.6, 5.6 Hz, 2H), 7.41 (d, *J* = 8.1 Hz, 1H), 7.33 (s, 1H), 7.23 (t, *J* = 8.9 Hz, 2H), 7.15 (d, *J* = 7.6 Hz, 1H), 6.93 (d, *J* = 4.8 Hz, 1H), 5.22 (s, 2H), 4.62 (s, 2H).

Compound 72: *N*-(4-(3-Amino-1*H*-pyrazolo[3,4-*b*]pyridin-4-yl)-2-((1*S*)-1-(4-fluorophenyl) ethoxy) phenyl)-1,1-difluoromethanesulfonamide




Step 1: *N*-(4-(2-Chloro-3-cyanopyridin-4-yl)-2-((1*S*)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide

To a mixture of 2-chloro-4-iodopyridine-3-carbonitrile (150 mg, 0.57 mmol), 1,1-difluoro-*N*-(2-
 5 ((1*S*)-1-(4-fluorophenyl)ethoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)
 methanesulfonamide (294 mg, 0.62 mmol) and Na₂CO₃ (119 mg, 1.13 mmol) in 1,4-dioxane/water
 (9/1, 6 mL) was added Pd(dppf)Cl₂·CH₂Cl₂ (46.3 mg, 0.06 mmol), and the reaction was heated at
 100 °C under N₂ for 23 h. Once cooled, the mixture was concentrated *in vacuo* and the residue
 was partitioned between EtOAc (20 mL) and water (20 mL). The phases were separated, and the
 10 aqueous phase was extracted with EtOAc (3 x 20 mL). The combined organic fractions were
 washed with brine, dried over MgSO₄ and concentrated *in vacuo*. The residue was purified by
 column chromatography (0-50% EtOAc:*n*-Hep) to give the title product (214 mg, 78%) as a yellow
 solid. LCMS (Method D): 2.46 min, *m/z* 482.0 [M+H]⁺. ¹H NMR (300 MHz, DMSO-*d*₆): 10.61 (s,
 1H), 8.70 (d, *J* = 4.1 Hz, 1H), 7.61-7.57 (m, 3H), 7.43 (d, *J* = 8.2 Hz, 1H), 7.31 (d, *J* = 1.8 Hz, 1H),
 15 7.21-7.15 (m, 3H), 7.04 (t, *J* = 52.3 Hz, 1H), 5.70 (q, *J* = 6.2 Hz, 1H), 1.59 (d, *J* = 6.2 Hz, 3H).

Step 2: *N*-(4-(3-Amino-1*H*-pyrazolo[3,4-*b*]pyridin-4-yl)-2-((1*S*)-1-(4-fluorophenyl)ethoxy)phenyl)-
 1,1-difluoromethanesulfonamide

To a solution of *N*-(4-(2-chloro-3-cyanopyridin-4-yl)-2-((1*S*)-1-(4-fluorophenyl)ethoxy)phenyl)-
 1,1-difluoromethanesulfonamide (210 mg, 0.44 mmol) in *i*-PrOH (5 mL) was added NH₂NH₂·H₂O
 20 (63.1 μL, 1.30 mmol), and the reaction was heated at 80 °C with μW irradiation for 1 h. Once
 cooled, the mixture was diluted with water (25 mL) and extracted with EtOAc (3 x 25 mL). The
 combined organics were washed with brine, dried over MgSO₄ and concentrated *in vacuo*. The
 residue was purified by column chromatography (0-10% MeOH:DCM) to give the title product
 (145 mg, 70%) as a yellow solid. LCMS (Method D): 1.86 min, *m/z* 478.0 [M+H]⁺. ¹H NMR (300
 25 MHz, DMSO-*d*₆): 10.51 (s, 1H), 8.35 (d, *J* = 4.7 Hz, 1H), 7.58 (dd, *J* = 8.7, 5.5 Hz, 2H), 7.40 (d, *J*
 = 8.0 Hz, 1H), 7.18 (d, *J* = 8.9 Hz, 2H), 7.15-7.07 (m, 2H), 7.03 (t, *J* = 51.6 Hz, 1H), 6.77 (d, *J* =
 4.7 Hz, 1H), 5.72 (q, *J* = 6.3 Hz, 1H), 4.47 (s, 2H), 1.59 (d, *J* = 6.3 Hz, 3H).

Compound 65: *N*-(4-(3-amino-1*H*-pyrazolo[4,3-*c*]pyridin-4-yl)-2-((4-fluorophenyl)methoxy)
 30 phenyl)-2,2,2-trifluoroethane-1-sulfonamide



Step 1: 4-Chloro-2-(3-((4-fluorophenyl)methoxy)-4-nitrophenyl)pyridine-3-carbonitrile

To a mixture of 2,4-dichloropyridine-3-carbonitrile (692 mg, 4.0 mmol), 2-(3-((4-fluorophenyl)methoxy)-4-nitrophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.64 g, 4.40 mmol) and Na₂CO₃ (847 mg, 8.00 mmol) in 1,4-dioxane:water (9:1, 40 mL) was added Pd(dppf)Cl₂ (292 mg, 0.4 mmol), and the reaction was heated at 100 °C under N₂ for 18 h. Once cooled, the mixture was diluted with EtOAc, filtered over Celite and concentrated *in vacuo*. The residue was purified by column chromatography (0-50% EtOAc:c-Hex) to give the title compound & its regioisomer (5:2, 1.02 g, 48%) as a white solid. LCMS (Method D): 2.47 min, m/z 384.0 [M+H]⁺.

Step 2: 4-(3-((4-Fluorophenyl)methoxy)-4-nitrophenyl)-1H-pyrazolo[4,3-c]pyridin-3-amine

To a mixture of 4-chloro-2-(3-((4-fluorophenyl)methoxy)-4-nitrophenyl)pyridine-3-carbonitrile & its regioisomer (191 mg, 0.5 mmol) in *i*-PrOH (5 mL) was added NH₂NH₂·H₂O (48.4 μL, 1.0 mmol), and the reaction was heated at 80 °C with μW irradiation for 1 h. Once cooled, the precipitate was collected *via* filtration to give the title product (133 mg, 70%) as a yellow solid. LCMS (Method D): 1.46 min, m/z 380.9 [M+H]⁺. ¹H NMR (300 MHz, DMSO-*d*₆): 12.34 (s, 1H), 8.29 (d, *J* = 5.9 Hz, 1H), 8.06 (d, *J* = 8.3 Hz, 1H), 7.77 (d, *J* = 1.6 Hz, 1H), 7.55-7.47 (m, 3H), 7.33 (d, *J* = 5.9 Hz, 1H), 7.26 (dd, *J* = 8.9 Hz, 2H), 5.38 (s, 2H), 4.96 (s, 2H).


Step 3: 4-(4-Amino-3-((4-fluorophenyl)methoxy)phenyl)-1H-pyrazolo[4,3-c]pyridin-3-amine

To a solution of 4-(3-((4-fluorophenyl)methoxy)-4-nitrophenyl)-1H-pyrazolo[4,3-c]pyridin-3-amine (210 mg, 0.55 mmol) in EtOH:THF:H₂O (4:4:1, 18 mL) were added Fe (154 mg, 2.76 mmol) and NH₄Cl (29.6 mg, 0.55 mmol), and the reaction was heated at reflux overnight. Whilst hot, the mixture was filtered over Celite and the pad was rinsed with EtOH. The combined filtrates were concentrated *in vacuo* and the residue was purified by column chromatography (0-20% MeOH:DCM) to give the title product (127 mg, 66%) as a yellow glass. LCMS (Method D): 1.21 min, m/z 350.0 [M+H]⁺. ¹H NMR (300 MHz, DMSO-*d*₆): 12.33 (bs, 1H), 8.13 (d, *J* = 6.2 Hz, 1H), 7.57 (dd, *J* = 8.9, 5.6 Hz, 2H), 7.32 (d, *J* = 1.8 Hz, 1H), 7.25-7.19 (m, 3H), 7.12 (dd, *J* = 8.0, 1.8 Hz, 1H), 6.82 (d, *J* = 8.0 Hz, 1H), 5.28 (s, 2H), 5.16 (s, 2H), 4.94 (s, 2H).

Step 4: *N*-(4-(3-amino-1*H*-pyrazolo[4,3-*c*]pyridin-4-yl)-2-((4-fluorophenyl)methoxy) phenyl)-2,2,2-trifluoroethane-1-sulfonamide

To a solution of 4-(4-amino-3-((4-fluorophenyl)methoxy)phenyl)-1*H*-pyrazolo [4,3-*c*]pyridin-3-amine (120 mg, 0.34 mmol) in pyridine (3.43 mL) was added 2,2,2-trifluoroethanesulfonyl chloride (125 mg, 0.69 mmol), and the reaction was stirred at RT under N₂ overnight. The mixture was concentrated *in vacuo* and the residue was azeotropically distilled with MePh. The residue was purified by column chromatography (0-20% MeOH:DCM) followed by prep-HPLC purification (method B, gradient 30-60% MeCN) to give the title product (13.4 mg, 8%) as a yellow solid (as a formate salt). LCMS (Method D): 1.50 min, *m/z* 496.0 [M+H]⁺. ¹H NMR (300 MHz, DMSO-*d*₆): 12.35 (s, 2H), 9.90 (s, 1H), 8.24 (d, *J* = 6.0 Hz, 1H), 8.13 (s, 1H), 7.66-7.56 (m, 2H), 7.51 (d, *J* = 1.8 Hz, 1H), 7.44 (d, *J* = 8.1 Hz, 1H), 7.31 (dd, *J* = 8.1, 1.8 Hz, 1H), 7.29-7.18 (m, 3H), 5.23 (s, 2H), 4.88 (s, 2H), 4.35 (q, *J* = 9.9 Hz, 2H).


Compound 68: *N*-(4-(3-amino-1*H*-pyrazolo[4,3-*c*]pyridin-4-yl)-2-((4-fluorophenyl)methoxy) phenyl)-1,1-difluoromethanesulfonamide



Step 1: *N*-(4-(3-amino-1*H*-pyrazolo[4,3-*c*]pyridin-4-yl)-2-((4-fluorophenyl)methoxy) phenyl)-1,1-difluoromethanesulfonamide

To a solution of 4-(4-amino-3-((4-fluorophenyl)methoxy)phenyl)-1*H*-pyrazolo [4,3-*c*]pyridin-3-amine (160.3 mg, 0.46 mmol) in CHCl₃ (4.57 mL) were added pyridine (109 μL, 1.37 mmol) and difluoromethanesulfonyl chloride (60.7 μL, 0.69 mmol), and the reaction was stirred at RT under N₂ overnight. The mixture was concentrated *in vacuo* and the residue was purified by column chromatography (0-10% MeOH:DCM) followed by prep-HPLC purification (method B, gradient 30-60% MeCN) to give the title product (5.34 g, 3%) as a yellow solid. LCMS (Method D): 1.98 min, *m/z* 464.0 [M+H]⁺. ¹H NMR (300 MHz, DMSO-*d*₆): 8.62 (d, *J* = 5.8 Hz, 1H), 7.64 (d, *J* = 5.8 Hz, 1H), 7.58 (dd, *J* = 8.7, 5.6 Hz, 2H), 7.28 (d, *J* = 1.9 Hz, 1H), 7.26-7.16 (m, 2H), 7.07 (dd, *J* = 8.0, 1.8 Hz, 1H), 6.82 (d, *J* = 8.1 Hz, 1H), 5.89 (s, 2H), 5.30 (s, 2H), 5.14 (s, 2H).

Compound 69: *N*-(4-(3-Amino-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-yl)-2-((4-fluorophenyl)methoxy) phenyl)-1,1-difluoromethanesulfonamide



Step 1: *N*-(4-(6-Amino-5-cyanopyrimidin-4-yl)-2-((4-fluorophenyl) methoxy)phenyl)-1,1-difluoromethanesulfonamide

To a mixture of 4-amino-6-chloropyrimidine-5-carbonitrile (76.0 mg, 0.49 mmol), 1,1-difluoro-*N*-(2-((4-fluorophenyl)methoxy)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl) methanesulfonamide (225 mg, 0.49 mmol) and Na₂CO₃ (104 mg, 0.98 mmol) in dioxane:H₂O (9:1, 5.0 mL) was added and Pd(dppf)Cl₂·CH₂Cl₂ (40.1 mg, 0.05 mmol), and the reaction was heated at 100 °C under N₂ for 24 h. Once cooled, the mixture was diluted with water (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organics were washed with brine, dried over MgSO₄ and concentrated *in vacuo*. The residue was purified by column chromatography (0-100% EtOAc:*n*-Hep) to give the title product (93.1 mg, 42%) as a yellow solid. LCMS (Method D): 1.92 min, *m/z* 450.0 [M+H]⁺. ¹H NMR (300 MHz, DMSO-*d*₆): 10.61 (s, 1H), 8.60 (d, *J* = 2.8 Hz, 1H), 7.94 (bs, 2H), 7.63-7.58 (m, 3H), 7.49 (dd, *J* = 8.2, 1.9 Hz, 1H), 7.42 (d, *J* = 8.2 Hz, 1H), 7.27-7.21 (m, 2H), 6.96 (t, *J* = 52.4 Hz, 1H), 5.21 (s, 2H).

Step 2: *N*-(4-(6-Chloro-5-cyanopyrimidin-4-yl)-2-((4-fluorophenyl)methoxy)phenyl)-1,1-difluoromethanesulfonamide


To a solution of *N*-(4-(6-amino-5-cyanopyrimidin-4-yl)-2-((4-fluorophenyl)methoxy) phenyl)-1,1-difluoromethanesulfonamide (93.1 mg, 0.21 mmol) in MeCN (2.0 mL) were added CuCl₂ (55.6 mg, 0.41 mmol) and Isoamyl nitrite (55.6 μL, 0.41 mmol), and the reaction was heated at 65 °C for 5 h. Once cooled, the mixture was acidified to pH 3 with 1 M HCl and extracted with DCM (10 mL). The organic phase was dried over MgSO₄ and concentrated *in vacuo*. The residue was purified by column chromatography (0-50% EtOAc:*n*-Hep) to give the title product (26.0 mg, 27%) as a yellow solid. LCMS (Method D): 2.45 min, *m/z* 469.0 [M+H]⁺. ¹H NMR (300 MHz, CDCl₃): 9.12 (s, 1H), 7.87-7.75 (m, 3H), 7.44-7.40 (m, 2H), 7.30 (s, 1H), 7.13 (dd, *J* = 8.7 Hz, 2H), 6.31 (t, *J* = 53.5 Hz, 1H), 5.21 (s, 2H).

Step 3: *N*-(4-(3-Amino-1*H*-pyrazolo[3,4-*d*]pyrimidin-4-yl)-2-((4-fluorophenyl)methoxy) phenyl)-1,1-difluoromethanesulfonamide

To a solution of *N*-(4-(6-chloro-5-cyanopyrimidin-4-yl)-2-((4-fluorophenyl)methoxy) phenyl)-1,1-difluoromethanesulfonamide (26 mg, 0.06 mmol) in *i*-PrOH (554 μ L) was added $\text{NH}_2\text{NH}_2\cdot\text{H}_2\text{O}$ (5.37 μ L, 0.11 mmol) and the reaction was heated at 80 $^\circ\text{C}$ in a sealed tube for 1 h. Once cooled, the precipitate was collected *via* filtration to give the title product (4.20 mg, 16%) as a yellow solid.

5 LCMS (Method D): 1.68 min, m/z 465.0 [M+H]⁺. ¹H NMR (300 MHz, DMSO-*d*₆): 9.29 (s, 1H), 8.59 (s, 1H), 7.58 (ddd, *J* = 8.6, 5.5, 2.6 Hz, 2H), 7.52 (d, *J* = 2.0 Hz, 1H), 7.44 (dd, *J* = 8.3, 2.0 Hz, 1H), 7.38 (d, *J* = 8.3 Hz, 1H), 7.26-7.16 (m, 2H), 6.61 (t, *J* = 53.8 Hz, 1H), 5.12 (s, 2H).

Compound 70: N-(4-(3-Amino-6-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-2-((4-fluorophenyl)10 methoxy)phenyl)-1,1-difluoromethanesulfonamide



Step 1: 3-((4-Fluorophenyl)methoxy)-4-nitrobenzaldehyde

To a solution of 3-hydroxy-4-nitrobenzaldehyde (2.0 g, 11.9 mmol) in MeCN (24 mL) were added K₂CO₃ (1.96 g, 14.2 mmol) and 4-fluorobenzyl bromide (1.54 mL, 12.4 mmol), and the reaction was heated at reflux for 2 h. Once cooled, water (100 mL) was added and the mixture was extracted with Et₂O (4 x 50 mL). The combined organics were washed with brine, dried over MgSO₄ and concentrated *in vacuo* to give the title product (7.33 g, 99%) as a pale yellow solid. LCMS (Method D): 2.24 min, m/z 276.0 [M+H]⁺. ¹H NMR (300 MHz, CDCl₃): 10.03 (s, 1H), 7.94 (d, *J* = 8.1 Hz, 1H), 7.63 (d, *J* = 1.5 Hz, 1H), 7.56 (dd, 8.1, 1.5 Hz, 1H), 7.46-7.41 (m, 2H), 7.12-7.06 (m, 2H), 5.26 (s, 2H).

Step 2: 4-(3-((4-Fluorophenyl)methoxy)-4-nitrophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile

To a suspension of AcONH₄ (2.23 g, 29.0 mmol) in *n*-BuOH (15 mL) were added acetone (267 μL, 3.63 mmol), methyl 2-cyanoacetate (319 μL, 3.63 mmol) and 3-((4-fluorophenyl)methoxy)-4-nitrobenzaldehyde (1.0 g, 3.63 mmol), and the reaction was heated at reflux for 3 h. Once cooled, the precipitate was collected *via* filtration, washed with EtOH and *n*-Hep, and air-dried to give the title product (351 mg, 26%) as a pale orange solid. LCMS (Method D): 1.99 min, *m/z* 378.8 [M-H]⁻. ¹H NMR (300 MHz, DMSO-*d*₆): 8.04 (d, *J* = 8.4 Hz, 1H), 7.65 (d, *J* = 1.6 Hz, 1H), 7.53-7.49 (m, 2H), 7.34 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.28-7.22 (m, 2H), 6.36 (s, 1H) 5.33 (s, 2H), 2.33 (s, 3H).

Step 3: 2-Chloro-4-(3-((4-fluorophenyl)methoxy)-4-nitrophenyl)-6-methylpyridine-3-carbonitrile

A mixture of 4-(3-((4-fluorophenyl)methoxy)-4-nitrophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile (0.43 g, 1.13 mmol, from multiple iterations) and PCl_5 (470 mg, 2.26 mmol) in POCl_3 (5 mL) was heated at reflux for 5 h. Once cooled, the mixture was poured into ice-water and neutralised with sat. NaHCO_3 . The precipitate was collected *via* filtration, washed with water and dried under vacuum for 15 h to give the title product (425 mg, 95%) as a light orange solid. LCMS (Method D): 2.64 min, m/z 398.0 $[\text{M}+\text{H}]^+$. ^1H NMR (300 MHz, $\text{DMSO}-d_6$): 8.09 (d, $J = 8.3$ Hz, 1H), 7.81 (d, $J = 1.6$ Hz, 1H), 7.70 (s, 1H), 7.54-7.49 (m, 2H), 7.45 (dd, $J = 8.3, 1.6$ Hz, 1H), 7.28-7.23 (m, 2H), 5.34 (s, 2H), 2.63 (s, 3H).

Step 4: 4-(4-Amino-3-((4-fluorophenyl)methoxy)phenyl)-2-chloro-6-methylpyridine-3-carbonitrile

To a solution of 2-chloro-4-(3-((4-fluorophenyl)methoxy)-4-nitrophenyl)-6-methylpyridine-3-carbonitrile (425 mg, 1.06 mmol) in EtOH (10.6 mL) was added $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ (1.19 g, 5.30 mmol) in portions, and the reaction was heated at 70 °C under N_2 for 2 h. Once cooled, the mixture was poured into NH_4OH (25%, 25 mL) and extracted with EtOAc (3 x 25 mL). The combined organics were washed with brine (2 x 25 mL), dried over MgSO_4 and concentrated *in vacuo*. The residue was purified by column chromatography (0-10% MeOH:DCM) to give the title product (94.7 mg, 24%) as a brown solid. LCMS (Method D): 2.45 min, m/z 368.0 $[\text{M}+\text{H}]^+$. ^1H NMR (300 MHz, $\text{DMSO}-d_6$): 7.59-7.54 (m, 3H), 7.30 (d, $J = 2.0$ Hz, 1H), 7.24-7.14 (m, 3H), 6.78 (d, $J = 8.2$ Hz, 1H), 5.48 (s, 2H), 5.15 (s, 2H), 2.54 (s, 3H).

Step 5: *N*-(4-(2-Chloro-3-cyano-6-methylpyridin-4-yl)-2-((4-fluorophenyl)methoxy) phenyl)-1,1-difluoromethanesulfonamide


To a solution of 4-(4-amino-3-((4-fluorophenyl)methoxy)phenyl)-2-chloro-6-methyl pyridine-3-carbonitrile (90 mg, 0.24 mmol) in CHCl_3 (2.5 mL) were added pyridine (98.2 μL , 1.22 mmol) and difluoromethanesulfonyl chloride (43.3 μL , 0.49 mmol), and the reaction was stirred at RT under N_2 overnight. The mixture was concentrated *in vacuo* and the residue was azeotropically distilled with MePh. The residue was purified by column chromatography (0-50% EtOAc:*n*-Hep) to give the title product (65.9 mg, 56%) as a yellow solid. LCMS (Method D): 2.80 min, m/z 480.8 $[\text{M}-\text{H}]^-$. ^1H NMR (300 MHz, $\text{DMSO}-d_6$): 7.72-7.64 (m, 3H), 7.57-7.52 (m, 3H), 7.49 (t, $J = 51.5$ Hz, 1H), 7.44 (dd, $J = 8.2, 1.9$ Hz, 1H), 7.26 (dd, $J = 8.9$ Hz, 2H), 5.29 (s, 2H), 2.62 (s, 3H).

Step 6: *N*-(4-(3-Amino-6-methyl-1*H*-pyrazolo[3,4-*b*]pyridin-4-yl)-2-((4-fluorophenyl)methoxy) phenyl)-1,1-difluoromethanesulfonamide

To a solution of *N*-(4-(2-chloro-3-cyano-6-methylpyridin-4-yl)-2-((4-fluorophenyl)methoxy) phenyl)-1,1-difluoromethanesulfonamide (65 mg, 0.13 mmol) in *i*-PrOH (2 mL) was added $\text{NH}_2\text{NH}_2 \cdot \text{H}_2\text{O}$ (12.9 μL , 0.27 mmol) and the reaction was heated at 80 °C with μW irradiation for 1 h. Once cooled, the mixture was partitioned between EtOAc (10 mL) and water (10 mL). The

phases were separated, and the aqueous fraction was extracted with EtOAc (2 x 10 mL). The combined organics were washed with brine (10 mL), dried over MgSO₄ and concentrated *in vacuo*. The residue was purified by column chromatography (0-10% MeOH:DCM) to give the title product (16.3 mg, 25%) as a yellow solid. LCMS (Method D): 1.83 min, m/z 478.0 [M+H]⁺. ¹H NMR (300 MHz, DMSO-*d*₆): 12.14 (s, 1H), 10.48 (s, 1H), 7.61 (dd, *J* = 8.5, 5.7 Hz, 2H), 7.42 (d, *J* = 8.0 Hz, 1H), 7.38 (d, *J* = 1.8 Hz, 1H), 7.25 (t, *J* = 8.9 Hz, 2H), 7.18 (dd, *J* = 8.1, 1.8 Hz, 1H), 6.94 (t, *J* = 52.7 Hz, 1H), 6.85 (s, 1H), 5.25 (s, 2H), 4.55 (s, 2H), 2.54 (s, 3H).

Compound 71: N-(4-(3-Amino-6-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-2-((4-fluorophenyl)methoxy)phenyl)-1,1-difluoromethanesulfonamide



Step 1: 4-(3-((4-Fluorophenyl)methoxy)-4-nitrophenyl)-2-oxo-6-phenyl-1,2-dihydropyridine-3-carbonitrile

To a suspension of AcONH₄ (2.23 g, 29.0 mmol) in *n*-BuOH (15 mL) were successively added acetophenone (423 μ L, 3.63 mmol), methyl 2-cyanoacetate (319 μ L, 3.63 mmol) and 3-((4-fluorophenyl)methoxy)-4-nitrobenzaldehyde (1.0 g, 3.63 mmol), and the reaction was heated at reflux for 3 h. Once cooled, the precipitate was collected *via* filtration, washed with EtOH and *n*-Hep, and air-dried to give the title product (687 mg, 43%) as a pale orange solid. LCMS (Method D): 2.38 min, m/z 442.0 [M+H]⁺. ¹H NMR (300 MHz, DMSO-*d*₆): 8.07 (d, *J* = 8.3 Hz, 1H), 7.90 (d, *J* = 7.9 Hz, 2H), 7.78 (d, *J* = 1.7 Hz, 1H), 7.59-7.46 (m, 6 H), 7.29-7.21 (m, 2 H), 6.90 (d, *J* = 1.7 Hz, 1H) 5.37 (s, 2H).

Step 2: 2-Chloro-4-(3-((4-fluorophenyl)methoxy)-4-nitrophenyl)-6-phenylpyridine-3-carbonitrile

A mixture of 4-(3-((4-fluorophenyl)methoxy)-4-nitrophenyl)-2-oxo-6-phenyl-1,2-dihydropyridine-3-carbonitrile (680 mg, 1.54 mmol) and PCl₅ (641 mg, 3.08 mmol) in POCl₃ (7 mL) was heated at reflux for 5 h. Once cooled, the mixture was poured into ice-water and neutralised with sat. NaHCO₃. The precipitate was collected *via* filtration, washed with water and dried under vacuum for 15 h to give the title product (703 mg, 99%) as a pale yellow solid. LCMS (Method D): 2.37 min, molecular ion not observed. ¹H NMR (300 MHz, DMSO-*d*₆): 8.08 (d, *J* = 8.3 Hz, 1H), 7.91 (d,

$J = 7.0$ Hz, 2H), 7.79 (d, $J = 1.6$ Hz, 1H), 7.60-7.47 (m, 6H), 7.28-7.22 (m, 2H), 6.92 (s, 1H) 5.37 (s, 2H).

Step 3: 4-(4-Amino-3-((4-fluorophenyl)methoxy)phenyl)-2-chloro-6-phenylpyridine-3-carbonitrile

To a solution of 2-chloro-4-(3-((4-fluorophenyl)methoxy)-4-nitrophenyl)-6-phenylpyridine-3-carbonitrile (700 mg, 1.52 mmol) in EtOH (15 mL) was added $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ (1.73 g, 7.70 mmol) in portions, and the reaction was heated at 70 °C under N_2 for 2 h. Once cooled, the mixture was poured into NH_4OH (25%, 25 mL) and extracted with EtOAc (3 x 50 mL). The combined organics were washed with brine (2 x 50 mL), dried over MgSO_4 and concentrated *in vacuo*. The residue was purified by column chromatography (0-10% MeOH:DCM) to give the title product (48.5 mg, 7%) as a yellow glass. LCMS (Method D): 3.04 min, m/z 430.0 $[\text{M}+\text{H}]^+$. ^1H NMR (300 MHz, $\text{DMSO}-d_6$): 8.21-8.18 (m, 2H), 8.08 (s, 1H), 7.61-7.54 (m, 5H), 7.41 (d, $J = 2.0$ Hz, 1H), 7.29 (dd, $J = 8.2$, 2.0 Hz, 1H), 7.25-7.19 (m, 2H), 6.82 (d, $J = 8.2$ Hz, 1H) 5.52 (s, 2H), 5.19 (s, 2H).


Step 4: *N*-(4-(2-Chloro-3-cyano-6-phenylpyridin-4-yl)-2-((4-fluorophenyl)methoxy) phenyl)-1,1-difluoromethanesulfonamide

To a solution of 4-(4-amino-3-((4-fluorophenyl)methoxy)phenyl)-2-chloro-6-phenylpyridine-3-carbonitrile (45 mg, 0.10 mmol) in CHCl_3 (1.0 mL) were added pyridine (42.0 μL , 0.52 mmol) and difluoromethanesulfonyl chloride (18.4 μL , 0.21 mmol), and the reaction was stirred at RT under N_2 overnight. The mixture was concentrated *in vacuo* and the residue was azeotropically distilled with MePh. The residue was purified by column chromatography (0-20% EtOAc:*n*-Hep) to give the title product (48.5 mg, 85%) as a yellow solid. LCMS (Method D): 3.21 min, m/z 544.8 $[\text{M}+\text{H}]^+$. ^1H NMR (300 MHz, $\text{DMSO}-d_6$): 8.34 (s, 1H), 8.28-8.25 (m, 2H), 7.79 (d, $J = 1.8$ Hz, 1H), 7.69 (dd, $J = 8.1$, 5.3 Hz, 1H), 7.60-7.53 (m, 7H), 7.51 (t, $J = 51.5$ Hz, 1H), 7.29-7.23 (m, 2H), 5.33 (s, 2H).

Step 5: *N*-(4-(3-Amino-6-phenyl-1*H*-pyrazolo[3,4-*b*]pyridin-4-yl)-2-((4-fluorophenyl)methoxy) phenyl)-1,1-difluoromethanesulfonamide

To a solution of *N*-(4-(2-chloro-3-cyano-6-phenylpyridin-4-yl)-2-((4-fluorophenyl)methoxy) phenyl)-1,1-difluoromethanesulfonamide (48 mg, 0.09 mmol) in *i*-PrOH (1.0 mL) was added $\text{NH}_2\text{NH}_2 \cdot \text{H}_2\text{O}$ (8.55 μL , 0.18 mmol) and the reaction was heated at 80 °C with μW irradiation for 1 h. Once cooled, the mixture was partitioned between EtOAc (10 mL) and water (10 mL). The phases were separated, and the aqueous fraction was extracted with EtOAc (2 x 10 mL). The combined organics were washed with brine (10 mL), dried over MgSO_4 and concentrated *in vacuo*. The residue was purified by column chromatography (0-10% MeOH:DCM) to give the title product (6.50 mg, 14%) as a yellow solid. LCMS (Method D): 2.35 min, m/z 540.0 $[\text{M}+\text{H}]^+$. ^1H NMR (300 MHz, $\text{DMSO}-d_6$): 12.40 (s, 1H), 10.53 (s, 1H), 8.16 (dd, $J = 8.3$, 1.7 Hz, 2H), 7.64-7.55 (m, 2H), 7.52-7.46 (m, 6H), 7.31-7.22 (m, 3H), 6.95 (t, $J = 52.7$ Hz, 1H), 5.29 (s, 2H), 4.65 (s, 2H).

Compound 173: 4-(4-{4-amino-3-[4-(difluoromethanesulfonamido)-3-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl]-1-methyl-1H-pyrazolo[4,3-c]pyridin-7-yl]-1H-pyrazol-1-yl)cyclohexane-1-carboxylic acid



5 Step 1: tert-butyl 4-hydroxycyclohexane-1-carboxylate

To a 0 °C solution of tert-butyl 4-oxocyclohexane-1-carboxylate (3 g, 15.1 mmol) in MeOH (20 mL) was added NaBH₄ (2.85 g, 75.5 mmol) in portions, and the mixture was stirred at 0 °C for 1h. The mixture was concentrated under reduced pressure, then diluted with H₂O (60 mL) and extracted with Et₂O (3 x 80 mL). The combined organics were concentrated under reduced pressure to afford the title product (3.08 g, >100%) as yellow oil.

Step 2: tert-butyl 4-(methanesulfonyloxy)cyclohexane-1-carboxylate

To a 0 °C mixture of tert-butyl 4-hydroxycyclohexane-1-carboxylate (4.36 g, 21.7 mmol) and Et₃N (10.9 g, 108 mmol) in MeCN (40 mL) was slowly added a solution of MsCl (4.97 g, 43.4 mmol) in MeCN (15 mL), and the reaction was stirred at 0 °C for 1h. The mixture was concentrated under reduced pressure, then diluted with H₂O (120 mL) and extracted with EtOAc (3 x 150 mL). The combined organics were concentrated under reduced pressure to afford the title product (6.62 g, >100%) as yellow oil.

Step 3: tert-butyl 4-(4-bromo-1H-pyrazol-1-yl)cyclohexane-1-carboxylate

A mixture of tert-butyl 4-(methanesulfonyloxy)cyclohexane-1-carboxylate (6.11 g, 21.9 mmol), Cs₂CO₃ (21.3 g, 65.6 mmol) and 4-bromo-1H-pyrazole (3.21 g, 21.9 mmol) in MeCN (60 mL) was stirred at 80 °C overnight. The mixture was concentrated under reduced pressure, then diluted with H₂O (100 mL) and extracted with EtOAc (3 x 120 mL). The combined organics were concentrated under reduced pressure and purified by column chromatography (PE:EA = 30/1 to 20/1) to afford the title product (4.07 g, 56%) as a white solid. LCMS (Method B): 2.68 min, m/z 329.1, 331.1 [M+H]⁺.

Step 4: tert-butyl 4-(4-{4-amino-3-[4-(difluoromethanesulfonamido)-3-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl]-1-methyl-1H-pyrazolo[4,3-c]pyridin-7-yl]-1H-pyrazol-1-yl)cyclohexane-1-carboxylate

A mixture of N-(4-{4-amino-7-iodo-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl}-2-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl)-1,1-difluoromethanesulfonamide (850 mg, 1.37 mmol), tert-butyl 4-(4-bromo-1H-pyrazol-1-yl)cyclohexane-1-carboxylate (583 mg, 1.78 mmol), B₂pin₂ (1.08 g, 4.26 mmol), Pd(OAc)₂ (260 mg, 1.16 mmol), butyl-di-1-adamantylphosphine (695 mg, 1.94 mmol) and K₂CO₃ (803 mg, 5.81 mmol) in 1,4-Dioxane/H₂O (4/1, 30 mL) was stirred at 80 °C under N₂ for 2.5 h. The mixture was concentrated under reduced pressure, then diluted with H₂O (80 mL) and extracted with EtOAc (3 x 100 mL). The combined organics were concentrated under reduced pressure, and the residue was purified by column chromatography (DCM/MeOH = 70/1 to 60:1) to afford the title product (488 mg, 24%) as a black solid. LCMS (Method B): 2.37 min, m/z 740.3 [M+H]⁺.

Step 5: 4-(4-{4-amino-3-[4-(difluoromethanesulfonamido)-3-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl]-1-methyl-1H-pyrazolo[4,3-c]pyridin-7-yl]-1H-pyrazol-1-yl)cyclohexane-1-carboxylic acid

A solution of tert-butyl 4-(4-{4-amino-3-[4-(difluoromethanesulfonamido)-3-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl]-1-methyl-1H-pyrazolo[4,3-c]pyridin-7-yl]-1H-pyrazol-1-yl)cyclohexane-1-carboxylate (488 mg, 0.66 mmol) in HCOOH (15 mL) was stirred at RT under N₂ for 4 h. The mixture was concentrated under reduced pressure and the residue was purified by Prep-TLC (DCM/MeOH = 10/1) to give the title product (80 mg, 18%) as a black solid. LCMS (Method B): 1.93 min; 682.2 [M-H]⁻. ¹H NMR (400 MHz, DMSO-*d*₆): 7.98 (s, 1H), 7.62-7.53 (m, 4H), 7.40 (d, *J* = 8.0 Hz, 1H), 7.20-7.08 (m, 4H), 5.97 (s, 2H), 5.65 (q, *J* = 6.3 Hz, 1H), 4.27 (dd, *J* = 8.9, 4.4 Hz, 1H), 3.69 (s, 3H), 2.62-2.55 (m, 1H), 2.48 (s, 1H), 2.12 (s, 1H), 2.00 (dt, *J* = 25.2, 8.5 Hz, 5H), 1.58 (d, *J* = 6.2 Hz, 3H), 1.23 (s, 1H).

BIOLOGY

IN VITRO ASSAY

Binding affinity of the test compounds for human MLKL (full length), mouse MLKL (full length), human RIPK1 and human RIPK3 was determined using the KINOMEScan™ technology developed by DiscoverX (USA; <http://www.discoverx.com>). The assay was conducted according to manufacturer instructions.

Protocol Description

Kinase assays. For most assays, kinase-tagged T7 phage strains were grown in parallel in 24-well blocks in an *E. coli* host derived from the BL21 strain. *E. coli* were grown to log-phase and infected with T7 phage from a frozen stock (multiplicity of infection = 0.4) and incubated with

shaking at 32 °C until lysis (90-150 minutes). The lysates were centrifuged (6,000 x g) and filtered (0.2 µm) to remove cell debris. The remaining kinases were produced in HEK-293 cells and subsequently tagged with DNA for qPCR detection. Streptavidin-coated magnetic beads were treated with biotinylated small molecule ligands for 30 minutes at room temperature to generate affinity resins for kinase assays. The liganded beads were blocked with excess biotin and washed with blocking buffer (SeaBlock (Pierce), 1% BSA, 0.05% Tween 20, 1 mM DTT) to remove unbound ligand and to reduce non-specific phage binding. Binding reactions to screen test compounds for kinase binding activity were assembled by combining kinases, liganded affinity beads, and test compounds in 1x binding buffer (20% SeaBlock, 0.17x PBS, 0.05% Tween 20, 6 mM DTT). All reactions were performed in polypropylene 384-well plates in a final volume of 20 µL. The assay plates were incubated at room temperature with shaking for 1 hour and the affinity beads were washed with wash buffer (1x PBS, 0.05% Tween 20). The beads were then re-suspended in elution buffer (1x PBS, 0.05% Tween 20, 0.5 µM non-biotinylated affinity ligand) and incubated at room temperature with shaking for 30 minutes. The kinase concentration in the eluates was measured by qPCR.

Compound Handling

An 11-point 3-fold serial dilution of each test compound was prepared in 100% DMSO at 100x final test concentration and subsequently diluted to 1x in the assay (final DMSO concentration = 1%). Most K_D s were determined using a compound top concentration = 30,000 nM. If the initial K_D determined was < 0.5 nM (the lowest concentration tested in the initial serial dilution), the measurement was repeated with a further 11 point 3-fold serial dilution starting at 3,000 nM.

Binding Constants (K_D s)

K_D for each test compound was calculated with a standard dose-response curve using the Hill equation (equation (1)):

$$Response = Background + \frac{Signal - Background}{1 + (K_D^{Hill\ Slope} / Dose^{Hill\ Slope})} \quad (1)$$

The Hill Slope was set to -1.

Curves were fitted using a non-linear least square fit with the Levenberg-Marquardt algorithm.

Refs:

- Fabian, M.A. et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23, 329-336 (2005).
- Karaman, M.W. et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127-132 (2008).

• Hill, A.V. The possible effects of the aggregation of the molecules of hemoglobin on its dissociation curves. J. Physiol. (Lond.). 40, iv-vii (1910).

• Levenberg, K. A method for the solution of certain non-linear problems in least squares. Q. Appl. Math. 2, 164-168 (1944).

- 5 The results of the *in vitro* screening of the compounds described above are shown below in Tables 20 and 21.

Table 20: Results of binding assay for compounds of the invention against human MLKL, human RIPK1 and human RIPK3. Binding affinity is measured by the equilibrium dissociation constant (K_D). The smaller the K_D value, the greater the binding affinity of the ligand for its target. Activity is provided as follows:

++++ = $K_D < 1$ nM

+++ = $1 \text{ nM} < K_D < 100 \text{ nM}$

++ = $100 \text{ nM} < K_D < 10,000 \text{ nM}$

+ = $K_D > 10,000 \text{ nM}$

15

Compound ID	Human MLKL(full-length) (K_D)	Human RIPK1 (K_D)	Human RIPK3 (K_D)
1	+++	+	+
2	+++	+	+
3	++++	+	+
4	+++	+	+
5	++++	+	+
6	++++	+	+
7	+++	+	+
8	++++	+	+
9	++++	+	+
10	+++	+	+
11	+++	+	+
12	++++	+	+
13	++++	+	+

14	++++	+	+
15	++++	+	+
16	++++	+	+
17	++++	+	+
18	++++	+	+
19	++++	+	+
20	++++	+	+
21	++++	+	+
22	++++	+	+
23	+++	+	+
24	++++	+	+
25	++++	+	+
26	++++	+	+
27	+++	+	+
28	++++	+	+
29	++++	+	+
30	+++	+	+
31	++++	+	+
32	+++	+	+
33	+++	+	+
34	+++	+	+
35	++++	+	+
36	++++	+	+
37	++++	+	+
38	++++	+	+
39	++++	+	+
40	++++	+	+
41	++++	+	+

42	++	+	+
43	+++	+	+
44	+++	+	+
45	+++	+	+
46	+++	+	+
47	+++	+	+
48	+++	+	+
49	+++	+	+
50	++++	+	+
51	+++	+	+
52	+++	+	+
53	++++	+	+
54	+++	+	+
55	++++	+	+
56	++++	+	+
57	+++	+	+
58	++++	+	+
59	++++	+	+
60	+++	+	+
61	+++	+	+
62	++	++	+
63	++	+	+
64	++	+	+
65	+++	+	+
66	++++	+	+
67	++++	+	+
68	++	+	+
69	++++	+	+

70	++++	+	+
71	+++	++	+
72	++++	+	+
73	++++	+	+
74	++++	+	+
75	++++	+	+
76	++++	+	+
77	++++	+	+
78	++++	+	+
79	++++	+	+
80	++++	+	+
81	++++	+	+
82	++++	+	+
83	+++	+	+
84	+++	+	+
85	+++	+	+
86	+++	+	+
87	+++	+	+
88	++++	+	+
89	++++	+	+
90	+++	+	+
91	++	+	+
92	++++	+	+
93	++++	+	+
94	++++	+	+
95	+++	+	+
96	++++	+	+
97	++++	+	+
98	++++	+	+
99	++++	+	+
100	++++	+	+
101	++++	+	+
102	++++	+	+

103	++++	+	+
104	++++	+	+
105	++++	+	+
106	+++	+	+
107	++++	+	+
108	++++	+	+
109	++++	+	+
110	++++	+	+
111	+++	+	+
112	+++	+	+
113	++++	+	+
114	+++	+	+
115	+++	+	+
116	+++	+	+
117	+++	+	+
118	+++	+	+
119	+++	+	+
120	+++	+	+
121	++++	+	+
122	++++	+	+
123	++++	+	+
124	++	+	+
125	+++	+	+
126	+++	+	+
127	+++	+	+
128	+++	+	+
129	++++	+	+
130	++++	+	+
131	+++	+	+
132	++++	+	+
133	++++	+	+
134	+++	+	+
135	++++	+	+
136	nd	nd	nd

137	nd	nd	nd
138	+++	+	+
139	+++	+	+
140	+++	+	+
141	+++	+	+
142	++++	+	+
143	++++	+	+
144	++++	+	+
145	+++	+	+
146	+++	+	+
147	+++	+	+
148	+++	+	+
149	nd	nd	nd
150	++++	+	+
151	++++	+	+
152	nd	nd	nd
153	+++	+	+
154	++++	+	+
155	+++	+	+
156	+++	+	+
157	+++	+	+
158	+++	+	+
159	++++	+	+
160	++++	+	+
161	++++	+	+
162	++++	+	+
163	++++	+	+
164	++++	+	+
165	+++	+	+
166	+++	+	+
167	+++	+	+
168	++++	+	+
169	nd	nd	nd
170	+++	+	+

171	+++	+	+
172	+++	+	+

Table 21: Results of binding assay for compounds of the invention against mouse MLKL. Binding affinity is measured by the equilibrium dissociation constant (K_D). The smaller the K_D value, the greater the binding affinity of the ligand for its target. Activity is provided as follows:

5 ++++ = $K_D < 1$ nM

+++ = 1 nM $< K_D < 100$ nM

++ = 100 nM $< K_D < 10,000$ nM

+ = $K_D > 10,000$ nM

Compound ID	Mouse MLKL(full-length) (K_D)
Compound 5	++++
Compound 7	++++
Compound 8	++++
Compound 9	+++
Compound 11	+++
Compound 12	++++
Compound 13	++++
Compound 15	++++
Compound 18	+++
Compound 19	++++
Compound 20	++++
Compound 60	++++
Compound 61	+++
Compound 66	+++
Compound 69	+++
Compound 70	+++
Compound 72	+++

CELLULAR ASSAY: Screening compounds for inhibition of TSQ induced necroptosis, 384 well plate format.

Cell Line ID: U937 human histiocytic leukemia cell line.

- 5 **Cell Concentration (cells/well):** Final cell density is 20000 cells per well.

Cell growth medium: HT-RPMI medium + 7.4% Fetal Bovine Serum (FBS). Cells are cultured in Corning 150cm² tissue culture flasks with vented caps at 37 °C/5% CO₂.

Incubation: Plates were incubated at 37 °C/5% CO₂ in a humidified incubator for 48 hours following addition of compounds and death stimuli (TSQ cocktail).

- 10 **Compound concentration:** 36 µM starting concentration, 1:3 dilution, 10 point

DMSO final concentration (% v/v): 0.3%.

Compounds in TSQ cocktail (T: TNF; S: Smac mimetic; Q: Q-VD-OPh) and their final concentrations:

- 15 hTNF-Fc (100 ng/ml) – produced by standard procedures as shown in Bossen et al., J. Biol. Chem., 2006, 281(20), 13964-13971.

Compound A (500 nM) - Smac mimetic, Tetralogic and SYNthesis med chem

Q-VD-OPh (10 µM) – MP Biomedicals

Assay experimental outline

The cellular assay was carried out according to the following steps:

- 20 1. Each well was prepared by sequential addition of:
- a. DMSO (control; columns 1-2 and 23-24) or compound in DMSO – addition was performed using acoustic transfer of nL volumes of stock compound to give final test concentrations of 36,12, 4, 1.3, 0.44, 0.148, 0.049, 0.016, 0.005 and 0.002 µM. All wells were backfilled with DMSO to a final total volume in the well of 100 nL.
- 25 b. Following compound/DMSO addition in step (a), 40 µL of cell suspension (5 x 10⁵ cells/mL) was added to provide a final cell concentration of 20,000 cells per well, and
- c. Following cell addition in step (b), 10 µL of 5x TSQ cocktail (except to positive controls; columns 1 and 23) was added to each well.
- 30 2. After 48 hours, plate was removed from the 37°C incubator and equilibrated to room temperature for 45 minutes.
3. 15 µL of room temperature CellTitre-Glo2™ (Promega™) was added to each well.
4. Shook plates for 2 minutes (~600 rpm) and incubated at room temperature for 15 minutes to allow signal to stabilise.

5. Read luminescence readout on a plate reader.

Analysis:

Percent viability was calculated for each compound according to equation (2):

$$\% \text{ viability} = 100 \times ((\text{RawData} - \text{NSA})/(\text{TA} - \text{NSA})) \quad (2)$$

- 5 wherein

RawData is the readout of any cell containing a compound of the invention.

TA is the total activity provided by the luminescence readout from DMSO only wells (columns 2 and 24) = 100% viability.

NSA is the non-specific activity provided by DMSO+TSQ wells (columns 1 and 23) = 0% viability

- 10 **Curve fitting:** 10-point titration curves are fitted with the 4-parameter logistic nonlinear regression model and the IC₅₀ reported is the inflection point of the curve

Analysis: Data was loaded into Dotmatics™ and visualised using the Tibco® Spotfire™ software. 10 point titration curves were fitted with the 4 parameter logistic nonlinear regression model and the IC₅₀ reported reflect the inflection point of the curve for curve fitting.

- 15 **Interpretation of results:**

- Assay involving the TSQ cocktail** (T: TNF; S: Smac mimetic; Q: Q-VD-OPh): TSQ treatment ensures that cells specifically undergo necroptotic cell death. TNF activates the TNF receptor, Smac mimetic directs the signal away from proinflammatory signaling and toward the RIPK1/RIPK3-mediated cell death pathways, and Q-VD-OPh ensures that the apoptotic response
- 20 is blocked leaving only the programmed necrosis response. The compounds' activity (solution in DMSO) tested in this TSQ-induced assay was evaluated by determining the number of viable cells in culture by measuring the amount of ATP present as measured by CelltiterGlo.

- Counter screen:** In parallel, all compounds were tested for their ability to affect cell viability. The same U937 cells were treated with compound in DMSO without the TSQ cocktail. This counter
- 25 screen enabled evaluation of off-target effects. In this case, cell viability was measured by CelltiterGlo.

The results of the cellular screening of the compounds described above are shown below in Table 22.

- Table 22:** Table showing the results of cell-based assays performed, analysed as the half
- 30 maximal inhibitory concentration (IC₅₀), being the concentration of the test compound needed to

inhibit TSQ induced necroptosis by 50%. The lower the IC₅₀, the more potent the compound. Activity is provided as follows:

++++ = IC₅₀ < 10 nM

+++ = 10 nM < IC₅₀ < 1,000 nM

5 ++ = 1,000 nM < IC₅₀ < 10,000 nM

+ = IC₅₀ > 10,000 nM

Compound No	Inhibition of TSQ-induced necroptosis (IC ₅₀ cell-based assay)	Off-target effect (IC ₅₀ cell-based assay)
Compound 1	++	+
Compound 7	+++	++
Compound 9	+++	++
Compound 12	++	+
Compound 13	+++	+
Compound 14	++	+
Compound 15	+++	+
Compound 16	++	+
Compound 18	+++	+
Compound 19	++++	+
Compound 20	+++	+
Compound 21	++	+
Compound 23	++	+
Compound 24	+++	+
Compound 25	+++	+
Compound 26	+++	+
Compound 27	+++	+
Compound 28	+++	+
Compound 29	++++	+
Compound 30	++++	+

Compound 31	++++	+
Compound 32	++	+
Compound 35	+++	+
Compound 36	++++	+
Compound 37	+++	+
Compound 38	++++	+
Compound 39	+++	+
Compound 40	++++	+
Compound 41	++++	+
Compound 42	++	+
Compound 43	+++	+
Compound 44	+++	+
Compound 45	+++	+
Compound 46	+++	+
Compound 48	++	++
Compound 50	+++	+
Compound 51	+++	+
Compound 52	+++	+
Compound 55	++	+
Compound 56	+++	+
Compound 57	+++	+
Compound 58	+++	+
Compound 59	+++	+
Compound 60	+++	+
Compound 61	+++	+
Compound 62	++	+
Compound 72	+++	+
Compound 73	+++	+

Compound 74	+++	+
Compound 75	++++	+
Compound 76	++++	+
Compound 77	++++	+
Compound 78	+++	+
Compound 79	+++	+
Compound 80	+++	+
Compound 81	++++	+
Compound 82	+++	+
Compound 83	+++	+
Compound 84	++	+
Compound 85	++	+
Compound 86	+++	+
Compound 87	++	+
Compound 88	+++	+
Compound 89	+++	+
Compound 92	+++	+
Compound 93	+++	+
Compound 94	+++	+
Compound 95	+++	+
Compound 96	+++	+
Compound 97	+++	+
Compound 98	+++	+
Compound 99	+++	+
Compound 100	++++	+
Compound 101	++++	+
Compound 102	+++	+
Compound 103	++++	+
Compound 104	++++	+
Compound 105	+++	+
Compound 106	+++	+
Compound 107	+++	+
Compound 108	+++	+
Compound 109	++++	+
Compound 111	+++	+
Compound 113	++++	+

Compound 115	+++	+
Compound 116	++++	+
Compound 117	+++	+
Compound 119	+++	+
Compound 120	++++	+
Compound 121	+++	+
Compound 122	+++	+
Compound 123	++++	+
Compound 126	+++	+
Compound 128	+++	+
Compound 129	+++	+
Compound 131	+++	+
Compound 132	+++	+
Compound 133	+++	+
Compound 134	+++	+
Compound 135	+++	+
Compound 136	+++	+
Compound 137	++++	+
Compound 138	+++	+
Compound 139	+++	+
Compound 140	+++	+
Compound 141	+++	+
Compound 142	+++	+
Compound 145	++++	+
Compound 146	++++	+
Compound 147	+++	+
Compound 148	++++	+
Compound 149	++++	+
Compound 152	++++	+
Compound 153	+++	+
Compound 154	++++	+
Compound 155	++++	+
Compound 156	+++	+
Compound 157	+++	+
Compound 158	++++	+
Compound 159	++++	+
Compound 160	+++	+
Compound 161	++	+
Compound 162	++++	+
Compound 163	+++	+
Compound 164	++++	+
Compound 165	+++	+
Compound 166	+++	+
Compound 167	+++	++
Compound 168	+++	+

Compound 170	+++	+
Compound 171	+++	+
Compound 172	+++	+
Compound 173	++	+

CELLULAR ASSAY: Screening compounds for inhibition of TSI induced necroptosis in , 384 well plate format.

Cell Line ID: Immortalised Mouse Dermal Fibroblasts (MDFs).

- 5 **Cell Concentration (cells/well):** Final cell density is 2200 cells per well.

Cell growth medium: DMEM medium + 7.4% Fetal Bovine Serum (FBS). Cells are cultured in Corning 150cm² tissue culture flasks with vented caps at 37°C/10% CO₂.

Incubation: Plates were incubated for 30 minutes following addition of compounds and then 3 hours incubation with death stimuli (TSI cocktail) at 37°C/10% CO₂ in a humidified incubator.

- 10 **Compound concentration:** 36 µM starting concentration, 1:3 dilution, 10 point

DMSO final concentration (% v/v): 0.3%.

Compounds in TSI cocktail (T: TNF; S: Smac mimetic; I: IDN-6556) and their final concentrations:

rhTNF (100ng/ml)

- 15 Compound A (500 nM) - Smac mimetic, Tetralogic and SYNthesis med chem

IDN-6556 (10 µM) – Selleckchem (S7775)

Assay experimental outline

The cellular assay was carried out according to the following steps:

1. Each well was prepared by sequential addition of:
 - 20 a. 40µL of cell suspension (5.5×10^4 cells/mL) was added to each well to provide a final cell concentration of 2,200 cells per well.
 - b. After 24 hours, DMSO (control; columns 1-2 and 23-24) or compound in DMSO – addition was performed using acoustic transfer of nL volumes of stock compound to give final test

concentrations of 36,12, 4, 1.3, 0.44, 0.148, 0.049, 0.016, 0.005 and 0.002 μM . All wells were backfilled with DMSO to a final total volume in the well of 100nL.

5 c. Following compound/DMSO addition in step (b), Plates were incubated for 30 minutes at 37°C/10% CO₂ in a humidified incubator and then 10 μL of 5x TSI cocktail (except to positive controls; columns 2 and 24) was added to each well.

2. After 3 hours, plate was removed from the 37°C incubator and equilibrated to room temperature for 15 minutes.

3. 15 μL of room temperatured CellTitre-Glo2™ (Promega™) was added to each well.

10 4. Shook plates for 2 minutes (~600 rpm) and incubated at room temperature for 15 minutes to allow signal to stabilise.

5. Read luminescence readout on a plate reader.

Analysis:

Percent viability was calculated for each compound according to equation (2):

$$\% \text{viability} = 100 \times ((\text{RawData} - \text{NSA}) / (\text{TANSA})) \quad (2)$$

15 Wherein RawData is the readout of any cell containing a compound of the invention.

TA is the total activity provided by the luminescence readout from DMSO only wells (columns 2 and 24) = 100% viability.

NSA is the non-specific activity provided by DMSO+TSI wells (columns 1 and 23) = 0% viability

20 **Curve fitting:** 10-point titration curves are fitted with the 4-parameter logistic nonlinear regression model and the IC₅₀ reported is the inflection point of the curve

Analysis: Data was loaded into Dotmatics™ and visualised using the Tibco® Spotfire™ software. 10 point titration curves were fitted with the 4 parameter logistic nonlinear regression model and the IC₅₀ reported reflect the inflection point of the curve for curve fitting.

Interpretation of results:

25 **Assay involving the TSI cocktail** (T: TNF; S: Smac mimetic; I: IDN-6556): TSI treatment ensures that cells specifically undergo necroptotic cell death. TNF activates the TNF receptor, Smac mimetic directs the signal away from proinflammatory signaling and toward the RIPK1/RIPK3-mediated cell death pathways, and IDN-6556 (Caspase inhibitor) ensures that the

apoptotic response is blocked leaving only the programmed necrosis response. The compounds' activity (solution in DMSO) tested in this TSI-induced assay was evaluated by determining the number of viable cells in culture by measuring the amount of ATP present as measured by CelltiterGlo.

- 5 The results of the cellular screening of the compounds described above are shown below in Table 23.

10 **Table 23:** Table showing the results of cell-based assays performed, analysed as the half maximal inhibitory concentration (IC_{50}), being the concentration of the test compound needed to inhibit TSI induced necroptosis by 50%. The lower the IC_{50} , the more potent the compound. Activity is provided as follows:

++++ = < 100nM

+++ = 100 nM < IC_{50} < 1,000 nM

++ = 1,000 nM < IC_{50} < 10,000 nM

Compound No	Inhibition of TSI-induced necroptosis (IC_{50} cell-based assay) in MDF
Compound 3	++
Compound 11	++
Compound 13	++
Compound 19	+++
Compound 29	++
Compound 30	++
Compound 46	+++
Compound 79	++
Compound 80	+++
Compound 81	++
Compound 97	++
Compound 98	++
Compound 99	++
Compound 103	++
Compound 104	+++


Compound 109	+++
Compound 113	+++
Compound 116	++
Compound 120	++
Compound 121	++
Compound 122	++
Compound 131	++
Compound 132	++
Compound 137	++
Compound 139	++
Compound 142	++
Compound 145	++++
Compound 146	++
Compound 147	+++
Compound 148	+++
Compound 149	+++
Compound 150	++
Compound 152	+++
Compound 153	+++
Compound 154	++++
Compound 155	+++
Compound 157	++
Compound 158	++++
Compound 159	++++
Compound 162	++++
Compound 163	++
Compound 164	++++
Compound 166	++
Compound 167	++++
Compound 168	+++
Compound 170	++++
Compound 171	++++
Compound 172	++++

It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the above-described embodiments, without departing from the broad general spirit and scope of the present disclosure. The present embodiments are, therefore, to be

5 considered in all respects as illustrative and not restrictive.

CLAIMS


1. A compound of formula (I)




(I)

- 5 wherein

J is selected from the following moieties J1 and J2:



J1



J2

A¹ and A⁴ are independently selected from N and C;

A² and A³ are independently selected from N, NR¹, CH, O and S;

- 10 wherein at least one of A¹, A², A³ and A⁴ is selected from N, NR¹, O and S;

A⁵ is CH or N;

A⁶ is N or CR²;

R¹ and R³ are independently selected from H and an optionally substituted C₁₋₆-alkyl;

R² is selected from:

- 15 (i) H,
(ii) optionally substituted C₁₋₄alkylamido,
(iii) optionally substituted C₁₋₄alkylaryl,

- (iv) optionally substituted C₂₋₄alkynyl,
- (v) optionally substituted aryl,
- (vi) optionally substituted 5- or 6-membered heterocyclyl
- (vii) cyano;

5 X is selected from optionally substituted C₁₋₆alkyl, optionally substituted haloC₁₋₆alkyl, optionally substituted C₂₋₆alkynyl, optionally substituted cycloalkyl, optionally substituted halocycloalkyl, optionally substituted aryl, optionally substituted alkylaryl, optionally substituted C₁₋₆alkylcycloalkyl and optionally substituted amino;

Y and Z are independently selected from H, R⁴ and -OR⁴;

10 wherein at least one of Y and Z is H and the remaining one of Y and Z is selected from R⁴ and -OR⁴;

R⁴ is selected from optionally substituted C₁₋₆alkyl, optionally substituted aryl, optionally substituted C₁₋₆alkylaryl, optionally substituted heterocyclyl, optionally substituted C₁₋₆alkylheterocyclyl, optionally substituted cycloalkyl, optionally substituted C₁₋₆alkylC₃₋₁₀cycloalkyl, optionally substituted C₃₋₁₀cycloalkylaryl, optionally substituted C₃₋₁₀cycloalkylheterocyclyl, optionally substituted C₃₋₁₀cycloalkylC₃₋₁₀cycloalkyl, optionally substituted 3-6 membered non-aromatic heterocyclyl-aryl, optionally substituted 3-6 membered non-aromatic heterocyclylC₃₋₁₀cycloalkyl and optionally substituted 3-6 membered non-aromatic heterocyclyl-3-10 membered heterocyclyl; and

20 R⁵ is selected from H, optionally substituted C₁₋₆alkyl, optionally substituted C₃₋₁₀cycloalkyl and optionally substituted aryl;

or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer and/or prodrug thereof.

2. The compound of claim 1, or pharmaceutically acceptable salt, solvate, tautomer, stereoisomer and/or prodrug thereof,

wherein Y is -OR⁴ and Z is H.

3. The compound of claim 1 or 2, or pharmaceutically acceptable salt, solvate, tautomer, stereoisomer and/or prodrug thereof,

wherein X is selected from C₁₋₆alkyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl, aryl, -(CH₂)_naryl, -(CH₂)_ncycloalkyl, and -N(R⁷)R⁸

n is 1 or 2,

wherein each alkyl and alkynyl is optionally substituted with one or more groups selected from halo, nitrile, $-OR^6$, $-N(R^7)R^8$;

R^6 , R^7 and R^8 are independently selected from H, C_{1-6} alkyl and halo C_{1-6} alkyl, and

5 wherein each aryl and cycloalkyl is optionally substituted with one or more groups that are independently selected from halo, nitrile, C_{1-4} alkyl, C_{1-4} alkoxy, halo C_{1-4} alkyl and halo C_{1-4} alkoxy.

4. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer and/or prodrug thereof, wherein X is selected from C_{1-4} alkyl and C_{1-4} alkylhalo.

10 5. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer and/or prodrug thereof, wherein

R^4 is selected from C_{1-6} alkyl, aryl, cycloalkyl, heterocyclyl, C_{1-6} alkyl C_{3-10} cycloalkyl, C_{1-6} alkylaryl and C_{1-6} alkylheterocyclyl,

15 wherein each alkyl is optionally substituted with one or more groups independently selected from halo, C_{1-4} alkoxy, hydroxy, nitrile, amino, C_{1-4} alkylamino, $(C_{1-4}alkyl)_2$ amino, aryl, cycloalkyl and heterocyclyl;

wherein each aryl is optionally substituted with one or more groups independently selected from halo, hydroxy, nitrile, amino, C_{1-4} alkylamino and $(C_{1-4}alkyl)_2$ amino, C_{1-4} alkyl, C_{1-4} alkoxy, halo C_{1-4} alkyl, halo C_{1-4} alkoxy, aryl, cycloalkyl and heterocyclyl;

20 wherein each cycloalkyl is optionally substituted with one or more groups independently selected from halo, hydroxy, nitrile, amino, C_{1-4} alkylamino and $(C_{1-4}alkyl)_2$ amino, C_{1-4} alkyl, C_{1-4} alkoxy, halo C_{1-4} alkyl, halo C_{1-4} alkoxy, aryl, cycloalkyl and heterocyclyl; and

wherein each heterocyclyl is optionally substituted with one or more groups independently selected from halo, hydroxy, nitrile, amino, C_{1-4} alkylamino and $(C_{1-4}alkyl)_2$ amino, C_{1-4} alkyl, C_{1-4} alkoxy, halo C_{1-4} alkyl, halo C_{1-4} alkoxy, cycloalkyl, heterocyclyl and aryl.

25 6. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer and/or prodrug thereof, wherein R^4 has partial structure (A):



(A)

wherein

R^d is selected from H, optionally substituted C₁₋₄alkyl, optionally substituted C₁₋₄alkoxy, optionally substituted C₁₋₄alkoxyC₁₋₄alkyl, optionally substituted C₁₋₄alkylhydroxy, optionally substituted C₁₋₄alkylnitrile, optionally substituted C₁₋₄alkylamino and optionally substituted (C₁₋₄alkyl)₂amino, optionally substituted cycloalkyl and optionally substituted C₁₋₄alkylcycloalkyl; and

R^e is selected from optionally substituted aryl, optionally substituted C₁₋₅alkylaryl, optionally substituted heterocyclyl, optionally substituted C₁₋₅alkylheterocyclyl, optionally substituted cycloalkyl, and optionally substituted C₁₋₅alkylC₃₋₁₀cycloalkyl.

7. The compound of claim 6, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer and/or prodrug thereof, wherein R^d is selected from optionally substituted C₁₋₄alkyl, and wherein the carbon atom to which R^d and R^e are attached is enriched in the (S) stereoisomer.

8. The compound of any one of claims 1-7, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer and/or prodrug thereof, wherein R² is a 5- or 6-membered heterocyclyl selected from: pyrazolyl, pyridyl, tetrahydropyridyl, isozazolyl, pyrimidinyl, piperidinyl and tetrahydropyranyl,

and wherein the 5- or 6-membered heterocyclyl is optionally substituted with one or more group(s) selected from: halo, optionally substituted C₁₋₆alkyl, optionally substituted C₃₋₈cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted C₁₋₆alkoxy, optionally substituted C₁₋₆alkyl-OH and optionally substituted C₁₋₆alkylhalo.

9. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer and/or prodrug thereof, wherein R² is a 5- or 6-membered heterocyclyl optionally substituted with one or two groups selected from: methyl, methoxy, methoxyethyl, trifluoromethyl, difluoromethyl, trifluoroethyl, isopropyl, tert-butyl, 2-hydroxyethyl, dimethylamino, cyclopentyl, oxitanyl, tetrahydrofuranyl, piperidinyl, N-methyl-piperidinyl, tetrahydropyranyl and N-methyl-piperazinyl-2-ethyl.

10. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer and/or prodrug thereof, wherein R³ is H.


11. The compound of any one of claims 1-10, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer and/or prodrug thereof, wherein J is J1.

12. The compound of claim 11, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer and/or prodrug thereof, wherein A¹, A², A³ and A⁴ are selected from the following embodiments:

No.	A ¹	A ²	A ³	A ⁴
1	C	CH	O	C
2	C	N	NMe	C
3	C	CH	N	N
4	C	N	N ⁱ Pr	C
5	C	N	CH	N
6	C	N	S	C
7	C	CH	S	C
8	N	CH	N	C

13. The compound of any one of claims 1-10, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer and/or prodrug thereof, wherein J is J2.

14. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer and/or prodrug thereof, provided by the following formula (IIA)



wherein

G is selected from:

- (i) C₁₋₄alkylamido,
 (ii) C₁₋₄alkylaryl,
 15 (iii) C₂₋₄alkynyl,
 (iv) aryl,
 (v) 5- or 6-membered heterocyclyl

each R¹⁰ is independently selected from: halo, an optionally substituted C₁₋₆alkyl, an optionally substituted C₃₋₈cycloalkyl, an optionally substituted aryl, an optionally substituted heterocyclyl, an optionally substituted C₁₋₄alkoxy, an optionally substituted C₁₋₄alkyl-OH, an optionally substituted

20

C₁₋₄alkylhalo, an optionally substituted C₁₋₄alkylheterocyclyl, an optionally substituted C₁₋₄alkylC₃₋₈cycloalkyl, an optionally substituted C₁₋₄alkylaryl; and

w is an integer from 0-3.

15. The compound of claim 1, or a pharmaceutically acceptable salt, solvate, tautomer,
5 N-oxide, stereoisomer and/or prodrug thereof, wherein the compound is selected from:

Compound Number	Chemical name
1	N-(4-(4-amino-1-methyl-7-(pyridin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((4-fluorobenzyl)oxy)phenyl)ethanesulfonamide
2	N-(4-amino-3-(4-(ethylsulfonamido)-3-((4-fluorobenzyl)oxy)phenyl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-7-yl)acetamide
3	N-(4-(4-amino-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)furo[3,2-c]pyridin-3-yl)-2-((4-fluorobenzyl)oxy)phenyl)ethanesulfonamide
4	N-(4-(4-amino-7-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)furo[3,2-c]pyridin-3-yl)-2-((4-fluorobenzyl)oxy)phenyl)ethanesulfonamide
5	N-(4-(4-amino-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)furo[3,2-c]pyridin-3-yl)-2-((4-fluorobenzyl)oxy)phenyl)-1,1-difluoromethanesulfonamide
6	N-(4-(4-amino-7-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)furo[3,2-c]pyridin-3-yl)-2-((4-fluorobenzyl)oxy)phenyl)-1,1-difluoromethanesulfonamide
7	(S)-N-(4-(4-amino-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)furo[3,2-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
8	(S)-N-(4-(4-amino-7-(1-methyl-1H-pyrazol-4-yl)furo[3,2-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
9	(S)-N-(4-(4-amino-7-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)furo[3,2-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
10	N-(4-(4-amino-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((4-fluorobenzyl)oxy)phenyl)-1,1-difluoromethanesulfonamide
11	N-(4-(4-amino-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)furo[3,2-c]pyridin-3-yl)-2-((4-fluorobenzyl)oxy)phenyl)-2,2,2-trifluoroethane-1-sulfonamide
12	N-(4-(4-amino-7-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((4-fluorobenzyl)oxy)phenyl)-1,1-difluoromethanesulfonamide
13	N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((4-fluorobenzyl)oxy)phenyl)-1,1-difluoromethanesulfonamide
14	N-(4-(4-amino-1-methyl-7-(pyridin-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((4-fluorobenzyl)oxy)phenyl)-1,1-difluoromethanesulfonamide
15	(S)-N-(4-(4-amino-7-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
16	N-(4-(4-amino-1-methyl-7-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((4-fluorobenzyl)oxy)phenyl)-1,1-difluoromethanesulfonamide
17	(S)-N-(4-(4-amino-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
18	(S)-N-(4-(4-amino-1-methyl-7-(pyridin-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide

19	(S)-N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
20	(S)-N-(4-(4-amino-1-methyl-7-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
21	(S)-N-(4-(4-amino-1-methyl-7-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
22	(S)-N-(4-(4-aminopyrazolo[1,5-a]pyrazin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
23	(S)-N-(4-(4-amino-1-methyl-7-(2-(trifluoromethyl)pyridin-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
24	(S)-N-(4-(4-amino-1-methyl-7-(2-methylpyridin-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
25	(S)-N-(4-(4-amino-1-methyl-7-(pyridin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
26	(S)-N-(4-(4-amino-1-methyl-7-(6-methylpyridin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
27	(S)-N-(4-(4-amino-7-(2-methoxypyridin-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
28	(S)-N-(4-(4-amino-7-(6-methoxypyridin-3-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
29	(S)-N-(4-(4-amino-7-(1-(2-methoxyethyl)-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
30	(S)-N-(4-(4-amino-7-(1-cyclopentyl-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
31	(S)-N-(4-(4-amino-7-(1-isopropyl-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
32	(S)-N-(4-(4-amino-1-methyl-7-(3-methylpyridin-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
33	(S)-N-(4-(4-amino-7-(3,5-dimethylisoxazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
34	(S)-N-(4-(4-amino-7-benzyl-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
35	(S)-N-(4-(4-amino-7-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
36	(S)-N-(4-(4-amino-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
37	(S)-N-(4-(4-amino-7-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
38	(S)-N-(4-(4-amino-1-methyl-7-(1-(oxetan-3-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
39	(S)-N-(4-(4-amino-7-(pyridin-4-yl)pyrazolo[1,5-a]pyrazin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
40	(S)-N-(4-(4-amino-1-methyl-7-(pyrimidin-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
41	N-(4-(4-amino-1-methyl-7-(1-(tetrahydrofuran-3-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide

42	(S)-N-(4-(4-amino-1-methyl-7-(1-methylpiperidin-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
43	(S)-N-(4-(4-amino-7-(3,6-dihydro-2H-pyran-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
44	(S)-N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-2,2,2-trifluoroethane-1-sulfonamide
45	(S)-N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)ethanesulfonamide
46	(S)-N-(4-(4-amino-1-methyl-7-(1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
47	(S)-N-(4-amino-3-(4-((difluoromethyl)sulfonamido)-3-(1-(4-fluorophenyl)ethoxy)phenyl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-7-yl)acetamide
48	(S)-N-(4-(4-amino-7-(2-(tert-butyl)pyridin-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
49	(S)-N-(4-(4-amino-7-(2-(dimethylamino)pyridin-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
50	(S)-N-(4-(4-amino-1-isopropyl-7-(pyridin-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
51	(S)-N-(4-(4-amino-1-isopropyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
52	(S)-N-(4-(4-amino-1-isopropyl-7-(1-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
53	(S)-N-(4-(4-amino-1-isopropyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
54	(S)-N-(4-(4-amino-1-methyl-7-(1,2,5,6-tetrahydropyridin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
55	(S)-N-(4-(4-amino-1-methyl-7-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
56	(S)-N-(4-(4-amino-1-methyl-7-(prop-1-yn-1-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
57	(S)-N-(4-(4-amino-7-(2-(difluoromethyl)pyridin-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
58	(S)-N-(4-(4-amino-1-methyl-7-((tetrahydro-2H-pyran-4-yl)ethynyl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
59	(S)-N-(4-(4-amino-1-methyl-7-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
60	(S)-N-(4-(4-amino-1-methyl-7-(1-(2-(4-methylpiperazin-1-yl)ethyl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
61	(S)-N-(4-(4-amino-1-methyl-7-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
62	N-(4-(3-amino-1H-indazol-4-yl)-2-((4-fluorobenzyl)oxy)phenyl)ethanesulfonamide
63	N-(4-(8-aminoimidazo[1,5-a]pyrazin-1-yl)-2-((4-fluorobenzyl)oxy)phenyl)ethanesulfonamide

64	N-(4-(4-aminopyrazolo[1,5-a]pyrazin-3-yl)-2-((4-fluorobenzyl)oxy)phenyl)ethanesulfonamide
65	N-(4-(3-amino-1H-pyrazolo[4,3-c]pyridin-4-yl)-2-((4-fluorobenzyl)oxy)phenyl)-2,2,2-trifluoroethane-1-sulfonamide
66	N-(4-(3-amino-1H-pyrazolo[3,4-b]pyridin-4-yl)-2-((4-fluorobenzyl)oxy)phenyl)-1,1-difluoromethanesulfonamide
67	N-(4-(3-amino-1H-pyrazolo[3,4-b]pyridin-4-yl)-2-((4-fluorobenzyl)oxy)phenyl)-2,2,2-trifluoroethane-1-sulfonamide
68	N-(4-(3-amino-1H-pyrazolo[4,3-c]pyridin-4-yl)-2-((4-fluorobenzyl)oxy)phenyl)-1,1-difluoromethanesulfonamide
69	N-(4-(3-amino-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-2-((4-fluorobenzyl)oxy)phenyl)-1,1-difluoromethanesulfonamide
70	N-(4-(3-amino-6-methyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-2-((4-fluorobenzyl)oxy)phenyl)-1,1-difluoromethanesulfonamide
71	N-(4-(3-amino-6-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl)-2-((4-fluorobenzyl)oxy)phenyl)-1,1-difluoromethanesulfonamide
72	(S)-N-(4-(3-amino-1H-pyrazolo[3,4-b]pyridin-4-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
73	N-(4-(4-amino-1-methyl-7-(1-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
74	N-(4-(4-amino-7-(1-(azepan-4-yl)-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
75	(S)-N-(4-(4-amino-7-(1-(2-(3,3-dimethylazetidin-1-yl)ethyl)-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
76	(S)-N-(4-(4-amino-7-(1-(1-isopropylazetidin-3-yl)-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
77	(S)-N-(4-(4-amino-1-methyl-7-(1-(1-(2,2,2-trifluoroethyl)azetidin-3-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
78	(S)-N-(4-(7-(1-(2-azaspiro[3.3]heptan-6-yl)-1H-pyrazol-4-yl)-4-amino-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
79	(S)-N-(4-(4-amino-1-methyl-7-(piperidin-4-ylethynyl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
80	(S)-N-(4-(4-amino-1-methyl-7-((1-methylpiperidin-4-yl)ethynyl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
81	2-(4-(4-amino-3-(4-((difluoromethyl)sulfonamido)-3-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-7-yl)-1H-pyrazol-1-yl)-N-isopropyl-N-methylpropanamide
82	(S)-N-(4-(4-amino-1-methyl-7-(1-(2-(methylamino)ethyl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
83	(S)-N-(4-(4-amino-7-(5-cyano-1-methyl-1H-pyrrol-3-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
84	(S)-N-(4-(4-amino-7-(3-chlorophenyl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide

85	(S)-N-(4-(4-amino-7-(2-chlorophenyl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
86	(S)-N-(4-(4-amino-1-methyl-7-phenyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
87	(S)-N-(4-(4-amino-7-(4-chlorophenyl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
88	N-(4-(4-amino-1-methyl-7-(1-(pyrrolidin-2-ylmethyl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
89	(S)-N-(4-(4-amino-7-(1-(1-(aminomethyl)cyclopropyl)-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
90	(S)-N-(4-(4-amino-1-methyl-7-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
91	(S)-N-(4-(4-amino-1-methyl-7-(5-methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
92	(S)-N-(4-(4-amino-1-methyl-7-(1-(1-methylazetidin-3-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
93	N-(4-(4-amino-1-methyl-7-(1-(1-methylpyrrolidin-3-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
94	(S)-N-(4-(4-amino-7-(1-(azetidin-3-yl)-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
95	N-(4-(4-amino-1-methyl-7-(1-((3R,5R)-5-methylpiperidin-3-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
96	rac-(R)-N-(4-(4-amino-7-(1-(1-cyanocyclopropyl)-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
97	(S)-N-(4-(4-amino-7-(1-(1-hydroxy-2-methylpropan-2-yl)-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
98	(S)-N-(4-(4-amino-7-(1-(3-(cyanomethyl)oxetan-3-yl)-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
99	(S)-N-(4-(4-amino-1-methyl-7-(1-(2-methyl-2-azaspiro[3.3]heptan-6-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
100	(S)-N-(4-(4-amino-7-(1-(2-(dimethylamino)ethyl)-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
101	N-(4-(4-amino-7-(1-(1-(isopropyl(methyl)amino)propan-2-yl)-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
102	N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)-2-methoxyethoxy)phenyl)-1,1-difluoromethanesulfonamide

103	(S)-N-(4-(4-amino-1-methyl-7-(1-(1-(methyl-d3)piperidin-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
104	N-(4-(4-amino-1-methyl-7-(1-(1,6,6-trimethylpiperidin-3-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
105	(S)-N-(4-(4-amino-1-methyl-7-(2-(4-methylpiperazin-1-yl)pyrimidin-5-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
106	(S)-N-(4-(4-amino-7-(2-(dimethylamino)pyrimidin-5-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
107	(S)-N-(4-(4-amino-1-methyl-7-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
108	(S)-N-(4-(4-amino-7-(2-aminopyrimidin-5-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
109	(S)-N-(4-(7-(1-(1-acetyl piperidin-4-yl)-1H-pyrazol-4-yl)-4-amino-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
110	(S)-N-(4-(4-amino-1-methyl-7-(2-morpholinopyrimidin-5-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
111	(S)-N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)-2-methoxyethoxy)phenyl)-1,1-difluoromethanesulfonamide
112	(R)-N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)-2-methoxyethoxy)phenyl)-1,1-difluoromethanesulfonamide
113	N-(4-(4-amino-1-methyl-7-(1-(1,2,2-trimethylpiperidin-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
114	(S)-N-(4-(4-amino-1-methyl-7-(2-(pyrrolidin-1-yl)pyrimidin-5-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
115	(S)-N-(4-(4-amino-1-methyl-7-(6-morpholinopyridin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
116	(S)-N-(4-(4-amino-1-methyl-7-(1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
117	(S)-N-(4-(4-amino-1-methyl-7-(6-(trifluoromethyl)pyridin-3-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
118	(S)-N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(2-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
119	(S)-N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)methanesulfonamide
120	N-(4-(4-amino-7-[1-(3,3-difluorocyclopentyl)-1H-pyrazol-4-yl]-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl)-1,1-difluoromethanesulfonamide
121	(R)-N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide

122	(S)-N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(3-chlorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
123	(S)-N-(4-(4-amino-7-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
124	3-{4-[(dimethylsulfamoyl)amino]-3-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl}-1-methyl-7-[1-(oxan-4-yl)-1H-pyrazol-4-yl]-1H-pyrazolo[4,3-c]pyridin-4-amine
125	(S)-N-(4-(4-amino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1-phenylmethanesulfonamide
126	(S)-1,1-difluoro-N-(2-(1-(4-fluorophenyl)ethoxy)-4-(4-imino-1-methyl-7-(1-methyl-1H-pyrrol-3-yl)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl)methanesulfonamide
127	(S)-N-(2-(1-(4-fluorophenyl)ethoxy)-4-(4-imino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl)-1-phenylmethanesulfonamide
128	(S)-1,1-difluoro-N-(2-(1-(4-fluorophenyl)ethoxy)-4-(4-imino-1-methyl-7-((1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethynyl)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl)methanesulfonamide
129	(S)-1,1-difluoro-N-(4-(4-imino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-methoxyphenyl)ethoxy)phenyl)methanesulfonamide
130	N-(2-((3-chlorobenzyl)oxy)-4-(4-imino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl)-1,1-difluoromethanesulfonamide
131	(S)-1,1-difluoro-N-(2-(1-(4-fluorophenyl)ethoxy)-4-(4-imino-1-methyl-7-(1-(3,3,3-trifluoropropyl)-1H-pyrazol-4-yl)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl)methanesulfonamide
132	N-(2-((4-chloro-3-fluorobenzyl)oxy)-4-(4-imino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl)-1,1-difluoromethanesulfonamide
133	(S)-N-(4-(4-amino-7-cyano-1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
134	(S)-1,1-difluoro-N-(2-(1-(4-fluorophenyl)ethoxy)-4-(4-imino-1-methyl-7-(1-(trifluoromethyl)-1H-pyrazol-4-yl)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl)methanesulfonamide
135	1,1-difluoro-N-(3-((3-fluorobenzyl)oxy)-4-(4-imino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl)methanesulfonamide
136	N-(2-((5-chloropyridin-2-yl)methoxy)-4-(4-imino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl)-1,1-difluoromethanesulfonamide
137	(S)-N-(2-(1-(4-chlorophenyl)ethoxy)-4-(4-imino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl)-1,1-difluoromethanesulfonamide
138	(S)-1,1-difluoro-N-(2-(1-(4-fluorophenyl)ethoxy)-4-(4-imino-1-methyl-7-(2-(methylimino)-1,2-dihydropyrimidin-5-yl)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl)methanesulfonamide
139	1,1-difluoro-N-(2-(1-(4-fluorophenyl)-2-methoxyethoxy)-4-(4-imino-1-methyl-7-(1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl)methanesulfonamide

140	1,1-difluoro-N-(2-(1-(4-fluorophenyl)cyclopropoxy)-4-(4-imino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl)methanesulfonamide
141	(S)-1,1-difluoro-N-(2-(1-(4-fluorophenyl)ethoxy)-4-(4-imino-1-methyl-7-morpholino-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl)methanesulfonamide
142	1,1-difluoro-N-(2-((S)-1-(4-fluorophenyl)ethoxy)-4-(4-imino-1-methyl-7-(1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazol-4-yl)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl)methanesulfonamide
143	1,1-difluoro-N-(4-(4-imino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(thiazol-2-ylmethoxy)phenyl)methanesulfonamide
144	1,1-difluoro-N-(4-(4-imino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-isopropoxyphenyl)methanesulfonamide
145	1,1-difluoro-N-(2-((S)-1-(4-fluorophenyl)ethoxy)-4-(4-imino-1-methyl-7-(1-(4-methyl-4-azaspiro[2.5]octan-7-yl)-1H-pyrazol-4-yl)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl)methanesulfonamide
146	(S)-N-(4-(7-(1-(4,4-difluorocyclohexyl)-1H-pyrazol-4-yl)-4-imino-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
147	N-(4-(7-(1-(1,2-dimethylazetidin-3-yl)-1H-pyrazol-4-yl)-4-imino-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
148	1,1-difluoro-N-(2-((S)-1-(4-fluorophenyl)ethoxy)-4-(4-imino-1-methyl-7-(1-(1-methyl-2-(trifluoromethyl)piperidin-4-yl)-1H-pyrazol-4-yl)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl)methanesulfonamide
149	1,1-difluoro-N-(2-((S)-1-(4-fluorophenyl)ethoxy)-4-(4-imino-1-methyl-7-(1-(2-(trifluoromethyl)piperidin-4-yl)-1H-pyrazol-4-yl)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl)methanesulfonamide
150	N-(2-(cyclohexylmethoxy)-4-(4-imino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl)-1,1-difluoromethanesulfonamide
151	1,1-difluoro-N-(4-(4-imino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(oxazol-2-ylmethoxy)phenyl)methanesulfonamide
152	N-(4-(7-(1-(2,2-dimethyl-1-(methyl-d3)piperidin-4-yl)-1H-pyrazol-4-yl)-4-imino-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
153	1,1-difluoro-N-(2-((S)-1-(4-fluorophenyl)ethoxy)-4-(4-imino-1-methyl-7-(1-(8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octan-3-yl)-1H-pyrazol-4-yl)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl)methanesulfonamide
154	1,1-difluoro-N-(2-((S)-1-(4-fluorophenyl)ethoxy)-4-(4-imino-1-methyl-7-(1-((R)-1,2,2-trimethylpiperidin-4-yl)-1H-pyrazol-4-yl)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl)methanesulfonamide
155	1,1-difluoro-N-(2-((S)-1-(4-fluorophenyl)ethoxy)-4-(4-imino-1-methyl-7-(1-((S)-1,2,2-trimethylpiperidin-4-yl)-1H-pyrazol-4-yl)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl)methanesulfonamide
156	1,1-difluoro-N-(2-((S)-1-(4-fluorophenyl)ethoxy)-4-(4-imino-1-methyl-7-(3-methyl-1-(1,2,2-trimethylpiperidin-4-yl)-1H-pyrazol-4-yl)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl)methanesulfonamide

157	1,1-difluoro-N-(2-((S)-1-(4-fluorophenyl)ethoxy)-4-(4-imino-1-methyl-7-(5-methyl-1-(1,2,2-trimethylpiperidin-4-yl)-1H-pyrazol-4-yl)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl)methanesulfonamide
158	N-(4-(7-(1-(2-(difluoromethyl)-1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)-4-imino-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
159	N-(2-((S)-1-(4-chlorophenyl)ethoxy)-4-(4-imino-1-methyl-7-(1-(1,2,2-trimethylpiperidin-4-yl)-1H-pyrazol-4-yl)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl)-1,1-difluoromethanesulfonamide
160	(S)-1,1-difluoro-N-(2-(1-(4-fluorophenyl)ethoxy)-4-(7-(2-hydroxy-1-methyl-1H-benzo[d]imidazol-6-yl)-4-imino-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl)methanesulfonamide
161	(S)-N-(4-(7-(1,3-dimethyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)-4-imino-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-(1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
162	(S)-1,1-difluoro-N-(2-(1-(4-fluorophenyl)ethoxy)-4-(4-imino-1-methyl-7-(1-(1,2,2,6,6-pentamethylpiperidin-4-yl)-1H-pyrazol-4-yl)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl)methanesulfonamide
163	1,1-difluoro-N-(2-((S)-1-(4-fluorophenyl)ethoxy)-4-(4-imino-1-methyl-7-(1-((3aR,6aS)-octahydrocyclopenta[c]pyrrol-5-yl)-1H-pyrazol-4-yl)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl)methanesulfonamide
164	1,1-difluoro-N-(2-((S)-1-(4-fluorophenyl)ethoxy)-4-(4-imino-1-methyl-7-(1-((3aR,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl)-1H-pyrazol-4-yl)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl)methanesulfonamide
165	(S)-1,1-difluoro-N-(2-(1-(4-fluorophenyl)ethoxy)-4-(4-imino-1-methyl-7-(1-methyl-2-oxoindolin-5-yl)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl)methanesulfonamide
166	(S)-1,1-difluoro-N-(2-(1-(4-fluorophenyl)ethoxy)-4-(4-imino-1-methyl-7-(1-methyl-1H-indazol-5-yl)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl)methanesulfonamide
167	N-(4-(7-(1-(2,2-dimethyl-1-(2,2,2-trifluoroethyl)piperidin-4-yl)-1H-pyrazol-4-yl)-4-imino-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
168	N-(4-(7-(1-(3-(dimethylamino)cyclopentyl)-1H-pyrazol-4-yl)-4-imino-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
169	N-(2-(benzo[d][1,3]dioxol-5-ylmethoxy)-4-(4-imino-1-methyl-7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl)-1,1-difluoromethanesulfonamide
170	N-(4-(4-amino-1-methyl-7-(1-((S*)-4-methyl-4-azaspiro[2.5]octan-7-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
171	N-(4-(4-amino-1-methyl-7-(1-((R*)-4-methyl-4-azaspiro[2.5]octan-7-yl)-1H-pyrazol-4-yl)-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-((S)-1-(4-fluorophenyl)ethoxy)phenyl)-1,1-difluoromethanesulfonamide
172	N-(4-(4-amino-1-methyl-7-[1-(1,3,5-trimethylpiperidin-4-yl)-1H-pyrazol-4-yl]-1H-pyrazolo[4,3-c]pyridin-3-yl)-2-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl)-1,1-difluoromethanesulfonamide
173	4-(4-(4-amino-3-[4-(difluoromethanesulfonamido)-3-[(1S)-1-(4-fluorophenyl)ethoxy]phenyl]-1-methyl-1H-pyrazolo[4,3-c]pyridin-7-yl)-1H-pyrazol-1-yl)cyclohexane-1-carboxylic acid

16. A medicament comprising a compound of any one of claims 1-15, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer and/or prodrug thereof.

17. A pharmaceutical composition comprising a compound of any one of claims 1-15, or
5 a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer and/or prodrug thereof, and a pharmaceutically acceptable excipient.

18. A method of treating necroptosis, comprising administering to a subject in need thereof an effective amount of a compound of any one of claims 1-15, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer and/or prodrug thereof, the medicament
10 of claim 16, or the pharmaceutical composition of claim 17.

19. The method of claim 18, wherein the subject has a disease selected from the group consisting of diseases of the bones, joints, connective tissue and cartilage, muscular diseases, skin diseases, cardiovascular diseases, circulatory diseases, hematological and vascular diseases, diseases of the lung, diseases of the gastro-intestinal tract, diseases of the liver,
15 diseases of the pancreas, metabolic diseases, diseases of the kidneys, viral and bacterial infections, severe intoxications, degenerative diseases associated with the Acquired Immune Deficiency Syndrome (AIDS), disorders associated with aging, inflammatory diseases, auto-immune diseases, dental disorders, ophthalmic diseases or disorders, diseases of the audition tracts, diseases associated with mitochondria, neuronal loss, ischemic reperfusion injury, cancer
20 and metastatic cancer, and diseases of the central nervous system.

20. Use of a compound of any one of claims 1-15, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer and/or prodrug thereof, in the manufacture of a medicament for treating necroptosis.

21. A compound of any one of claims 1-15, or a pharmaceutically acceptable salt, solvate,
25 tautomer, N-oxide, stereoisomer and/or prodrug thereof, for use in the treatment of necroptosis.

22. A method of inhibiting mixed lineage kinase domain-like protein (MLKL), comprising contacting a cell with a compound of any one of claims 1-15, or a pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer and/or prodrug thereof.

23. A MLKL inhibitor comprising a compound of any one of claims 1-15, or a
30 pharmaceutically acceptable salt, solvate, tautomer, N-oxide, stereoisomer and/or prodrug thereof.